Current advance of nanotechnology in diagnosis and treatment for malignant tumors.

Introduction

Cancer is one of the leading causes of death globally, with an approximate incidence of 19.3 million newly diagnosed cases and about 10.0 million fatalities annually. 1 , 2 Due to its ever-growing incidence and mortality rate, it has become one of the highest challenges for a longer life expectancy worldwide. Although in developed countries like the United States, general cancer incidence and mortality rates have been gradually decreasing in the past decade owing to new research on tumor mechanisms, improved diagnostic tools, and new therapeutic strategies, the burden of cancer remains a major challenge in developing as well as developed economies. 2 – 7 It is in urgent demand for more ground-breaking innovations and ever-improving tactics, together with a better understanding and utilization of existing cancer management strategies.

Common treatments, including surgery, radiotherapy, and chemotherapy, have been applied to most patients with malignant tumors, either in combination or separately. Although surgery is regarded as an irreplaceable treatment for most solid localized tumors, systematic treatment is required as a supplement upon the occurrence of metastasis. 8 – 14 Radiation therapy is used in more than half of patients with cancer and is one of the most effective treatment modalities, 15 – 21 but it remains a huge challenge to alleviate short- and long-term toxicity. 15 , 22 – 26 Traditional chemotherapy is also facing great challenges due to its inherent properties, such as instability, insolubility, drug resistance, and prominent tissue damage. 27 – 34 Also, the traditional systematic administration of drugs has put all somatic cells at risk of toxicity. However, there are ways of reducing side effects and avoiding the drawbacks of chemotherapy by enclosing drugs inside a tiny compartment, absorbing the drug into well-designed pores or mediums, providing a relatively stabilized microenvironment, enabling active interactions within the body with the assistance of biomimicking membranes, and releasing drugs after being transported to the desired sites. This is what nanotechnology is attempting to do.

Nanomedicine, after being brought forward conceptually, has been investigated as being used in a large number of diseases, 35 – 41 especially in the efficient transportation of anti-tumor drugs, diagnosis, and imaging, giving credit to its prominent physiochemical and structural characteristics (Fig. 1 ). 42 – 46 In the past years, nanomedicine has undergone a long history of evolution, namely, from non-targeting to targeting, from simple materials to mixed systems, and from single to combined technologies. The combination of nanotechnology and conventional tumor therapy can not only enhance the properties of chemoradiotherapy drugs but also reduce the incidence of poisoning and other side effects. 39 , 47 – 58 Regulatory authorities have authorized several therapeutic nanoparticle (NP) platforms, such as liposomes, albumin, and polymeric micelles, for cancer treatment. These NPs can rapidly cross the human biological barriers, even in a targeted manner 59 – 61 and continuously release the content to maintain the appropriate blood concentration of the drug. 62 , 63 A growing interest in manufacturing new formulations inside the NPs can avoid the disadvantages of both traditional treatment and nanotechnology and promote preclinical and clinical efficacy. 64 – 66 Fig. 1 Nanomedicine in cancer diagnosis and treatment. CT computed tomography, MRI magnetic resonance imaging, PET positron emission tomography, SPECT single-photon emission tomography, US ultrasound, FI fluorescence imaging. (Drawn by Figdraw)

Meanwhile, along with the advantages nanomedicines are offering, the challenges ahead are also worth mentioning. There are mainly two unresolved issues in the nanomedicine area. Enhanced permeability and retention (EPR), a widely recognized routine of nanomedicine, has provided limited improvement in the survival outcomes of patients, even though EPR has been confirmed to decrease the risk of adverse effects and enhance efficacy during the preclinical trial and in the animal model. 67 – 72 On the contrary, immune-checkpoint inhibition (ICI), which can inhibit the immune-checkpoint molecule of cancer, improves the survival outcome of patients with cancer considerably. 73 , 74 However, the incidence rate of adverse effects in ICI is higher than that of EPR, and only <13% of patients can benefit after the treatment. 75

This review focuses on summarizing nanomedicines of all types and their diagnostic and therapeutic use in the treatment of various types of cancer. Firstly, the morphological characteristics, uses, and recent advances of each type of nanomedicine are explained, including polymeric nanoparticles, liposomes, micelles, hydrogels, exosomes and other extracellular vesicles, natural membrane nanoparticles, viruses, and inorganic nanoparticles. Secondly, the applications of nanomedicine to malignant tumors are systematically explained, including digestive system, lung (respiratory system), intracranial, hematological, genitourinary, skeletal, skin, and thyroid cancers. The advantages and disadvantages of nanomedicine in the treatment of these tumors are then outlined. Finally, we discuss the prospects and challenges for nanotechnology in malignant tumors (Tables 1 – 3 ). Table 1 Features of different nanoparticles Types of NPs Advantages Disadvantages Polymeric NPs Natural polymers Biocompatibility and degradability, Excellent transmucosal capability Low stability Synthetic polymers High stability, bioavailability and loading capacity Tissue accumulation, Low degradability, Unfavorable side effects Liposomes Excellent biocompatibility, Wide adaptability to drugs, Reduced adverse effects, avoiding bio-clearance of agents Low storage of lipophilic molecules, opsonization, immunogenicity and instability, High costs Micelles Alleviating toxicity, Enabling transportation of lipophilic drugs, Reducing the uptake by macrophages, Prolonging the circulation time, Targeting drug release Instability in vivo, Low solubility of small size particles, Low drug loading capacity Hydrogels High biocompatibility, High drug loading capacity, Controllable and adjustable of drug release, Highly adjustable chemical and physical properties Fast clearance, Off-target accumulation Extracellular vesicles Targeted drug delivery, High biocompatibility, Loading a large variety of cargos Difficult for isolation, purification and differential recognition, Abnormal accumulations in the liver Natural membrane-coated NPs Prolonging the blood circulation time, Evading clearance from immune system, Boosting therapeutic effects, Improving target capabilities Complexity of scale-up manufacturing, Accumulating in livers or reticuloendothelial systems, Difficulties with purification and storage Virus Outstanding targeting capability, Potential in immunotherapy or vaccination strategies Lacking of clinical translation Inorganic NPs Mesoporous silica Easy functionalization and surface modification, High capacity of storing drugs, Simple production process High costs Gold NPs Low toxicity, High stability, Simple synthesis, Bioconjugation of desired molecules, Efficient light-to-heat conversion Prone to accumulating in tissue and toxicity potential, Unsatisfactory clinic treatment outcomes Carbon nanomaterials Excellent optical properties, Thermal conductivity, Electrical conductivity, Chemical stability, Functionalization Potential problems of biosafety Table 2 Approved nanomedicine for cancer Therapeutic type Product name Therapeutic agent Nanocarrier Administration route Indications First approval Chemotherapy Doxil Doxorubicin PEGylated liposomes iv. Kaposi sarcoma, breast cancer, ovarian cancer, multiple myeloma USA 1995 Chemotherapy Caelyx Doxorubicin PEGylated liposome iv. Metastatic breast, Kaposi’s sarcoma, multiple myeloma USA 1996 Chemotherapy DaunoXome Daunorubicin Liposomes iv. Kaposi sarcoma USA 1996 Chemotherapy Myocet Doxorubicin Liposomes iv. Metastatic breast cancer USA 1996 Chemotherapy DepoCyt Cytarabine Liposomes iv. Lymphomatous meningitis USA 1999 Chemotherapy Eligard Leuprolide Polymeric micelles iv. Prostate cancer USA 2002 Chemotherapy Lipusu Paclitaxel Liposomes iv. Ovarian cancer, metastatic gastric cancer China 2003 Chemotherapy Oncaspar Pegaspargase Polymeric micelles iv. Acute lymphoblastic leukemia USA 1994 Chemotherapy MEPACT Mifamurtide Liposomes iv. Osteosarcoma Europe 2009 Chemotherapy Ameluz 5-aminolevulinic acid Liposomes it. Nodular basal cell carcinoma USA 2011 Chemotherapy Marqibo Vincristine sulfate Liposomes iv. Philadelphia chromosome-negative acute lymphoblastic leukemia USA 2012 Chemotherapy Lipodox Doxorubicin hydrochloride Liposome iv. Kaposi’s sarcoma, ovarian cancer, multiple myeloma, metastatic pancreatic cancer Chnia 2013 Chemotherapy Kadcyla DM1(or Emtansine) Protein iv. Breast cancer USA 2013 Chemotherapy Paclical Paclitaxel polymeric nanoparticle-based iv. Pancreatic cancer, metastatic breast cancer USA 2015 Chemotherapy Onivyde Irinotecan PEGylated liposomes iv. Metastatic pancreatic cancer USA 2015 Chemotherapy VYXEOS Cytarabine/daunorubicin (5∶1) Liposomes iv. Acute myeloid leukemia USA 2017 Chemotherapy Pazenir Paclitaxel Micelle iv. Metastatic breast cancer, metastatic pancreatic cancer, non-small cell lung cancer USA 2019 Chemotherapy Apealea Paclitaxel Nanocrystal iv. Ovarian cancer, peritoneal cancer, fallopian tube cancer USA 2018 Chemotherapy Abraxane Paclitaxel Albumin iv. Breast cancer, non-metastatic small cell lung cancer, metastatic adenocarcinoma of the pancreas USA 2005 Chemotherapy Ontak Denileukin Diftitox Protein iv. Cutaneous T-cell lymphoma USA 1999 Chemotherapy Genexol-PM Paclitaxel Polymeric micelles iv. Breast cancer, lung cancer Korea 2007 Chemotherapy Nanoxel Paclitaxel Polymeric micelles iv. Breast cancer, ovarian cancer India 2007 Chemotherapy Paclical Paclitaxel Polymeric micelles iv. Ovarian cancer Russia 2015 Chemotherapy PICN Paclitaxel Polymer/lipid NP iv. Metastatic breast cancer India 2014 Chemotherapy DHP107 Paclitaxel Lipid NP po. Advanced gastric cancer Korea 2016 Chemotherapy LipoplatinTM, NanoplatinTM Cisplatin Liposomes iv. Pancreatic cancer, lung cancer USA 2018 Hyperthermia NanoTherm Fe2O3 Metallic iv. Glioblastoma, prostate cancer, pancreatic cancer. USA 2013 Hyperthermia NanoTherm — Iron oxide NP it. Recurrent glioblastoma Europe 2010 Radiotherapy enhancer Hensify — Hafnium oxide NP it. Locally advanced soft tissue sarcoma Europe 2019 iv. intravenous, po . peros, it. intratumoral Table 3 Anti-tumor nanomedicines in clinical trials Therapeutic type Product name Therapeutic agent Nanocarrier Administration route Indications Trial No. Stage Chemotherapy ThermoDox Doxorubicin Liposome iv. Liver cancer NCT02181075 Phase 1 Chemotherapy LEP-ETU Paclitaxel Liposome iv. Neoplasm NCT00080418 Phase 1 Chemotherapy Nano-QUT Quercetin PLGA-PEG NPs iv. Oral cancer NCT05456022 Phase 2 Chemotherapy NK 105 Paclitaxel Micellar nanoparticle iv. Breast cancer NCT01644890 Phase 3 Chemotherapy Docetaxel-PM Docetaxel polymeric micelle iv. Esophagus squamous cell carcinoma, metastatic cancer NCT03585673 Phase 2 Chemotherapy BIND-014 Docetaxel Polymeric micelles iv. KRAS positive non-small cell lung cancer, squamous cell non-small cell lung cancer NCT02283320 Phase 2 Chemotherapy Genexol PM Paclitaxel Polymeric micelles iv. Bladder cancer, ureter cancer NCT01426126 Phase 2 Chemotherapy Nab-paclitaxel (Abraxane) Paclitaxel Albumin iv. Non-small cell lung cancer NCT02016209 Phase 2 Chemotherapy Abraxane Paclitaxel Albumin iv. Pancreatic cancer NCT00691054 Phase 2 Chemotherapy NC-6004 Cetuximab polymeric micelle iv. Head and neck neoplasms NCT02817113 Phase 1 Chemotherapy MBP-426 Oxaliplatin Liposome iv. cancer NCT00355888 Phase 1 Chemotherapy FF-10850 Topotecan Liposomes iv. Advanced solid tumors NCT04047251 Phase 1 Chemotherapy Cetuximab nanoparticles Cetuximab Ethylcellulose nanoparticles iv. Colon cancer NCT03774680 Phase 1 Chemotherapy Docetaxel-PNP Docetaxel Liposome iv. Advanced solid malignancies NCT01103791 Phase 1 Chemotherapy ABT-888 Doxorubicin PEGylated liposomes iv. Ovarian cancer NCT01113957 Phase 2 Chemotherapy CPX-351 Cytarabine and daunorubicin at 5:1 ratio Liposomes iv. Acute myeloid leukemia NCT02286726 Phase 2 Chemotherapy LipoVNB Vinorelbine tartrate Liposomes iv. Advanced malignancy NCT02925000 Phase 1/2 Chemotherapy CriPec Docetaxel Polymeric micelles iv. Ovarian cancer NCT03742713 Phase 2 Chemotherapy LY01610 Irinotecan hydrochloride Liposomes iv. Small cell lung cancer NCT04381910 Phase 2 Chemotherapy Liposome doxorubicin Doxorubicin Liposomes iv. Desmoid tumor NCT05561036 Phase 3 Chemotherapy EndoTAG-1 Paclitaxel Cationic liposomes iv. Breast cancer NCT01537536 Phase 2 Chemotherapy KM1 Carboplatin Virus iv. Ovarian cancer NCT05684731 Phase 1 Immunotherapy mRNA-NP vaccine Autologous total tumor mRNA Liposome iv. Melanoma NCT05264974 Phase 1 Immunotherapy Dex2 Antigen Exosome iv. Non-small cell lung cancer NCT01159288 Phase 2 Radiotherapy AGuIX-NP Cisplatin Inorganic NPs — Gynecologic cancer NCT03308604 Phase 1 Radiotherapy AGuIX-NP Temozolomide Inorganic NPs — Glioblastoma NCT04881032 Phase 1/2 Radiotherapy NBTXR3 — Hafnium Oxide NPs it. Advanced and/or metastatic malignant solid neoplasm, metastatic malignant liver cancer, metastatic malignant lung cancer NCT05039632 Phase 1/2 Gene therapy iExosomes KRAS G12D siRNA Exosomes iv. Metastatic pancreas cancer NCT03608631 Phase 1 iv. intravenous, po. peros, it. intratumoral

Materials to construct the drug carriers

Material design is the footstone for nanotechnology, with the hope of constructing drug delivery systems for tumor therapy. We have generally categorized the currently developed materials into the following types: polymeric NPs (including natural and synthetic ones), liposomes, micelles, hydrogels, exosomes, and other extracellular vesicles; natural membrane-coated NPs (including red blood cell-NPs, leukocyte-like carriers, and plateletsomes); and viruses; and inorganic NPs (including mesoporous silica, gold NPs, and carbon nanomaterials). Though nanomaterials are categorized into different types in this review, the combination strategy of various materials is not excluded. Notably, an increasing number of studies focus on hybrid materials, which can combine the advantages of two or more types of materials. For instance, polymeric materials can be modified on the surface of gold NPs to overcome the low rigidity of polymers and improve the biocompatibility of gold-based NPs.

Polymeric nanoparticles

Polymeric nanoparticles include a wide range of biomaterials with sizes ranging from 10 to 100 nm. There are different classifications of polymeric nanoparticles. 38 , 76 – 78 Generally, polymeric nanoparticles can be sorted into three subgroups: synthetic polymers, natural products, and hybrid ones, which combine the synthetic and the natural together with the potential to achieve various functions. All of them have featured characterizations in the application of nanoparticle drug delivery systems, including biodegradability, biocompatibility and nontoxicity. Herein, synthetic and natural polymeric nanoparticles and their properties are discussed.

Natural polymers

Natural polymeric nanocarriers are polymers firstly discovered and produced by organisms, including polysaccharides and protein NPs. 79 Both can be easily acquired from natural organisms and put into use after fabrication. Strictly speaking, there is nearly no complete “natural polymer” that can be used as a nanocarrier without any modification.

The most widely used polysaccharide-based biomaterial in the architecture of nanomedicine is regarded as chitosan. Chitosan is a water-soluble, biocompatible, and biodegradable polysaccharide material that originates from the shells of crustaceans. 38 , 80 , 81 Due to the excellent capability of transmucosa, chitosan-based biomaterials are commonly used for drug delivery systems through varied kinds of epithelia, such as the eye 82 , 83 and the intestinal. 84 , 85 Yeh et al. 86 found chitosan can “permeabilize” the mucosa epithelium by means of mediating the opening of a tight junction between cells of the mucosa so that a drug or other therapeutic component can cross the mucosa barrier and act on malignant tissue. Therefore, the oral route of administration is widely recognized as the most comfortable and compliant approach for patients. 87 , 88 Another advantage of chitosan is that it can inspire other scientists to modify or design brand new biomaterials with chitosan. 84 , 87 – 112 In recent research, 87 a new design of chitosan named AuNP-siRNA-glycol chitosan-taurocholic acid nanoparticles (AR-GT NPs) was used to treat liver metastasis from colorectal cancer in an animal trial. This delivery system has potential for treating liver-related tumors. In addition, chitosan itself has the potential to be an add-on therapy to upregulate the function of the immune system during the procedure of tumor treatment. According to Carroll et al., chitosan can induce type I interferons (IFN) to promote the maturation of dendritic cells and enhance the sensitivity of Th1 through the cGAS and STING pathways. 89 Generally, the application of chitosan is very promising. However, chitosan and other nanocarriers with positive charges on their surfaces were once thought to be limited in clinical application due to their toxicity and inflammatory response. 113 In the study of Wei et al. 113 , injection of chitosan could lead to rapid progress of necrocytosis because of intracellular Na + overload caused by excessive “permeabilized effect” instead of inflammation. This is also a significant mechanism that has implications for the better design of safer chitosan-based nanocarriers. Taken together, chitosan has been widely adapted in the therapeutic approach with great hope, especially via oral administration; however, more basic or clinical trials and a more sophisticated design are required to ensure its unpredictable safety issues.

Another widely explored natural polymer-based nanocarrier is protein NPs, especially human serum albumin (HSA). HSA is potentially ideal for chemotherapeutic drug delivery due to several key characteristics, including: (1) it is an endogenous carrier from the human body, so it is unlikely to cause an inflammatory and corresponding toxic response; (2) it is a natural carrier for various ions and compounds in the circulatory system; (3) it has a long circulation time, so it can be remodeled to release drugs sequentially 114 ; (4) it can be biodegraded and reproduced by metabolism 115 ; (5) it tends to accumulate at the site of abnormal vasculature, including leakage or capillaries in the TME; (6) cancer cells, which require numerous types of substances to grow, are likely to approach HAS. 38 , 77 , 116 Besides, like chitosan, HSA can also be modified to optimize its properties. As a typical protein, HSA has both carboxylic acid and amino groups, which enable HSA to have characteristic isoelectric points (pI). The pI of HSA is variable because the ratio of amino acids and acids can be mediated by chemical modification. 38 Tian et al. 117 have achieved flexible isoelectric points through this method in the gene transfer of virus vectors. HSA is also promising to deliver negatively charged molecules, including nucleic acid. As a drug, more trials are required to resolve the restriction on TME. A newly designed nanomaterial consisting of three components, including Au(1)Ag(9) (<8 nm; stimulus component), docetaxel (an anticancer drug), and bovine serum albumin, showed high efficacy and biosafety in chemotherapy therapy induced by near-infrared light. 118 At present, however, the most tested application of HSA is HSA-based photothermal therapy (PTT) due to the precise localization characteristic of the tumor (most of them used bovine serum albumin, BSA, instead of HSA). 118 – 122 Li et al. 119 combined BSA-based gadolinium oxide nanodots (GdNDs) with a small-molecule NIR-II fluorophore (FS) named FS-GdNDs, which demonstrated an excellent photothermal conversion efficiency of 43.99%, good photothermal stability, and favorable capability of MR/NIR-II imaging performance at low doses. During the toxicity test, it also showed outstanding biocompatibility and biodegradability, which are of enormous potential in photothermal applications. In addition, serum albumin is also explored in the areas of immunotherapy 123 – 125 and radiotherapy, 126 – 130 but they still require advanced study for clinical translation.

Synthetic polymers

Synthetic polymers for drug delivery have already been widely adopted in tumor treatment, with a relatively longer history than other nanoparticles. Some of them have been approved by the FDA for clinical applications, such as polylactic acid (PLA) 131 – 133 and poly (lactic-co-glycolic acid) (PLGA). 134 – 136 Recently, however, ever-decreasing concerns concentrate on the application of synthetic polymers solely but hybrid polymers such as polymeric micelles, which are mostly composed of both natural and synthetic polymers. When polymers are assembled into micelles, their functions and characteristics will be only partly reserved, and their applications will be different from each other. 137

PLA is a biocompatible, biodegradable polymer, and its monomer, lactic acid, is a safe substance that is the basic particle in carbohydrate metabolism. 131 PLGA, based on the structure of PLA, is the most widely used FDA-approved type of polymer. PLGA became well-known in 1994 when PLGA-PEG NPs were invented. PLGA inherits all of the advantages of PLA and has a long circulating half-life and continuous release properties, which makes it more suitable than other synthetic polymers. 39 In recent studies, PLGA is not only ideal for chemotherapy drug delivery but also promising in immunotherapy 138 , 139 and photothermal therapy, 138 , 140 , 141 just like HSA. R837-αOVA-ApoE3-HNP, 142 a recently designed nanovaccine, is composed of a PLGA core and a capsule of adjuvant imiquimod (R837), and a phospholipid membrane with antigen peptide (αOVA) and apolipoprotein E3 (ApoE3). Actually, this nanovaccine is a kind of antigenic analog that can boost antigen into DCs directly instead of being engulfed by DCs passively. After that, strong responses, including the maturation of specific CD8 (+) T cells, an increasing number of IFN-γ (+) CD8 (+) T cells, and the secretion of IFN-γ (+), were observed in this study, which showed tremendous potential to be a new method of cancer immunotherapy. By contrast, a recent study showed PLGA-carrying rapamycin can partly inhibit the activation of B cells and enhance the function of Treg cells, which can inhibit the development of antidrug antibodies in order to improve efficacy and minimize the hypersensitive effect during the agent treatment. 143 It seems that PLGA tends to interact with not only tumor cells but also certain kinds of immune cells, which has significant guidance for scientists to tackle the TME dilemma.

Dendrimers, unlike other synthetic polymers, have a three-dimensional, repetitively branched shape, just as their name suggests (‘dendri’ means ‘tree-like’ in Greek). Due to this featured structure, dendrimer has a remarkable hydrophilicity with a small size of less than 20 nm, 144 , 145 which makes it easy to cross biological barriers, including the mucosa, endothelium, and epithelium. Generally, dendrimers have several features, including: (1) nontoxicity; (2) bioavailability; (3) drug stability; (4) enhanced biological activities of the encapsulated and conjugated drugs; and (5) outstanding transmembrane capability. In addition, the most prominent feature of dendrimer is its highly multidirectional homogeneity. 146 – 149 In this case, dendrimer can effectively interact with certain targets, including ligands or antigens, just like a polyvalent antibody. On one hand, dendrimer itself can be bioactive as a potential agent. 144 , 150 On the other hand, dendrimers can be a platform to cooperate with other immunoactive substances, such as programmed death ligand 1 (PD-L1), a famous ICI agent. In a recent study, 151 dendrimer-ICI conjugates (G7-aPD-L1) demonstrated better strength than free aPD-L1. From what has been discussed above, both effects provide possibilities for designing a new platform for cancer immunotherapy.

Liposomes

Liposomes are spheres consisting of two lipid layers and encircling an aqueous core, ranging from 50 to 450 nm in size in medical applications. 152 They are capable of carrying both hydrophilic (inside the aqueous solution core) and hydrophobic (associated within the lipid bilayer) molecules. 152 Liposomes were firstly discovered by Alec Bangham in 1961 153 and were among the first generation of lipid-based drug delivery systems introduced to clinics. 154 Some liposome-formulated anti-cancer drugs have already been marketed, including Myocet liposomal, liposomal doxorubicin (DOX), and Marqibo, with several other liposomal formulations in clinical trials. 155 – 157 There are generally four categories of liposomes: (a) traditional types, consisting of a lipid, mostly phospholipids; (b) bilayer PEGylated types, liposomes with polyethylene glycol (PEG) coating on the surface for a longer circulation period; (c) ligand-target types, linked with targeting ligands such as peptides, monoclonal antibodies, vitamins, or carbohydrates to target the desired cell types; (d) theranostic types, a multifunctional type with targeting ligands, imaging agents, and drugs inside. 158

Liposome-based delivery systems have several advantages in terms of targeted and precise drug delivery, reducing systemic drug toxicity, ensuring a stable environment for drugs inside during transportation, and avoiding bio-clearance upon delivering gene therapy agents to the cytosol. 159 – 165 Recent research shows liposomes conjugated to antibodies for EphA2, enclosing the docetaxel prodrug, can effectively reduce the toxicity of antitumor drugs, improve overall tolerability, maintain a desirable exposure of the drug in cancer tissue, and remarkably improve the antitumor activity in comparison with non-nanodelivery and non-targeted nanodelivery controls. 166 There are also problems for liposome-based delivery, such as low storage of lipophilic molecules, opsonization, immunogenicity, and instability. 38 , 76 , 167 The physical stimuli-responsive liposome has been a hotspot in recent years. 168 – 170 Compared with conventional liposome-based medicines, they offer new practical options for controlled drug release at the desired sites, yet very few preclinical candidates have entered the clinical trial, not to mention reaching the hospital. 155 , 171 , 172 These intelligent carriers face even more challenges than conventional ones, such as the choice of light source and wavelength settings, phospholipids with proper stimuli properties, and the toxicity of synthesized lipids.

Micelles

Micelles are spheres composed of self-aggregated amphiphilic molecules with a size between 10 and 100 nm in diameter. In aqueous solutions, the monolayer of surfactants strikes a balance by thermodynamics, forming a hydrophilic surface contacting the medium as well as separating a hydrophobic core in the center. 173 , 174 Both synthesized polymers and natural molecules can be utilized for the formation of micelles. 175 However, it follows certain conditions, including the concentration of the minimal amphiphilic molecules, known as the critical micelle concentration (CMC), the structure of the chemical group, the temperature known as the Krafft temperature, under which micelles may collapse, and the medium. 176 , 177 A wide variety of materials can be encapsulated into the micellar core; as a result, toxicity caused by the widespread administration of drugs can be alleviated. 178 , 179 Meanwhile, it enables easier transportation of lipophilic drugs, which are otherwise hard to dissolve, and quickly eliminated them from the internal environment. 180

Block polymers, with the fundamental components of a shell-forming part and a core-forming part, have different properties based on the materials. Several materials are available for micellar shells, including poly(ethylene glycol), polyvinyl alcohol, poly( N -vinyl-2-pyrrolidone), poly[ N -(2-hydroxypropyl) methacrylamide], poly(oxazolines), poly(amino acid)s, zwitterionic polymers, and polysaccharides. Some are for cores, including polyether, polyester, polyamino acids, poly(ethylene imine), and poly(amino acid)s, all with different inherent properties. 137 , 181 , 182 Poly(ethylene glycol), or PEG, one of the most investigated materials for the shell, creates a sheath on the surface of the micelles, thus reducing the uptake by macrophages and prolonging the circulation time. 183 – 187 Regardless of the type of micelles, the selection of polymers should always consider these vital aspects: the type of loading drugs, biocompatibility, immunogenicity, toxicity, biodegradability, and special other properties. 175 , 188 – 190 As reported, fine-adjustment of the components of micelles makes a precise spatiotemporal control available by enabling the micelles to respond to endogenous (for instance, pH, enzymes, ROS, and ATP) or exogenous stimuli (including light, temperature, and ultrasound treatment). 137 , 191 Those properties can be combined when needed, functioning as double insurance for targeted drug releases. In recent research, 192 Su et al. designed a pH and metalloproteinase double-sensitive PEGylated micelle for transporting and releasing anti-programmed death 1 (PD-1) antibody and paclitaxel in a targeted manner and achieved on-demand sequential release of antitumor medicine. Apart from reacting to stimuli, targeted micelles can be achieved by enhancing penetrability and retention through attaching ligands or monoclonal antibodies to the surface. 178 , 193 As several micelle-based medicines enter the market, micelles seem to enjoy an optimistic future in clinical applications. 38

Hydrogels

Hydrogels are 3-dimensional chemically or physically crosslinked polymer chain networks with versatile properties achieved by fine-tuning. 194 – 196 Cross-linking physical interactions mainly include hydrogen bonds, while chemical ones are mainly covalent bonds. Hydrogels are highly biocompatible, capable of loading several types of drugs simultaneously, controllable and adjustable in drug release, sensitive to stimuli, and capable of transferring physical states, which makes them potentially valuable for resolving obstacles in cancer management that the current drug delivery systems may encounter. 194 , 197 – 202 Due to their highly adjustable chemical and physical properties, hydrogels are widely utilized in a great number of medical fields, including tissue engineering, wound healing, medical imaging, environmentally sensitive drug delivery, cancer vaccines, gene editing, biosensors, cell culture, and so on. 203 – 212

The nanotherapeutic systems have faced obstacles in clinical trials due to inadequate dispersion within the body, limited ability to break down naturally, harmful effects on cells, and inconsistent effectiveness. 213 Hydrogels are a newly developed polymer substance that closely resembles healthy tissues, making them very compatible with biological systems. Biological organisms exhibit a high degree of tolerance towards them, as they have minimal levels of toxicity. In addition, nanohydrogels possess a comparatively low surface to volume ratio when compared to numerous other nanomaterials, which aids in the process of cellular uptake. 214 Nanohydrogels can be generated from either natural polymers or synthetic polymers. Natural polymers possess benefits such as exceptional biodegradability, biocompatibility, and the ability to be easily excreted or cleared by the kidneys. On the other hand, synthetic polymers offer stability, superior mechanical qualities, the capacity to regulate their structure, and favorable characteristics for drug release. 215 The characteristics of nanohydrogels render them a highly promising carrier for delivering anticancer drugs. Furthermore, their controlled release, enhanced permeability, and protection of loaded drugs allow nanohydrogels to serve as topical drug delivery systems, potentially improving drug delivery through the skin and treating skin diseases, including cutaneous malignancies. 216

Immune checkpoint blockers (ICBs) are a promising targeting strategy in cancer immunotherapy, yet they only benefit a small proportion of patients. Numerous studies have been investigated to tackle this problem, and recent research with a hydrogel endeavor seems to yield optimistic results. Wang et al. designed a prodrug hydrogelator to locally transport ICBs, boosting immunity against brain and colon cancer. 217 Hydrogel functioned as a reservoir for long-term and stimulated discharge of camptothecin and aPD1 at the tumor site, resulting in a 100% tumor regression on all mice models. Meanwhile, hydrogels can be designed for enhanced penetration and retention, which is also a hotspot in cancer immunology research. Recent research showed the supramolecular tubustecan hydrogel formed hydrogel spheres upon being injected into the tumor tissues. 218 They were capable of encapsulating the antitumor drug DOX, or curcumin, and enhancing penetration and retention. Besides that, hydrogels loaded with other nanoparticles provide us with a broader platform for combining multiple types of nanomedicine to solve the problem of tumor multidrug resistance. 219

Exosomes and other extracellular vesicles

Extracellular vesicles (EVs) are particles with a cell-originated membrane released by cells. Loaded with biological components with unrecognized functions, EVs were initially believed to be more like carriers of metabolites, waste, or cell debris, and their functions were gradually identified over time. 220 , 221 Exosomes are tiny, single-membrane-enclosed vesicle organelles released by cells, with a diameter ranging from 30 to 200 nm and containing proteins, lipids, and other biological components. 222 , 223 It is one of the most important and well-recognized EVs. Apart from exosomes, the first type of identified extracellular vesicles, 224 there is an increasing number of EVs that are being recognized, and their classification is constantly and rapidly evolving. 225

EVs, especially exosomes, are biologically important for a variety of cellular behaviors and intercellular communication. Recent research has revealed their significant importance in neoplasia, tumor growth promotion, local immunosuppression, and metastasis. 226 – 234 However, EVs have the potential to be developed and utilized in several fields regarding cancer diagnosis and management. To our best knowledge, research on EVs is focused on three scopes: (i) non-invasive cancer diagnosis, 235 – 237 achieved by various technologies of detecting exosomes and recognizing their biochemical components, which gives a hint of the biological components and pathophysiological conditions of the donor cells 222 , 238 ; (ii) targeted drug vehicles, as the biocomponent of the membrane reflects that of the donor cell, making it possible to combine preferentially with certain cells 235 , 239 , 240 ; (iii) EVs-based cancer immunotherapy, contributing to an activation of immunity towards tumor cells.

EVs are especially appropriate vehicles for targeted drug delivery because they are natural vesicles deriving from cells that are highly biocompatible. EVs from different kinds of cells are suitable for loading a large variety of cargos with precise modification. 241 – 243 Oligonucleotide, natural or synthesized compounds are mostly studied and most frequently used drugs carried by EVs, among which RNA carried by EVs has been regarded as a great breakthrough in cancer nanodrugs. 225 , 244 , 245 Mesenchymal stem cell-derived exosomes were reported to be used as carriers of microRNA-124a to treat glioblastoma. 246 In vitro experiments showed that anti-glioma microRNAs containing exosomes remarkably reduced the viability and clonogenicity of cancer cells compared with the control groups. In vivo experiments showed favorable survival benefits, and 50% of mice had at least 110 days of life. Sancho-Albero et al. designed a cancer-derived exosome for transporting biorthogonal catalytic drugs into cancer cells. 247 The catalysts were transported by those “Trojan Horses” exosomes and activated the prodrugs within them. Besides the normal cargos mentioned above, several new combinations of nanomedicines are constantly emerging, making it possible to combine cancer-treating strategies like gene therapy and attempts with oncolytic viruses. 248 , 249

Cancer immunotherapy, which generates or enhances immunity against cancer cells, has attracted increasing attention in the past decade. 250 EVs play significant roles in modulating the immune responses to cancer, both in positive and negative ways. 251 – 253 Among all kinds of EVs, tumor-derived EVs (TEVs) and immune cell-derived EVs are regarded as promising new directions in tumor immunotherapy. One major characteristic of TEVs is that several kinds of immunogenic molecules are on the surface, which can induce the immune response against cancer cells, including Hsp 70, miRNAs, and MHC-1 225 , 254 – 258 and could be developed as cancer vaccines. 259

Functions of immune cell-derived EVs include presenting antigen, activating immune cells, Treg cell differentiation, suppressing immune responses, and suppressing inflammation. 252 , 260 For example, EVs derived from NK cells (NK-EVs) have been reported to share similar cytotoxic abilities and have been used as anti-tumor therapies. 261 – 263 Zhu et al. recently reported a method to enhance this potency. 261 NK-EVs were priming with interleukin (IL)-15 and were separated from the normal NK-EVs. They were injected separately into cancer model mice intravenously, and NK-EVs (IL-15) showed significantly stronger cytolytic properties towards human tumor tissues. At the same time, gene expressions related to the cytotoxicity of NK cells were also promoted. Dendritic cell-derived exosomes (DEXs) were also utilized to treat cancer. Lu et al. reported using exosomes released from α-fetoprotein-expressing DCs (DEX AFP ) in hepatocellular carcinoma (HCC) mice models. 264 Mice treated with DEX AFP had significantly improved survival rates and better control of tumor growth.

Although some crucial problems remain to be solved, such as interference of biochemical backgrounds, technologies for better isolation and purification, differential recognition of exosomal surface compounds, lack of understanding of the biology of EVs, abnormal accumulation of EVs in the liver, etc., 236 , 238 , 265 – 267 the emerging research aimed at solving these problems gave us great expectations of a potential giant leap in the diagnostic and therapeutic applications of EVs.

Natural membrane-coated NPs

Besides natural extracellular vesicles, artificial nanoparticles with natural membranes are being investigated during these years in the field of drug delivery. Like natural EVs, these cell-mimicking nanoparticles, with characteristics borrowed from natural ones, can be highly biocompatible and exhibit limited immunogenicity. 268 , 269 Membrane from several kinds of cells can be used to artificially synthesize nanoparticles with different properties according to the original cell. 270 – 272

Red blood cell-NPs

Erythrocyte-originated nanoparticles, also called RBC-membrane-coated nanoparticles (RBC-NPs), are commonly investigated as drug delivery vehicles. RBC-NPs have shown several priorities compared with normal drug delivery systems: (i) prolonging the blood circulation time for the loaded drugs 241 , 273 – 278 ; (ii) evading clearance from the immune system 273 – 275 , 277 ; (iii) boosting the therapeutic effects of loaded drugs 241 , 274 , 276 , 278 , 279 ; and (iv) improving the cancer cell target capabilities when integrating biomimetic modifications. 275 , 280 Interestingly, several researchers combined membranes from erythrocytes and cancer cells to create a hybrid one, with the intention of utilizing the advantages of RBC-NPs to homotypically target cancer cells. 274 , 276 Jiang et al. fused the erythrocyte membrane with the MCF-7 (breast cancer cell line) membrane and produced hybrid melanin particles for in vivo photothermal treatment. 274 Bearing proteins from both RBC and cancer cells onto the surface, together with a melanin core, the fused nanoparticles showed enhanced antitumor properties, along with several advantages listed above. In their research, the proportion of the fusion membrane was also discussed, which may be a crucial problem in similar coatings of NPs with merged membranes in the coming study. Looking ahead, NPs coated with cell membranes could be an interesting way of adding or augmenting the desired characteristics of nanomedicines. However, it still should be recognized that the surface property, intracellular interactions, and circulating capability of the cell membrane-coated nanomedicine are not completely equal to those of the original cells, since during the membrane preparation, fusion, and coating procedures, some compositions of the membrane might be finely tuned.

Leukocyte-like carriers

Leukocyte-like carriers, fabricated either by coating nanoparticles with leukocyte membranes 272 , 281 , 282 or by decorating liposomal nanoparticles with biochemical components from leukocyte membranes, 283 are leukocyte-mimicking nanoparticles designed for improving pharmaceutical efficacies and reducing toxicities. Most research on leukocyte-like carriers has focused on their ability to target tissues with inflammation, 282 , 284 – 286 which is a basic pathological process in many diseases, including cancer. 287 Palomba et al. investigated the functions of the leukocyte membrane on silicon particles. 281 With several critical receptors on the surface, those particles exhibited higher abilities of permeating tumor blood vessels. Leukocyte-like carriers have other possibilities when combined with tumor cell membranes. They et al. designed composite nanoparticles composed of exogenous phospholipids fused with the leukocyte and tumor cell membranes, namely leutusomes, with a paclitaxel (PTX)-constructed core. 283 Compared with liposomes consisting of only leukocytes or cancer cell membranes, leutusomes showed advanced tumor-retention ability with few systemic adverse effects. The research group noticed this phenomenon in leutusomes with membrane components from both head and neck tumor cells (HN12 and B16 melanoma cells), suggesting the potential generalization of this tactic.

Plateletsomes

Platelets, one of the most important modulators of homeostasis, have long been known to play promoting roles in tumor progression and metastasis. 288 , 289 Thus, there has been an anti-tumor strategy to deplete tumor-associated platelets or suppress their activities in a tumor-related environment. 290 , 291 Besides, there is growing interest in NPs with platelet membrane or platelet-membrane moieties as new treatments for cancer, among which platelet membrane-coated NPs are receiving the most attention. Recently, research reported small interfering RNA (siRNA) delivered by a platelet membrane-enclosed metal-organic framework with high loading capacity and pH sensitivity. 292 The membrane enabled particles with specific cancer-binding abilities while silencing target genes efficiently in vitro and achieving fine therapeutic efficacy in vivo. Also, another combination of leukocyte membrane and nano-magnetic nanoparticles was reported, which sensitized effective ferroptosis and boosted the immune response triggered by anticancer agents. 293

Virus

In contrast to the nanoparticles explained above, virus NPs, or virus-like nanoparticles (VLPs), are relatively unexplored. Viral vectors, such as adenoviruses, have shown success in gene therapy as well as in treating tumors. VLPs were once considered an optional deliver that could carry antibodies, small molecule-based drugs, siRNA, and contrast agents 268 , 294 because of their outstanding targeting capability. In the most up-to-date study, since VLPs consist of the nontoxic viral capsid with antigen-analog, antigen-presenting cells, including DC, 295 will take in the VLPs so that targeted transportation is achieved. After the process of immune response, certain immune cells will be upregulated and attack tumor cells, which means VLPs can mediate the function of the immune system. Although limited studies showed the advantages of VLPs in tumor treatment, several studies exhibit their potential in immunotherapy or vaccination strategies. Generally, VLPs can be sorted into plant VLPs and other VLPs. Due to their non-pathogenicity with humans, researchers have achieved more progress in plant VLPs than others. Potato virus X (PVX) has been reported to exhibit excellent performance as an immunotherapy. 296 Lee et al. 296 designed double-functional NPs (PVX-DOX) by combining DOX with PVX in order to produce both immunotherapeutic and chemotherapeutic effects on B16F10 melanoma. In this study, PVX played a critical role not only in drug delivery but also as an in-situ vaccine. More importantly, PVX+DOX was reported to have better efficacy for in situ vaccination than DOX carried by PVX, which means their interactions enhanced their effects when they were used separately. Another promising plant virus is cowpea mosaic virus (CPMV), which can be applied in tumor imagination and chemotherapeutic delivery due to its specific icosahedral shape. 297 Nonetheless, the purity of carrier-used CPMV is not enough that some foreign matters, such as lipopolysaccharides, can lead to an unexpected hypersensitivity response. 298 A new Lyo-eCPMV was introduced by Zheng et al. to tackle this dilemma. 298 In addition, other VLPs, including Hepatitis B virus core (HBc) particles, 299 HPV16 L1 VLP, 300 and bacteriophage Qβ VLP, 295 , 301 have potential clinical values, especially in immunotherapy. However, more studies are required for clinical translation.

Inorganic NPs

Inorganic NPs, as drug carriers, have distinct physical, chemical, and biological properties due to their small size, large surface area to volume ratio, high drug loading capacity, controllable release, great biocompatibility, and biological stability. These characteristics make them extremely promising for use in a variety of medication delivery applications.

Despite the exceptional performance of inorganic nanoparticles, it is crucial to address the safety risks associated with them. After ingestion, biological distribution, and metabolism, inorganic nanoparticles can be excreted from the body through the kidneys via urine or the liver via bile. Nonetheless, some studies have indicated that certain types of inorganic nanoparticles might not degrade or be excreted. 302 Furthermore, under certain circumstances, inadequate elimination may cause certain nanoparticles to remain in the body for a long time. Consequently, they may disrupt the normal function of organs or tissues and induce toxicity. 303 This underscores the importance of not overlooking safety assessment while focusing on efficacy.

Mesoporous silica

Mesoporous silica, which can be produced utilizing structure-directed agents (SDAs) co-packaged with a silica precursor in the presence of a catalyst, is made of an amorphous silicon dioxide wall with equally dispersed pores (mesoporous structure). 304 – 306 There are many advantages making it possible to utilize this kind of NP to develop controlled release systems, such as easy chemical modification on surface and interior pores, high capacity for storing anticancer drugs, and a simple production process. 306 , 307 Mesoporous silica nanoparticles (MSNs) are internalized into cells by endocytosis, phagocytosis, and pinocytosis, depending on size, aspect ratio, and surface molecules. 308 After entering cells, MSNs can release the encapsulated drug only by particularly interacting with intrinsic or extrinsic stimuli, and the release of “gatekeeper” is followed. 309 – 311 Most MSNs will encounter an acidic environment in the endosome or lysosome after being absorbed, so a low pH is regarded as a trigger for content release from pores. Based on this conception, Liu et al. designed a kind of MSN called MSN/DOX@CaCO 3 @CM, 312 in which the core was filled with a highly efficient DOX and CaCO 3 interlayer. Their purpose was to regulate drug release in accordance with pH levels; furthermore, the encapsulation of the cancer cell membrane around the outer layer could enhance the stability of the colloid and promote tumor accumulation. Another important inner stimulus is the redox condition. Liang et al. invented a redox-sensitive DOX-loaded MSN called MSN-SS-GHA (DOX@MSN-SS-GHA), 313 which shows promise for efficient redox-responsive targeting drug delivery and magnetic resonance imaging (MRI). Besides, magnetic fields and light are important external factors to promote drug release. A new MSN, referred to as MMSNs cloaked with RBC membrane, has been created to effectively combine photosensitizer delivery, immunological adjuvant, and MF-assisted targeting photodynamic therapy, offering a novel strategy for cancer treatment. 314 As for the excretion, studies have shown that a large variety of silicon materials were detected in the feces and urine of animal models after injection and were likely to metabolize in the liver, be removed in the intestine, or be cleared by the kidney due to their highly positive charge. 315 , 316 In addition, MSNs can be degraded into silicic acid, 317 which occurs during drug delivery and ultrasound or MRI, 318 , 319 which might be applied to follow the trail of transport and distribution of the particles in circulation. 320 Because of the structural stability of MSNs, siRNA and low-molecular-weight polyethylene imine (PEI) can be bound to particles together through the interaction of anion and cation. With this method, siRNA will not be hydrolyzed by endonuclease in the serum or cytoplasm, so as to shut down the expression of the tumor gene. 321 Recently, it was reported that MSNs carrying siRNA against TWIST plus cisplatin can overcome the clinical challenges of chemical drug resistance and tumor metastasis in epithelial ovarian cancer and other cancers with TWIST overexpression. 322

Gold NPs

In addition to MSNs, gold nanoparticles have broad application prospects in cancer diagnosis and treatment because of their unique optical and Surface Plasmon Resonance (SPR) properties. 323 , 324 The synthesis method of gold nanoparticles is relatively simple and consists of three main methods: physical, chemical, and biological processes. Biosynthesis is the most representative and attractive synthetic method in recent years, including plant 325 – 328 and microbial-mediated 329 synthesis. The shape of gold nanoparticles, such as gold nanocages, nanorods, nanocubes, nanostars, and nanospheres, 330 is synthesized by different methods, which also determines that these different shapes of gold nanoparticles have different characteristics and different utilizations. For example, Yang et al. demonstrated that the shape-dependent SPR response of colloidal AuNPs and their respective effects can promote PDT efficiency. 331 When gold NPs enter the body, they will be covered by various proteins in the physiological environment, such as albumin, collagen fiber, IgG, IgM, and transferrin, forming a “corona”, 332 also known as the protein complex of nanoparticles, which is closely related to the transportation of nanoparticles in plasma, exchange with histones, and biodistribution. 333 Meanwhile, the artificially designed NP protein complex coat can prevent the particles from being recognized by the immune system, thus prolonging their half-life in the blood. 334 The chemical modification of gold nanoparticles is based on the negative potential on their surface. There are many kinds of molecules, such as small-molecule-based drugs, targeted ligands, genes, and so on. It has been reported that peptide-drug conjugates have demonstrated promising potential for increasing the targeted effectiveness of chemotherapeutic medications. Nevertheless, their limited uses may arise from their relatively short half-lives. However, this challenge can be solved by conveniently conjugating them with gold NPs. 335 The characteristics of biocompatibility, non-toxicity, and no side effects contributed greatly to the anti-cancer therapy. What’s more, gold NPs can be used in photothermal therapy, photodynamic therapy, and photoimaging based on their favorable conductivity for heat. 336 , 337 Photothermal therapy, wherein NPs encapsulated within tumors produce thermal energy when exposed to exogenously administered laser light, has been extensively documented as a unique approach to treating cancer with exceptional selectivity. Gold NPs play a crucial role in photothermal applications due to several advantageous properties they possess. Firstly, gold-based NPs exhibit biocompatibility, making them suitable for use in biological systems. Additionally, their small diameters facilitate tumor penetration when delivered systemically. Moreover, gold-thiol bioconjugation chemistry provides a straightforward method for attaching desired molecules. Furthermore, gold-based NPs demonstrate efficient conversion of light to heat, making them effective in photothermal processes. Lastly, their capacity to be adjusted to absorb near-infrared light allows them to penetrate tissues more deeply than other wavelengths. 338 , 339 Through continuous integration, we found that the development of inorganic nanoparticles is not independent and separate.

Carbon nanomaterials

Carbon NPs have been shown to be a highly valuable subset of nanomaterials. Carbon-based nanomaterials, encompassing carbon dots, carbon nanotubes, and graphene, have been widely employed across diverse consumer and industrial sectors. These applications involve the improvement of biomedical vehicles, composites, electronics, sporting equipment, and lubricants. 318 , 340 – 343 The relative proportions of sp, sp2, and sp3 hybridizations in carbon nanomaterials have a crucial role in determining the structural characteristics of these materials. Specifically, these hybridizations govern the development of two-dimensional nanomaterials with a flat morphology, such as graphene, one-dimensional nanomaterials with a hollow structure, like carbon nanotubes, as well as closed nanomaterials with zero-dimensional attributes, such as nanodiamonds. Furthermore, this ratio additionally influences several characteristics of carbon nanomaterials, including their structural integrity, electrical conductivity, chemical reactivity, and magnetic behavior, all of which contribute to the distinct benefits of different carbon nanomaterials in various applications. 344 In this review, we mainly focus on two types of carbon materials: carbon nanotubes (CNTs) and nanodiamonds (NDs). The unique electrostatic fields of NDs are characterized by eight square facets with positive charges, three hexagonal facets with negative charges, and three hexagonal facets with neutral or intermediate charges.

Based on these chemical modifications on NDs, we can covalently attach anticancer drugs to their surface to solve the problem of drug resistance. 345 , 346 For example, Liao et al. 347 developed a nanocomposite consisting of ND conjugated with paclitaxel (PTX) and cetuximab (Cet) to specifically target EGFR-positive triple-negative breast cancer (TNBC) cells. Their study showed that the ND-PTX-Cet nanocomposite effectively induced mitotic catastrophe and apoptosis in TNBC cells by targeting the EGFR receptor. This finding suggested that the ND-PTX-Cet nanocomposite could be a promising therapeutic strategy for TNBC. Additionally, the flexibility to adjust functional groups on NDs and the natural fluorescence of fluorescent nanodiamonds (FNDs) make NDs a compelling platform for creating biomedical imaging tools and clinical diagnostics. 348

Similar to NDs, CNTs can undergo various surface changes to enhance their functionality. The combination of this feature, together with the intrinsic benefits of CNTs, such as their high flexibility, tensile strength, and electrical conductivity, makes CNTs a desirable platform for various biological applications. 349 – 352 Covalent functionalization of CNTs was employed to create a capping technique that responds to stimuli. In this technique, gold NPs were designed to obstruct the open ends of multiwalled CNTs (MWCNTs). 353 The caps consisted of 40-nm gold nanoparticles that were attached to oxidized CNTs using linkers that were responsive to biochemical stimuli. These stimuli included changes in pH (achieved through a hydrazone bond that is broken under acidic conditions in tumors), a highly reducing environment (achieved through a disulfide bond that breaks in the presence of higher levels of glutathione inside cells), and esterase concentration (achieved through an ester bond). High-resolution imaging verified the existence of gold NPs mostly at the ends of CNTs, indicating the successful formation of a covalent bond between the gold nanoparticles and the open tips of the CNTs. 354

Many particles contain two or more inorganic materials to form a hybrid. A variety of multi-material mixed inorganic nanoparticles exploit the advantages of single-material NPs and make up for the shortage of single-material nanoparticles. Meanwhile, the price is relatively low, which is more conducive to the realization of clinical translation and large-scale production.

Different designs and different types of materials are always exhibiting various functions and properties, based on which the downstream applications should be carefully considered after understanding the detailed pathological features and microenvironment of different tumors. In other words, tailorable materials-based nanotechnology is serving the tumor therapy requirements. During the research, there are two strategies that can be followed: (1) the biological characteristics of the tumor are well understood, which pushes us to find appropriate nanomedicines to overcome the dilemma that traditional protocols cannot solve; (2) novel materials with newfangled capabilities are first recognized or developed, urging scientists to search for their potential fit applications among the tumors. Both strategies require us not to be doctrinal and inflexible in the investigation of such stereotypes devoid of innovative contents.

Nanomedicine in digestive system tumors

Digestive system tumors are common malignant tumors, including colorectal cancer, gastric cancer, esophageal cancer, liver cancer, pancreatic cancer, and other digestive organ cancers. According to the latest cancer statistics, the number of new cases and deaths of digestive system tumors is estimated to be the first of all tumors in the United States in 2023. 1 Colorectal cancer ranks as the second leading cause of cancer-related fatalities, 355 , 356 and most colorectal cancers originate from cancer stem cells (CSCs) in colorectal inner wall polyps, which are the accumulation of genetic and epigenetic variations. 357 Liver cancer is the sixth in terms of global cancer incidence and the fourth in terms of cancer-related deaths. The primary risk factors comprise chronic hepatitis B virus (HBV), hepatitis C virus (HCV), excessive alcohol use, aflatoxin infection, smoking, type II diabetes, obesity, and others. 358 , 359 Pancreatic cancer, sometimes referred to as the “king of cancers,” is recognized as one of the most challenging malignant tumors globally, presenting a 5-year survival rate of less than 9%. By 2030, pancreatic cancer is estimated to become the second most prevalent malignant tumor globally. 360 Gastric cancer and esophageal cancer rank as the fifth and sixth most prevalent forms of cancer worldwide, respectively. The mortality rate of gastric cancer ranks second behind lung cancer, while over half of all cases of esophageal cancer are reported in China. 358 , 361

Although traditional therapy (surgery, radiotherapy, and chemotherapy) has improved the treatment of digestive system tumors, it is accompanied by many side effects, including toxicity and drug resistance to normal cells and tissues. There is an urgent requirement to develop a novel treatment approach that can enhance the efficacy of treatment and minimize the occurrence of adverse effects.

In the past decades, nanotechnology has made considerable progress, and nanotechnology has also been widely used in the research of digestive system tumors, including NPs, dendrimers, liposomes, polymers, light-triggered therapy, and nanotechnology combined for diagnosis or treatment. 362 – 366 Here, we summarize the research results of novel nanotechnology applied to digestive system tumors in recent years and provide new prospects for early screening and treatment for digestive system tumors.

Diagnosis

Like other types of cancer, monitoring and diagnosis of digestive system malignancies mostly rely on the identification of tumor biomarkers and the utilization of imaging techniques. The early detection of tumors mainly depends on blood biomarkers, but most of the biomarkers fall off the tumor. After blood circulation, the secreted biomarkers are diluted, leading to a lack of specificity. Imaging tactics include CT, MRI, colonoscopy, endoscopic ultrasonography (EUS), and so on. 367 – 370 However, they have similar problems, such as low sensitivity. Nanotechnology has obvious advantages in enhancing the specificity of biomarker detection, improving imaging effect, imaging time, and targeting, achieving local tumor aggregation, and reducing non-specific interference.

A nanosensor is a highly sensitive and specific tumor detection method. Loynachan et al. designed a multi-protease nanosensor for exogenous drug release. 371 The sensor takes the renally cleared catalytic AuNCs as the template and couples them with a neutral avidin protein scaffold through a biotinylated protease-cleavable peptide connector to form the AuNC-NAV complex, which is stable in vivo without interference and retains catalytic activity. In the diseased site, it was disassembled due to the disorder of protease activity, including serine protease thrombin and zinc-dependent matrix metalloproteinase 9 (MMP9), among which the MMP-responsive AuNC-P2 20-NAV nanosensor was cleaved by MMP in the tumor site with abnormally higher MMP expression and released AuNC with a size of about 2 mm. AuNC was discharged into the urine through renal filtration, and then the disease status was detected simply and sensitively by detecting the ability of AuNC to catalyze peroxidase substrate. The results showed that the urine colorimetric signal of colon cancer mice was stronger than that of healthy mice, and the specificity of biomarkers was overcome by monitoring protease activity. At the same time, the nanosensor can be eliminated by renal excretion without being toxic. The up-regulation of significant biomarkers often occurs in hepatocellular carcinoma, and the individual differences are large. High-sensitivity detection of multiple biomarkers is very important for the early detection and diagnosis of liver cancer. Based on the enhanced Raman scattering (SERS) frequency shift immunoassay, Tang et al. designed a SERS-responsive silver nanoparticle film to simultaneously detect α-fetoprotein and glypican-3, which improved the sensitivity of liver cancer detection. 372 CA19-9, a mucin-glycoprotein tumor marker, is the most sensitive marker for pancreatic cancer reported so far. The serum CA19-9 level in most patients with pancreatic cancer is significantly increased. 373 Thapa et al. used carbon nanotubes (CNT) and PEI to construct thin films on the gold surface through the layer-by-layer (LBL) protocol. NHS-EDC was used to activate the carboxylic group on the CNT, and an anti-CA19-9 antibody was anchored on the surface of the membrane to form a biosensor. The detection limit of CA19-9 was 0.35 U/mL in buffer solution by impedance spectroscopy. Meanwhile, the samples containing glucose, ascorbic acid, and p53 antigen were tested to confirm the selectivity of the biosensor for the CA19-9 biomarker. 374

The current CT and MRI imaging technology cannot accurately detect and visualize cancer staging. The combination of nanotechnology and endoscopic ultrasound (EUS), CT, and MRI to achieve active targeted imaging can increase the practicability of early screening and improve tumor monitoring. Liu et al. prepared NPs with diethylenetriamine pentaacetic acid (DTPA) by solvent diffusion method and then synthesized PLA-PEG-PLL-Gd NPs by chelating Gadolinium (Gd) ion with DTPA group on the surface of NPs. The PLA-PEG-PLL-Gd NP was further modified with a vascular endothelial growth factor (VEGF) antibody to obtain a new multifunctional polymer nano contrast agent (anti-VEGF PLA-PEG-PLL-Gd NPs) with an average size of 69.8 ± 5.3 nm. Compared with the non-VEGF-modified nanoparticles, the uptake of VEGF PLA-PEG-PLL-Gd NPs in cells increased. In vivo and in vitro MRI showed that the contrast agent could significantly improve the relaxation of the chelating unit and enhance the imaging signal. The duration of imaging was observed to be substantially extended from less than one hour to twelve hours, suggesting that the utilization of anti-VEGF PLA-PEG-PLL-Gd NPs as a nano contrast agent holds considerable promise for the early detection of liver cancers. 375 Li et al. prepared a targeted uPAR nanoprobe DGLU11 by using endrograft poly- L -lysine (DGL) as a platform to couple the uPAR targeted peptide U11, gadolinium diethylenetriamine penta acetic acid (Gd DTPA), and cyanine dye cy5.5. The dual-mode MR/near-infrared fluorescence (NIRF)-targeted molecular imaging of precancerous pancreatic intraepithelial neoplasia (PanIN) and pancreatic ductal adenocarcinoma (PDAC) lesions was performed. The results revealed that the targeted probe had higher sensitivity in fluorescence imaging of MRI images. 376 Shi et al. reported that Gd-dopping CuS NPs combined with tumor targeting and MMP-2 can be effectively used in magnetic resonance biomimetic/fluorescence imaging of gastric cancer. The study demonstrated that T-MAN nanoprobes can identify lymph node and gastric cancer metastasis in mice. 377

One of the largest advantages of nanotechnology in cancer treatment is that it can overcome the dilemma of drug delivery and in vivo toxicity. Nanotechnology provides a platform for the delivery of insoluble or unstable drugs and improves the bioavailability and efficacy of drugs.

Treatment

Chemotherapy

Traditional chemotherapy lacks specificity, and the concentration of drugs in tumors is so low that it often needs a high dose to give full play to the curative effect. The advent of nanotechnology has resulted in the extension of drug retention within the body, augmented drug accumulation at tumor locations through passive and active targeting mechanisms, and improved the specificity and efficacy of chemical therapy. 378 – 385 Chen et al. designed superparamagnetic iron oxide with high magnetization and loss power (MnFe 2 O 4 @CoFe 2 O 4 ) silica NPs loaded with DOX. The drug can be controlled and released by magnetic heating under an alternating magnetic field (AMF), which can effectively reduce the activity of pancreatic cancer cells. 386 According to the EPR effect of tumor tissue, nanodrug can effectively penetrate and stay in the tumor lesion. Cervello et al. synthesized a brush copolymer PHEA-BIB-ButMA (PBB) using α-poly ( N -2-hydroxyethyl)- D , L -aspartic acid (PHEA), and poly (butyl methacrylate) (ButMA) as raw materials by the atom transfer radical polymerization (ATRP) method. 387 Then, the NPs loaded with sorafenib were prepared by the dialysis method for in vitro and in vivo anti-liver cancer research. The results showed that the nano-drug could accumulate significantly at the tumor site, and the anticancer effect of the drugs was enhanced. Based on cell penetrating peptide (CPP) and PDAC homing in vivo, He et al. modified the aptamer (GBI-10) targeting extracellular matrix (ECM) component (tenescin-C) onto matrix permeable CPP to prepare aptamer/cell penetrating peptide-camptothecin prodrug Apt/CPP-CPTD NPs. 388 As a tumor-homing ligand, aptamer can target tumors and realize the accumulation of nanodrugs in the tumor site. At the same time, tenascin-C present in the PDAC matrix has the ability to segregate GBI-10 from CPP, and the presence of exposed CPP can facilitate PDAC’s continued penetration and tumor cell endocytosis. Following the internalization of Apt/CP-CPTD NP into PDAC cells, a heightened intracellular redox potential can subsequently induce the regulated release of chemical medicines both in vitro and in vivo, hence leading to a more effective anti-tumor effect. Sun et al. developed a novel polyethylene glycolated liposome (ES-SSL-OXA) that specifically targeted estrogen receptors. This liposome was loaded with oxaliplatin, leading to enhanced metabolic characteristics, an improved safety profile, and increased effectiveness against tumors compared to conventional oxaliplatin formulations. 389 Yu et al. made the butyrate-modified NPs that were individually encapsulated with sorafenib and salinomycin. Butyrate, a multifunctional ligand, was found to facilitate transcytosis by interacting with monocarboxylate transporter 1 (MCT-1), which was found to be highly expressed on the surface of hepatocellular carcinoma (HCC) cells. 390

Nanotechnology can effectively overcome the problems of low bioavailability, low efficacy, and toxicity of traditional chemotherapy drugs. 391 – 393 FOLFOX, a combination of folic acid (FnA), 5-fluorouracil (5-FU), and oxaliplatin (OxP), is a standard drug for the treatment of colorectal cancer. Guo et al. prepared PEGylated lipid nanoparticles (Nano-Folox) targeting aminoethyl anisidine by nanoprecipitation technology, which were composed of the active forms of OxP ([Pt (Dach) (H 2 O) 2 ] 2+ ) and FnA. The results showed that PEGylated nanoparticles enhanced the blood circulation of Pt by about 10-fold. The encapsulation efficiency (EE) and loading content (LC) of the NPs were about 99% and 67 wt%, respectively. Through the drug uptake experiment in vitro, higher Pt uptake was achieved in CT26-FL3 cells. In the in situ CRC mouse model, the Pt tumor accumulation (~40% ID/g) achieved by nano Folox targeting AEAA was remarkably higher than that of its non-targeted counterpart (~23% ID/g). The combination of nanoFolox and 5-FU exhibited a more potent chemotherapeutic effect while remaining non-toxic in comparison to FOLFOX. 394 Irinotecan is an important chemotherapeutic drug for colorectal cancer and pancreatic cancer, but it has bone marrow and gastrointestinal toxicity. 395 Although Onivyde (the irinotecan liposome) has been used in patients with PDAC, the toxicity of Onivyde still needs to be solved in the treatment of colon cancer. In a recent study from Ning et al., irinotecan loaded with lipid bilayer (LB)-coated MSNPs was studied, showing efficient drug delivery. Compared with free drugs and Onivyde, MSNPs showed higher efficacy and reduced bone marrow and gastrointestinal toxicity. 396 Li et al. reported that the hydrophobic antitumor drug docetaxel (Dtxl) was loaded into the 125-nm-diameter polyethylene glycol silica nanotubes (SN-PEG) by electrostatic adsorption. The IC 50 in vitro was only 7% of that of free Dtxl. Compared with Taxotere, SN-PEG-Dtxl showed stronger antitumor activity. 397

Single chemical drug therapy is easy to produce drug resistance, and the treatment effect is not favorable. Nanocarriers can realize the synergetic chemotherapy of multiple drugs, reduce drug resistance, improve the pharmacokinetics of drugs in vivo, and enhance the anti-tumor effect. 380 , 387 , 398 – 400 Albumin paclitaxel combined with gemcitabine is one of the recommended regimens for the treatment of pancreatic cancer, according to NCCN guidelines in clinic. 401 Chen et al. designed a micelle for the co-delivery of paclitaxel and phosphorylation of gemcitabine based on the ethylene glycol-polyarginine-polylysine (PEG- p Arg- p Lys) platform. The AE105 peptide can specifically bind to the urokinase-type plasminogen activator receptor (uPAR), which is overexpressed in tumors and stromal cells. The micelle is modified by the AE105 peptide and a pH-sensitive molecule (2-propan-3-methylmaleic anhydride, CDM) to achieve targeting and a pH response. The micelles exhibited stability within the outer layer of the tumor, which possessed a higher pH value. In the tumor with a lower pH value, the micelles were decomposed to release paclitaxel to destroy the internal tumor matrix and phosphorylated gemcitabine to kill pancreatic cancer cells. Meanwhile, the relatively complete external matrix reduced the tumor metastasis, and the liposome has the ability to modulate the immunosuppressive microenvironment of tumors by enhancing the population of cytotoxic T cells and restricting the proportion of T regulatory cells. 402 Cancer-associated fibroblasts (CAF) can remodel tumor extracellular matrix, resulting in low permeability and drug resistance to traditional drugs. Chen et al. prepared a novel FH-SSL-Nav liposome targeting the tumor matrix. FH is a peptide of small size that has strong affinity for tenascin C (TNC), a protein released by CAF. On the other hand, Navitoclax (NAV) is a tiny molecule with targeted and high affinity properties, capable of selectively inducing apoptosis in CAFs. The FH-SSL-Nav liposome can enhance the infiltration of hepatocellular carcinoma cells, down-regulate the deposition of ECM, reduce tissue fluid pressure (IFP), and promote blood perfusion. Combined with Nav and DOX therapy, the results revealed that the FH-SSL-NAV model could significantly improve the inhibitory effect of liposome adriamycin (7PEP-SSL-DOX) on hepatocellular carcinoma and partially reverse the microenvironment-induced chemotherapeutic drug resistance. 403

Gene therapy

Tumor gene therapy is a focus of current attention, including restoring or enhancing gene function, reducing abnormal gene pathogenicity, inhibiting the expression of some genes, enhancing immunity, and reducing the risk factors of disease. Many forms of gene therapy have been explored for the treatment of digestive system tumors. 404 – 407 The vector of gene therapy is regarded as important for gene therapy. The traditional virus vector has some security problems, such as immunogenicity and mutation. The non-viral vector based on nanotechnology overcomes the shortcomings of the viral vector and can achieve a higher curative effect through modification.

Safe and effective gene repair can be realized through nano-mediated tumor suppressor gene delivery, and the corresponding anti-tumor effect can be achieved. Kim et al. synthesized galactosylated a polyethylene glycol chitosan-grafted spermine (GPCS) copolymer by using the amide bond between galactosylated polyethylene glycol and melamine to load the programmed cell death protein 4 (PDCD4) gene, namely the GPCS/DNA complex. The particle size distribution of GPCS/DNA complex was uniform, and further in vitro and in vivo transfection studies showed that GPCS/DNA complex had higher transfection efficiency than PCs/DNA complex. The high level of GFP expression in liver tissue indicates that the specific ligand–receptor interaction between the galactose part of the GPCS copolymer and ASGPRs may effectively transfer the tumor suppressor gene PDCD4 to hepatoma cells. 408 In light of the pronounced upregulation of vascular endothelial growth factor receptor (VEGFR) in HCC and the positive correlation between up-regulation of AChE expression and apoptosis, Liu et al. coupled YC21 targeting EGFR to a PC vector composed of β-cyclodextrin and PEI600 to form the EGFR targeting gene vector YPC. The YPC vector has high gene transfer ability to EGFR-positive hepatoma cells, promoting AChE gene expression and significantly inhibiting liver cancer in vivo and in vitro by inhibiting p -ERK and cyclin D1. 409 Activated hepatic stellate cells (AHSC) promote the activation of immunosuppressive cells such as M2 and MDSC and form a matrix barrier to restrict the migration and function of T cells through CXCL12/CXCR4 and various growth factors such as TGF-β, which creates a favorable environment for tumor growth. Intrahepatic relaxin (RLN), an anti-fibrosis peptide, can inhibit the activity of aHSCs and alleviate liver fibrosis. Hu et al. used liposome calcium phosphate nanoparticles (LCPs) modified by aminoethyl anisamide (AEAA) targeting the sigma-1 receptor to deliver the RLN gene into tumor and reverse the inhibitory microenvironment. In the liver metastasis model of colorectal cancer and pancreatic cancer, pRLN LCPs nanodelivery gene therapy can significantly inhibit the progression of tumor metastasis, prolong the survival time, and reactivate the immune internal environment. 406

Gene therapy can also achieve therapeutic effects by silencing tumor overexpression genes or oncogenes. Research has been focused on gene therapy that can deliver siRNA via nanocarriers. Pancreatic cancer exhibits a significant upregulation of the nerve growth factor (NGF) gene. Accordingly, Lei et al. prepared a novel fluorescent gold nanocluster (GNC) through a one-step reaction. The GNC particle size was 2.6 ± 0.5 nm, and it had a positive surface charge of 19.9 ± 0.8 mV. The NGF siRNA was adsorbed to form a GNC-siRNA complex with 16.6 ± 3.0 nm through electrostatic interaction. X-ray photoelectron spectroscopy (XPS) and electrophoretic mobility change analysis found that siRNA was successfully bound to GNC. Furthermore, the GNC siRNA complex has demonstrated significant efficacy in safeguarding siRNA molecules from destruction by serum nucleases. In vitro studies have shown that GNC siRNA can protect siRNA from degradation, promote cell uptake, and escape from the lysosome into the cytoplasm, thus achieving effective siRNA-mediated gene silencing. Concurrently, in vivo studies showed that GNC could extend the duration of siRNA circulation within the bloodstream while also augmenting the concentration of siRNA specifically within tumor tissues via the EPR effect. In the subcutaneous pancreatic cancer model, compared with the saline control group, the tumor volume of mice treated with GNC-siRNA decreased by 52%, and the NGF mRNA of mice treated with GNC-siRNA decreased by 69%. In the pancreatic cancer in situ model, the tumor volume in the GNC-siRNA treatment group was also the smallest. Compared with the saline control group, the GNC-siRNA group significantly reduced the expression of NGF mRNA in the tumor in situ. All these results indicated that the GNC siRNA complex could enhance the knockdown of a specific NGF gene in the pancreatic tumor, which can effectively inhibit tumor growth in the pancreatic tumor model without adverse effects or toxicity. 410 Cancer-associated fibroblast (CAF) is an important part of the tumor microenvironment. By secreting growth factors, stimulating angiogenesis, altering the extracellular matrix, and inhibiting the anti-tumor immune response, it can facilitate tumorigenesis. Some studies have found that IL-6-mediates the interactions between gastrointestinal tumor cells and CAF by promoting the activation of fibroblasts. 411 Salimifard et al. delivered IL6 specific siRNA through hyaluronic acid PEG chitosan lactate (H-PCL) nanoparticles (NPS), which could inhibit the proliferation and metastasis of CT26 cells and inhibit cancer progression. 412

Immunotherapy

The challenges of effectively treating tumors using immunotherapy arise from the immunogenic nature of tumor cells and the immunosuppressive characteristics of the tumor microenvironment. The combination of nanotechnology and immunotherapy can enhance the sensitivity of tumor to immunotherapy. 413 – 417

A therapeutic tumor vaccine is a method to induce antigen-specific adaptive immunity against tumors. A TLR agonist, a kind of immune adjuvant, has been used in clinical cancer treatment. However, its low solubility and poor pharmacokinetics limit its application in cancer immunotherapy. 418 – 421 Ni et al. designed a novel double adjuvant antigen nano-vaccine (banNVs) for colon cancer therapy research. 422 Firstly, the primer-PEG-PLA micelles were synthesized in two steps. The micellar and CpG-coding template DNA were subjected to a nanometer template RCR reaction to self-assemble into PEG-PLA and CpG polymer core-shell structure particles loaded with hydrophobic R848. Then, the cationic PEG-g-PPT was used to shrink the particles, while PPT was loaded with hydrophobic new antigens to form banNVs, realizing the synergistic delivery of peptide neoantigens (Adpgk), Toll-like receptor 7/8 (TLR7/8) agonist R848, and TLR9 agonist CpG. Antigen presentation and APC stimulation in vivo and in vitro have shown that banNVs might increase the expression of costimulatory factors CD80 and CD86 on DC and promote the intracellular delivery and release from endocytosis continuously of antigen and adjuvant, which led to persistent antigen presentation and DC maturation. Antigen-specific T cell response studies showed that the frequency of Adpgk+ induced by banNVs treatment was increased by 5.6 times, and CD8+ T cells were enhanced. Systemic T cell response and immunogenicity were enhanced in vivo, which was beneficial to achieve effective and lasting immunotherapy. Vaccines are also a fine choice for liver cancer treatment. To achieve the efficacy of a complete cancer vaccine, it is necessary to effectively deliver cancer antigen and immune enhancer at the same time, prevent off-target strong release, and maintain good biocompatibility. Li et al. prepared an Ms@Mof cancer vaccine containing OVA antigens and immune enhancer polyI:C, which is targeted and pH-responsive and can be efficiently delivered to the lymph nodes to enhance its availability and minimize off-target effects. Combined with the anti-PD1 antibody, it showed a synergistic effect, reversed immunosuppression of the tumor microenvironment, and was effective in long-term anti-tumor therapy. 423

Cytokine is a common immunotherapeutic agent, yet its clinical application is limited by its toxicity, such as IL12. The optimization of the NP carrier can improve its application to some extent. 424 , 425 In a recent paper, Barberio et al. prepared PLE IL-12 NPs by layer-by-layer (LBL) assembly, which can effectively encapsulate and release cytokines. The toxicity of PLE-IL-12-NPs was observed in healthy C57BL/6 mice. The results showed that the mice without carrier IL-12 lost weight rapidly during the administration, while the mice treated with PLE-IL-12-NPs changed barely. PLE-NPs reduced the toxicity of IL12, enhanced the activity of tumor lymphocytes, and slowed down the growth of colon cancer. 426 Xu et al. used tripolyphosphate (TPP) as the coagulated cross-linking agent to form CS-TPP/IL-12 NPs loaded with IL12. With the increase in the weight ratio of chitosan/TPP, the average diameter of NPs was 178–372 nm. In contrast to the mice who received IL-12 treatment, the mice treated with CS-TPP/IL-12 exhibited a notable reduction in liver enzymes, namely ALT and AST. Furthermore, no evident pathological alterations were observed in the heart, liver, spleen, lung, or kidney of these mice. It can be concluded that CS-TPP can shield the toxicity of IL-12 in the process of circulation in mice. Subsequent investigations conducted in vivo have demonstrated that the CS-TPP/IL-12 complex effectively suppresses the liver metastasis of colorectal cancer (CRC) through the facilitation of NK cell infiltration and the recruitment of certain T cell populations. 427 In addition to IL12, tumor immunotherapy mediated by nano-carrier delivery has many other cytokines, such as IL15, tumor necrosis factor-associated apoptosis-inducing ligand (TRAIL), transforming growth factor (TGF), TNF, etc. 428 – 432

According to the characteristics of digestive system tumors, different immunotherapies have been used in anti-tumor research. CRC that is microsatellite-stable exhibits resistance to immunotherapy. Studies have found that quercetin (Q) and malonate lactone (A) in the molar ratio of 1:4 (Q: A) can synergistically induce immunogenic cell death (ICD). To achieve proportional delivery of Q and a for colon cancer, Zhang et al. prepared QA-M micelles using 1,2-distearyl-sn-glycerin-3-phosphate ethanolamine-n-methoxy-poly (ethylene glycol 2000) (DSPE-PEG2000) and D -α-tocopherol polyethylene glycol succinate (TPGS). The average diameter of the micelles was 20 ± 0.6 nm, and their distribution was relatively narrow. The entrapment efficiency of the micelles was more than 90%. QA-M micelles could remarkably inhibit the tumor of colon cancer in situ in mice. The reactivation of anti-tumor immunity was achieved by the induction of ICD, which resulted in cytotoxic effects and the regulation of the immunosuppressive tumor microenvironment. 433 Goodwin et al. used lipid calcium phosphate (LCP) NPs to co-coat phosphorylated adjuvant 5’pppdsRNA, RIG-1 ligand, and CRC model phosphorylated tumor-specific peptide antigen (p-AH1-A5). In the CT-26 FL3 in-situ CRC liver metastasis model, the growth rate of primary colon cancer was significantly slowed, and the formation of liver metastasis was inhibited. Meanwhile, the vaccine component 5’pppdsRNA adjuvant enhanced the CD8 + T cell population without increasing the immunosuppressive cell type, such as T-regulatory cells or myeloid-derived inhibitory cell population. 434 The liver is a natural immune tolerance organ and is more severe under the conditions of liver disease and inflammation. Ceramide is a sphingolipid metabolite that can affect T cell signal transduction and induce the apoptosis of cancer cells. However, its hydrophobicity and poor cell permeability limit its application. Li et al. designed C6-ceramide nanoliposomes (LipC6), which enhanced the cell permeability of ceramide. The findings from the in vivo mouse model demonstrated that the administration of LipC6 effectively suppressed tumor growth by decreasing tumor cell proliferation and Akt phosphorylation and promoting tumor cell apoptosis. LipC6 could also increase the activity of CD8 + T cells, reduce the number of tumor-associated macrophages, and alleviate TAM tolerance. 435 , 436 Hepatic sinusoidal endothelial cells (LSEC) can lead to immune tolerance in the liver. Melittin, a natural cationic host defense peptide, has unique LSEC targeting capability, tumor cytotoxicity, and immunoregulatory effects. However, melittin is highly toxic and cannot be intravenously injected. The α-peptide-NP drug delivery platform solves the problem of melittin delivery, regulates hepatic sinusoidal endothelial cells (LSECs), breaks the inherent tolerance of the liver, and activates LSECs that can mediate immune cell recruitment and reverse the inhibition of other immune cells. 437 In view of the poor immunogenicity of pancreatic cancer, Li et al. constructed a mixed micellar delivery system targeting M2 tumor-associated macrophages, which specifically blocked PI3K=γ and colony stimulating factor-1 receptor (CSF-1R) pathways. The micellar can activate the anti-tumor immune response through a dual mechanism, including reducing the tumor inhibition signal and the infiltration of MDSC and remodeling the immunosuppressive microenvironment into the immune active microenvironment, which improved the immunotherapeutic effect of pancreatic cancer. 438

Combining therapy

In order to achieve better therapeutic effects and reduce toxicity, most reported studies use multi-functional drugs to treat tumors. Nanotechnology provides a broad platform and selectivity for the combination of multiple drug delivery methods, which contributes to the optimization of drug delivery schemes, the realization of complementary advantages, and the enhancement of the anti-digestive system tumor effect. 394 , 439 – 442

The integration of chemotherapy with gene therapy is a very efficacious and pioneering approach in the treatment of cancer. siRNA can not only inhibit cancer itself by silencing the oncogenes but also enhance the sensitivity of cancer cells to chemotherapy, thus improving the overall therapeutic effect. Li et al. developed lactic acid (LA)-modified redox reactive NPs (LA NPs) to deliver 10-hydroxycamptothecin (HCPT) poly and sibcl-2 RNA for synergistic anti-hepatoma. The size of the NPs was around 85 nm, and the encapsulation efficiency of siRNA was 80%. Through LA-specific recognition of the overexpressed ASGP receptor on HCC cells, the NPs could accumulate in the tumor tissues and target HCC cells. The highly reducing GSH catalyzed the prodrug transformation in the liver tumor microenvironment, where the hydroxyl camptocamptoid molecule and siBcl-2 were rapidly released. Apoptosis induced by HCPT and siBcl-2 silenced anti-apoptotic genes coordinated to increase apoptosis and inhibit tumor growth. 443 The poor prognosis of esophageal cancer is related to the lack of targeted treatment. The combination therapy of nano targeted delivery systems can provide a novel way for the therapy of esophageal cancer. A new nanocarrier EYLN designed by Jun et al. was loaded with the chemical anticancer drug adriamycin and a small interfering RNA targeting LPCAT1, which was highly expressed in esophageal cancer, to form EYLN-DOX/siLPCAT1. EYLN-DOX/siLPCAT1 was coated with proinflammatory leukocyte membrane to obtain mEYLNs-DOX/siLPCAT1, which was easy to internalize by esophageal cancer cells, target tumors, and significantly inhibit the proliferation and migration of esophageal cancer cells. The inhibitory efficacy of EYLNS-DOX was shown to be superior to that of the original DOX formulation. Moreover, the introduction of siLPCAT1 was observed to significantly augment the tumor inhibition capabilities of EYLNS-DOX. Thus, the combination of chemical and gene therapy achieved higher efficacy. 444

Sorafenib is a molecularly targeted drug used to treat HCC by oral administration. Nevertheless, the therapeutic efficacy of Sorafenib is still inadequate. Yu et al. developed an oral delivery platform consisting of nanoparticles that were modified with butyrate. These nanoparticles were individually loaded with sorafenib and salinomycin. In contrast to regular hepatocytes, the expression of monocarboxylate transporter 1 (MCT-1) was found to be significantly elevated on the surface of HCC cells. In addition, butyrate exhibited an interaction with MCT-1, hence aiding in the process of transcytosis. Therefore, this platform demonstrated the ability to enhance transepithelial transport in the intestine, facilitate drug accumulation in the liver, and promote HCC cell uptake through MCT-1-mediated endocytosis. The efficacy of this combination approach was established through in vivo research conducted on an orthotopic HCC model. These experiments revealed that the strategy generated substantial damage through ferroptosis and stimulated a robust systemic immune response, ultimately resulting in effective tumor elimination. 390 Although immunotherapy has been widely used in the treatment of cancer, certain in vivo and in vitro factors, such as myelosuppressive cells (MDSC) and tumor-associated macrophages (TAMS), can cause immune escape and make tumors resistant to immunotherapy. 445 – 450 Immunogene therapy can suppress factors related to immune escape, improve the immunosuppressive environment of tumors, and enhance the immunotherapy of tumors. 451 – 453 Chen et al. demonstrated that the administration of chemotherapeutic drugs resulted in the upregulation of Xkr8 gene expression at the transcriptional level in both in vitro and in vivo. Xkr8 is a protein that functions as a scramblase and is known to be activated in the context of apoptosis. The researchers utilized the aforementioned finding to create a nanocarrier capable of simultaneously delivering Xkr8 short interfering RNA (siRNA) and FuOXP, which is a prodrug combination consisting of 5-fluorouracil and oxoplatin. The intravenous injection of the nanocarrier demonstrated significant inhibition of tumor development in both pancreatic and colon cancer models, accompanied by an augmented immune response targeting the tumors (Fig. 2 ). 454 Fig. 2 The proposed strategy aims to counteract the effects of chemotherapy drugs, specifically the induction of Xkr8 and the resulting immunosuppression. This reversal strategy involves delivering siXkr8 directly to the affected site, simultaneously with the chemotherapy drugs. This approach not only targets the specific gene responsible for these effects but also utilizes the synergy between siXkr8 and the chemotherapy drugs to achieve a more effective therapeutic outcome. (Created with BioRender.com) Reproduced with permission from Chen et al. 681 , Copyright 2022 Springer Nature Limited

Microenvironment formation in colon cancer is closely related to the intestinal microbiome and chronic inflammatory response. The intestinal microbiome can influence tumor immunotherapy. 455 – 459 Lipopolysaccharide (LPS) is the product of intestinal Gram-negative bacteria, and LPS can activate colon cancer-related oncogenes, which are related to the immunosuppressive microenvironment. 460 Based on nanotechnology, Wang et al. used LPS to trap plasmid selectively blocking LPS and lipid-protamine to compose LPD nanoparticles with a size of 140 nm and a surface charge of + 40.5 mV. After being injected into mice bearing CT26-FL3 tumors in situ through the caudal vein, LPS trap was highly expressed in the tumor. Meanwhile, CD8 + , CD4 + T cells, MHCII + , and CD86 + DC increased, while MDSC decreased, indicating that the targeting of LPS has the potential to substantially enhance the functioning of DCs, the infiltration of T cells, and concurrently decrease the population of immunosuppressive cells. Combined with anti-PD-L1 therapy, more CD8 + and CD4 + T cells were produced, which extended the survival period of mice and enhanced the checkpoint blockade therapy of anti-PD-1/PD-L1 with no response to CRC. 461 , 462 Huang et al. prepared a pH-responsive lipid of dendritic polymers-calcium phosphate (TT-LDCP) NPS modified with tumor targeting peptide (SP94), which carried the immunosuppressive factor of small interfering RNA (siRNA) and encoded immune stimulation cytokines IL-2 plasmid DNA (pDNA). TT-LDCP NP was capable of transferring siRNA and pDNA to hepatoma cells, thereby increasing the infiltration of CD8 + T cells into the tumor. This, in turn, reprogrammed the TME and inhibited the development of primary HCC and distant metastases. Combined with the HCC vaccine, TT-LDCP NP increased the sensitivity of HCC to the cancer vaccine. 463

Phototherapy showed efficacy in the removal of lesions by non-invasive methods, employing either photothermal (PTT) or photodynamic (PDT) methods. They are widely used in the treatment of various cancers. 464 PDT can induce apoptosis by promoting the formation of reactive oxygen species (ROS). It has space-time selectivity and low systemic toxicity. The use of phototherapy in gastrointestinal tumors is particularly advantageous due to the availability of gastrointestinal endoscopy and its tubular organ structure. 465 However, in biological tissue, low light penetration leads to a low curative effect, while the accurate delivery of photosensitizer is also a problem. 466 – 469 Nanotechnology provides a reliable way for photosensitizer delivery and PDT combined with other therapies (chemotherapy, gene therapy, and immunity) to enhance efficacy. 470 – 478 Furthermore, using nanomaterials in photosensitizers makes them more soluble, bioavailable, targeted, stable, and lowers their toxicity. 479

In a recent study, Hu et al. integrated β-cyclodextrin-grafted hyaluronic acid (HA-CD) with a heterodimer (NSP) crosslinked by a disulfide bond between photosensitizer pyrodemethylchlorophyll A (PPA) and 2,3-dioxygenase-1 (IDO-1) inhibitor NLG919 to form a multifunctional supramolecular nanocomposite (HCNSP). In this study, HA can target the CD44 receptor on the surface of colon tumor cells, and near-infrared (NIR) laser radiation can help release reactive oxygen species, which stimulated the infiltration of cytotoxic T lymphocytes in tumor cells with anti-tumor immunogenicity. Meanwhile, NLG919 inhibited IDO-1 and reversed the immunosuppressive tumor microenvironment. HCNSP realized photodynamic immunotherapy and IDO-1 blocking to synergistic suppress CT26 immunoreactive mice colorectal tumors. The hydrodynamic diameter of HCNSP was determined to be 48.2±0.6 nm, while its negative surface charge was found to be −29.7 ± 0.8 mV, and it possessed superior reduction sensitivity. Irradiation of CT26 cells with a 671 nm laser could effectively induce ROS production of HCNSP, inhibit tumor cell activity, and induce immunogenic cell death (ICD), CRT exposure, and DC cell maturation. The antitumor effect of HCNSP was further evaluated by a Balb/C mouse model of the CT26 tumor. The HCNSP treatment group showed significant tumor accumulation, inhibition of tumor growth, and prolongation of survival time. After treating tumors, analysis found that the tumor cells in the HCNSP+laser group were significantly apoptotic, accompanied by upregulation of IDO-1. For the immunoassay and distal HCNSP tumor effect analysis, the HCNSP+laser group showed an increase in tumor infiltration of T lymphocytes and only 12.6% tumor infiltration of Treg, which was 2.2 times lower than Treg tumor infiltration in the PBS group. Although the increase of IFN-γ secretion and IDO-1 expression induced by laser led to the highest ratio of Kyn to Trp in the HCNSP+laser group, the release of NLG919 resulted in a two-fold decrease in the ratio of Kyn to Trp, which effectively overcomes the immunosuppression of TME and increases the number of memory T lymphocytes, indicating that the synergistic PDT and IDO-1 inhibition could induce a strong immune response and an anti-tumor effect. 480 Gao et al. prepared pH- and redox-responsive chemotherapeutic drug doxorubicin (DOX) and photosensitizer zinc (II) phthalocyanine (ZnPc) polymer micelles with a particle size of 160–180 nm and neutral charge. The polymer micelle was stable in the aqueous medium. When acting on liver cancer cells, the chemotherapeutic agent and photosensitizer produce synergistic cytotoxicity. 481 Yuan et al. found that photosensitized NPs (mTHPC@VeC/T-RGD NPs) killed cancer cells under 660 nm near infrared (NIR) laser light, sensitized the tumor to PD-L1 blocking therapy, decreased primary and distant tumor growth, and created long-term host immunological memory to avoid recurrence. 482 Similarly, Liu et al. created multifunctional nanoparticles (OIMH NPs) by synthesizing metal-organic framework MIL-100 (Fe) NPs and then modifying them with hyaluronic acid (HA), loading oxaliplatin (OXA), and indocyanine green (ICG). The OIMH NPs combined chemotherapy and PTT to kill tumor cells and sensitized them to PD-L1 checkpoint inhibition. 483

Diagnosis and treatment integration

The unique and excellent performance of nanotechnology can realize multi-material loading and integration of diagnosis and treatment. The therapeutic drugs and various contrast agents can be encapsulated in nanoparticles at the same time, which can realize the imaging diagnosis and visual treatment effect. 484 – 488 Jing et al. developed a nanoprobe based on extracellular vesicles, which have a high affinity for tumor cells. This nanoprobe was used in combination with PET, CT, and NIRF imaging to clearly visualize in situ colon cancer models for guided surgery. Tumor location and margins in mouse tumor resection can be clearly seen with real-time NIRF imaging. 489 Aiming at the T cell immune resistance induced by the interaction between programmed PD-L1 and PD-1 on T cells in gastric cancer, Luo et al. combined folic acid (FA) and disulfide (SS)-polyethylene glycol (PEG)-conjugated polyethyleneimine (PEI) with a superparamagnetic iron oxide nanoparticles (SPIONs) composite as a PD-L1 siRNA delivery system, which could effectively target PD-L1 in gastric cancer and be used as a T2-weighted contrast agent for cancer MRI. 490

Diagnostic imaging can also be combined with phototherapy. Zhang et al. prepared amphiphilic JNP NPs that delivered hydrophilic drugs (DOX) and hydrophobic drugs (docetaxel) simultaneously. The nanoparticles had independent pH and near-infrared sensitivity, which was conducive to controlled drug release. Meanwhile, AuNC and Fe(OH) 3 nanomaterials had the ability of CT/MR imaging and could cause the benefit of chemical photothermal therapy under near-infrared laser irradiation, which led to multiple effects to significantly inhibit tumor growth. 491 Zeng et al. designed Au@MSNs ICG, which was a kind of MSN based on NIR response PTT and loaded with the imaging diagnostic agent indocyanine green (ICG). For hepatoma cells, the NPs had stable fluorescence, biocompatibility, and NIR/CT signals. The NPs could produce a fine temperature response under NIR laser irradiation, which was conducive to the precise treatment of tumors. 492 Qiu et al. developed a drug delivery system called arsenic trioxide (ATO)/PFH NPs@Au-cRGD. This system was designed to function as a nano-ultrasound contrast agent, enabling the synergistic utilization of ultrasound imaging and immune stimulation through ferroptosis and PTT. 478

Nanomedicine in lung cancer

Lung carcinoma is a type of malignant neoplasm that has a significant incidence and an unsatisfactory mortality rate. With a five-year survival rate of approximately 19%, lung cancer is responsible for over 1.8 million deaths annually worldwide, making it the leading cause of cancer-related fatalities. This poses a significant threat to human life and well-being. 1 , 358 , 493 – 495 During the initial phase, lung cancer typically does not exhibit any symptoms. The symptoms will occur gradually as their illness progresses, including cough, hemoptysis (hemoptysis), blood in the sputum, dyspnea, asthma, weight loss, fatigue, and dysphagia. Based on the histological features of cancer cells, lung cancer can be categorized into two primary forms: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). 495 – 497 The molecular mechanism of lung cancer has a complex molecular basis. It is controlled by many genetic and epigenetic parameters. Any DNA damage will stimulate the transformation of lung epithelial cells into tumor cells. Therefore, it is a challenge to accurately understand which mutations are the main cause of lung cancer. Genomics suggests that the variation in lung cancer arises from the alteration of particular biological compounds. V-Ki-ras2 Kirsten ratsarcoma viral oncogene homolog (KRAS) and epidermal growth factor receptor (EGFR) were the most frequent mutations observed, along with p53, Kelch-like ECH-associated protein 1 (Keap1), serine/threonine kinase 11 (STK11), and neurofibromatosis 1 (NF1) as tumor suppressor genes. 498 , 499 The expression of EGFR is significantly high in over 70 to 80 percent of NSCLC, making it a crucial focus for the treatment of lung cancer. 500 – 502

Currently, the management of lung cancer primarily involves surgical intervention, the administration of chemical drugs, and radiation therapy. 503 – 506 The primary option for treating lung cancer is surgical resection, and patients with early-stage lung cancer have a higher five-year survival rate following surgical resection. However, lung cancer patients are usually diagnosed when it is already in the late stages, and the survival rate of patients is reduced due to ineffective treatment. Patients with advanced lung cancer mainly receive chemotherapy and radiotherapy. The chemotherapy drugs used in clinical practice primarily consist of four main categories of cytotoxic agents. The first category is alkylating agents, such as cisplatin and carboplatin, which directly damage DNA and disrupt its replication and transcription. The second category is antimetabolites, including pemetrexed and gemcitabine, which can interfere with the synthesis of nucleic acids. The third category is topoisomerase inhibitors, such as topotecan and etoposide. Lastly, the fourth category is spindle poisons, including vinorelbine, paclitaxel, and docetaxel, which impact the polymerization of microtubules in the mitotic spindle. Platinum salts are the mainstay of NSCLC treatment among these medications. Nevertheless, conventional medications possess drawbacks such as drug resistance, a limited half-life period, and numerous adverse effects (like kidney damage, heart toxicity, blood disorders, and gastrointestinal reactions), significantly constraining their usage in clinical applications. Hence, it is crucial to devise novel approaches for early diagnosis in order to prolong survival time among individuals with lung cancer. Additionally, the discovery of alternative therapeutic strategies that minimize adverse reactions and maximize treatment effectiveness is imperative. 507 , 508

Over the past few years, the gradual advancement of nanotechnology has overcome the limitations of conventional medications in managing lung cancer. Nanotechnology can be employed during chemotherapy to resolve the negative side effects and drug resistance associated with chemotherapy drugs. As a drug carrier, NPs have unique advantages in the treatment of lung cancer, including overcoming the physiological barrier, effectively delivering hydrophobic drugs, optimized-release drugs, and targeting tumor tissue specifically to enhance the accumulation of drugs at the target sites. 500

Diagnosis

Clinically, bronchoscopy is a useful method for assessing lesions in the central airways, but it is an invasive procedure that can only examine a few upper bronchi. 509 According to the guidelines, the clinic imaging diagnoses for lung cancer include CT, MRI, single-photon emission computed tomography (SPECT), and positron emission tomography (PET). These are no-doubt powerful noninvasive diagnostic tools. However, weaknesses of these techniques are obvious, such as noneffective detection for small lesions, short blood circulation time of the contrast agent, non-specificity to the target tissue, and high concentration-induced nephrotoxicity. 510 , 511

Furthermore, the biomarker is an essential diagnostic tool for lung cancer. As molecular biology and related technologies develop, more and more tumor biomarkers are discovered. People in good health and those in the early stages of disease exhibit little to no sign of these markers, indicating the presence of malignant tumors only when the concentration of serum tumor biomarkers rises. Recently, the molecular biomarkers utilized in clinical settings primarily consist of autoantibodies, complement fragments, microRNAs, circulating tumor DNA, blood proteins, etc. The value of circulating tumor DNA and proteins as a biomarker in advanced tumor diagnosis has been confirmed. 512 Nevertheless, the efficacy of their use to diagnose early-stage lung cancer remains uncertain. 513

Nanotechnology gradually improves the development of tumor diagnosis, and provides influential breakthroughs in medicine and healthcare. NPs have a variety of properties that allow them to overcome the biological and chemical barriers of the human body, increasing therapeutic efficacy while reducing invasiveness and optimizing biocompatibility. 514 For instance, the rapid development of nanomaterials in imaging substances exceeds the constraints of contrast agents frequently used in clinical settings. NPs provide substantial advantages for CT/MR imaging, such as improved enhancement, increased specificity for tumor lesions, and enhanced imaging accuracy when compared to conventional CT or MR contrast agents. 515 Thus, it is essential to continue developing low-cost, non-invasive diagnostic methods for the early identification of the disease. This is now possible due to the swift advancement of nanotechnology. 516

Nanotechnology-based biomarkers

Biomarkers linked to tumors can be found in the bloodstream through liquid biopsy, which presents a significant opportunity for early detection of lung cancer. Nanoscaled extracellular vesicles (EVs), such as exosomes, are small vesicles released by various cell types and are highly present in bodily fluids. 517 To be more precise, exosomes isolated from lung cancer tissue include molecules linked to tumors, such as chemokines, different microRNAs, and the epidermal growth factor receptor (EGFR). These exosomes play a crucial role in facilitating cellular communication and have significant involvement in the development of tumors. 518 Hence, investigating particular biomarkers obtained from EVs in the bloodstream can offer valuable insights that are challenging to obtain through medical imaging, 519 making it a rising method in the clinical detection of lung tumors. Recently, it has been discovered by scientists that exosomal miRNAs, such as miR-205, miR-19a, miR-19b, miR-30b, and miR-20a, experienced a decrease in the bloodstream following surgical removal. These compounds could potentially serve as valuable indicators for diagnosing squamous cell lung carcinoma. Potential biomarkers for the diagnosis of NSCLC include exosomal miR-126, miR-96, miR-23a, miR-30b/30c, 517 miR-19b-3p, miR-21-5p, miR-221-3p, miR-584-5p, miR-425-5p, miR-409-3p, 520 , 521 as well as lncRNA TBIL A, AG AP2-AS1, 522 AHSG, and ECM1. 523 , 524 Here we summarize the research progress of nanotechnology-based biomarkers explored in the diagnosis of lung cancer in recent years.

A high concentration of exosomes in the circulatory system is one of the noninvasive markers for early diagnosis of NSCLC, but there is no practical and accurate method to distinguish the normal and tumor cell exosomes. Fan et al. established a biosensor to accurately identify the origin of exosomes through between interaction of antibodies and the biological affinity of different recognition sites. Therefore, it provides a choice for high-throughput screening of biomarkers in clinical specimens. 521 Yang et al. developed an immune biochip that can capture tumor-derived exosomes by using antibodies that target proteins associated with tumors. They can also measure the amount of exosomal RNA in the biochip using cationic lipid complexes that contain molecular beacons. The outcome demonstrated that the biochip can effectively distinguish tumor-derived exosomes from other exosomes and improve detection sensitivity and specificity with a short testing time. 525 EVs contain a set of biomarkers under intense investigation. At present, the clinical utilization of EVs is restricted by troublesome and nonstandard separation methods and large-scale instruments. Liu et al. reported a simple and easy-to-use EV separation tool based on size that can help separate high-yield and high-purity EVs from biological fluids. 526 The microRNA targeted biochip designed by Lee et al. can capture EVs and form large nanocomposites, promoting the combination of RNA and molecular beacons near the chip interface, thus improving the detection sensitivity. 527

Cell-free DNA (cfDNA) is released by necrotic or apoptotic cells. Compared with cell-free DNA (cfDna), nanoscaled EV-derived DNA (nEV-DNA) is released from living cells, contains a relatively more complete fragment, and requires less plasma for detection. Wan et al. used PCR to examine nEV-DNA and cfDNA obtained from NSCLC patients and discovered a strong linear association between the quantities of nEV-DNA or cfDNA and tumor volume in the early stages of NSCLC. The sensitivity of nEV-DNA in the early diagnosis of NSCLC was 25.7% and 14.2%, while the specificity was 96.6% and 91.7%, respectively. These results suggest that nEV-DNA is superior to cfDNA in accurately identifying NSCLC at an early stage. 528 Moreover, 60% of NSCLC patients are resistant to immunosuppressive therapy targeting T790M (a mutation of the EFGR site in DNA). So, non-invasive detection of the EFGR T790M mutation is necessary. However, there are too few cfDNA fragments detectable in circulation, so the sensitivity is low. Elena et al. put forward the combination usage of cfDNA and exosomal RNA/DNA (exoRNA/exoDNA), which can improve the diagnostic accuracy of lung cancer. By simultaneously capturing exosomal RNA/DNA and cfDNA, the sensitivity of detecting the T790M mutation achieved 92%, and the specificity achieved 89%. 529 Krug et al. also demonstrated that exosomal RNA combined with cfDNA can improve the sensitivity of EGFR mutation detection in patients with NSCLC, especially in metastatic patients with low circulating tumor DNA levels; the sensitivity increased from 26% to 74%. 530

Conventional analytical methods for biomarkers, such as Western blot, ELISA, and mass spectrometry, have complex reaction steps and complicated operations, thus limiting their clinical applications. For electrochemical technology, though it’s a technique with fast response, relatively low cost, and a wide range of detection, improvements are still needed for examining a wider range of biomarkers. Nanotechnology-based biomarker detection tools have been developed recently. Shoja et al. synthesized reduced graphene oxide (rGO), ordered mesoporous carbon (OMC), and Ni-oxytetracycline (Ni-OTC) NPs as the electroactive label, and fabricated the electrochemical geno-biosensor to detect the EGFR exon 21 mutation. This electrochemical biosensor possessed excellent sensitivity, satisfactory stability, and reproducibility. 531 Besides, label-free electrochemical DNA sensing is the most important method to construct low-density DNA microarrays for clinical diagnosis. However, due to defects such as poor arrangement of DNA on the transducer surface and inconsistent data, label-free electrochemical detection suffers from poor selectivity and sensitivity. Divya et al. synthesized carbon-dot-stabilized silver NPs (CD-AgNPs), which are sensitive and specific for detecting low-density DNA. The use of short-chain DNA as a model system for label-free DNA sensing allows for effective differentiation of the hybridization state of the target DNA by altering the charge transfer resistance. This method is simple, rapid, and highly sensitive to molecular affinity reactions. 532

In recent years, new technologies, such as photoelectric detection technology and surface-enhanced Raman spectroscopy (SERS), have become simpler and more sensitive than traditional biological detection methods. 533 , 534 However, there are still some shortcomings. The development of nanotechnology provides a rich technical basis for the construction of multifunctional SERS nanoprobes. However, due to the heterogeneous composition of exosomes on the surface, even the exosomes secreted by the same cell may have uneven peaks in each spectrum. Shin et al. carefully analyzed the unique Raman bands of lung exosomes and tried to use principal component analysis (PCA) to learn the unique peaks of major patterns. The results indicated that several Raman bands had a strong association with the biomarkers of NSCLC, which are helpful for further study of exosomal biomarkers in cancer diagnosis. 535 Moreover, Shin et al. explored the characteristics of SERS through machine learning and found a similarity between plasma exosomes. The classification accuracy was 95%, and the area under curve (AUC) was 0.912. The results indicated that deep learning combined with exosomal analysis is a potential method for early lung cancer liquid biopsy. 519

Imaging diagnosis

Recently, NP-based contrast agents have been highly valued. Through modifications of NPs, limitations such as poor targeting and high toxicity could be partially solved. For example, the clinical use of CT imaging agents relies on iodine molecules that are quickly eliminated from the bloodstream by the kidneys because of their compact size. Iodine encapsulated with NPs can prolong the circulation time and reduce the required dose. 514 Besides CT, nanotechnology can also overcome an important defect of traditional MRI contrast agents. Currently, paramagnetic gadolinium (Gd)-chelates used in clinical settings as MRI contrast agents have the risk of releasing free gadolinium ions and may result in the development of nephrogenic systemic fibrosis due to their potential toxicity. Gd NPs can reduce toxicity by preventing Gd 3+ leakage. Thus, several gadolinium NPs have been developed, including Gd 2 O 3 , Gd-Si oxide NPs, and Gd-based silica NPs. 515

Metal NPs, including gold, bismuth, and tantalum, have received increasing attention in the imaging diagnosis of cancer due to their steerable size and versatile surface chemistry characteristics. NPs can facilitate their targeting behavior towards the tumor by conjugating or attaching to biomolecules such as antibodies, aptamers, or peptides. Therefore, NPs are expected to effectively aggregate in the tumor sites by binding to specific ligands to enhance permeability and retention. However, NPs have not yet been utilized to maximal effect due to their surface properties and the non-negligible clearance of reticuloendothelial system (RES) organs. 536 In order to solve these problems, different approaches were applied, and some progress was achieved. Perfluorocarbons (PFC) have the feature of high biocompatibility. Wu et al. have implied a PFC NP for MRI of lung cancer diagnosis in the rabbit model and found that paramagnetic PFC NPs increasingly accumulate in the primary lung tumors during the first 12-h post-intratracheal administration. Though it was not targeted, the accumulation and prolonged contact with tumor cells led to a similar result. 537 Furthermore, pEGFR-targeted Ba2GdF7 NPs, a contrast agent that can be eliminated by the kidneys, were recently developed by Feng et al. By binding to EGFR-targeted peptides, this agent is intended to target tumors in MR/CT dual-mode imaging. Mouse model tests have confirmed that pEGFR-targeted Ba2GdF7 NPs with renal-clearing capabilities show good biocompatibility, effective kidney elimination, successful tumor targeting, and improved contrast enhancement. 538

The unique configuration of positive and negative charges in zwitterions has led to the discovery of the possibility of producing antifouling NPs recently. The formation of a thick layer of hydration on the particle’s surface increases its colloidal stability and corrosion resistance, prolongs its half-life in the circulation, and protects it from immune system destruction. 515 Recently, Wu et al. created Gd@C-dots NPs that were modified with Ac-Cys-ZEGFR: 1907. These NPs have a high-affinity probe for targeting EGFR, and their size can be controlled. They are also non-toxic and can be efficiently cleared by the kidneys without any leakage of free Gd 3+ into the plasma or urine. 536 Furthermore, there have been reports of the utilization of nanocomposites based on dendrimers as imaging agents due to their distinct structural features, controllable surface properties, and excellent compatibility with living organisms. According to Chen and colleagues, the targeting probe for NSCLC, Cy5.5-Gd-Au DENP-FA, has been synthesized for CT, MR, and optical tri-modal imaging. The active binding of folic acid (FA) to the folate receptors on tumor cells is likely responsible for promoting the uptake of nanoprobes. Hence, these nanoprobes exhibit positive compatibility with biological systems in vitro and in vivo and are primarily eliminated through the reticuloendothelial system and renal pathway. 539

Although nanotechnology for the lung cancer imaging has been rapidly developed, nanoparticles used in clinical trials were demonstrated to induce fibrosis and asbestos-like scarring in the lung. Therefore, it is emphasized to adequately assess the underlying toxicological effects and the possibility of large-scale manufacturing of nanomaterials, which is also an important issue that should be solved in the future. In addition, many clinical studies are currently in the early stages, and the acute and chronic toxicity, detection range, depth, and reliability of these new materials need additional validation through clinical trials. 540

Treatment

Chemotherapy

Although chemotherapy can be effective in treating cancer, it can still be difficult to suppress the spread of drug-resistant cancer cells, which can harm healthy cells. Therefore, it is imperative to immediately investigate novel and effective therapeutic approaches for eliminating cancer cells and preventing the occurrence or spread of tumors. Drug delivery systems that use nanotechnology are accelerating the advancement of cancer treatment. The loading of small-molecule chemotherapeutic medications onto NPs for transportation enhances drug accumulation, improves the permeability and retention (EPR) effect, and greatly diminishes the adverse impact on healthy tissues. Here we summarize the recent advances in research on nanotechnology in lung cancer chemotherapy.

Platinum chemotherapy, followed by a second-line chemotherapy medication, is the standard treatment for the majority of patients with advanced NSCLC. The use of a therapeutic regimen containing cisplatin is commonly employed as a chemotherapy drug for treating different types of cancer, such as NSCLC. Cisplatin attaches to the DNA double-helix chain, disrupts DNA duplication, and hinders the production of biomolecules. Nevertheless, cisplatin frequently leads to significant toxicity, particularly nephrotoxicity, by stimulating the generation of substantial quantities of reactive oxygen species. Moreover, the utilization of cisplatin in conjunction with alternative chemotherapy medications has been employed for the treatment of NSCLC. Nevertheless, the effectiveness of this therapy is restricted due to the diverse methods of administration, resulting in patients’ inadequate adherence as well as the varying pharmacokinetics and physicochemical characteristics of the two medications. Recent research has attempted to explore solutions to these problems based on nanotechnology.

Curcumin, a naturally occurring antioxidant, shows promise as a means to boost the therapeutic impact of cisplatin by enhancing its anti-tumor metastatic activity through synergistic effects when combined with cisplatin. Through a series of sophisticated designs, Chen et al. developed a nanosystem that releases cisplatin and curcumin in response to changes in both redox potential and pH. This nanosystem is constructed using a disulfide link and phenylboronate ester and is coated with a polyethylene glycol (PEG) shell. This nanosystem possesses the capability to evade elimination by the reticuloendothelial system and sustain its stability inside the circulatory system. Upon reaching the tumor microenvironment, these chemical bonds may be disrupted, causing a change in the physical composition of the NPs, which leads to the quick release of the enclosed medicines. Both in vitro and in vivo experiments have shown that the nanosystem is better tolerated and has enhanced anti-tumor metastatic activity. 541

Metformin is a common antidiabetic drug that has been shown to have significant anti-growth and pro-apoptotic effects in several cancers and is also used in combination with cisplatin to treat NSCLC. 542 However, metformin needs to be administered orally, whereas cisplatin needs to be injected, leading to variable pharmacokinetic differences and reduced patients’ compliance. It is complicated to properly evaluate the synergistic effects of the two drugs, resulting in poor antitumor efficacy. 542 , 543 To address these issues, Xiong et al. described a new approach for combining CDDP and metformin within a single self-assembled core-shell nanoparticle structure. The positively charged polymeric metformin (polymet) exhibits an electrostatic reaction with the negatively charged PGA-CDDP coupling to produce negatively charged nuclei, which are then anchored with PEGylated cationic liposomes. Experiments proved that the polymet-cisplatin NPs system successfully mitigated the nephrotoxic and weight-loss effects of cisplatin and significantly improved the targeting ability of drugs. Importantly, polymet-cisplatin NPs can be used in multiple doses without inducing drug resistance, which is not even possible when cisplatin is used alone. 544

Demethyl cantharidin (DMC), an inhibitor of protein phosphatase 2A (PP2A), enhances the antitumor activity of DNA-damaging agents by specifically inhibiting PP2A without apparent toxicity. Previous studies have shown that cisplatin combined with DMC can be synergistic in cancer therapy. For combining two drugs and directly monitoring the fate of the drugs, Cong et al. designed a fixed DMC/cisplatin ratio, dual-sensitive, dual-drug backbone shattering polymer (DD-NP). Under an intracellular reducing/acidic microenvironment, DD-NP will be disintegrated in a chain-shattering manner, releasing dual synergistic drugs (cisplatin and DMC) in a precise (1:2) ratio to achieve the best anti-cancer effect. It has been proven that the use of DD-NP can significantly eliminate the tumor load. In addition, the high cisplatin content in the DD-NP can be directly tracked by Pt-based drug-mediated CT and ICP-MS. 545

DOX can interfere with DNA replication and induce apoptosis in tumor cells. Previous studies have demonstrated that loading DOX and cisplatin into the same NP can achieve strong synergistic effects and effectively treat cancer. Xu et al. realized that the conventional approach to systemic medication administration presented numerous disadvantages, including inadequate tumor accumulation, limited effectiveness in inhibiting tumors, and significant toxic side effects. In comparison to systemic drug delivery, pulmonary drug delivery enables direct and efficient drug delivery to the lungs, resulting in lower dosage, higher efficacy, and reduced systemic side effects. This method avoids the liver-related first-pass effect by effectively controlling drug release and decreasing the frequency of drug administration. Xu et al. synthesized methoxy poly (ethylene glycol)-poly(ethylenimine)-poly( L -glutamate) (mPEG-OEI-PLG) copolymers, which loaded DOX by electrostatic interactions and loaded cisplatin by chelate interactions, respectively. The system could deliver DOX and cisplatin directly to the lung. In vitro experiments showed that Co-NPs were highly cytotoxic for tumor cells. In vivo experiments showed a high accumulation efficiency in the lung tumor, and rare aggregation in normal pulmonary tissue. In addition, Co-NPs exhibited superior antitumor efficacy against metastatic lung cancer compared to single treatment with DOX or cisplatin, and no significant adverse effects were seen throughout the course of treatment. 546

Although several new approaches to treat NSCLC have been developed, chemotherapy for SCLC has not progressed satisfactorily, and the combination of etoposide (ETO) and platinum remains the mainstay of treatment. 547 Drug co-delivery in nanosystems remains a challenge due to the differences in solubility and pharmacokinetics of different drugs. Wan et al. reported that a nanopolymer micelle, co-loaded with ETO and platinate, was used to coordinate the drug release ratio, which greatly increased the ratio of ETO to platinate. The combining effect can safely and effectively treat SCLC and NSCLC lung cancer. 548 At the same time, there are many side effects of ETOs to treat SCLC, such as gastrointestinal reactions, leukopenia, thrombocytopenia, and alopecia. In addition, the pharmacokinetics of etoposide are unstable, and the therapeutic index is narrow, so there is an urgent need for a suitable drug carrier to overcome the inter- and intra-drug generation variability and improve the bioavailability. Although several NPs for chemotherapeutic drug loading have been developed to improve the bioavailability and anticancer efficacy of ETO, the cyclic metabolism and toxicity of NPs remain unsolved problems. To this end, Zhu et al. used the coprecipitation method to load ETO into pH-sensitive layered double hydroxide (LDH) nano-hybrids. The nano-hybrids could enhance the uptake of ETOs by lung cancer cells and induce apoptosis by inhibiting PI3K-AKT and ERBB signaling pathways, which increased the tumor suppression effect of ETOs by 3-fold. The nanosystem could also significantly reduce the hepatotoxicity and hematotoxicity of ETO as the laminar structure of LDH remained stable in plasma at pH = 7.4. 549

Besides cisplatin, other chemotherapy drugs used for NSCLC therapy have also been explored in a better way based on nanotechnology. Docetaxel (DTX), a cell cycle-specific antineoplastic drug that inhibits microtubule depolymerization, has received approval as both first- and second-line therapy for NSCLC. However, the clinical administration of DTX can lead to severe side effects, such as hypersensitivity reactions, nephrotoxicity, and cardiotoxicity. 550 In order to enhance the therapeutic efficacy of DTX, several nanocarriers, including PLGA, have been developed. Nevertheless, current PLGA-based nano-therapies commonly encounter challenges such as low plasma stability, premature drug release, inadequate tumor accumulation and retention, and inefficient uptake by tumor cells. Wu et al. reported an easy-to-fabricate HA-coated PLGA nano-docetaxel (DTX-HPLGA) system. Research has demonstrated that this system has notably potent anti-tumor capabilities and can decrease systemic side effects in comparison to free DTX. The application of a hyaluronic acid coating to PLGA NPs resulted in improved colloidal stability and increased specificity towards tumor cells, both in vitro and in vivo. The DTX-HPLGA exhibited an extended circulation period and showed a substantial increase in accumulation within the malignant lung tissues. 551

Gemcitabine (GmcH), a potent chemotherapy drug, is widely utilized in the treatment of lung cancer to combat its growth. Nevertheless, GmcH faces challenges in its clinical utilization, such as limited duration in the bloodstream, inadequate pharmacokinetic and pharmacological effectiveness, and insufficient ability to infiltrate the intricate surroundings of lung cancer cells. 552 In order to solve these challenges, Soni et al. employed the emulsification and solvent evaporation methods to load GmcH onto mannosylated solid lipid NPs (GmcH-SLNs). Additionally, they modified the surface of GmcH-SLNs by using the mannose ring-opening approach. The presence of mannose enhanced the drug loading rate, reduced drug release in the systemic circulation, decreased hemolytic toxicity, and allowed for a safer intravenous infusion of the drug. Furthermore, the presence of mannosyl facilitated the specific transportation of GmcH into lung tumor cells through the process of endocytosis. This led to a substantial enhancement in the toxicity of GmcH towards lung tumor cells while minimizing its harmful effects on normal cells. 553

Photoluminescent semiconductor quantum dots (QDs) possess unique photochemical properties, such as sharper spectra and photostability. High-ZnO quantum dots (ZnO-QDs) are a cheap, low-toxicity, and pH-sensitive type of nanomaterial. Cai et al. developed a drug delivery method utilizing pH-sensitive ZnO-QDs to effectively load DOX. The system exhibited stability at a pH that is characteristic of normal bodily conditions, due to the safeguard provided by PEG. The system has the ability to attach to CD44, a protein that is abundantly present on the outer surface of cancer cells, in order to enhance the specific targeting effect. Due to the destabilization of ZnO-QDs in acidic intracellular environments, DOX can be precisely released within the cell. Furthermore, ZnO-QDs carriers can undergo complete biodegradation in the acidic environment of tumors and demonstrate anticancer action by selectively eliminating cancer cells. Hence, the synergistic effect of DOX and ZnO-QDs might greatly augment the process of cell death in cancer cells. 554

Supramolecular drug-drug delivery systems (SDDDS), which involve the use of pure drugs through supramolecular interactions, present a hopeful approach for the treatment of cancer. Zhang et al. introduced an effortless approach to building SDDDS by combining the NSCLC medication gefitinib (GEF) and the tripeptide tyroservatide (YSV) using different intermolecular connections like hydrogen bonding and polyethylene glycol. Nanoparticles with consistent shape and size for drug administration were observed through transmission electron microscopy (TEM) and dynamic light scattering (DLS) when examining GEF and YSV self-assembly. Studies conducted in vitro and in vivo have demonstrated that SDDDS exhibits a superior ability to accumulate specifically in tumor tissues, resulting in remarkable therapeutic effectiveness without any notable adverse reactions. Significantly, the ready SDDD was uncomplicated and did not necessitate intricate chemical alterations, successfully evading unfavorable alterations in drug composition and characteristics. 555

Although there are numerous benefits associated with lung administration, the utilization of inhaled nanoparticles in lung cancer treatment is restricted due to various factors, including lung dimensions, morphology, surface properties, and reduced metabolic function. The effectiveness of inhaled treatments for lung cancer relies heavily on (1) where and how much of the drug is deposited in the respiratory system; (2) the ability of the drug to pass through mucus in the airways; (3) the clearance of macrophages to avoid capture; and (4) the interactions with cells that are the intended target. Hence, the development of inhalable nanoparticles that can target specific cells in the tumor microenvironment or release therapeutic substances at precise locations is crucial. Conte et al. synthesized a novel redox-responsive PLGA-PEG NPs (RR-NPs). Upon entering the tumor microenvironment, this particular NP has the ability to adjust its surface properties, thereby improving the internalization of both particles and drugs by cells. The NPs demonstrated prolonged stability in the simulated biological fluids and a strong capacity to penetrate the artificial mucus layer, thanks to the external PEG coating. Simultaneously, the external covering of the NPs can be rapidly eliminated, thereby initiating the controlled release of the medication. Using RR-NPs, researchers have successfully developed a novel approach to improve the absorption of cancer cells with medication through the breakdown of proteins both inside and outside the cells, as well as the use of hydrophilic blocks to protect the cells. 556 Mottaghitalab et al. created a silk fibroin NPs (SFNPs)-based inhalable delivery system for the efficient administration of gemcitabine (Gem) throughout the body. To target cancerous lung tissues, the researchers connected the SP5-52 peptide with Gem-loaded SFNPs. SFNPs enriched with specific gemstones demonstrated increased cytotoxicity against tumors, as well as enhanced cellular uptake and accumulation in lung tissue. According to the examination of tissue samples and imaging scans, animals that received targeted SFNPs demonstrated an increased rate of survival and showed no indications of metastasis. 557

Epidermal growth factor receptor (EGFR), which is found in approximately 40% to 50% of cancer cells, including those in lung cancer, plays a crucial role in signaling pathways related to the metastasis, growth, and angiogenesis of cancer cells. Blocking the EGFR signaling pathway by inhibiting tyrosine kinase can result in the death of cancer cells. 558 Hence, identifying effective drug delivery systems for EGFR signaling inhibitors is a crucial objective in the treatment of lung cancer. Erlotinib has the capability to inhibit the enzymatic function of tyrosine kinase and is effective in the treatment of various cancers, including NSCLC. However, the administration of this medication regularly leads to notable adverse reactions such as toxicity to living organisms, diarrhea, perforation in the gastrointestinal tract, reduced stability of the drug, and resistance to EGFR. Saravanakumar et al. have developed a pH-dependent chitosan NPs (CSNPs) loading with erlotinib and an adaptor AS1411 (APT) targeting the nucleolin receptor. By utilizing pH-sensitive and nucleolin receptor-targeting characteristics, the CSNPs have the ability to improve the absorption of erlotinib by cancer cells. This, in turn, facilitates the effective release of erlotinib into lung cancer cells, resulting in cancer cell death and ultimately enhancing the effectiveness of erlotinib for therapeutic purposes. 559 Afatinib, another clinically approved drug targeting EGFR for treating lung cancer, is hydrophobic and has low bioavailability, making it easy to spread systemically and causing serious side effects. Cryer et al. proposed a new afatinib-gold NP (AuNP). It is formulated to enhance the efficacy and biocompatibility of afatinib. When tested on lung cancer cells in a laboratory setting, the killing effectiveness of the substance increased by 3.7 times, and it notably suppressed the growth of cancer cells. In addition to afatinib, this design offered a fresh opportunity for the advancement of unconventional AuNP pairings to be used with other molecules possessing therapeutic or diagnostic attributes. Furthermore, this design holds the potential for integration with photothermal therapy. 560

EGFR resistance frequently occurs after 8–16 months when EGFR tyrosine kinase inhibitors like erlotinib and afatinib are utilized. 561 Addressing drug-resistant lung cancer poses a significant obstacle in the realm of lung cancer treatment. Treating drug-resistant NSCLC can be achieved by using a combination of other chemotherapeutic agents along with tyrosine kinase inhibitors. Jeannot et al. reported a nanosystem with the ability to encapsulate both gefitinib, an inhibitor of EGFR tyrosine kinase, and vorinostat, an inhibitor of histone deacetylase, at the same time. It is a self-assembled NP with a 30-nm size consisting of a hyaluronic acid-based copolymer. The NPs, which are composed of hyaluronic acid, have the ability to carry both hydrophobic and hydrophilic chemotherapy drugs. They also offer targeted drug delivery through CD44 to avoid premature release of the drugs while in circulation. The drug-carrying nanoparticles triggered increased cancer cell apoptosis, and their antitumor effects in live organisms surpass those of free drug combinations. By applying these NPs on a weekly basis, the drug release is effectively regulated, leading to significant suppression of tumor growth while maintaining good tolerance. 562 In order to achieve the optimal therapeutic outcome, additional experiments are required to enhance the drug combination’s concentration and the loading ratio of medications. Yang et al. created a pulmonary microsphere platform to concurrently administer afatinib and paclitaxel (PTX) for the treatment of NSCLC resistant to EGFR tyrosine kinase inhibitors. The authors loaded afatinib into stearic acid-based solid lipid NPs, and then co-loaded these NPs with PTX into poly-lactide-co-glycolide-based porous microspheres. Cellular studies demonstrated that the combination drug delivery system exhibited a remarkable therapeutic impact on drug-resistant NSCLC. The in vivo tests showed that afatinib and PTX in nanomaterials could remain in the lung at elevated levels for 96 hours, indicating the potential of this approach as a promising drug delivery method for the treatment of drug-resistant cancers. 563

Biomimetic nanoengineering shows promise as a strategy for modifying the surface of nanoparticles in EGFR-mutated drug-resistant NSCLC. This approach involves using cell membranes derived from platelets, erythrocytes, leukocytes, and mesenchymal stem cells. Therefore, the nanoparticles that are coated with proteins associated with the membrane of cancer cells can penetrate into the cancer cells by binding to specific isotypes. Wu et al. created a bio-nanoparticle using a cancer cell membrane protein to combat drug-resistant NSCLC and improve the effectiveness of chemotherapy involving DOX and icotinib. In vitro, the bio-NPs demonstrated superior stability and enhanced homologous targeting ability compared to the control group. Intravenous administration of bionic nanoparticles resulted in higher tumor suppression with fewer side effects. 564

The efficacy of many chemotherapy medications is reduced when used against tumors and metastases that are resistant to multiple drugs (MDR). Enhancing the dosage of medications yields minimal impact while enhancing the toxicity of the medication. Podophyllotoxin (PPT) is a cytotoxic drug that inhibits microtubule function, causing cell cycle arrest and programmed cell death. Additionally, it exhibits potent cytotoxicity against multidrug-resistant (MDR) cancer cells. Nevertheless, because of its limited solubility and lack of specificity, it is not suitable for systemic use. Roy et al. synthesized Celludo, a self-assembled PPT NP, through the covalent linkage of PPT and PEG to CMC-Ac, which was acetylated carboxymethyl cellulose, using ester bonds. Celludo exhibited an extended circulation time, with a half-life 18 times longer than that of free PPT. Additionally, it demonstrated a significant 9000-fold increase in accumulation under the curve (AUC) and a remarkable 1000-fold decrease in clearance compared to free PPT. The Celludo group exhibited a 500-fold increase in tumor delivery compared to the free PPT group. Celludo treatment in the animal model resulted in a significant increase in median survival without any observed toxicity. 565 Additionally, in order to overcome the MDR in NSCLC, Cheng et al. developed a delivery system using polydopamine-coated mesoporous silica nanoparticles functionalized with TPGS and d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS) for the controlled and pH-sensitive release of DOX. The existence of TPGS on the NPs’ surface caused a change in zeta potential from negative to positive, which in turn increased the uptake of tumor cells due to their negatively charged membranes. Furthermore, the TPGS alteration can provide NPs with the capability to uphold elevated levels of drugs within cells. MTT and in vitro cellular uptake experiments have demonstrated that NPs modified with TPGS can partially overcome MDR. The drug delivery system’s passive targeting capability can be improved by degrading the PH-sensitive PDA coating at low pH levels. 566 The use of Cold atmospheric plasma (CAP), an innovative technique in the medical field, has the potential to enhance the potency of medications, thereby potentially mitigating drug resistance. Yu et al. reported a new strategy for treating cancer by combining CAP with innovative PTX-loaded NPs. They combined PTX with magnetic NPs and used biodegradable polylactic acid (PLA) as the NP shell. The results of the experiments indicated that the combination of PTX-loaded nanoparticles and CAP had a stronger inhibitory effect on the growth of A549 cells compared to the sole use of CAP. Therefore, the fusion of PTX-encapsulated nanoparticles and CAPs offers a hopeful instrument for the advancement of treatment approaches for NSCLC. 567

Targeting mitochondria for antitumor purposes has garnered attention due to the pivotal regulatory role they play in cell apoptosis. Nevertheless, the delivery of drugs targeted at mitochondria encounters various obstacles, such as intricate and multi-step preparation, limited drug capacity, and the potential for systemic toxicity caused by the vector. 568 In order to tackle these concerns, numerous NPs have been created. Song et al. constructed a mitochondria-targeted nanodrug by employing a straightforward nanoprecipitation technique with BDs, which are berberine derivatives substituted with 9-O-octadecyl. To enhance stability, the BDs-based nanodrugs were modified using DSPE-PEG2000, a derivative of bis-stearyl-phosphatidylethanolamine-methoxy-polyethylene glycol 2000. BDs-NDs underwent dual modification using PEG and hyaluronic acid, resulting in a surface charge of −25.8 mV and a significant capacity for drug loading. The degradation of HA by HAase in the tumor tissue leads to the exposure of positively charged PEG/BD NDs to cells. This exposure facilitates cellular uptake, escape from lysosomes, and targeting of mitochondria, ultimately leading to cell apoptosis. Mitochondria-targeted BD NDs provide an alternative approach for cancer therapy by improving drug loading and minimizing vector toxicity, in contrast to traditional NPs. 569 Hydroxyapatite NPs (HAPNs) displayed fine biocompatibility and bioactivity, which are widely used in repairing hard tissue injuries. They are also used as carriers for drugs, proteins, and genes. The toxic effects of hydroxyapatite on different types of cancer cells have been documented. It has the ability to induce apoptosis through mitochondria-dependent pathways or accumulate in the endoplasmic reticulum, thereby inhibiting protein synthesis. Nevertheless, the precise cytotoxic mechanisms of HAP towards cancer cells remain inadequately comprehended, underscoring the significance of elucidating the specific interactions between HAP and cancer cells in the realm of nanomedicine. During their research, Sun et al. discovered that without any surface modification or bio-coupling targeting, HAP has the ability to successfully move into the mitochondria of cancer cells. This leads to a reduction in mitochondrial membrane potential and an increase in caspase-3 and caspase-9 enzyme activities, ultimately causing mitochondria-mediated apoptosis in A549 cells. The viability of 16HBE tracheal epithelial cells is not affected by HAP. Therefore, HAP has a promising future as a new safe and effective targeted anti-lung cancer drug. 570

The multiphase Fenton reaction can continuously produce toxic hydroxyl radicals through the redox reaction of lattice iron ions with H 2 O 2 in a high H 2 O 2 levels environment, while normal physiological concentrations of catalase can protect healthy cells from this kind of attack. Compared to normal cells, cancer cells have high H 2 O 2 level and low catalase levels. Therefore, the application of a heterogeneous Fenton reaction can selectively kill cancer cells. The recently synthesized spinel oxide SnFe 2 O 4 as a magnetically recyclable multiphase Fenton catalyst showed excellent degradation efficiency, and Lee et al. successfully developed a specific H 2 O 2 redox catalyst for SnFe 2 O 4 nanocrystals. The findings clearly indicated that the SnFe 2 O 4 nanocrystals treated with ultra-sonication exhibited a significant cytotoxic effect on tumors. The cancer cells can efficiently aggregate them through the use of either the EPR effect or the magnetically guided drug targeting technique. Meanwhile, SnFe 2 O 4 nanocrystals can be slowly degraded in the lysosomes and eventually converted to metal ions for rapid excretion through the kidneys. 571 Sun et al. developed cysteine-surface-modified FePt NPs. Extensive in vitro and in vivo investigations demonstrated that these nanoparticles effectively hindered tumor development by suppressing cell proliferation, enhancing sensitivity to radiotherapy, impeding cell migration and invasion, diminishing angiogenesis, and inducing the production of ROS. The release of FePt-Cys nanoparticles in lysosomes could potentially occur via the Fenton reaction. In vivo, the safety and effectiveness of FePt-Cys NPs have been shown in animal experiments. Nevertheless, further research is required to examine their pharmacokinetics and systemic toxicity. 572

Gene therapy

Conventional therapies for lung cancer include surgical resection, chemotherapy, and radiotherapy. Owing to the deeper understanding of cancer development and progression at the gene level, gene therapy is expected to be an emerging and encouraging strategy for lung cancer. It involves specifically targeting and regulating abnormal genetic expressions via oligonucleotides such as small interfering RNA (siRNA), microRNA (miRNA), and long non-coding RNA (lncRNA). 573 Nevertheless, on account of their negative charges, these oligonucleotides are lacking in the capacity to move across the cell membrane and enter the nucleus to exhibit an effective impact on cancer cells. Therefore, developing suitable and useful delivery systems for genes and molecules is necessary. With the development of nanotechnology, various NPs have been developed and widely used in gene delivery for lung cancer treatment. The delivery systems based on nanotechnology can protect the genetic fragments from degradation and effectively transport them into cancer cells. 574 What’s more, through surface modification or conjugation with biomolecules of NPs, they can more precisely act on the aimed cells. Here we outline the research on NP delivery systems applied in gene therapy for lung cancer in recent years.

Recognized as a potent element in the treatment of lung cancer, siRNA is the primary driving force behind RNA interference (RNAi) technology. However, its poor cell absorption and high clearance limited its further application. 575 Yan et al. developed a functional polyester capable of specifically delivering siRNA to lung cancer cells while sparing normal cells. The researchers created a collection of 840 functional polyplex NPs using a polymer-based library. These NPs were formed by combining diacyl chlorides with trimethylolpropane allyl ether, allowing for an adjustable molecular weight. By conducting high-throughput screening of libraries, it was discovered that polyesters possessing reduced molecular weight and hydrophobic side chains exhibited enhanced stability for siRNA delivery. Subsequently, the researchers introduced a small interfering RNA (siRNA) that specifically targeted ubiquitin B (UBB) into the NPs. They observed that these functional polyplex NPs effectively suppressed tumor growth by promoting siUBB-induced apoptosis while exhibiting no harm to healthy cells. 576 Shi et al. consequently developed a nanoplatform with a poly( L -histidine) foundation that serves multiple functions. At pH 7.4, the combination of siRNA and the dendritic poly- L -lysine (PLL) was linked to the copolymer mPEG-PHis-PSD, which consists of methoxy poly (ethylene glycol), poly ( L -histidine), and poly (sulfadimethoxine). The pH-sensitive delivery mechanism has the potential to enhance cellular uptake and facilitate the release of siRNA, evading the impact of the endo/lysosome. Furthermore, studies have demonstrated greater efficacy in suppressing tumors and a more favorable safety profile. 577

The biological progression of lung tumor is greatly influenced by miRNA, particularly in relation to the tumor environment. 517 , 578 Nowadays, more and more studies suggest that specifically miRNA may be involved in tumor management via monitoring and regulating tumor growth and resistance to the immune system. 579 , 580 However, current studies on miRNA delivery are insufficient. P53, the tumor suppressor gene, is lacking or mutated in half of NSCLC cases. Mouse double minute 2 (MDM2) is an important modulator of P53. Morro et al. developed the CCL660 system encapsulated miR-660, which targets MDM2 in cationic Lipid-NPs. 581 Systemic administration of CCL60 in mice models of lung cancer resulted in an upregulation of miRNA levels within tumors and an inhibition of tumor growth in both P53 wild-type and mutation-type tumors. This was achieved through the restoration of P53 and the suppression of MDM2 levels. It also exhibited no side effects on the surrounding normal tissues. Besides, it could also inhibit tumor metastasis. MiR-200c is another miRNA that plays a significant role in NSCLC. Its lower expressions are associated with a low grade of differentiation in tumors. It has been demonstrated to be capable of inhibiting cancer growth. Similar to the other gene therapies, miR-200c also needs a suitable delivery system. Peng et al. employed monomethoxy poly (ethylene glycol) as the hydrophilic backbone and ethyl-p-aminobenzoate (EAB) as the hydrophobic pendant groups to create an amphiphilic polyphosphazene polymersome with a neutral charge. This NP embedded miR-200c and protected it from being damaged. Due to the system’s electroneutrality, systemic toxicity could be avoided, and miR-200c can maintain a longer period of stability in circulation. 582 Furthermore, Maryna et al. constructed a delivery system that delivers miRNA-29b into mucin-1(MUC1)-overexpressing cells. They combined IgG with poloxamer-188 to stabilize the system and conjugated MUC1 aptamer to the surface of the particles to achieve MUC1 targeting. This hybrid NP delivery system could limit the 100% release of miRNA-29b in an environment of pH = 5, so as to ensure that no miRNA enters the blood or tumor extracellular microenvironment and achieve effective release of miRNA to targeted positions and cells. 583

Current studies for the restoration of p53 expression, including small molecules and DNA, have achieved progressive success but still have limitations. Interestingly, Kong et al. developed a NP platform for effective delivery of p53-encoding mRNA, which is redox-responsive and promotes a large amount of p53 expression. By inducing cell cycle arrest and apoptosis, the researchers exhibited a notable suppression of lung tumor cell growth. Additionally, it was discovered that the reintroduction of p53 could greatly enhance the responsiveness of cancer cells to everolimus, a medicine that inhibits mTOR. 584

Lung cancer has been extensively demonstrated to be influenced by lncRNAs, which serve as significant and innovative regulators. One lncRNA, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), has been considered critical in lung tumor spread. 585 More lncRNAs related to lung cancer are being established and defined. However, unlike siRNAs and miRNAs, lncRNA is rarely employed to treat lung cancer based on NPs. Despite this, they possess immense possibilities in the realm of lung cancer therapy. For instance, recently, Teng et al. constructed a delivery complex via coating Au NPs with antisense oligonucleotides (ASOs) and a nucleus-targeting TAT peptide. Au NPs have excellent biocompatibility and enzyme resistance. The TAT peptide helps the complex enter the nucleus through the nuclear pore complex. Then ASO recognizes and binds to MALAT1 to form a DNA-RNA heteroduplex. It will be degraded by RNase to achieve downregulation of gene expression. 586

Immunotherapy

The progress of cancer vaccines, which activate the immune system’s anti-cancer reactions, has encountered challenges primarily because of the complexities of efficiently administering tumor neoantigens. Ji et al. introduced a new strategy that involved the use of a hybrid antigenic peptide influenza virus (CAP-Flu) platform. The main purpose of this system is to efficiently transport influenza A virus (IAV)-coupled antigenic peptides exclusively to the lung. The scientists combined weakened influenza A viruses (IAVs) with the natural immune-boosting substance CpG. Afterwards, they used to click chemistry to covalently display the model antigen ovalbumin (OVA) on IAV-CPG. The use of this structure via immunization led to a significant uptake of antigens by dendritic cells, a focused immune cell reaction, and a remarkable increase in the presence of lymphocytes infiltrating the tumor, in contrast to the use of peptides alone. Furthermore, the IAV was specifically engineered to produce nanobodies that target PD1-L1, leading to an enhanced reduction in lung metastases and an extended survival time in mice (Fig. 3 ). 587 Fig. 3 Schematic diagram of the PAPV-ICI platform for personalized cancer immunotherapy using peptide-armed PTC virus for lung cancer vaccination. PTC virus infection causes a transient proinflammatory state turning ‘cold’ TEM to hot, PAPV endows high DC Recruitment linked with generation and trafficking of antigen-specific CTLs; PAPV-ICI in situ delivers anti-PD-L1 nanobody synergizing anti-cancer immunotherapy. PAPV: peptide-armed PTC virus, PTC virus: the live but non-productive influenza A virus, ICI: immune checkpoint inhibitor. (Created with BioRender.com) Reproduced with permission from Ji et al. (2023), Copyright 2023 Springer Nature America, Inc

CpG oligodeoxynucleotides are among the most potent activators of toll-like receptor 9 (TLR9). Preclinical studies and clinical trials have demonstrated promising results. The combination of CpG and TLR9 can trigger both innate and adaptive immune responses. Initially, it stimulates the dendritic cells, resulting in a cascade of subsequent effects, such as the release of proinflammatory cytokines, the activation of natural killer cells, and the proliferation of T cell populations. Perry et al. used PRINT (particle replication in nonwetting templates) NPs as vectors for CpG, which could deliver CpG into the lungs of mice through intratracheal instillation. The results indicated that this system could effectively promote the substantial regression of tumors and induce the developed immune memory of treated mice. Moreover, the employing of this NP-based system prolonged the retention time of CpG in the lungs as well as promoted the levels and duration of antitumor cytokines. Therefore, PRINT-CpG is an efficacious nanotechnological platform applied in local treatments for lung cancers and may also have the capacity to potentially treat lung metastases of various kinds of malignancies. 588

Radiotherapy

The use of radiation therapy is an essential component in the management of lung cancer. To date, 60% of NSCLC patients require radiotherapy. Nevertheless, conventional radiotherapy still presents obstacles like significant adverse reactions and a limited rate of local control due to the insufficient radiation absorption by cancer tissues and the administration of high levels of ionizing radiation, ultimately impacting the patients’ prognosis. Therefore, it is important to avoid leftover cancer cells, which could produce resistance to radiotherapy. It is reported that tumor growth and aggressiveness were distinctly decreased through low-dose radiation (LDR) pretreatment followed by radiotherapy. Moreover, the molecular mechanism has been studied in that miR-30a and miR-30b were overexpressed after LDR treatment in NSCLC, which could downregulate the expression of plasminogen activator inhibitor-1 (PAI-1). 589 The advancement of nanotechnology has significantly broadened the use of radiotherapy for lung cancer. 590 , 591

To strengthen the curation effects, sensitizers are widely used during radiotherapy. Sun et al. have successfully created cysteine-modified FePt-Cys NPs that are safe and effective. These NPs exhibit an enhanced radiotherapy effect by activating the caspase cascade reaction and also inhibit DNA damage repair in lung cancer. Thus, the FePt-Cys NPs have the potential to act as a sensitizer for chemo-radiotherapy. 572 Reda et al. developed a novel PLK1 and EGFR-targeted nanomaterial, which emerged as a finely targeted therapy and enhanced radiation sensitivity in NSCLC. 592 In another study, Sanche et al. indicated that Au nanomaterials have the potential to act as proficient sensitizers in cisplatin when exposed to X-ray radiation. This resulted in a three-fold increase in breaks in the DNA double strand when one cisplatin molecule was combined with one Au NP and a 7.5-fold increase when two cisplatin molecules were combined with one Au NP. 593 Silver nanomaterials have also been studied to improve the radio-sensitivity activity, which could not only induce X-ray absorbance in cancer cells but also enhance electron trapping and ROS generation due to the production of Ag + . 590 , 594 , 595 In non-small lung tumor cells, it has been studied that chitosan-coated Ag triangular nanomaterials enhanced the radio-sensitization effect. 596 A recent study reported that DM1-NO-coated PLGA-b-PEG NPs could selectively sensitize H1299 cells to radiation therapy. 597

Compared with normal tissues, the tumor microenvironment is hypoxic, which leads to more radiotherapy tolerance in tumor tissues. 598 It has been reported a kind of synthetic NPs, perfluorocarbon (PFC), composed of fluorine and carbon atoms, has been used due to its high oxygen carrying property, satisfactory biocompatibility, and nontoxic ability. The work first emerged oxygen in the lung by PFC nano-droplets, and then a low-power ultrasound transducer could help oxygen release in the tumor, resulting in remarkable tumor oxygenation and improved treatment effects. 599 Meanwhile, the PFC nanomaterials also demonstrated satisfactory biocompatibility and strong tumor penetration for better MR imaging upon being administered intravenously into the lung cancer rabbit model. 537

Furthermore, the standard treatment for lung cancer often involves the utilization of both chemotherapy and radiotherapy. 600 – 602 Administering chemotherapeutic medications systemically can enhance the effectiveness of radioisotope tracers on primary cancers and also suppress the growth of distant metastatic malignancies. However, this combination may induce higher toxicities than a single treatment. Nanomaterials show prominent advantages, such as targeting properties and controlled drug release. Ma et al. have designed Bi 2 S 3 NPs composed of mesoporous silica (BMSNs), which exhibited a strong carrying DOX capability and stable drug release kinetics, as well as improved antitumor effects against multidrug resistance compared with that of free DOX. Meanwhile, a better therapeutic effect was observed when X-ray radiotherapy was added to nanotechnology chemotherapy. 603 Thus, the BMSNs may be a promising nano-system agent to enhance radiotherapy for clinic applications.

Photothermal therapy

In recent decades, photothermal therapy (PTT) has made great progress, and cancer treatment has also been rapidly developed. As for the patients with local NSCLC who have not yet undergone a surgical operation, PTT is a selectable therapy method. 604 This method mainly depends on PTT agents, which are able to absorb light and then dissipate heat energy locally, causing irreversible cell damage. 604 However, it still faces challenges due to the low efficiency of photothermal conversion by NIR-II materials. In a recent study, researchers used organically conjugated small molecules to remold PTT agents and found that they could reach the NIR-II region by only replacing one type of atom. In vivo and in vitro experiments have demonstrated that this reconstructive agent has efficient tumor treatment capabilities with a 77% photothermal conversion efficiency. IR-SS NPs also showed significant killing effects from the photothermal therapy in the A549 cells under NIR-II irradiation. 605 In another study, innovative GNPs were assembled for hPD-L1 siRNA delivery, forming GNPs-hPD-L1 siRNA as a hyperthermia agent for PTT. The HCC827 cell growth was significantly depressed, and the hPD-L1 expression was down-regulated with the combination of GNPs-hPD-L1 siRNA and PTT. Innovation in an alliance with GNPs and hPD-L1 siRNA may be an effective strategy in clinical applications. 606

In the clinic, gefitinib is a targeted drug to cure advanced NSCLC. However, resistance to gefitinib can be mainly induced by the activation of bypass signaling, including insulin growth factor-1 receptor signaling (IGF1R). It has been reported that CuS NPs could enhance the ROS level in tumor cells by near-infrared laser irradiation, thus impeded bypass IGF1R and its downstream AKT/ERK/NF-κB signaling cascades to solve the resistance of gefitinib induced by IGF1R bypass. This can provide a new strategy to cure drug-resistant tumors. 607

For early-stage peripheral lung tumors, research has adopted a minimally invasive method, which showed superiority in that the synthesized porphysome NP could accumulate in lung tumors. The ability to selectively accumulate in tumor segments greatly enhances the efficacy and safety of PTT. Meanwhile, the fluorescence-directed bronchoscope could deliver real-time imaging of lung tumors for transbronchial PTT. In the clinic, the use of nanomaterials in the newly developed technology could potentially offer a secure and efficient treatment option for peripheral lung cancer in its early stages. 608

Combined therapy

Furthermore, there are some other studies that also indicate that combined therapy of siRNA and chemotherapeutic drugs carried on NPs has enormous potential in clinical treatment for lung cancer. 609 – 612 For lung cancer, particularly advanced NSCLC, monotherapy based on chemotherapy or other strategies lacks enough efficacy. As mentioned earlier, cisplatin often induces adverse effects and drug resistance. Incorporating siRNA can enable the use of a lower drug dosage, mitigate the side effects, and augment the medical effectiveness of chemotherapeutic treatments.

Mitotic arrest deficient-2 (Mad2), an essential mitotic checkpoint gene, is significantly related to the proper segregation of chromosomes during mitosis. So Mad2 silencing by siRNA is an attractive gene therapy. Nascimento was encapsulated with siRNA targeting Mad2 into PEGylated chitosan NPs and then mixed with EGFR-targeted CS to construct a targeted NP system. The findings indicated that reducing the expression of Mad2 through siRNA could overcome drug resistance and enhance the responsiveness of lung cancer cells to cisplatin while causing minimal toxicity. 613 Mutation of the Kirsten ras sarcoma viral oncogene homolog (KRAS) is also commonly seen in NSCLC. Besides, the loss of p53 function can accelerate KRAS-derived tumorigenesis. Hence, the restoration of p53 and the suppression of the KRAS oncogene are feasible treatment strategies. Gu et al. embedded cisplatin in liposomes and then constructed them with multiple polyelectrolyte layers containing siR-KRAS and miR-34a. This multifunctional layer-by-layer NP displayed a preferential uptake in lung tumors and improved the effect of cisplatin, due to the fact that siR-KRAS could knock down the KRAS oncogene and miR-34a stimulated the p53 functional pathway. Moreover, the duration of treatment was extended owing to the control of drug release by the NP. 614 Tumor progression involves the promotion of angiogenesis by VEGF, which is abundantly present in numerous malignant tumors. Anti-angiogenic agents such as siR-VEGF and etoposide contributed to tumors inhibition. However, the efficacy of anti-angiogenic monotherapy is unsatisfactory and insufficient; VEGF siRNA suffers from enzymatic degradation, while etoposide has poor solubility. To solve this problem, Li et al. designed a multi-functional NP composed of cationic liposomes to co-deliver VEGF siRNA and etoposide, targeting orthotopic NSCLC. These NPs can avoid drug leakage and assure sufficient concentration, while this combined therapy has been proven to have significant anti-tumor effects in vitro experiments. 615

The most aggressive types of NSCLC are those that have mutated EML4-ALK gene expression. So, the mutation of EML4-ALK has become a unique target in NSCLC. SiRNA is mostly expected to be applied to suppress ALK mRNA. Nevertheless, solely suppressing ALK mRNA is not sufficient; thus, miR-301a, also relating to the progression of lung cancers, is considered a new target. Therefore, Li et al. prepared a gold nanoshell-based system carrying ALK siRNA and miRNA-301 inhibitors, which was also coated with DOX via electrostatic adsorption. This delivery system significantly increased vascular permeability and therefore promoted drug accumulation in tumors, depending on its photothermal effect and dense spherical structure. Most importantly, it indicated that this method, based on gold nanoshells, has the potential to serve as a highly effective platform for the combination targeted therapy of siRNA, microRNA, and drugs. 616

Genistein, naturally occurring in soybeans, has been proven to elevate the anticancer effects of some chemotherapeutic drugs. MiRNA-29b can suppress the antiapoptotic defense or stimulate the apoptosis of tumor cells. To assess the therapeutic outcomes of the combined treatment of genistein and miRNA-29b for NSCLC, Sacko et al. constructed genistein-miRNA-29b-loaded functionalized hybrid NPs (GMLHN) with MUC 1-aptamer. They found that GMLHN functioned better in proliferation suppression of tumor tissues than monotherapy with genistein or miRNA-29b, with lower possible toxicity. Because genistein and miRNA act on different targets by various mechanisms, their combination based on NPs can effectively downregulate oncoproteins such as phosphorylated protein kinase, myeloid cell leukemia sequence 1, phosphorylated phosphoinositide 3-kinase, etc. 617

Apart from the combined therapies above, Garbuzenko et al. put forward a novel multi-tier biotechnology treatment approach because current non-surgical treatment strategies for NSCLC bring about tremendous disadvantages. Chemotherapy will result in many side effects and drug resistance. Using monoclonal antibodies, or TKIs, to block targets like EGFR is limited to a small portion of patients. They encapsulated PYX and a pool of siRNAs that specifically target the four main EGFR-TKIs together into nanostructured lipid carriers (NLC) with luteinizing hormone-releasing hormone (LHRH) decapeptide. The LHRH decapeptide helped the loaded drug and siRNA reach the cancer cells of the lung and enhanced the accumulation of the NP system in lung tumors after inhalation delivery. They also found that the co-delivery system had a significantly higher efficacy in tumor growth inhibition than monotherapy. 618

The use of photosensitizer and laser irradiation to generate ROS makes photodynamic therapy (PDT) an innovative method for treating tumor diseases. For a better treatment, it is necessary to combine PDT and ROS-responsive chemotherapy. 619 , 620 Yue et al. developed NP Ce6-CPT-UCNPs with fine biocompatibility. The researchers have verified that the nanoparticle is capable of generating reactive oxygen species (ROS) when exposed to 980 nm laser radiation and releasing the anticancer medication CPT. The Ce6-CPT-UCNPs have effectively accumulated in lung tissues and inhibited the growth of cancer in both in situ lung tumor-bearing mice models and subcutaneous lung cancer models following intratumoral injection of Ce6-CPT-UCNPs and 980 nm laser irradiation. Tumor recurrence and metastasis have not emerged even after fifty days. 620 Xia et al. designed gold nanocluster-based Ce6-DOX-GNCs-MMP2 polypeptide NPs (CDGM NPs) for imaging and the combined treatment. They made a complex to deliver the photosensitizer chlorin Ce6, the chemical drug DOX, and the targeting effects of the MMP2 polypeptide into A549 cells. This particle exhibited a fine combination effect, which may be a potentially effective nanoprobe for lung cancer treatments. 621 Zhong et al. have reported a novel and creative NaCeF 4 : Gd, Tb scintillator. In this field, cerium (Ce) was responsible for ROS generation due to photocatalytic activities and also acted as a sensitizer to help Tb ions release fluorescence by X-ray irradiation. Furthermore, both the Ce and Tb ions could assimilate the energy of secondary electrons under X-rays to generate ROS for radio dynamic therapy. Through the absorption of X-rays, the nanomaterials could help with CT imaging and radiotherapy sensitization. More than that, due to the heavy atoms of Ce, Gd, and Tb ions, the local radiation dose deposition was also significantly enhanced in vitro. The anticancer efficiency of combination therapy was higher than that of RT alone in the A549 mice model. Their work mainly adopted ScNPs to guide multimodal imaging into deep tumors, which is considerable for further study and clinical applications. 622 In the situation of recurrence and metastasis of lung cancer, it may be a considerable approach to combine immunotherapy and photodynamic therapy. Song et al. have creatively designed PplX-1MT nanomaterials, which could include the photosensitizer PpIX and the immune checkpoint inhibitor 1MT. When stimulated by 630 nm light, the nanomaterials induced the apoptosis of cancer cells by generating ROS and strengthened the immune system by releasing 1MT. They were able to promote the activation of CD8 + T cells, showing a better treatment effect. 623

To overcome the weaknesses of high toxicity, poor imaging effect, and ineffective curation of some nanomaterials, it has been reported that a novel BiOI@CuS NP co-coated with DOX, aspirin, phenacetin, and caffeine. This NP showed a safe and effective therapy effect in lung cancer, and it can also alleviate the inflammatory response caused by PTT. In this study, this NP possessed chemo-photothermal treatment function and favorable CT imaging features. Consequently, BiOI@CuS NP may be a potential imaging and treatment technology for lung cancer. 624

For early lung cancer, the main detection method is spiral CT. 625 In the curation of lung cancer, near-infrared fluorescence (NIRF) imaging has been instrumental in better diagnosis and treatment, which could provide high-contrast pictures. 626 , 627 The NIRF molecules can also be used as a contrast agent in surgery due to their clear distinction between tumor regions and normal segments in real time. 628 However, the NIRF molecules usually stay in bloodstream for a short time. On et al. synthesized glycol chitosan nanoparticles (CNPs) modified with a fluorophore. These NPs were able to effectively aggregate in the tumor region. The NIRF signals emitted by the nanomaterials were utilized to accurately locate the tumor in mouse and rabbit VX2 lung cancer models. Meanwhile, CNPs were utilized as an imaging contrast agent for performing surgery under image guidance. Hence, CNPs can be used in the diagnosis and treatment of tumors. 629

Nanomedicine in glioblastoma

Glioblastoma is a broad classification for tumors that develop from glial cells and neuronal cells within the nervous system. It is the prevailing type of brain tumor, known for its aggressive nature and high fatality rate. In the United States, glioma has an estimated annual occurrence of around 6 instances per 100,000 individuals. Glioblastoma represents roughly 60% of these cases, with males being predominantly affected. 630 The 2016 World Health Organization (WHO) reclassified glioblastoma into: (1) Gioblastoma, IDH-wildtype (about 90% of cases), which commonly associates with primary or de novo glioblastoma; (2) Glioblastoma, IDH mutation type (about 10% of cases), is similar to so-called secondary glioblastoma, which has a history of low-grade diffuse glioma, especially in young patients; (3) Glioblastoma, NOS, cannot be evaluated with full IDH and is classified as such. 631 What’s more, in addition to primary tumors, cancer patients with lung cancer, breast cancer, and melanoma often have brain metastasis or secondary brain tumors. 632 , 633

Diagnosis

It is well known that glioblastoma is highly aggressive and easily penetrates normal brain tissue around tumor cells. Surgical resection is usually the treatment standard for glioblastoma, but physical methods such as surgery often lead to poor therapeutic effects and a high recurrence rate of GBM after surgery because the tumor boundary far exceeds the annular enhancement of T1 contrast MRI radiographic imaging and the whole tumor cannot be completely resected. 634 At present, imaging diagnostic technologies commonly used in treating glioblastoma mainly include CT, PET, MRI, etc., but these imaging technologies have their drawbacks. Hence, it is imperative to create novel imaging techniques or contrast substances to ensure glioblastoma patients can obtain a precise diagnosis, which serves as the first vital phase in effectively treating glioblastoma. 635 With the rise of nanotechnology, imaging diagnostic technology has developed rapidly. In many clinical trials, some nanocarrier systems, such as liposomes, micelles, or polymer NPs, have been developed to deliver imaging or therapeutic agents into the brain. 636 , 637

Aiming at related clinical problems of tumor imaging, Hou et al. 638 utilized a pre-targeting strategy to develop PET imaging technology. To begin with, the integration of supramolecular NPs and bioorthogonal chemistry is employed for the synthesis of tumor-targeting agents known as TCO⊂SNPs. Following the administration of TCO⊂SNPs through intravenous injection, the tumor’s EPR phenomenon facilitates the selective gathering of TCO⊂SNPs within the tumor. As TCO⊂SNPs build up in the tumor, they break down to release TCO/CD-PEI, which is a molecular building block grafted with TCO. Subsequently, a radiolabeled reporter molecule (64Cu-TZ) is administered while TCO/CD-PEI remains present in the tumor. Following that, the bio-orthogonal reaction takes place, simultaneously ensuring the swift removal of any remaining 64Cu-TZ from the body. High-contrast PET imaging of the tumor is significantly enhanced due to the limitation of radioactivity in the tumor by the conjugation adduct (64Cu-DHP/Cd-PEI), resulting in improved imaging quality. Using bimodal and fluorescently labeled iron oxide NPs, Karimian-Jazi et al. 639 successfully established a multimodal imaging technology platform using MR-MPM with iron oxide NPs as the core as the innate immune cell response in the microenvironment of glioma tumors, using related MRI and multi-photon microscopy (MR-MPM) with mouse glioma as the model. The imaging technology allows for the dynamic and static visualization of tumor-associated macrophages and microglia (TAMs) within the TME. It also enables the tracking of innate immune cells within the same animal, allowing for longitudinal studies on the dynamics of these cells in the TME. This provides a valuable reference for future research on glioblastoma.

Near-infrared fluorescence (NIRF) imaging, typically conducted at an excitation wavelength of 700–800 nm, can enhance the precision of glioblastoma boundary identification during surgery. This enables neurosurgeons to remove tumors with heightened sensitivity and accuracy. 640 However, it is difficult to locate the glioblastoma boundary accurately, especially its infiltration area, which hinders the application of this technique. Recently, Reichel et al. 641 conjugated ferumoxytol (FMX), a superparamagnetic iron oxide NP sensitive to MRI approved by the FDA, with heptamethine cyanine (HMC), and designed an HMC-FMX fluorescent nanoparticle probe based on near-infrared fluorescence (NIRF), which can be used for visualizing tumor boundaries and image-guided drug delivery to glioblastoma. The NPs can pass through the BBB and selectively accumulate in tumors to visualize invasive tumor tissues. Furthermore, HMC-FMX has the capability to enclose anti-cancer medications like paclitaxel or cisplatin and transport them to glioblastoma tumors.

However, before applying NPs imaging to clinical practice, it is necessary to further study the biological distribution and clearance of NPs, especially in nerve applications with damaged blood-brain barriers, and also consider the safety of NPs contrast agent residues in the brain. 642

Treatment

Although surgical resection is still the preferred treatment for glioblastoma, its prognosis is poor, and glioblastoma recurs easily. Adjuvant chemotherapy used after surgery normally has unsatisfactory efficacy due to the presence of BBB. The development of nanotechnology has promoted the delivery of drugs to glioma cells by different mechanisms, such as the EPR effect, P-glycoprotein inhibition, CMT-mediated, and EMT-mediated active targeting. 643 Simultaneously, nano-drugs have been effectively utilized in research involving microenvironment, targeted therapy, gene therapy, and immunotherapy through active targeting.

Chemotherapy

Cytotoxic drugs are usually used to kill tumor cells in chemotherapy, but due to their lack of targeting, they often have a toxic effect on normal cells and have great toxic and side effects. In addition, the presence of BBB makes it difficult for drugs to act on glioblastoma through BBB. The development of nanotechnology has contributed greatly to treating complex diseases and overcoming the challenges of various drugs reaching the brain. Utilizing NPs as a means of delivering medication can achieve focused treatment, shield drugs from metabolic deterioration, enhance the localized drug concentration, and mitigate the harmful and adverse impacts of drugs on healthy cells. 644 , 645 Nano-drugs can be passively targeted for the accumulation and diffusion of brain tumors using the EPR effect. However, due to the lack of specific targeting, the therapeutic effect is sometimes poor. 646 Another method is called active targeting. With BBB, or overexpressed vectors or receptors in glioblastoma, as the target, it can be targeted to the tumor through BBB mediated by CMT or RMT. On the one hand, it can improve the accumulation of drugs and their efficacy. On the other hand, toxic effects and side effects can be reduced. Among these, the receptors that have been extensively researched for brain targeting are transferrin receptors, low-density lipoprotein (LDL) receptors, and insulin receptors. 647 – 649

Transferrin receptor 1 (TfR1), which is highly expressed in BBB and glioblastoma cells, can mediate the transport of iron into the brain through the binding and intracellular transport of transferrin (Tf). A research group has found that heavy-chain ferritin (HFn) can specifically bind to TfR1 and use HFn as nanocarriers to load drugs and specifically deliver them to targeted tissues through TfR1-mediated targeting without any ligand modification. 650 – 652 At the same time, they found that HFn targeted at glioma cells almost accumulates in lysosomes, causing the glioma cells to be killed without affecting the surrounding healthy tissues. 653 On the other hand, studies have found that the receptors of Apoferritin (APO) and lactoferrin (LF) are overexpressed in various cells, so they can also be designed as NPs to specifically target brain tumors. 654 , 655 In addition, low-density lipoprotein receptor (LDLR)-mediated targeted transport has also attracted extensive attention. Researchers functionalized novel polyester-based nanoparticles with a peptide with a special affinity for LDLR (the regulator EGR) and prepared paclitaxel-loaded nanoparticles. The results also showed that the functionalized nanoparticles increased transport in BBB and enhanced antiproliferative efficiency. 656

Glioblastoma treatment commonly involves the use of Temozolomide (TMZ), which is the first-line chemotherapy medication. TMZ is used during radiotherapy (75 mg/m 2 every day), followed by 6 courses of TMZ (150–200 mg/m 2 , once every 28 days on the first to fifth days). However, long-term use of TMZ therapy will lead to drug resistance in patients, and direct use of chemotherapy drugs will cause serious systemic problems. To solve these problems, researchers are committed to transforming nanoparticles (for example, iron oxide NPs, gold NPs, nanoliposomes, etc.) as a drug delivery system to deliver chemotherapy drugs into the body. The aforementioned NPs have the ability to cross the BBB and transport medicinal substances to the specific location of glioblastoma tumors. 657 In addition, it is reported that the NPs are loaded with DOX, camptothecin, paclitaxel, curcumin, indomethacin, and other drugs, which can not only prolong the drug release time but also significantly improve the drug release selectivity. 658 Norouzi et al. 659 employed DOX-loaded biocompatible magnetic iron oxide NPs (IONPs) that were stabilized with trimethoxysilylpropyl-ethylenediamine triacetic acid (EDT) as the carrier for glioblastoma chemotherapy. The DOX-loaded EDT-ions have the capability to release DOX in a span of 4 days, and the acidic microenvironment can enhance its ability to release adriamycin. According to the study, DOX-EDT-IONPs have been found to enhance the absorption of DOX by U251 cells by 2.8-fold and effectively suppress the growth of U251 cells. In addition, it can effectively induce the apoptosis of glioblastoma cells.

Recently, there has been an increasing focus on the use of virus-like NPs to advance novel drug delivery methods. Certain nanocarriers inspired by viruses have demonstrated effectiveness in delivering drugs and genes. 660 – 662 The research team created and assessed the nano-carrier MILB@LR, which is inspired by the remarkable capability of the rabies virus (RABV) to penetrate the central nervous system. This nano-carrier is built on the metal-organic framework called Materials Institut Lavoisier (MIL) metal-organic framework (MOFs), utilizing an iron atom as the foundation. By manipulating the water quantity during the synthesis of MIL, the morphology of MIL was modified to produce MILB. Subsequently, MiLB was further functionalized to obtain MILB@LR, which was then loaded with oxaliplatin. The vector closely resembles the elastic framework and surface functionality of the natural RABV. The findings indicate that MILB@LR loaded with OXA benefits from a more extensive RABV simulation approach, exhibits superior capacity to suppress tumor growth, has the potential to be a targeted and therapeutic drug for glioblastoma, and serves as a foundation for a bionic strategy to overcome biological barriers in vivo. This could ultimately enhance the diagnosis and treatment of central nervous system diseases. 662 Despite numerous studies demonstrating the efficient transportation of drugs to tumor sites by virus vectors, the use of virus particles for drug delivery still poses inherent safety concerns, necessitating further research. 663

Gene therapy

RNA interference (RNAi) technology has the characteristics of high specificity and low toxicity. The siRNA is introduced into cells to inhibit gene expression with high sequence specificity. Therefore, siRNA interference is a new and promising treatment method. By knocking out the gene expression that promotes cancer cell survival, migration, and tumorigenicity, siRNA can become a powerful tool to treat glioblastoma. 664 – 666 Because gene drugs are easy to degrade in vivo and difficult to pass through the cell membrane, it is challenging to deliver genes safely and effectively into cells. Viruses are often used as nucleic acid delivery vectors, but their immunogenicity and toxicity hinder their application. Numerous advances have been made in the development of nanotechnology in the gene delivery system. A safer, more effective, and easier-to-produce siRNA delivery system has been developed by using nanotechnology to design and synthesize vectors carrying related genes, such as liposomes, 667 silica nanoparticles, 668 and dendritic polymers. 669 , 670

There have been reports about encapsulating siRNA into nanocarriers for gene therapy for glioblastoma. Glioblastoma was targeted by a self-assembled gene delivery system created by a research team, which consisted of 1,2-dioleoyl-3-trimethylammonium-propane and methoxy poly (ethylene glycol)-poly (lactide) copolymer (DMP), enabling the delivery of Gli 1 siRNA. 671 The researchers noted that the pairing of DMP and Gli 1-siRNA resulted in a notable decrease in Gli-1 protein expression, effectively impeding cell growth and enhancing apoptosis in glioma cells. Van Woensel et al. developed chitosan NPs containing siRNA (siGal-1) that specifically targets Gal-1 in the TME to achieve gene silencing. According to the research, the elimination of the Gal-1 gene resulted in a decrease in the transition of macrophages from the M1 (pro-inflammatory) to the M2 (anti-inflammatory) state during the advancement of glioblastoma. 672

Researchers have recently developed a nano-drug called Ang-3I-NM@siRNA, which is sensitive to ROS and stabilized through triple interactions involving electrostatic forces, hydrogen bonding, and hydrophobic interactions. The addition of extra hydrogen and hydrophobic interaction has greatly enhanced the physiological stability, in contrast to siRNA nano-drugs that solely depend on electrostatic interaction for stability. Moreover, when Ang-3I-NM@siRNA comes into contact with cancer cells that are abundant in reactive oxygen species (ROS concentration in cancer cells reaching up to 100 µM 673 ), the hydrophobic phenylboronic ester undergoes a conversion into its hydrophilic form with carboxyl groups. This transition from hydrophobic to hydrophilic depletes the hydrophobic stability, and at the same time, the newly formed carboxyl groups disrupt the interaction between static electricity and hydrogen bonds. As a result, siRNA can be efficiently released. 674 The novel siRNA nano-drug exhibits threefold interaction stability and incorporates a self-destruction delivery capability, thereby offering a robust and efficient platform for targeted siRNA therapy of GBM. Moreover, it holds potential practical significance in RNA interference therapy for various tumors or brain disorders. 675

Immunotherapy

In the field of cancer treatment, immunotherapy is rapidly advancing. In addition to chemotherapy, immunotherapy presents itself as a compelling alternative approach for addressing the tumor microenvironment in glioblastoma. 676 – 678 Nevertheless, the limited success of immunomodulation in glioblastoma is attributed to the distinctive immune conditions of the central nervous system, including the BBB and blood-brain-tumor barrier, as well as the heterogeneous immunosuppressive microenvironment of glioblastoma. 679 The outcomes of glioma immunotherapy vaccine clinical trials, oncolytic virus clinical trials, phase III clinical trials of checkpoint inhibitor antibodies, and chimeric antigen receptor-modified T cells (CAR-T cells) expressing chimeric antigen receptors were summarized in a recent review. However, the findings proved to be unsatisfactory. 673 Up to now, no treatment method is superior to the standard therapy for glioblastoma represented by TMZ and radiotherapy. 674 , 680

Glioblastoma multiforme poses significant challenges in terms of therapy due to its high recurrence rate. It is widely believed that the presence of glioma stem cells (GSCs) is linked to the occurrence of postoperative relapse. Chen and colleagues presented their creation of a nanoporter-hydrogel superstructure that can be injected into brain cavities. This superstructure is capable of generating chimeric antigen receptor (CAR) macrophages and microglia (MΦs) that are specific to CD133 as well as GSCs. These CAR MΦs surround the cavity, subsequently serving as a preventive measure against glioblastoma relapse. Additionally, the combination of anti-CD47 further increased the tumor suppression impact (Fig. 4 ). 681 Fig. 4 Intracavity generation of glioma stem cell-specific CAR macrophages for preventing postoperative glioblastoma relapse. (Created with BioRender.com) Reproduced with permission from Chen et al. 681 , Copyright 2022 American Association for the Advancement of Science

With the development of nanotechnology and deepening understanding of immunotherapy, nanotechnology can be combined with immunotherapy to deliver nano-sized immunoconjugates to glioblastoma, which is expected to achieve successful immunotherapy. 682 Galstan et al. prepared targeted nanoconjugates using poly (β- L -malic acid) (PMLA) covalently bound to CTLA-4 and PD-1 antibodies (aCTLA-4 and a-PD-1) to deliver them to brain tumor cells via the transferrin receptor (TfR)-mediated exocytosis, and they observed an obvious increase in NK cells, CD8 + T cells, and macrophages in mice with intracranial GL261 glioblastoma, and the combination treatment with a checkpoint inhibitor also prolonged the animal survival compared to the use of a single checkpoint inhibitor. 683

Schizophyllan (SPG), a soluble β-1,3-glucan extracted from Schizophyllan commune , is recognized as a dectin-1 ligand capable of effectively delivering brief DNA sequences into immune cells like macrophages and dendritic cells. 684 Further, recent research has indicated that SPG NPs can function as a dectin-1 ligand that is not an agonist, facilitating the transfer of the payload to TLR9 within the body. 685 Thus, Tiwari et al. evaluated the effects of C6 rat glioblastoma cells by using the fungal polymer SPG to load CpG ODN 1826 into prepared NPs. The NPs possessed a threshold size of 25.49 nm and had the capability to traverse the blood-brain barrier. This resulted in a notable rise in intracellular ROS and the expression of IFN-γ, along with IL-1β. The findings indicate that by stimulating significant levels of oxidative burst and inflammatory cytokines, M2 macrophages are prone to transitioning into the desired M1 phenotype, presenting a promising delivery mechanism anticipated to become a novel therapeutic approach for GBM. 686 Therefore, the emergence of nanotechnology will promote the application of immunotherapy in glioblastoma treatment.

Combined therapy

Currently, there is a focus on developing approaches that can integrate chemotherapy and immunotherapy in order to amplify their effectiveness against tumors. Improved survival may be achieved by combining local chemotherapy and immunotherapy, which can reassemble tumor-infiltrating immune cells and memory T cells within the glioblastoma tumor microenvironment, thereby protecting animals from tumor re-attack. Preventing tumor recurrence relies on the crucial role of memory T cells in enhancing immune memory through immunotherapy. Xie et al. developed a nanocarrier that could deliver doxorubicin to glioma using a size-tunable strategy of Hsp70-targeting and acid-triggered self-assembled gold NPs. In vivo investigations showed that when combined with PD-1 checkpoint immunotherapy, the median survival time was significantly prolonged. 687

Most immune cells express the TRL9 ligand known as the CpG oligonucleotide, which has been demonstrated to have the ability to initiate immunologic rejection and promote long-lasting immunity against glioma. 688 , 689 In order to achieve this objective, researchers have investigated the use of carbon nanotubes loaded with CpG to efficiently treat gliomas through intracerebral administration. 690 – 692 Compared with other nanocarriers, high-density lipoprotein (HDL) has a longer half-life and can circulate in plasma for up to 3–4 days. 693 Hence, Kadiyala et al. created glioblastoma-targeted chemo-immunotherapy carriers utilizing sHDL nanodiscs containing CpG, a Toll-like receptor 9 (TLR9) stimulant, and docetaxel (DTX), a chemotherapy drug. Upon delivery of the DTX-sHDL-CpG nanodiscs to the tumor site, the findings revealed the initiation of tumor-specific T cells through the activation of tumor antigen-presenting dendritic cells and macrophages. This subsequently triggered both innate and acquired immune responses within the tumor microenvironment, with no apparent adverse effects observed. Furthermore, the combination of DTX-sHDL-CpG treatment and radiation therapy led to the regression of 80% of glioblastoma tumors in animals, ensuring their long-term survival. Notably, the mice remained completely free of tumors even when tumor cells reinvaded the opposite cerebral hemisphere, suggesting the development of immune memory against glioblastoma. 694 To summarize, the utilization of radiotherapy in conjunction with this glioblastoma therapeutic approach holds significant promise for tumor regression, prolonged survival, and the development of immune memory.

The challenges in diagnosis and treatment

Currently, surgical resection is listed as the preferred treatment for glioblastoma. However, because most surgical resections are incomplete and glioblastoma is highly invasive, residual cells often result in a dismal prognosis and poor quality of life. 695 Cancer cells can be killed by radiation with high energy (~MeV) ionizing radiation deep into the brain, but the effects of radiation are often weakened by the hypoxia tumor microenvironment (TME) and intrinsic radiation resistance. 696 Meanwhile, chemotherapy is controlled by many factors, including toxicity to normal cells, chemotherapeutic resistance of tumor cells, the existence of glioma stem cells, the blood-brain barrier (BBB), etc., 697 , 698 among which the existence of the BBB plays an important role in the chemotherapy process. In addition to the therapies listed above, researchers are working on the treatment of glioblastoma with cytotoxic precursor drugs, angiogenesis inhibitors, PI3K/Akt/mTOR pathway inhibitors, matrix MMP inhibitors, and other drugs. 699 – 702 At present, the toughest challenges in the diagnosis and treatment of glioblastoma mainly lie in the following aspects: the blood-brain barrier, perivascular/perineural microinvasion, hypoxia microenvironment, drug resistance, intratumoral molecular heterogeneity, etc. 632 , 703 , 704 We will present the below contents from the facing difficulties.

Blood–brain barrier (BBB)

In the late 1800s, Paul Ehrlich unintentionally stumbled upon the fact that when dye was injected intravenously into laboratory animals using in vivo staining methods, all organs except the brain became colored. Thus, the veil of BBB was adjourned. In the BBB, tightly connected brain capillary endothelial cells form tight intercellular junctions with low transcytosis and no perforated proteins. Preservation primarily occurs via interactions involving mural cells, glial cells, immune cells, and nerve cells. The BBB effectively controls the transportation of molecules, ions, and cells, 705 ensuring the brain’s protection against harmful substances (including medications) and pathogens present in the bloodstream. Additionally, it supplies essential nutrients like glucose and amino acids to support proper functioning. Carrier-mediated transport (CMT) plays a crucial role in maintaining the brain’s steady state by utilizing the BBB. 635 , 706 – 708

Due to the difference between the endothelial cells and peripheral cells in BBB, it is difficult for drugs and other chemicals to cross BBB, and it is one of the main obstacles to the development of treatments for brain tumors such as glioblastoma. 709 The advancement in comprehending the biology of BBB has resulted in the creation of innovative approaches for administering medication. 710 It is widely acknowledged that a solid tumor typically possesses “leakage” blood vessels that enhance the drug’s permeability and retention capacity, known as the EPR effect. 711 However, various types of gliomas still have a blood-brain tumor barrier, which makes them resistant to chemotherapy, so people try to use a variety of methods to bypass the BBB for drug delivery. One of the most common methods is chemotherapy. On the one hand, by increasing the lipophilicity of the reagent and using non-polar materials with small molecular particle sizes, the polarity and ability to form hydrogen bonds can be weakened to pass more easily through BBB endothelial cells. 701 , 712 BBB is home to large quantities of CMT and receptor-mediated transport (RMT) that can also be treated using a “Trojan Horse” strategy in conjunction with nanotechnology. 713 However, it is important to consider the impact of the BBB drug efflux pump on drug transportation. In BBB endothelial cells and glioblastoma, a p-glycoprotein with a molecular weight of 170 kDa is present on the cell membrane. This protein belongs to the ATP-binding cassette (ABC) transporter superfamily and has the ability to actively remove various substances from cells. It plays a role in the transportation of chemotherapy drugs across the BBB into the brain and contributes to the development of chemotherapeutic resistance in glioma cells. 635 , 714 At present, some physical strategies have gradually entered people’s vision, such as radiation, electroporation, focused ultrasound, and so on. 715 Although these methods can bypass the BBB and increase the local concentration of the drug in the brain, they are highly invasive and lead to an increased risk of brain infection.

The microenvironment of glioblastoma

The glioblastoma microenvironment consists of both cellular and non-cellular elements. The cellular elements comprise neurons, astrocytes, endothelial cells, and immune cells, whereas the non-cellular elements consist of diverse ECM components, fluids, chemokines, cytokines, and other soluble factors. 716 Studies have shown that the invasion of GBM is the result of a continuous two-way interaction between tumor cells and their microenvironment. 717 Glioma cells release various soluble factors that attract different cell types to participate in the TME, such as astrocytes, endothelial cells, and numerous other immune cells. This process subsequently stimulates the local synthesis of cytokines, chemokines, and growth factors. Afterwards, these cytokines engage with components of the extracellular matrix (ECM) to ultimately impact the phenotypic alterations of immune cells and facilitate the growth and spread of glioblastoma. 718 , 719 Drug resistance and tumor recurrence are the consequences of the proliferation of glioblastoma and its interaction with the tumor microenvironment. 720 Most of the tumor microenvironment is composed of inflammatory infiltrates dominated by microglia and macrophages. 721 Every complex substance in the tumor microenvironment plays a role in hindering immune recognition and response and promoting the rapid proliferation of tumor cells and infiltration and the invasion of normal tissues.

In glioblastoma, there exists a profoundly immunosuppressive microenvironment where tumor-associated macrophages (TAMs) play a crucial role as the primary infiltrating immune cell population. TAMs engage in interactions with tumor cells, facilitating their progression and advancement. In general, TAMs can be categorized as M1 macrophages, which are considered “classical activated” anti-tumor cells, and M2 macrophages, which are known as “alternative activated” cells that promote tumor growth. Among them, TLR ligand and IFN stimulate the production of M1 macrophages and induce the production of IFNγ, IL12, etc., forming a positive feedback loop. M2 macrophages are driven by IL4, IL13, transforming growth factor, and glucocorticoids, and then IL18, and IL22 are produced to enhance the function of NK cells. Studies have shown that tumor-promoting TAMs have stronger phagocytic ability. 722 – 725 The migration and invasion capabilities of glioma-related microglia and macrophages are enhanced during the polarization process of M1/M2, thanks to the release of lactadherin and osteopontin by tumor cells, which promote the contraction of actin filaments and rearrangement of microtubules. Simultaneously, research has indicated that TGF-β derived from glioblastoma (glioma-associated microglia/macrophages) can enhance the expression of MMP-2 in the matrix, consequently facilitating the deposition of ECM and encouraging the invasion of glioma. 726 , 727 Recently, the composition of TME and the number of cytotoxic CD8 T cells, or regulatory T cells, have been defined as predictive markers of the survival and treatment responses of various solid tumors, including gliomas. 639 Recently, many new immunotherapies against glioblastoma that have been established for the adaptive immune system play a therapeutic role by regulating the tumor microenvironment. 724 , 728 A better comprehension of the infiltration of immune cells in the glioblastoma microenvironment enables the improved development of therapeutic approaches that utilize immune checkpoint inhibitors (ICI) for regulating the immune response towards glioblastoma. 729 In addition, based on some characteristics of the tumor microenvironment, such as tumor internal pressure, hypoxia, acidic environment, etc., special nanomaterials that can respond to these environments can be used to enhance tumor uptake of nanoparticles, thus enriching the lesion area to achieve a better effect. 730

The emergence of nanotechnology has opened up new windows for treating various diseases, and nanomaterials have received more and more attention in the delivery of drugs or genes. Therapeutic NPs originated in the 1950s with Jatzkewitz’s development of a polymer-drug conjugate, followed by Bangham’s discovery of liposomes in the mid-1960s. Many nanomaterials, such as inorganic NPs, polymer NPs, etc., are designed for the treatment of diseases and show great advantages, such as passive and active targeting, sustained drug release, low toxicity, etc. 731 Effective delivery of brain tumors has been reported using polymer NPs, micelles, liposomes, protein nanocages, and inorganic NPs in the past few years. 732 Researchers have been able to customize NPs for brain tumor accumulation by utilizing advancements in nanotechnology, which allow for adjustments in size, shape, body density, lipophilicity, and surface chemistry. 733 Studies have shown that particles with a size of 50–200 nm and neutral or negative zeta potential have the best effect, while NPs with higher potentials will damage the BBB. On this basis, Lundy et al. 734 found that a small-dose intravenous injection of VEGF can temporarily enhance the permeability of the BBB and use this short-term opportunity to deliver nanomedicine to the brain tissue for the treatment of glioblastoma. In addition, NP-mediated drug delivery can also significantly reduce the required dose of drugs, stabilize the drug in the blood, increase the bioavailability of the drug, and decrease side effects. Here, we will summarize the relevant research progress of nanotechnology in the treatment of glioblastoma from several aspects, such as detection, diagnosis, and treatment.

Nanomedicine in hematological malignancies

Hematological malignancies (HM) are mainly divided into three types, including leukemia, lymphoma and multiple myeloma. HM is responsible for a higher number of fatalities compared to all other types of cancers among children, adolescents, and young adults. 735 Tumor localization primarily occurs in the bone marrow, as well as in peripheral blood and secondary lymphatic organs like the spleen and lymph nodes. Current therapy for HM includes chemotherapy, hematopoietic stem cell transplantation, radiotherapy, and immunotherapy. Although their therapeutic effects have been proven in numerous studies, they are still challenging in clinical application to date. 736 Therefore, it is urgent to explore an appropriate drug/molecular delivery system to improve the therapeutic effects and safety.

Employing nanotechnology has been demonstrated to be effective in cancer therapy. 737 , 738 The research of nanotechnology in treating hematological tumors has received widespread attention. In this part, we discuss the progress of nanotechnology on hematological malignancies in recent years.

Diagnosis

Early diagnosis of leukemia is crucial to prevent irreversible damage and mortality. Currently, leukemia is diagnosed primarily by examining peripheral blood and bone marrow, which involves bone marrow biopsy, complete blood count (CBC), and analysis of blood smears. The first technique is an extremely invasive process with complications, whereas the second one is non-invasive but typically lacks sensitivity for early detection. The advent of nanotechnology has paved the way for a fresh avenue in the diagnosis of leukemia.

Nanosized biomarkers known as extracellular vesicles (EV), such as exosomes, are considered highly promising ways for cancer diagnosis. The molecular characteristics obtained from disease-specific extracellular vesicles found in blood or other bodily fluids can assist in the diagnosis and prognosis of leukemia. However, examining the EV data specific to the disease remains a difficult task. Belov et al. developed an antibody microarray (DotScan) that comprises a collection of fixed antibodies capable of identifying clusters of antigens present on the exterior of EVs derived from tumors. This technique can be utilized for the extraction and examination of the surface protein expression pattern of extracellular vesicles obtained from cancer cells or the plasma of patients with chronic lymphocytic leukemia (CLL). 739 DotScan has introduced a novel approach for the detection and identification of leukemia. Nevertheless, the limited concentration of cancer-derived exosomes in bodily fluids restricts their potential use. Efficient acquirement of EV is still a challenging task. To solve this problem, Lin et al. developed a fluorescent biosensing platform. In their design, leukemia-derived exosomes can be captured by anti-CD63 antibody on the platform. The exosomes were bound by a set of DNA primers that specifically targeted the nucleolin-recognition aptamer (AS1411), initiating the amplification reaction and resulting in the production of a significant number of repeated sequences. Subsequent repetitions were hybridized with GNP-DNA-FAM, a gold nanoparticle conjugated with FAM fluorescent dye. The accumulated fluorescence signals from FAM would then be detected. 740

The mutation status of the immunoglobulin heavy-chain variable region (IgVH) gene is a robust predictor of leukemia prognosis. The expression level ZAP-70 gene, which encodes a type of tyrosine kinase, is the most significant difference between the mutated lgVH and unmutated lgVH in CLL patients. Therefore, the expression level of ZAP-70 gene can be used to accurately predict the lgVH gene mutation status. Based on the features of ZAP-70 gene in CLL patients, Ensafi et al. designed a biosensor for the identification and differentiation of two variations of CLL (IgVH gene mutation status). A highly sensitive conversion platform for detecting the level of ZAP-70 gene and distinguishing CLL types through genetic analysis is created using a gold NPs (AuNPs) coated with ZAP-70 oligonucleotide probe on the surface of the biosensor. 741 Furthermore, caspase-3, a well-established indicator of cellular programmed cell death, can be triggered in both the intrinsic and extrinsic pathways of apoptosis. Detecting the activity of caspase-3 allows for the evaluation of the impact of chemotherapy. Wen et al. introduced a straightforward and precise technique for surface-enhanced Raman scattering (SERS) utilizing interconnected plasmonic bio-interfaces. When caspase-3 is present, it can specifically identify and cut the N-terminus of the biotinylated DEVD-peptide that is immobilized on the SERS substrate. The remaining peptide then attaches to the streptavidin-modified AuNPs probe through the biotin-streptavidin interaction. The interaction between the electromagnetic field of the titanium dioxide nanotube arrays modified with gold nanoparticles can significantly amplify the Raman signal of the reporter molecule, thereby indicating caspase-3 activity. The broad application prospects of this technique in monitoring cell apoptosis are widely approved. 742

Multiple myeloma (MM) is an incurable disease of plasma cell disorder. This condition is marked by the uncontrollable proliferation of monoclonal plasma cells within the bone marrow, leading to excessive production of inefficient immunoglobulin or immunoglobulin chains. The buildup of these antibodies and the interaction of atypical monoclonal plasma cells with other cells in the bone marrow can result in a range of symptoms, including debilitating fractures, infections, anemia, fatigue, pain, renal failure, and hypercalcemia. The incidence of MM is age-related, and it occurs mostly in people over 40 years old, especially those over 60 years old. The growth and expansion of myeloma cells occur predominantly within the bone marrow, 743 highlighting the crucial role of the bone marrow microenvironment in facilitating the proliferation and viability of myeloma cells. Within this small-scale environment, intricate relationships occur between various cell types, involving both reciprocal encouragement and discouragement. The functional components of the bone marrow microenvironment can be classified into cellular and non-cellular compartments. The progression of MM involves the interaction of various components within each compartment, each playing distinct roles. 744

Currently, the staging and assessment of MM have consistently depended on the examination of bone marrow and blood samples using molecular and flow cytometric analysis. 745 However, these tests have overlooked the spatial heterogeneity of the disease within the patient. The successful utilization of clinical diagnostic imaging techniques has enabled the prediction, evaluation, and monitoring of the disease. Nonetheless, the development of collaborative or supplementary detection technologies remains essential in order to establish non-intrusive approaches that allow for more accurate and frequent monitoring of disease activity. 746 , 747

Enhanced imaging of living tissues at the cellular level is frequently achieved through the use of optical coherence tomography (OCT), a non-invasive technique. Nevertheless, like other imaging methods that rely on coherence detection, the presence of speckle noise hinders the ability of OCT to provide cellular-level diagnostics due to its negative impact on spatial resolution. In speckle modulation OCT, a contrast agent made of gold nanorods was employed by a research group to identify individual polystyrene beads and myeloma cells of micron size within the bloodstream. The initial report demonstrates that OCT has the capability to identify individual cells in the bloodstream, creating a fresh opportunity for the real-time identification and measurement of circulating tumor cells in living organisms. 748 MRI, in comparison to CT, SPECT, or PET, has a superior ability to differentiate between benign and malignant lesions, and it enables earlier detection of bone marrow infiltration. Nevertheless, MRI is a lengthy and costly procedure that depends on the passive buildup of contrast agents not specifically targeted to the tumor microenvironment. This significantly hampers the accuracy and effectiveness of MRI detection. Detappe et al. created nano-sized gadolinium-based particles (<5 nm) that were attached to full-length antibodies targeting B cell maturation antigen (BCMA), demonstrating fast absorption by tumors and enhanced accuracy in detecting multiple myeloma. 747

In individuals diagnosed with multiple myeloma, plasma cells will generate a significant quantity of unbound immunoglobulin light chains, a substantial portion of which are unable to be utilized for the formation of complete immunoglobulin molecules. The surplus light chains in serum can be filtered into urine through the glomerulus, and the detection of Bence-Jones protein in urine is typically regarded as a diagnostic biomarker for multiple myeloma in clinical practice. Nevertheless, the conventional method for detecting protein in urine is not highly sensitive and requires a lot of effort. Recently, a research team has developed a new method that was demonstrated to be faster, more economical and convenient compared to traditional methods. They utilized macroporous silica foams (MOSF), a type of silica foam with a specific structure, to concentrate proteins in urine. Subsequently, they were able to identify and examine the composites of materials and proteins, which included Bence-Jones protein, using MALDI-TOF MS, a technique called matrix-assisted laser desorption ionization time-of-flight mass spectrometry. 749 This design provides a new option for clinical diagnosis of Bence-Jones protein.

Exosomes derived from tumors are becoming biomarkers that are emerging for personalized diagnosis of medical tumors. Nevertheless, there exists a dearth of effective technological frameworks for the isolation and characterization of exosomes. A research team has proposed a new method for detecting exosomes from MM. In their studies, Di Noto et al. designed a functionalized surface plasma resonance (SPR) biosensor chip combined with colloidal gold nanoplasmonics. By utilizing this nanomaterial, it was discovered that only exosomes derived from MM have the ability to attach to heparin. Heparin is a structural analog of heparan sulfate proteoglycans (HSPGs) and is recognized to be involved in facilitating exosome endocytosis. The utilization of this approach supplements the traditional biochemical analysis technique for exosomes and presents a fresh concept for the diagnosis of MM. 750 Iaccino et al. discovered that MM exosomes could express the B cell receptor for immunoglobulin (Ig-BCR) and could be targeted by specific binding peptides (Id-peptides). 751 Identifying MM-released exosomes using heparin or the Id peptide could potentially serve as a highly sensitive diagnostic approach for evaluating disease progression in the clinical setting.

Recently, Tang et al. developed a thermosensitive nano-platform that can simultaneously image and treat MM. This platform includes titanium dioxide (TiO2) NPs that can collect ultraviolet rays from Cherenkov radiation to stimulate the production of ROS to induce the death of cancer cells. This platform was covered with a cancer-focusing substance called transferrin (Tf) and labeled with a radioactive element (89Zr) to specifically target the bone marrow. This method can effectively inhibit tumor growth and achieve a combination of diagnosis/treatment. It provides an effective model for treating MM and other bone-related malignancies. 752

Treatment

Leukemia is one of the most prevalent fatal types of HM. Leukemia is classified into acute and chronic types based on the level of differentiation and the duration of the disease’s progression. The majority of leukemia cases are attributed to acute leukemia (AL), which can typically be categorized into two primary forms: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). AML is prevalent among adults, whereas ALL is more prevalent among children. The average survival period of AL is only approximate three months, while some patients will die even after a few days of diagnosis if they have not received treatment. Traditional treatment methods for leukemia are usually hypertoxic and will produce a series of side effects. 753 Nanotechnology is a new and promising method for cancer treatment to improve the diagnosis and therapeutic effect of leukemia.

Lymphoma is a cancerous growth that develops in the lymphoid hematopoietic system. It is characterized primarily by painless swelling of the lymph nodes and enlargement of the liver and spleen. It is usually accompanied by systemic symptoms, including fever, night sweats, weight loss, and itching. Lymphoma is categorized into non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL) based on the characteristics of the tumor cells. The NHL is a collection of various independent diseases with significant heterogeneity, and its incidence is significantly higher than HL. NHL can be classified into B cell, T cell, and NK cell lymphoma based on the various sources of lymphocytes. Lymphoma has a wide variety of types and a complex pathogenesis that is not yet clear. Its pathogenesis may be related to heredity, immune, or viral infection, etc. 754 Current treatments for lymphoma mainly include radiotherapy, chemotherapy, hematopoietic stem cell transplantation, and immunotherapy, such as CAR-T cells therapy. 755 – 757 Nanomedicine technology has also been made great progress for the treatment of lymphoma in recent years.

Although the survival rates of patients with MM are significantly improved, the brief infusion of small-molecule drugs into the bone marrow fails to allow sufficient time for the augmentation of MM cell-drug interactions. Consequently, some myeloma cells manage to evade initial treatment. 747 , 752 Over the last decade, there has been a growing validation of novel molecularly targeted treatments for MM, including immunomodulatory medications, proteasome inhibitors, inhibitors of histone deacetylation, as well as monoclonal antibodies targeting MM cell surface proteins or immune cell lineages. Although current treatments provide multiple opportunities to improve patients’ condition, there are still some challenges to be faced. It is necessary to find effective methods to overcome the toxicity of therapies and establish more accurate biomarkers for evaluating the effect of treatment. 746

Chemotherapy

Chemotherapy drugs used in clinic have obvious limitations, such as poor pharmacokinetics, reduced bioavailability, lack of specific targeting and toxic side effects. Moreover, unexpected drug resistance often occurs. Hence, a targeted drug delivery system for leukemia cells can effectively minimize toxicity and provide a significant benefit in the treatment of leukemia. During recent years, great progress has been made in utilizing nanomedicine technology in leukemia chemotherapy.

Numerous nanomaterials have been created to improve the precision of targeting and minimize the adverse effects caused by toxicity. Auristatin E is a cytotoxic tubulin modifier which has anti-tumor activity. Pallarès et al. developed a new type of T22-GFP-H6-Auristatin nanoconjugate for targeted administration of Auristatin E to selectively eliminate chemokine receptor type 4 (CXCR4) positive AML cells. In the AML animal model, the use of NPs greatly decreased the presence of leukemia cells in both the bone marrow and circulating blood, effectively preventing the spread of leukemia cells to extramedullary organs. 758 To obtain intelligent NPs, the researchers loaded FA-HSA-ATO, which stands for folic acid (FA)-labeled human serum albumin (HSA), with ATO. The study showcased that FA-HSA-ATO exhibited a distinct ability to identify CML cells that express folate receptor-β. Consequently, this recognition led to increased accumulation of ATO within the cells. 759 In addition, Yasinska et al. utilized platforms consisting of gold nanoparticles with a size of 5 nanometers, coated with rapamycin, for the precise targeting of cancer cells that express the immune receptor Tim-3, employing single chain antibodies. The nanoconjugate facilitated precise and effective transportation of cytotoxic rapamycin to malignant blood cells in humans, offering potential for targeted therapy of AML. 760 Activatable aptamers are being recognized as highly promising molecular instruments for the treatment of cancer, and Lei et al. developed a novel triangular DNA nanoarchitecture (NTri) as a prototype framework, equipping the NTri with numerous divided activatable aptamer probes (SAAPs) in a controllable manner regarding their location and alignment. NTri-SAAP exhibited a significantly enhanced affinity for the target, extremely low background interference, and strong durability in challenging environments, enabling the visualization of tumors with improved contrast for a prolonged duration of eight hours. Furthermore, NTri-SAAP has the potential to greatly enhance the body’s loading capacity and anti-cancer effect of DOX. 761

Primary or acquired multi-drug resistance (MDR) makes most human cancers untreatable. Therefore, it is necessary to explore a reliable strategy to avoid drug resistance. Bellavia et al. employed exosomes function as a vehicle for transporting therapeutic substances through the loading of diverse molecules. They used genetic engineering technology, to promote HEK293T cells to produce exosomes that are rich with Lamp2b protein and interleukin 3 (IL3). Meanwhile, they also designed exosomes to load the chemotherapeutic drug imatinib. The results demonstrated that the modified exosomes have the ability to successfully suppress the proliferation of cancer cells in vitro/in vivo and overcome the resistance of cancer cells to chemotherapy. 762 Due to its intrinsic ability to intercalate, daunorubicin is highly compatible with DNA-mediated delivery. Halley et al. employed a DNA nanostructure, created through the process of scaffolded DNA origami self-assembly, for the transportation of daunorubicin. The DNA nanostructure exhibited the ability to overcome drug resistance in an animal model of leukemia that was resistant to the drug. The research foundation provided by this design enables the clinical application of a drug delivery system to address the issue of drug resistance in leukemia and other types of blood cancers. 763

Hematological neoplasms differ from solid tumors as they lack a distinct form and specific site, with tumor cells dispersing throughout the circulatory system. Hence, in the development of nanomaterials, addressing the issue of managing drug release at the targeted site and extending the duration of drug effectiveness becomes crucial for treating leukemia. Black phosphorus nanosheets (BP-NS), being a type of novel two-dimensional nanomaterial, have demonstrated exceptional drug carrier capabilities due to their superior optical characteristics and compatibility with living organisms. A team of researchers has recently suggested a combination drug nanocarrier utilizing BP-NS, capable of conducting a synergistic and focused chemo-photothermal treatment for ALL. Electrostatic adsorption allows for the loading of drugs onto the BP-NS. Enhancing the physiological stability of BP-NS, the adsorbed polyethylene glycol (PEG) layer effectively shields the interior from water and air damage. Furthermore, the pH and NIR lasers can serve as triggers for the drug release from the nanocarrier. By employing a dual-stimulus responsive drug delivery system, the potential for drug leakage can be effectively mitigated, consequently leading to a reduction in adverse effects. 764 Boto et al. created NPs with the ability to store retinoic acid (RA) in leukemia cell cytoplasm for extended periods, utilizing light as a trigger. Upon being exposed to the blue/UV light, the RA will be released within a few minutes. Of greater significance, leukemia cells that have been transfected with light-responsive RA-NPs have the ability to migrate to the bone marrow in living organisms, undergo differentiation when exposed to blue light, and secrete paracrine factors that regulate neighboring cells. By utilizing this technique, the expected outcome of controlling cell populations and regulating leukemia cells from a distance was successfully achieved. 765 Xiong et al. utilized a blend of solvent substitution and the assistance of a static magnetic field to fabricate nanocomponents with superparamagnetic anisotropy (SAN). Vincristine (VCR) was used to build and load SANs, resulting in the formation of VCR-SANs. According to research findings, VCR-SANs exhibit fast and consistent release characteristics, along with extended duration in the bloodstream. 766

The treatment of lymphoma has enriched new concepts and approaches due to the rapid development of nanotechnology and the introduction of novel nanomaterials in recent years. Compared with traditional drug delivery systems, nano-drug delivery systems can enhance the pharmacodynamic properties and therapeutic effects of drugs by utilizing their unique size, shape, and materials. DOX is a commonly used drug in treating human malignant tumors with strong capability in killing tumor cells. However, the drawbacks of DOX are also bothersome as it has cardiac toxicity, myelosuppression and gastrointestinal adverse reactions. The combination of DOX and NPs can improve these adverse effects and promote its therapeutic effects. 767 , 768 Currently, the majority of studies in the field of lymphoma chemotherapy are primarily focused on the use of DOX for drug delivery facilitated by nanomaterials.

Srivastava et al. developed a mesoporous silica NPs-based nano-drug delivery system consisting of DOX, 5-fluoro-2-deoxy uridine, and folic acid, aimed at responding to triple stimuli. Dalton’s lymphoma, a highly aggressive murine lymphoma, was the target of delivery using this system. The fusion of active and passive targeting mechanisms provided an innovative hyper-chimeric framework for a drug delivery system that responds to stimuli. The precise delivery effect of folic acid successfully delivered DOX and 5-fluoro-2-deoxy uridine to the nearby region of cancer cells, leading to a substantial suppression of tumor cell proliferation. In comparison to the control group that did not receive treatment, the administration of the dual drug-carrying structure resulted in a significant decrease in tumor burden and enhanced the survival rate of mice. The treatment using the dual delivery system also enhanced the natural and acquired immune defense mechanisms of the animals. 769

Zhao et al. created a versatile Apt-NMed that enables precise chemotherapy and gene therapy for ALCL. DOX and synthetic oligonucleotides were used to create Apt-NMed, which consisted of a CD30-specific aptamer and ALK-specific siRNA targeting the oncogene. Apt-NMed displayed a clearly defined nanoscale structure (with a diameter of 59 mm) and remained stable in human serum. With the assistance of the aptamer, Apt-NMed precisely attached to and entered the designated ALCL cells. By delivering Apt-NMed into the cells, it induced the swift liberation of DOX and ALK-targeted siRNA, leading to a synergistic therapeutic outcome. The survival rate of mice was greatly enhanced by Apt-NMed therapy, which offers a novel approach for precise treatment of ALCL. 770

Goswami et al. synthesized luminescent blue copper nanoclusters (Tf-Cu) using Transferrin (Tf) as a template. They coupled DOX in spherical Tf-Cu NPs based on electrostatic interaction. In Tf-Cu, the absorption of DOX caused the blue luminescence to be quenched, resulting in a remarkable red luminescence observed in Forster resonance energy transfer (FRET). When the transferrin receptor (TfR) that was overexpressed on the cell surface internalized Tf-Cu, the cytoplasm of cancer cells regained its blue luminescence. In the core, red luminescence observed as DOX was gradually released from Tf-Cu. Biocompatible Tf-Cu showed excellent targeting efficiency for cells overexpressing TfR compared with cells expressing less TfR. The assessment of Tf-Cu in live mice with TfR-positive Dalton’s lymphoma ascites (DLA) demonstrated a notable suppression of tumor growth, leading to an extended survival period of mice. 771

ATP is an important transmitter that mediates various biological effects in cancer by P2X7 purinoceptors. Srivastava et al. studied the anti-tumor activity of ATP-modified biomineralization and DOX mesoporous silica against Dalton’s lymphoma. The results showed that the interactions between ATP and the phosphate group on calcium carbonate prevented the rapid release of DOX in the NPs and had obvious tumor-killing effects on anti-DOX tumor cells. This composite nanomaterial had excellent biocompatibility and higher absorption capacity via the participation of purinergic receptor P2X. 772

Xiao et al. developed a micellar formulation of DOX (DOX-DCMs) with reversibly disulfide cross-linking to target B-cell lymphoma. The DOX-DCMs exhibited a high capacity for drug encapsulation, an ideal particle size ranging from 15 to 20 nm, excellent stability in human plasma, and a drug release profile that is triggered by reducing conditions. The pharmacokinetics of DOX were greatly enhanced by DOX-DCMs, with its elimination half-life and area under the curve (AUC) being 5.5 times and 12.4 times higher than those of free DOX, respectively. The biodistribution study demonstrated that DOX-DCMs have a tendency to selectively gather at the tumor location while effectively decreasing the cardiac absorption of DOX. In a xenograft model of B-cell lymphoma in humans, DOX-DCMs demonstrated not only tumor growth inhibition and increased survival rate, but also a decrease in DOX-induced cardiotoxicity compared to equivalent amounts of free DOX and non-crosslinked DOX. 773

Guo et al. prepared two linear-dendritic telodendrimers (TDs) based on amphiphilic riboflavin (Rf) to achieve efficient delivery of DOX. DOX encapsulation was achieved using Rf-containing nucleophiles and a hydrophilic PEG shell in the composition of Micellar TD NPs. Due to the robust interaction between DOX and Rf, as well as the amphiphilic nature of Rf, these nanocarriers exhibited exceptional drug loading capacity for DOX, prolonged drug release, and optimal particle size ranging from 20 to 40 nm. The NPs have successfully targeted various tumors in living organisms and greatly prolonged the duration of DOX in the bloodstream, making them worth further development and utilization. 774

Sedlacek et al. developed and created a novel transportation mechanism for DOX utilizing a biocompatible hydrophilic poly(2-ethyl-2-oxazoline) (PEtOx) carrier with a linear structure and precise molar mass range. The medication was connected to the polymer structure through an acid-responsive hydrazone, enabling its controlled release within the tumor. Experiments conducted in live mice with EL4 lymphoma demonstrated that the PEtOx conjugated with a higher molecular weight polymer (40 kDa) exhibited extended blood circulation, enhanced tumor aggregation, and improved anti-tumor efficacy when compared to that with lower molecular weight polymer (20 kDa). Besides, the synthesis of PEtOx is simple, making it a possible alternative for drug delivery. 775

Significant advancements have been achieved in the management of lymphoma through the utilization of combining radiotherapy and chemotherapy. Man et al. selected Dox NPs, which are encapsulated with a ligand called SHAL and have a high affinity, for the treatment of tumors overexpressed HLA-DR antigen. Encapsulated DOX was delivered by the internalized NPs to cells expressing HLA-DR, resulting in enhanced immunogenic cell death. In addition to promoting ICD, the DOX also enhanced the susceptibility of cancer cells to radiation by causing cell cycle halt and inhibiting the restoration of DNA harm. In vivo studies on biodistribution and toxicity confirmed that the targeted NPs improved tumor uptake of DOX while decreasing its systemic toxicity. 776

Within the bone marrow, which has a dense network of blood vessels and a porous texture, NPs can serve as a smart method of delivering drugs. This allows them to reach deeper into different compartments of the bone marrow, ultimately improving the efficiency of drug delivery and enhancing their ability to target specific areas. MM can be treated with Bortezomib (BTZ), which is a novel proteasome inhibitor. Nevertheless, the administration by standard intravenous or subcutaneous injection can lead to numerous undesirable side effects. It is imperative to urgently address the clinical constraints associated with the utilization of anticancer medications like BTZ. Nigro et al. have created a nanodevice made of mesoporous silicon that includes BTZ. This nanodevice has the ability to release the drug in an acidic setting and specifically target folic acid. The folate receptor (FR) overexpressing on MM cells’ membrane can selectively identify BTZ, without harming or disrupting the metabolic balance of FR-negative healthy cells. Anticipated to efficiently deliver medications at the tumor microenvironment, this device that can be adjusted for pH is designed for acidic tumor microenvironments. 777 Lee et al. also designed a pH-sensitive nanomaterial to control BTZ release in cells. The micelle/hydrogel composites were created by combining phenylboronic acid (PBA) and catechol through a covalent bond to encapsulate BTZ within micellar NPs. These micelles, loaded with the drug, were then integrated into hydrogels, which have a core made of catechol-functionalized polycarbonate. When the composite material was circulated in the blood, the borate bond would be dissociated in the lysosome (pH 4.5–6.0) of cells to release the loaded drug. The composite of micelle/hydrogel loaded with BTZ can serve as a layer for storing drugs or as a barrier for diffusion, enabling a continuous release of medication and extending the duration of blood circulation. 778 De la Puente et al. utilized chitosan NPs that target CD38 to enhance the effectiveness and targeting efficiency of BTZ in MM cells. This approach also increased the proteasome-inhibitory activity and specificity of BTZ through CD38-mediated endocytosis. These findings suggest that this method holds promise as a potential treatment for MM. 779 One factor that leads to poor treatment of MM is the emergence of thrombotic complications. Developing a novel method for delivering drugs can enhance the existing treatment protocol and eradicate the associated complications, thereby providing significant advantages in managing MM. Hu et al. created a nanocarrier with a core-shell structure by enveloping the polymeric NPs’ surface with a platelet membrane. The NPs possessed characteristics that allowed them to specifically target bone marrow, effectively delivering BTZ/tissue plasminogen activator (tPA) and enhancing drug accumulation in bone marrow locations. This approach reduces unintended effects and eliminates thrombotic complications, while also inhibits the progression of MM. 780 Swami et al. engineered polymeric NPs specifically designed to target bone marrow and deliver therapeutics BTZ in a controlled manner over time. The NPs consisted of PLGA, PEG and bisphosphonate. On one hand, PEG can significantly reduce immune recognition and enhance circulation in the body. On the other hand, bisphosphonate molecules that chelate calcium ions are a group of encouraging ligands capable of reducing off-target effects and enhancing localized drug concentration. By enhancing pharmacokinetics and biodistribution, this delivery system holds the promise of enhancing drug utilization, offering specificity to the bone microenvironment and minimizing off-target effects. 781

Carfilzomib is another proteasome inhibitor approved by the FDA after BTZ. Similar with BTZ, it also has its limits in clinical application. In order to maintain the anti-tumor activity of carfilzomib and reduce toxicity, Ashley’s team used liposomal carfilzomib NPs to effectively target MM cells, thereby inhibiting the proteasome and inducing cancer cell apoptosis. 782 It is well known that combination of drugs can exhibit a synergistic effect, but it is usually difficult to achieve due to uneven administration process, pharmacokinetic properties, and multiplied toxicity. In order to maximize the anti-tumor effect of combination therapy and improve the prognosis of patients, Ashley et al. used polyethylene glycol liposome NPs as a carrier, double-loaded with carfilzomib and adriamycin. By controlling their release rate, biodistribution and metabolism, the best synergy ratio can be obtained at the tumor site. The effect of tumor growth inhibiting in vivo by using liposomal NPs for combination therapy is better than the combined application of free drugs, while reducing systemic toxicity and improving the prognosis effectively. 783

Gene therapy

Since the launch of gene therapy, some treatments have undergone clinical trials, including leukemia. This gene delivery systems have great potential and expectantly become an important tool for leukemia treatment. Compared with natural viral vectors, artificial nano-carrier is easier to prepare and modify with multiple functions. 784 It has fine biocompatibility and reliable transfer efficiency of gene, which generally will not cause a strong immune response. Research on gene delivery using nanomaterials has gained increasing attention due to the rapid development of nanotechnology.

The fusion of the gene breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog (ABL) occurs when the long arm segment of chromosome 22 translocates to the long arm of chromosome 9, leading to the manifestation of the Philadelphia chromosome. Philadelphia chromosome can be occurred in most CML, some ALL and a few AML. At present, several nano-treatment methods targeting the Philadelphia chromosome have been reported. Liu et al. reported a CRISPR/Cas9 plasmid into PEG-PLGA-based cationic lipid-assisted polymeric NPs (CLANs). The system’s gRNA has the ability to focus on the protruding fusion area of the BCR-ABL gene. The BCR-ABL fusion gene region was effectively eliminated by this system, while maintaining the regular expression of BCR and ABL genes. Following the administration of CLANs through intravenous injection, the CML mouse model showed enhanced survival due to the presence of pCas9/gRNA targeting BCR-ABL. 785 Hong et al. created a novel combination of viral and nonviral chimeric nanoparticles (ChNPs) that effectively target both crucial BCR-ABL-related pathways. The ChNPs comprised of a core made of adeno-associated virus (AAV) that induces pro-apoptotic BIM expression and a polymeric shell that can be degraded by acid. The shell effectively silences pro-survival MCL-1 expression through the encapsulated siRNA. CHNPs have the ability to suppress the growth of Philadelphia chromosome-positive cells. 786 Vinhas et al. designed a nanoconjugate for combined therapy of chemotherapy and BCR-ABL fusion gene targeting. The combination makes K562 cells more sensitive to chemotherapy and can overcome the resistance mechanism of imatinib, thereby providing effective treatment for patients with CML that exhibit drug tolerance. 787

Chimeric Antigen Receptor (CAR) T cell therapy, which is based on the manipulation of a patient’s T cells in vitro, is utilized to develop precise and efficient cancer treatments. Despite the impressive outcomes observed in trials, the complexity of current CAR T cell engineering techniques hinders their widespread use in cancer therapy. This is primarily due to the requirement of viral delivery vectors and the need to produce a substantial quantity of tumor-specific T cells in vitro. Nanotechnology has been successfully utilized by some research groups to attain favorable outcomes in the in vivo modification of T cells. Smith et al. demonstrated that NPs containing DNA can effectively transport CAR genes that target leukemia into the nuclei of T-cells, resulting in long-lasting remission of the disease. To initiate the process, T cell-targeting fragments anti-CD3 were attached to the exteriors of biodegradable poly (β-amino ester)-based NPs. This attachment allowed T lymphocytes to selectively internalize the NPs through receptor-mediated endocytosis. In the meantime, the researchers equipped the specific NPs with cancer-fighting abilities by incorporating plasmid containing the leukemia-specific 194-1BBz CAR. The manufacture of these polymer NPs in a stable state is simple and cost reduction can be achieved, potentially offering a practical and widespread solution for leukemia treatment. 788 Exploration of messenger RNA (mRNA) as a potential approach to induce temporary CAR expression in T cells has also been undertaken. Billingsley et al. developed a formulation of ionizable lipid nanoparticles (LNPs) capable of transporting CAR mRNA to T cells. The CAR expression on this platform was stimulated to the same extent as electroporation, but with significantly less toxicity, and it exhibited potent anti-cancer effects. 789

The siRNA treatment of hematological malignancies has been confirmed unsuccessful because of the resistance of standard transfection methods. Kedmi et al. described a self-assembled modular platform capable of constructing a limitless range of siRNA targeted carriers. The platform’s self-assembly relied on lipoproteins anchored to the membrane, which were incorporated into liposomes containing siRNA and engaged with antibodies that targeted Fc domains of crystalline fragments. In vivo, the findings indicated that the specific uptake of siRNAs by various leukocyte subsets was redirected by a straightforward exchange of eight distinct monoclonal antibodies. By specifically targeting cancer cells, this platform caused cell death and enhanced the survival of mice in a xenograft model of mantle cell lymphoma. The introduction of this modular distribution system marks a significant achievement in the development of precision medicine. 790

Non-Hodgkin B-cell lymphoma includes an aggressive and incurable form known as mantle cell lymphoma. Individuals diagnosed with mantle cell lymphoma typically exhibit advanced disease and die within ten years. The new treatment method will impact mantle cell lymphoma through a distinct mechanism. Knapp et al. produced a lipid NP that efficiently transported siRNA to JeKo-1 and MAVER-1 cell lines of mantle cell lymphoma. Three siRNAs targeting Cyclin D1, Bcl-2 and mcl1, which prevented cell apoptosis, were co-delivered to induce the silence of these three genes at the same time. Three days after transfection, nearly 75% of JeKo-1 cells underwent apoptosis. These data indicate that the multi-channel siRNA “cocktail” formulated with lipid NPs may be a useful supplement to treat mantle cell lymphoma and other aggressive cancers. 791

By inducing functional protein expression in a dose-dependent and time-controlled manner, the delivery of mRNA into B cells can be utilized to modify and investigate these biological functions. Nevertheless, the existing in vivo mRNA delivery mechanism is incapable to transfect B lymphocytes, mainly concentrated in hepatocytes and dendritic cells. Fenton et al. described a lipid-based nanoparticle platform capable of enclosing mRNA, specifically targeting the spleen, and delivering genetic material to B lymphocytes. Significantly, this system stimulated over 85% of overall protein synthesis in the spleen. The findings suggest that the lipid NP system has the ability to regulate the location of protein activation and stimulate protein synthesis in vivo. 792

Zilkowski et al. created neutral nanogels that can be chemically altered with peptides and are responsive to their oxidative conditions using linear thiolated poly(glycidol) (PGSH) as a carrier for delivering miR-34a.The discovery of miRNA transport and target gene inhibition in transfected drug-resistant multiple myeloma cells provides a novel approach for gene delivery and holds great significance in cancer investigation. 793

Targeted therapy

With the development of molecular mechanism of leukemia, some other molecules are used as targets of nanotechnology research. FMS-like Tyrosine Kinase-3 (FLT3) is a crucial therapeutic target in AML, while the overexpression or mutations of FLT3 have been shown to occur in most cases of AML. Although multiple tyrosine kinase inhibitors against FLT3 have promising activity for AML patients in combination with chemotherapy, their efficacy remains limited mainly by common FLT3-ITD mutations. Park et al. developed a new method targeting FLT3. They designed a soluble bioactive NP fused with anti-FLT3 antibody and the elastin-like polypeptide (ELP) A192. The fusion proteins have the ability to form multi-valent NPs that possess exceptional stability and pharmacokinetic characteristics. 794 Jiang et al. developed a new system, consisted of FLT3 ligand-conjugated G7 polyamide (PAMAM) nano-dendritic complex, to delivery miR-150 which is a key tumor suppressor and negative regulator of FLT3, which selectively and effectively target FLT3-overexpressing AML cells, significantly inhibits AML cell growth, and promotes apoptosis. 795 One third of all cancers in humans can be attributed to the functional suppression of the tumor suppressor protein p53 caused by its two negative regulators, murine double minute2 (MDM2) and MDMX. Targeting both MDM2 and MDMX with dual specificity is an extremely promising option for cancer treatment. Nevertheless, the primary challenges in the advancement of peptide-based therapeutics remain vulnerability to proteolytic degradation within the body and the incapacity to penetrate the cellular membrane. A team of researchers developed a versatile peptide drug delivery system using nanoparticles made of fluorescent lanthanide oxyfluoride (LONp). The polypeptide antagonists of MDM2/MDMX and the monoclonal antibody targeting CD33 were coupled to LONp by metallothioic acid bonds. This NP can activate the p53 pathway by antagonizing MDM2 and MDMX, thereby inducing apoptosis of AML cells. 796 Furthermore, a group of researchers disclosed the utilization of layer-by-layer NPs (LbL-NPs) that target both CD20 and CD44 to transport siRNA molecules targeting B-cell lymphoma 2 (BCL-2), a protein responsible for cell survival. By encapsulating siRNA within polyelectrolyte layers that cover a polymeric core, the LbL-NP offers protection against nucleases in the bloodstream.CD20 antibodies are covalently conjugated to hyaluronic acid, which forms the outermost layer and acts as a CD44-ligand. The outer layer that targets both CD20 and CD44 ensures accurate attachment to leukemia cells, effectively triggering leukemia cell apoptosis and inhibiting their proliferation. 797

The current options available for AML treatment are restricted due to the challenge of eliminating the population of leukemia stem cells (LSCs), which are accountable for both drug resistance and relapse. Eliminating the disease entirely may require focusing on LSC as a crucial measure. Nevertheless, LSCs exhibit resistance to traditional chemotherapy treatments, necessitating innovative strategies to eradicate these cells and enhance clinical results. By employing a new targeted NP containing anti-miR-126, Dorrance et al. showed the feasibility of therapy that targets miR-126 in LSCs. Targeting miR-126 as a novel therapeutic approach enhanced the effectiveness to treat AML by focusing on LSC. 798 In addition, Zong et al created a multi-tiered vector framework. Initially, mPEG-PLA micelles were combined with Parthenolide (PTL), which was subsequently enclosed within degradable porous silicon (pSi) particles (MSV-PTL) for protection. The MSV-PTL particles were treated with an E-selectin thioaptamer in order to direct them towards the bone marrow. This system can deliver sufficient levels of active PTL to ablate LSCs in vivo. 799

The treatment of lymphoma has been completely altered by molecular inhibitors, which is why researchers are becoming increasingly interested in them. Zhao et al. conducted a study to develop a novel nanodrug to combat lymphoma. The nanodrug consisted of two components: (1) a central component composed of Ag-MOFs, a metal-organic framework, loaded with PFK15, an inhibitor of tumor aerobic glycolysis; and (2) an outer component made up of red blood cell membrane incorporating a CD20 aptamer, a molecule with targeting capabilities. In both in vitro and in vivo settings, this nanodrug can effectively target B-cell lymphoma with the assistance of CD20 aptamer. The findings demonstrated that the nanodrug effectively suppressed tumor growth without any apparent adverse reactions, suggesting its precise targeting of tumor cells, alteration of aerobic glycolysis, and collaborative anti-tumor effect through Ag + and PFK15, making it a reliable and efficient drug for lymphoma treatment. 800 NHL has been verified to exhibit an overactive PI3K/mTOR pathway. Due to its inadequate solubility and toxicity, the use of BEZ235, a potent inhibitor of both PI3K and mTOR, has been discontinued in initial clinical trials. Man et al. developed a NP-based pre-targeting system to target lymphoma cells which express CD20 and HLA-DR. The pre-targeting mechanism comprised of dibenzocyclooctyne-modified anti-CD20 and anti-Lym1 antibodies used as tumor-targeting elements, along with azide-modified BEZ235.The research showed that the dual antibody pre-targeting approach successfully enhanced the amount of nanoparticles remaining in the tumor cells of interest, and enhanced the anti-cancer effectiveness of BEZ235 by blocking the PI3K/mTOR pathway. 801

STAT3 is an oncoprotein that has been shown to contribute to the resistance of MM. However, the application of STAT3 inhibitors (such as Stattic, S3I-201 and S3I-1757) in treating MM is still limited for relatively low therapeutic effects and high toxicity. Huang et al. used a new type of NPs to pack the STAT3 inhibitors, and modified these NPs with monoclonal anti-CD38 antibodies to further enhance the therapeutic efficacy of STAT3 inhibitors on MM. The results indicated that CD38-S3I-NP has better anti-tumor effect. 802

Immunotherapy

Immunotherapy and tumor vaccines have completely impacted the traditional cancer treatment methods. Stimulation of the host’s immune system through cancer immunotherapy can enhance the elimination of tumors by immune-mediated mechanisms. As a result, it offers unparalleled therapeutic benefits, including full recovery and prolonged survival for patients in advanced stages. Although immunotherapy has shown remarkable and impressive clinical outcomes, its limitations encompass low response rates and potentially fatal side effects resulting from non-specific activation of the immune system. The progress of nanotechnology has led to the development and utilization of numerous nanomaterials in immunotherapy, aiming to stimulate targeted anti-cancer immune reactions and minimize overall toxicity. 803 – 806

The potential of the mRNA that encodes tumor antigens is to induce a strong immune response against tumors. Verbeke et al. described a nanoparticle system known as mRNA Galsomes, which effectively delivered modified nucleoside antigen-encoding mRNA, glycolipid antigen, and immunopotentiator α-galactosylceramide (α-GC) to antigen-presenting cells through intravenous injection. The combination of a low-dose nucleoside-GC and mRNA Galsomes resulted in the activation of natural killer T cells (iNKT) in mice, leading to a targeted immune response against tumor cells. On the other hand, the authors noticed that mRNA Galsomes exhibited benefits compared to unaltered ovalbumin (OVA)-encoded mRNA cancer vaccines, as there was a 7-fold rise in the activation of specific cytotoxic T cells, iNKT cells, and NK cells. The data indicated that administering mRNA Galsomes through intravenous injection could deliver a manageable, diverse, and successful anti-cancer impact, particularly when used in conjunction with checkpoint inhibitors. 807

Enhancing the microenvironment that inhibits tumor growth can enhance the effectiveness of vaccines against tumors. Da Silva et al. investigated the function of poly (I:C), resiquimod (R848), and CCL20 (MIP3α) in the regulation of tumor immunity. In the tumor region, therapeutic peptide vaccines were combined with biodegradable polymer nanoparticles to serve as a carrier for the gradual and continuous release of drugs, ensuring specific immunotherapy. Administering poly (I:C) or R848 NPs resulted in improved therapeutic outcomes, and when combined with MIP3α, it significantly enhanced the anti-tumor response. The proportion of surviving patients in the long run rose to 75–100%. According to the data, the simultaneous administration of NP-facilitated poly (I:C), R848, and MIP3α demonstrated an increased impact on the efficacy of cancer vaccines. 808

The increase of tumor-induced myeloid-derived suppressor cells (MDSCs) will affect the effectiveness of tumor immunotherapy. Sasso et al. found that lipid NPs (LNCs) loaded with lauroyl-modified gemcitabine (GemC12) can effectively target MDSC subpopulations. Subcutaneous injection with GemC12-loaded LNCs can reduce the percentage of tumor infiltrating mesenchymal stem cells, which had a higher therapeutic effect than free gemcitabine. GemC12-LNCs administered at very low dose can attenuate tumor-related immunosuppression and improve the efficacy of T cell therapy. 809

Other therapy

Recently, novel nanomaterials have been continuously developed. Magnetic hyperthermia has become an innovative effective method for tumor treatment and has made breakthrough progress. Improving the ability of magnetic nanoparticles (MNPs) to target cancer cells and precisely regulating tumor cell temperature while preserving the integrity of surrounding healthy cells and tissues are the primary challenges faced by magnetic hyperthermia in cancer treatment. 810 Faruque et al. have utilized the technique of immobilizing epithelial cell adhesion molecule (EpCAM) antibodies on the surface of MNPs to increase the selectivity of MNPs towards leukemia cells. This method can selectively remove leukemia cells selectively from the blood through magnetic hyperthermia, with almost no effect on normal cells and tissues. 811

Peuler et al. designed a layered NP composed of cationic macromer and anionic polysaccharide at the center. A clickable polysaccharide was applied to the NPs’ surface, enabling bioconjugation with various drugs using the norbornene-tetrazine click chemistry. Enhanced protein sequestration, selective cell targeting, and controlled loading and release of chemotherapy drugs have been shown to be benefits of these layered NPs. 812 Jin et al. developed a non-toxic and natural biocompatible polysaccharide nanotube Se-containing nanoparticles. The stable inclusion compound BFP-Se is formed by the SeNPs embedded in the nanotubes, which consist of the triple helix β-(1,3)-D-glucan (BFP) derived from the black fungus. It has the ability to greatly inhibit the growth of AML cells and enhance the cytotoxicity, offering a novel approach to treat AML. 813 Ferumoxytol, a nanoparticle composed of iron oxide, is currently used in clinic to treat patients with iron deficiency anemia. Ferumoxytol consists of a combination of ferrous (Fe2 + ) and ferric iron (Fe3 + ), and when peroxides are present, both types of iron can generate detrimental ROS through the Fenton reaction. Trujillo-Alonso et al. demonstrated that both in vitro and in vivo, leukemic cells and leukemic stem/progenitor cells exhibit sensitivity to the production of ROS by ferumoxytol. This study first demonstrated the capacity to selectively target leukemia cells using oxidative ferrotherapy by the delivery of ferumoxytol. 814 Shen et al. described a therapeutic system (HDL-AuNPs-BMS) for AML that utilized AuNPs and targeted the AML-promoting factor fatty acid-binding protein 4 using BMS309403 (BMS), a small molecule with selective inhibition properties. The initial evidence demonstrates that HDL-AuNPs serve as a successful vehicle for AML treatment, promoting AML cell differentiation and minimizing AML disease progression without any apparent adverse reactions. This novel approach shows promising prospects in the management of leukemia. 815 Durfee et al. examined a protocell composed of lipid bilayers supported by mesoporous silica nanoparticles (MSN). The targeting agents used for modification of this nanocarrier were anti-EGFR antibodies. It has been proven to have low immunogenicity, constant circulation time and some other advantages. 816

Au et al. reported a novel radioimmunotherapy utilizing nanotechnology for the management of NHL. The pre-targeting setup consisted of an anti-CD20 antibody functionalized with dibenzylcyclooctyne (DBCO) and azide-yttrium-90-(90Y) bifunctional dendrimer. The findings demonstrated that the pre-target mechanism effectively transported radioactive substances exclusively to the tumor cells being targeted, thereby amplifying the anti-cancer effects. This outcome was verified through experiments conducted on mouse models with NHL xenotransplantation. 817

Nanomaterials-based photothermal therapy (PTT) has gained significant attention in recent years as a means to minimize the adverse effects of radiotherapy and chemotherapy. Zuo et al. reported a platelet membrane acted as a nanocarrier to co-load W18O49 NPs and metformin. The platelet membrane provides protection against oxidation and immune evasion for W18O49. Additionally, it can enhance the buildup of W18O49 in the cancerous region through both the passive EPR effect and the active bonding between platelets and malignant cells. The experiments provided evidence that this substance has the ability to effectively suppress the growth of tumors and induce apoptosis in tumor cells. 818 Optical imaging-guidance of indocyanine green (ICG) for PTT has great potential in treating tumors. However, the traditional optical image guidance method makes living tissues produce strong tissue autofluorescence, which makes it impossible to carry out precise infrared light irradiation. Zheng et al. designed a ICG and PLPs co-doped mesoporous silica nanocarriers for continuous luminescence imaging of PTT. 819 The findings indicated that this nanocarrier greatly enhanced the ratio of signal-to-noise in PTT luminescence imaging and the precision of photothermal treatment of tumor in vivo.

The presence of hematopoietic stem cells and progenitor cells in the bone marrow poses a significant challenge for selectively eliminating cancer cells in MM. 820 Increasing targeting and cellular uptake are essential to be solved. In order to solve the problem of drug targeting, VLA-4 is used as a targeting ligand, which can selectively target MM cells and inhibit the cell adhesion-mediated drug resistance. Stefanick et al. developed liposome NPs with accurate stoichiometry of targeting peptides, ensuring consistent high purity without variations between batches. The liposomes were modified by attaching a cyclic late antigen-4 (VLA-4) antagonist peptide, which was modified using EG peptide-linkers and a short oligolysine chain. This modification was done to improve the liposomes’ hydrophilia and the ability to target tumor. 821 Furthermore, they dual-targeted VLA-4 and lpam1 to prepare functionalized liposomes by two peptide antagonists that tend to bind to cancer cells to produce synergistic effects while minimizing damage to healthy cells and tissues. Compared with the traditional single-receptor targeting methods, it has higher selectivity and improves the targeting problem of cancer treatment. 822 Kiziltepe et al. have designed and developed a multifunctional NP that combined with traditional chemotherapy and VLA-4 targeting. Polyethylene glycol micellar NPs are used as a drug delivery system, combined with DOX and VLA-4. The accumulation of NPs in tumors was enhanced. A promoted tumor growth inhibition and reduced systemic toxicity were also observed. The study offers a preclinical theoretical foundation for assessing multifunctional NPs’ efficacy in improving tumor targeting. 823

By combining direct cytotoxicity, immune-stimulatory, and antiangiogenic mechanisms, phototherapy (PT) can provide precise and controlled tumor killing with high spatiotemporal accuracy. Kotagiri et al. successfully transformed chemotherapeutic medications into light-activated drugs with spatial and temporal functions. Additionally, they introduced untreated hydrophobic photosensitive drugs to lipid nanomicelles specifically designed to target tumors or human serum protein NPs. It can selectively deliver drugs to cancer cells and effectively inhibit the proliferation of diffuse multiple myeloma using Cerenkov radiation induction therapy (CRIT). 824

In addition to the use of phototherapy and magnetic hyperthermia, immunotherapy has also made significant progress in cancer treatment. B cell maturation antigen (BCMA) belongs to the superfamily of tumor necrosis factor (TNF) receptors. Due to its limited expression on MM and plasma cells and crucial function in enhancing tumor cell growth, survival, and drug resistance, it presents a hopeful objective for the development of immunotherapy. Recently, Bae et al. created and analyzed a nanovehicle-based formulation containing a heteroclitic BCMA peptide to enhance antigen delivery. This formulation induces stronger poly-functional BCMA-specific CD8 + cytotoxic T lymphocyte (CTL) responses against MM compared to vaccination with the peptide alone. The utilization of PLGA nanotechnology in this cancer vaccine improves the possible clinical use of BCMA in targeted immunotherapy for myeloma. 825

Diagnosis and treatment integration

The combination of targeting ligands, imaging markers and therapeutic drugs can achieve effectively controlled delivery in the body, which can perform non-invasive monitoring and treatment in real time. With the continuous exploration of multidisciplinary methods by scientific researchers, the use of nanotechnology will bring new directions for lymphoma therapy.

Bai et al. coupled biotinylated CD20 and CD3 antibodies to the surface of ultrafine Fe 3 O 4 NPs modified with streptavidin to construct a bispecific nanoplatform (BSNP). Compared with clinical Gd-chelated contrast agents, synthetic BSNP with a hydrodynamic size of 30 nm had better MRI capabilities. In vitro, the nano-platform specifically targeted Raji cells expressing CD20 and improved the killing mediated by T cells. Furthermore, it had the potential to impede the growth of tumors and extend the lifespan of in vivo transplantation models of NHL. The modularly designed BSNP has great potential as a versatile nano-platform. 826

Etrych et al. documented the efficacy against lymphoma and the potential for diagnosis of a recently developed near-infrared fluorescent dye, which includes polymer-DOX conjugates. The polymer DOX conjugate demonstrated substantial effectiveness against malignant lymphomas in murine models in comparison to the equivalent dosage of unconjugated DOX. Fluorine-labeled polymer prodrugs had good diagnostic potential. The fluorescence intensity of subcutaneous xenograft lymphoma was closely related to the change of lymphoma volume, so the treatment effect could be noninvasively evaluated. 827

Currently, the advancement of nanotechnology has led to an increasing number of unconventional nanotechnology discoveries, offering promising possibilities for the diagnosis and treatment of lymphoma. Traditional death/viability analysis usually requires laborious sample preparation and expensive equipment or reagents. The study of Ninno et al. used electrochemical impedance spectroscopy as a label-free method to describe living, necrotic, and apoptotic human lymphoma U937 cells. At a low frequency of 0.5 MHz, the signal intensity was capable of differentiating between live/necrotic cells and cell debris, and the phase information could be used to distinguish live cells from necrotic cells. At a higher frequency (10 MHz), the cell fragments of the two subgroups were distinguished, suggesting the important role of electrical impedance technology in the next generation of cell viability testing. 828 The tissue sample’s chemical atlas offers crucial data on biological processes. Over the past few years, there has been advancement in tissue imaging through desorption electrospray ionization mass spectrometry (DESI-MS). However, the capability of this technology in mapping lipids and metabolites is restricted. Hsu et al. documented the utilization of nano-DESI. Under atmospheric pressure, they only used a small amount of samples to visualize proteins in tissue samples without the need for labeling. Nano-DESI successfully detected multiple charged proteins with a mass of 15 kda. This imaging method can be further applied to MYC-induced lymphoma. 829

When studying tumor proteins expression information, only the volume of the serum sample is large enough to be used for single target analysis of multiple protein analysis. However, most traditional mouse experiments cannot collect serum samples frequently. Lee et al. established a magneto-nanosensors to detect protein expression in serum. The difference of cytokine expression in plasma can be accurately measured by using this nanosensor. This nano-magnetic field sensor-based technology can be used to longitudinally monitor the protein profile of lymphoma model mice, facilitating multiple analyses which use only a small quantity of samples. 830 To comprehend the diversity of cellular function and devise novel approaches for treating various ailments, it is imperative to conduct an examination of cytokine secretion at the single-cell level. Cell integrity is inevitably disrupted by the burdensome molecular labeling required in fluorescence and colorimetric-based methods. Li et al. discovered a groundbreaking optofluidic nanoplasmonic biosensor without the need for labels, enabling real-time examination of individual cells. The nanobiosensor utilized an innovative configuration of a versatile microfluidic system comprising of a compact microchamber and control channels to ensure accurate tracking of cytokine release from individual cells. Real-time determination of the secretion fingerprints of individual cells in space can be achieved through the utilization of optical spectral imaging in conjunction with sensor architecture. Anticipated to transform into a potent instrument for analyzing individual cellular signals in fundamental and medical investigations, this novel biosensor system holds great promise. 831

Nanotechnology has broad prospects in the treatment of lymphoma. Nevertheless, the challenge of translating them into clinical practice persists, despite the significant advantages demonstrated by NP-based systems in preclinical environments. The development of effective nanomedicine formulations involves addressing various challenges, including the incorporation of drug molecules into NPs, ensuring the stability of NP formulations, and achieving controlled release of the encapsulated drugs at the desired location within the body. Furthermore, the absence of suitable animal models that replicate the real clinical scenario (etiology, pathology and progression) in lymphoma poses challenges in forecasting positive results for clinical trials. However, nanomedicines have been recognized and demonstrated as promising mechanisms for delivering drugs. Numerous formulations have been effectively developed and approved for the treatment of various malignancies as well as chronic inflammatory conditions. Further exploration in the field will result in innovative NP formulations for lymphoma treatment in the coming years.

Nanomedicine in genitourinary system tumors

The genitourinary system is mainly composed of the urinary system and the reproductive system. The urinary system includes four parts: kidney, ureter, bladder and urethra, where the highest incidence of urinary system tumors is bladder cancer (BC), ranking ninth among all malignant tumors and sixth among male tumors. BC is characterized with rapid progression and high recurrence rate. There are approximately 549,000 cases diagnosed each year, and the incidence of women is always lower than that of men. 358 , 832 – 834 Most BCs are urothelial cancers. Presently, around 75% patients suffer from non-muscle invasive bladder cancer (NMIBC), with 25% of them experiencing muscle invasive or metastatic illness. 835 , 836 In 2016, the World Health Organization (WHO) “Blue Book” released the fourth edition of the WHO Classification of Tumors of the Genitourinary System, which suggested significant changes to male reproductive system tumors. 837 Prostate cancer is the predominant ailment among tumors affecting the male reproductive system, while ovarian cancer and breast cancer exhibit the highest occurrence among tumors impacting the female reproductive system. Around 230,000 females worldwide receive an ovarian cancer diagnosis annually, with a mere 46% survival rate within 5 years after diagnosis. 838 , 839 Additionally, breast cancer ranks as the second leading cause of cancer fatalities among women. 840 Currently, the treatments of tumors of the genitourinary system are mainly surgery, chemotherapy, radiotherapy and others, but the existing treatments cannot achieve satisfactory therapeutic effects, and chemotherapy and radiotherapy often produce toxic side effects onto normal cells which is unsatisfactory and harmful to the body. Besides, tumors are highly metastatic which brings huge challenges to treatment. Hence, developing new diagnostic and therapeutic strategies is the key to solving these problems.

In recent years, the great advancement of nanotechnology has sparked optimism for the cure of malignant tumors. Many nanomaterials, such as inorganic NPs, polymer NPs, are designed for treating genitourinary system tumors and show great advantages. 731 Presently, relying on nanomaterials as transporters for curative substances, external stimuli (light, magnetic waves, heat, etc) are introduced to expand their functions to realize drug release at tumor sites. While therapeutic compounds are often limited in clinical treatments due to poor aqueous solubility, ability to cross body barriers and penetrate into tumors, and low biological stability. 841 A series of new treatment strategies were developed for various malignant tumors after combining nanotechnology with therapeutic compounds. Nanomaterials as a delivery system can not only prolong drug residence time and improve bioavailability, but also reduce or even avoid induced adverse reactions/drug toxicity caused by drugs. Next, we will focus on the application of nanomaterials as a delivery system in several common tumors of the genitourinary system.

Diagnosis

The detection and diagnosis of tumors of genitourinary system is mainly through the detection of relevant biomarkers in the tumor and imaging methods. Early detection of tumors can be achieved by identifying biomarkers in the bloodstream, such as circulating tumor cells (CTC) or circulating tumor DNA (ctDNA), but most of the biomarkers are diluted after blood circulation, which leads to the difficulties with detection. Currently, imaging methods are widely used in the detection, location or staging of tumors. Commonly-used clinical imaging methods mainly include: X-ray, 842 ultrasound, 355 MRI, 843 digital chest tomography, 844 CT, PET, etc., which have the drawbacks of limited sensitivity and signal specificity, long acquisition time and the risk of ionizing radiation. 635 , 845 Determining the boundary between the lesion site and normal tissue cells, accurately detecting metastasis, and accurately judging small tumors and occult tumors are still challenges for current tumor imaging technology. Therefore, using a visualization system to detect and kill tumor cells is a tumor treatment strategy with low side effects and high efficiency. Precise positioning and visualization are of great significance to its success rate and reduction of tumor mortality. 846

The investigation of biomarkers for the prevention of early cancer and the mitigation of metastasis is a crucial undertaking and highly significant in clinical diagnosis and treatment. However, existing detection techniques demonstrate attributes of limited sensitivity, throughput, and affordability. 847 Recently, microRNA (miRNA) has been reported as an attractive tool for liquid biopsy in tumor screening. 848 The miRNA is an endogenously encoded non-coding RNA molecule consisting of around 22 nucleotides in length. It regulates protein-coding genes by specifically inhibiting translation or cutting ribonucleotide transcripts expression. There is growing evidence that miRNA is related to important tumor pathways. 849 Therefore, miRNA can be used as a tumor marker to improve the efficiency and sensitivity of tumor detection. Wei et al. 847 proposed a technique to detect miRNA associated with bladder cancer using photonic crystal (PhC) barcodes, which enables highly sensitive quantification of miRNA. The reflective peaks produced by periodic and organized porous nanostructures are distinctive features of PhC barcodes. Chemical coupling connects the probe to the barcode surface, while base pairing binds the miRNA. Simultaneously, the hybrid chain reaction (HCR) is utilized to amplify the detected signal. The findings indicate that the PhC barcode detection system exhibits excellent precision and correctness. Moreover, various categories of miRNAs can be measured simultaneously by attaching diverse probes onto the nanoparticles’ surface, enabling rapid, precise, and highly sensitive quantification of miRNA.

Exosomes are nanovesicles with a diameter of less than 200 nm, which fused with the plasma membrane in multivesicular endosomes (MVEs). Therefore, exosomes usually carry biological surface markers of specific membranes, such as surface proteins, which are receiving more and more attention in tumor detection and diagnosis. Moura et al. 850 have devised an electrochemical immunosensor that utilizes a magnet to detect exosomes generated from three distinct breast cancer cell lines. This sensor has the capability to increase the sensitivity of detection and accurately differentiate between healthy individuals and those with breast cancer. Furthermore, research has demonstrated that the TME plays a crucial role in facilitating the release of exosomes, which are mostly concentrated in the hypoxic TME. 851 , 852 An integrated magnetic-electrochemical exosome (iMEX) has been developed which was used to screen for ovarian cancer. Exosomes are captured from patients through immune-magnetics and analyzed through electrochemical reactions. Magnetic enrichment and enzyme amplification realize high-sensitive and specific exosome detection, as well as the miniaturization of sensors and the amplification of high-throughput measurement, which further improves the ability of rapid, high-throughput and on-site analysis.

Imaging technology cannot accurately detect and visualize cancer staging, however, the application of nanomaterials to tumor imaging can increase its sensitivity and targeting, reduce adverse reactions, improve imaging effects and achieve visualization. 853 Yang et al. 854 developed a therapeutic nano-drug (AuNCs-Pt) with both near-infrared-I/II (NIR-I/II) imaging and glutathione scavenging functions based on gold nanoclusters (AuNC). The AuNCs-Pt possesses the ability to perform NIR-II imaging in the model of abdominal lethal high-grade serous ovarian cancer (HGSOC), enhancing the visualization of platinum transportation in deep tissues. Consequently, it is anticipated to emerge as a valuable instrument for investigating the in vivo drug destiny. Meanwhile, AuNCs-Pt can also deplete glutathione in cells which minimizes the detoxification effect to platinum-based drugs, and maximize the chemotherapy effect. Recently, some studies have found that fluorescence and multispectral photoacoustic tomography (MSOT) imaging can detect local or distant breast cancer metastases caused by tumors in situ. 855 Some researchers have developed an activatable nanoprobe with aggregation-induced emission capability, which can detect and image breast cancer metastasis in mouse models through NIR-I and NIR-II fluorescence imaging 856 and MSOT. The nanoprobe is capable of detecting and reacting to an increased presence of nitroreductase in tumor hypoxia. It produces distinct NIR-I/NIR-II signals and photoacoustic signals, allowing for a comprehensive visualization of breast cancer metastasis. In addition, Zhao et al. 846 also proposed a new gene amplification strategy in nanoparticle tumor homing, and designed a prostate cancer cell-specific genetic probe (PDD3-TfR-WPRE-PCMV-Luc) to promote high expression of transferrin in cells. Then transferrin (Tf) modified by ultra-small iron oxide superparamagnetic nanoprobes (Tf-USPins) is used for detection. The results show that the contrast of MRI imaging compared with surrounding normal tissues is enhanced, which helps to be more accurate positioning. Additionally, Li et al. developed the polyethylene glycol-manganese dioxide NPs as a T1MRI contrast agent in renal cancer. 857

Typically, penile cancer is assessed by conducting a sentinel lymph (SN) node biopsy with the aid of 99mTc nano-colloid and blue dye. To improve the optical detection sensitivity, a combination of a dual-labeled tracer, comprising the fluorescent dye indocyanine green (ICG) and 99mTc nano-colloid (ICG-99mTc-nano-colloid), was used. The results showed that fluorescence imaging of the NPs improved the detection of optical SN without contaminating the surgical area or additional injections, improving the accuracy of detection of penile cancer preoperatively and intraoperatively. 858

Squamous-cell carcinoma antigen (SCC-Ag) is a biomarker found in the blood that is highly expressed in gynecological tumors of squamous-cell carcinoma. A recent study has demonstrated that the utilization of nanogold-labeled biomolecules can enhance the precision of detection. The sensitivity of SCC-Ag-GNP on SCC-Ag-antibody is greater, indicating that this method using a gold-labeled probe or target can assist in the identification and quantification of gynecological tumors, thereby assessing their severity. 859

Treatment

At present, surgical treatment, radiotherapy and chemotherapy are still the first choice for cancer of urogenital system. Because of its poor prognosis and easy to produce drug resistance, which affects patients’ mental health and happiness, it is imperative to develop new treatment strategies to alleviate patients’ pain and prolong their survival time. Currently, great progress has been made in the research of nano-drugs in prostate cancer, breast cancer and other high-incidence malignant urogenital tumors, including diagnosis, gene therapy, immunotherapy and targeted therapy.

Chemotherapy

Chemotherapy plays an important role in oncotherapy, but traditional chemotherapy normally lacks specificity. Besides, the concentration of drugs in tumors is always not high enough, so large doses of drugs are often required which can produce toxic side effects onto normal cells. Paclitaxel, as a clinical first-line anti-tumor drug, is widely used in treating breast cancer, prostate cancer and other malignant tumors, but its shortcomings such as poor water solubility and high toxicity greatly limit its applications. The emergence of nanotechnology provides a new treatment strategy. Using nanomaterials to load chemotherapeutic drugs can prolong the circulation of drugs in the body, increase the bioavailability of the drugs and reduce toxic side effects, etc., so as to enhance the therapeutic effect of chemotherapy. Guo et al. 860 developed a super-thermodynamically stable RNA 4WJ-X nanoparticle based on the PRNA-3WJ motif, which was used for solubilizing and loading paclitaxel for targeted cancer treatment. RNA-paclitaxel complex nanoparticles are chemically stable, and their water solubility is increased by as high as 32,000 times. The utilization of distinct ultra-heat resistant RNA nanoscale particles for the purpose of delivering paclitaxel intends to address the issue of RNA unwinding and nanoparticle separation during the loading of drugs at high density. According to the research findings, the administration of RNA-paclitaxel NPs through intravenous injection, along with ligands that specifically target breast cancer, effectively suppressed tumor growth in the mice model. Furthermore, almost no toxicity and immune responses were observed during the study.

In chemotherapy, in addition to the side effects caused by chemical drugs, the development of drug resistance is also one of the important reasons for the poor effect of tumor treatment. It has been found that prostate cancer is prone to develop drug resistance during chemotherapy, 861 and it has been proven that the development of drug resistance is caused by the aging mechanism of prostate cancer in preclinical and clinical studies. 862 Tannins was reported to show anti-tumor effects in prostate cancer and can prevent cancer cells from developing drug resistance. 863 However, the two drugs are not so useful when administrated separately due to drug resistance, dosage, etc. Therefore, a tannins-docetaxel self-assembly (DSA) nano-formulation was developed for this phenomenon. 863 The experimental results show that DSA shows superior tumor targeting, anti-cancer activity and inhibition of senescence blocking and the removal of the senescent cells in the tumor, which promotes the efficacy of docetaxel.

Chemotherapy, surgery, radiation therapy and targeted therapy are still the most commonly used treatments for cervical cancer. Cisplatin, one of the commonly employed treatments in radiotherapy and chemotherapy regimens for cervical cancer, is associated with significant systemic side effects and vulnerability to drug resistance. This event is strongly correlated with the rise in sulfur-containing compounds within the cell, particularly glutathione (GSH), as well as the increase of the glutathione S-conjugate pump, which relies on adenosine triphosphate (ATP). Luo et al. 864 utilized the nano-precipitation method to create the Pt (IV) prodrug nano-drug SSCV5NPs, which consists of a VES-modified prodrug and a VES-modified disulfide-rich carrier. The nano-sensitizer possesses the attributes of safety, redox sensitivity, a substantial disulfide density, and a high drug loading capacity (reaching up to 16.50%Pt or perhaps even more).

Radiotherapy

Since Roentgen discovered X-rays in 1895 to the first clinical application of radiotherapy in 1896, radiotherapy (RT) has undergone tremendous development during the years. Until now, radiotherapy is still one of the indispensable treatments for tumor treatment. However, it is still a challenge to deliver appropriate radiation doses to the tumor site to reduce damage to normal tissues in RT. Currently, there are reports of using radiosensitizers to reduce the side effects of RT. 865 In addition, MRI-guided RT can further improve the accuracy and effectiveness of treatment. A gold-gadolinium (III) NPs (Au-Gd (III)-PSMA) targeting PSMA (highly expressed in prostate cancer) was synthesized to selectively deliver gadolinium (III) contrast agents to prostate cancer. 866 The results indicated that the gold-gadolinium (III) PSMA NPs showed favorable tumor accumulation, and enhanced the cell’s magnetic resonance contrast and radio-sensitization, meanwhile they also reduced the damage to the surrounding normal tissues. In addition, the biological characteristics of the tumor will also have an important impact on the efficacy of radiotherapy. Insufficient oxygen supply has been proved to be one of the main drivers of tumor angiogenesis and metastasis. However, traditional low-dose radiotherapy may aggravate hypoxic conditions and impels the tumor cells less susceptible to radiation-induced killing. 867 In order to solve the challenges, Huo et al. 868 developed a nanocluster “bomb”. This “bomb” is used as a radiosensitizer for RT, and is composed of non-stoichiometric tungsten oxide nanoparticles (WO NP) to target a low-oxygen microenvironment and modified with a ligand of CCL-28 chemokine. The majority of these NPs maintain their original bigger size while circulating in the body, resulting in a prolonged half-life and passive targeting of tumors through EPR effects. When reaching the tumor site, the original NPs will be converted into small NPs under the stimulation of the TME (such as enzymes, pH) to promote the deeper penetration into the tumor. Meanwhile, it enables higher resolution nanoparticle-enhanced CT to achieve accurate imaging of the hypoxic contour of solid tumors. Local photothermal ablation of the tumor and the generation of free radicals can be achieved at the same time under 1064 nm laser irradiation and CT guidance. The induced free radicals reduce the resistance induced by hypoxia in an Akt-mTOR pathway-dependent manner, and enhance the tumor’s radiation killing sensitivity to action.

Gene therapy

Non-coding RNA (ncRNA) is becoming an important regulator in the process of various diseases, including circular RNA, lncRNA, siRNA, etc. Abnormal expression of non-coding RNA is associated with tumor occurrence; therefore, it attracts increasingly more researchers’ attention. 869 – 872 The role of siRNA in cancer has been well studied. siRNA is a double-stranded ribonucleic acid molecule 873 which is a powerful tool for gene silencing. It has an inhibitory effect on the expression of target genes and can target almost any gene, 874 , 875 so it has the potential to treat various diseases. Due to the poor stability of naked RNA in the blood, it is often degraded in endosomes/lysosomes, and negatively charged genes cannot pass through the plasma membrane. 876 Protecting siRNA from nucleases to reach cancer sites in deep tissues, and avoiding activating immune responses, etc. are challenges in the clinical application. 877 In addition, the choice of vector also has an important impact on the efficacy of gene therapy. The ideal gene vector should be highly effective, specific and biocompatible. Viral vectors frequently used in the past have shown high efficiency in delivering genetic material, but the application is greatly limited due to the packaging capacity, instability and immunogenicity of the vector. 878

In recent times, there has been a surge in the advancement of nanotechnology, leading to the emergence of novel approaches for delivering siRNA. Various materials (lipids, polymer micelles, etc.) have the purpose of acting as transporters for delivering siRNA, thereby prolonging the lifespan of RNA in the bloodstream. These carriers have a preference for accumulating in tumors, improving cellular uptake, and successfully escaping endo/lysosomes. Dong et al. developed the siRNA-loaded amphiphilic phospholipid dendrimers (AmPPDs). 879 They found that NPs protected siRNA from enzymatic degradation and promoted the uptake and release in prostate cancer. Besides, halloysite nanotubes (HNTs) are also commonly used as non-viral vectors to capture and release active agents. HNTs were used to deliver therapeutic siRNA to target RIPK4 (receptor interacting protein kinase 4) which are highly expressed in bladder cancer cells. 880 Studies have found that NPs coated with HNTs are more stable in the body, easily taken up by cells and accumulated in the bladder cancer lesion, thereby effectively inhibiting the occurrence and development of bladder cancer.

Although many nano-delivery systems have been developed for gene therapy, such as polymer NPs, liposomes, inorganic nanoparticles, genes encapsulated in an acidic environment rich in enzymes are easily degraded and inactivated. Meanwhile, the release of drugs is uncontrolled and inaccurate. These have greatly affected the therapeutic effect of gene therapy. Therefore, in the small nucleic acid nanomedicine therapy, another challenge is that most of the small nucleic acid-based drugs are rapidly transported to the lysosome, resulting in the degradation. Van de Vyver et al. 881 found that cationic amphiphilic drugs (CADs) can transiently induce the lysosomal membrane permeability and strongly promote the delivery of functional siRNA from lysosomal compartments.

The TME plays a crucial role in the development, proliferation, and spread of malignancies. Cancer-associated fibroblasts (CAF) are known to have a significant impact on the TME and various other processes, including extracellular matrix (ECM) remodeling, facilitation of local invasion, and promotion of metastasis. 882 C-X-X motif chemokine 12 (CXCL12) ligand participates in the migration of various cancer cells, 883 and activates multiple responses (such as migration, proliferation, etc. 884 ) through the CXCL12/CXCR4 pathway in the tumor microenvironment. Therefore, a group developed a nano-system targeting CAF and CXCL12 to inhibit the metastasis of prostate cancer. They used cell-penetrating peptide (CPP)-based self-assembled nanoparticles to load siRNA that can silence the CXCL12 gene, and modify the NPs with fibroblast activating protein-α monoclonal antibody to target CAF to specifically deliver siRNA to cells. The findings demonstrated a considerable inhibition of tumor cell migration, invasion, and tumor angiogenesis. 885 The microenvironment of malignant tumors is characterized with low oxygen and slight acidity. Xu et al. 312 designed a low-pH activated “nano-bomb” based on the acidic environment of tumor microenvironment to deliver POLR2A siRNA (SiPol2) and precisely target POLR2A in TP53 loss TNBC. This nano-delivery system reduces the growth of POLR2A loss tumors by inhibiting POLR2A. Meanwhile there is no obvious systemic toxicity.

Immunotherapy

Cancer immunotherapy aims to promote the immune system to recognize and eliminate cancer cells. A series of local cancer immunotherapies, such as in situ vaccines and oncolytic viruses, can help reverse the immunosuppression in TME and lead to a systemic anti-tumor response, which is regarded as a particularly promising intervention. 886 In prostate treatment, immunotherapy has also shown great success. For example, therapeutic anti-cancer vaccines, including dendritic cell (DC) (Provenge), whole cell (GVAX) and carrier (PROSTVAC)-based vaccines, are the main immunotherapy strategy used to treat prostate cancer. 887 , 888 However, issues such as targeting and off-targeting in immunotherapy have received widespread attention. The application of NPs holds great potential in addressing the issue of targeted distribution and mitigating off-target negative effects to a certain degree. Additionally, it has the potential to boost the stability, pharmacokinetics, and tumor accumulation, hence improving the effectiveness of anti-tumor actions and reducing systemic side effects in checkpoint blocking therapy. Nanocarrier vaccines have been reported to exhibit excellent stability and biocompatibility, and increase the accumulation of antigens/adjuvants in lymph nodes (LNs). Meanwhile, they can be delivered to DC in a controlled release manner, which may improve cytotoxic T lymphocyte (CTL) and humoral response. In addition, they can prolong the antigen presentation process, and significantly improve the anti-tumor immune response. 889 Virus-like nanoparticles (VLP) have become an attractive means of tumor immunotherapy due to their unique innate immune stimulating properties. Wang et al. 301 developed a bacteriophage QβVLPs-loaded Mg-based micromotor. It can be propelled autonomously in the peritoneal fluid so that complete immunostimulatory QβVLPs can be actively delivered to the abdominal cavity of mice with ovarian tumors. It greatly improves the local distribution and retention of QβVLPs, enhances immune stimulation, and improves the survival rate of tumor-bearing mice.

Targeted therapy

NPs can selectively target to tumors through appropriate surface modification. NPs are used as delivery vehicles, which can passively accumulate into the tumors through enhanced penetration retention effect. In addition, active targeting, using NPs modified with specific ligands for disease biomarkers, increases the affinity of NPs for target tissues. 890 , 891 Prostate-specific membrane antigen (PSMA) is a type II transmembrane protein composed of 170 amino acids. It is overexpressed in the new blood vessels of prostate cancer and other solid tumors (such as breast cancer). It has been identified to distinguish between benign and malignant tumors. 892 Joey et al. 890 constructed prostate-specific membrane-targeted gold NPs. The PSMA-1 ligand underwent conjugation with polyethylene glycol terminated with sulfhydryl groups. Subsequently, it was connected to the surface of gold nanoparticles that contained the fluorescent photodynamic therapy drug Pc4. This connection was achieved through a ligand exchange reaction. Experiments conducted in vivo and in vitro suggest that nanoparticles have the ability to specifically transport medications, while photodynamic therapy can interfere with the formation and growth of tumors. Approximately 20–30% of breast cancers exhibit an overexpression of human epidermal growth factor receptor-2 (HER2). HER2 belongs to the EGFR family and has a weight of 185 kDa. In the treatment of HER2-positive breast cancer, blocking HER2 signaling pathway is a successful approach. 893 , 894 A new strategy is to use HER2 N -glycan nanomolecular imprinted polymer (nano MIP) to effectively adhere to almost all HER2 polysaccharides. This attachment prevents the dimerization of HER2 with other members of the HER2 family, ultimately obstructing downstream signaling pathways and reducing cell proliferation by 30%. Consequently, this method successfully achieves the objective of inhibiting HER2-positive breast cancer. 894 The drug can be injected directly into the bladder through a catheter in the treatment of bladder cancer. Although the diseased tissue is directly exposed to drugs to increase the therapeutic effect and reduce systemic side effects, the efficacy of drugs may be affected due to the bladder wall glycosaminoglycan (GAG) mucosa and periodic urination and other factors. 895 Currently, micro-nanomotors or nano-nanomotors have great potential in drug delivery and have received great attention with the development of nanotechnology. 896 Hortelão et al. 897 designed an antibody-modified urease-driven nanomotor based on the over-expressed fibroblast factor 3 (FGFR3) in bladder cancer. Urea provides propulsion for nanomotors under the action of urease biocatalysis. The results show that the antigen-antibody interaction and targeting make the nanomotor composed of anti-FGFR3 show more effective internalization and the block of fibroblast growth factor (FGF) pathways which prevent cell proliferation and lead to cell death.

Combined therapy

As mentioned above, immunotherapy has played a favorable therapeutic effect in the treatment of prostate cancer, but due to the existence of immunosuppression in the TME, the application of therapeutic cancer vaccines is subject to certain restrictions. TME not only plays an important role in the progression of cancer, but also is a major obstacle to cancer immunotherapy. Regulatory T cells (Treg), and immune checkpoints, such as CTL associated protein (CTLA-4), PD-1, etc., play important roles in the immune suppression. 898 , 899 Therefore, overcoming tumor microenvironment is the key to successful cancer immunotherapy. It is reported that standard cancer treatment methods such as chemotherapy and radiotherapy can induce immunogenic stimulation or death of tumor cells and produce a large amount of tumor antigens. 900 Hence, the implementation of combined immunotherapy is an excellent approach for treatment. A novel formulation called Fer-ICB-UPMSNPs, consisting of Ferumoxytol (Fer) and anti-programmed cell death-ligand 1 antibodies, loaded onto ultralarge pore mesoporous silica nanoparticles, was created. This formulation aims to provide sequential MRI-guided local immunotherapy following cabazitaxel (Cbz) chemotherapy, specifically for the treatment of prostate cancer and other tumors of the urogenital system. 901 The findings indicated that the T cell infiltration is effectively activated by the local delivery of Fer-ICB-UPSnPs guided by MRI following Cbz treatment. Meanwhile, it also reduces the role of Treg in the tumor-specific adoptive immune response and significantly inhibits the tumor growth.

A combination therapy consisting of gene therapy and chemotherapy is an effective method to treat tumors. It was reported that a photo-activated Pt (IV) prodrug backbone polymer nanoparticle system (CNP PtCP/si(c-fos) ) could deliver small interfering RNA (si(c-fos)) in a light-controlled manner. This system was employed in conjunction with light-activated chemotherapy and RNA interference (RNAi) to treat platinum-resistant ovarian cancer. 902 CNP PtCP/si(c-fos) can produce oxygen-independent N 3 • with slight oxidation energy under blue light (430 nm) irradiation. The N 3 • assisted photochemical internalization (PCI) mechanism can effectively escape the action of lysosomes or endonucleases and reduce the inactivation of gene c-fos. Subsequently, while the Pt (IV) prodrug is activated to be Pt (II), CNP PtCP/si(c-fos) is dissociated, and the active Pt (II) and si(c-fos) are released. Both in vitro and in vivo experiments have shown that CNP PtCP/si (c-fos) has an outstanding synergistic therapeutic effect on platinum-resistant ovarian cancer. This system can further improve the effect of gene therapy even in the hypoxic TME.

Nanomedicine in primary bone tumors

Neoplasms originating from bones are exceptionally uncommon, constituting less than 0.2% of all cancer cases. However, accurately determining their incidence is challenging due to the infrequency of these tumors. 903 In 2019, approximately 3500 people were diagnosed with this disease, resulting in around 1660 deaths in the United States. 3 Primary bone tumors exhibit diverse clinical variability and can frequently be cured with appropriate therapy. Bone cancers are classified according to their histologic origin. The three most prevalent types of bone cancer are osteosarcoma (35%), chondrosarcoma (30%), and Ewing sarcoma (16%). Chondrosarcoma originates from cartilage, osteosarcoma originates from bone, fibrosarcoma of bone originates from fibrogenic tissue, hemangioendothelioma and hemangiopericytoma originate from vascular tissue, and chordoma arises from notochordal tissue. The histologic origin of several primary bone cancers, such as Ewing sarcoma, remains unknown.

The prognosis for patients with osteosarcoma and Ewing sarcoma has significantly improved due to the development of multiagent chemotherapy regimens for neoadjuvant and adjuvant treatment. 904 – 906 As a result of current multimodality treatment approaches, approximately three quarters of all osteosarcoma patients are cured, and 90% to 95% of osteosarcoma patients are successfully treated with limb-sparing approaches rather than amputation. In some cases, patients diagnosed with metastatic disease at presentation can still achieve a cure, especially among those with Ewing sarcoma and osteosarcoma. 907 Among current multimodality treatment, nanotechnology is widely recognized as a promising drug delivery platform. This section will provide an overview of the most recent findings and advancements in nanotechnology for detecting and treating primary bone cancer.

Diagnosis

Osteosarcoma is the prevailing primary cancer of bone tissue, disproportionately impacting children and teenagers compared to other age groups. This is the most frequently detected primary bone cancer, with a yearly occurrence of 0.2–3 cases per 100,000 in children and 0.8–11 cases per 100,000 in adolescents. The highest occurrence is observed during the second ten years of life. Although only 20% of individuals show clinically detectable metastasis, it is presumed that the majority of the remaining 80% have undetectable micro-metastases upon diagnosis. 908 Cancer may be detected on the surface of the bone, inside the bone, or in locations outside the bone, such as the lung. 909 – 911 The malignant bone tumor is identified by the creation of immature osteoid extracellular matrix and originates from mesenchymal cells. 318 , 910 , 912 Nanotechnology-based approaches are increasingly utilized in the detection and therapy of osteosarcoma to enhance its early identification.

When a patient experiences pain, plain radiographs are frequently used to initially identify osteosarcoma. Typically, MRI with contrast enhancement is the subsequent stage in the diagnostic evaluation, and the images should encompass both the entire affected bone and the neighboring bones. The histopathological identification of osteosarcoma relies primarily on observations in specimens stained with hematoxylin and eosin, despite the wide range of morphological variations seen in osteosarcoma. In addition to visualizing the main tumor, it is crucial to conduct a chest CT scan during the initial stage to determine the extent of metastasis to the lungs, as this is the most common site for osteosarcoma metastasis. Typically, it is advisable to undergo either a bone scan or a PET scan to assess the presence of distant bone metastases. 913 , 914 Nevertheless, it has been revealed that the utilization of nanotechnology in the detection of osteosarcoma has made minimal advancements, although there are still numerous groundbreaking investigations. Meng et al. 915 proposed a novel approach involving negative CT contrast agents (NCTCAs) in order to decrease the CT-DV associated with osteosarcoma. Clinical iodides, which are the existing positive CT contrast agents (PCTCAs), exhibit a significant CT density value (CT-DV). Nevertheless, they lack the ability to provide precise diagnoses for certain diseases that have a high CT-DV, like osteosarcoma. Since bones and PCTCAs in osteosarcoma typically produce comparable levels of X-ray attenuations. Simultaneously, they fabricated empty mesoporous silica nanoparticles, incorporating ammonia borane molecules and subsequently modifying them with polyethylene glycol. These nanoparticles have been synthesized as NCTCAs for the detection of osteosarcoma. By reacting to the acidic microenvironment of osteosarcoma, the nanocomposites have the ability to generate H 2 directly at osteosarcoma sites, leading to an approximate 20-fold decrease in CT density within osteosarcoma regions. By creating a significant difference in CT density between bones and osteosarcoma, this method effectively enables precise detection and diagnosis of osteosarcoma. In addition to identifying primary osteosarcoma, it is crucial to use imaging techniques to detect lymph node metastasis in bone tumors, as it serves as a significant factor in assessing patients’ prognosis. Accurately imaging the lymph nodes is crucial for tumor staging and surgical planning, such as in the case of osteosarcoma. From a clinical perspective, the use of a radio-nanocolloid for nodal tracing is frequently restricted due to the unavailability of live visuals and insufficient anatomical data. The study conducted by Xu et al. 916 showed that the (99m)Tc-biomineralization nanoprobe has the potential to be utilized in the precise and sensitive examination of lymphatic drainage in a model of orthotopic osteosarcoma.

Early diagnosis and treatment of osteosarcoma can be bridged with the assistance of nanotechnology, which can enhance the ratio of successful cures for the disease. A novel variant of mesoporous silica-coated bismuth sulfide nanoparticles (Bi2S3@MSN NPs) was developed by Lu et al. 917 Upon being covalently linked to the arginine-glycine-aspartic acid (RGD) peptide [c(RGDyC)], the NPs demonstrated remarkable selectivity towards osteosarcoma. Because of this, their accumulation in tumor cells is ten times higher than that in the surrounding peritumoral tissues. This makes CT imaging and tumor ablation possible.

Treatment

Chemotherapy

Nanomedicine has become a prominent field in biomedical research technology, supporting the detection, treatment, and control of various diseases. Nanocarriers have the ability to effectively incorporate drugs and various molecules for precise treatment. To facilitate the therapy, various nanosystems have been created. 918 – 923 In current researches, nanotechnology-based approaches for cancer therapy are highly relevant as they aim to improve targeting efficiency, minimize systemic adverse effects, and lower drug dosage. In the realm of cancer treatment, various methods have been explored, including diverse pharmacological and mechanistic techniques.

Significant advancements have been made in the field of novel drug delivery systems, and the utilization of nanotechnology in biomedicine has emerged as a highly advantageous method. This method greatly improves the drugs’ availability (by making them more stable and dissolvable) and their distribution throughout the body. It also allows for controlled release, longer circulation, targeted delivery to specific sites, and higher levels of accumulation in tumors. As a result, it achieves a selective targeting delivery. 924 – 926 Numerous studies have demonstrated that DOX, a traditional medication for osteosarcoma, can enhance the cytotoxicity to osteosarcoma cells when utilized in conjunction with various drug delivery systems. 917 , 927 – 941 These systems include hyaluronic acid (HA) nanogel, polymeric NPs, exosomes, mesoporous silica NPs, Fe 3 O 4 NPs, calcium carbonate (CaCO 3 )-core-crosslinked NPs, liposomes, and platinum NPs (PtNPs). The use of these nanoparticles has been instrumental in addressing the challenges of drug resistance and metastasis. They have effectively enhanced the accumulation of drugs in solid tumors while minimizing the adverse effects of chemotherapy medications. Though the specific mechanisms and pathways of these drug delivery platforms to achieve targeted therapy are not completely the same, their effects on traditional chemotherapy drugs are similar and obvious.

In addition to DOX, there are other drugs that can be encapsulated in the NPs, such as berberine, methomyl, paclitaxel, curcumin and other chemotherapeutic drugs. Utilizing nanotechnology in conjunction with these medications can significantly enhance drug effectiveness while minimizing adverse reactions. For instance, Hsu et al. 942 created a new formulation of berberine NPs using heparin (HP) and BBR, with or without a shell made of linear polyethyleneimine (LPEI) to improve its effectiveness in inhibiting tumor growth in osteosarcoma U-2 OS cells. Li et al. 943 investigated the use of poloxamer-modified trimethyl chitosan (TMC) encapsulated MTX to enhance the effectiveness of osteosarcoma treatment and reduce the harmful side effects linked to the clinical application of MTX. The researchers discovered that MTCN displayed higher toxicity in MG63 cells when compared to free MTX, primarily because of its improved cellular absorption. Martella et al. 944 provided a comprehensive analysis of photo- and chemo-active keratin NPs that were loaded with two different substances. These NPs were proposed as an innovative method for delivering drugs to treat osteosarcoma, both in vitro and in a chemical context. The high molecular weight and water-soluble keratin is used to prepare the NPs, which are then functionalized with the photosensitizer Chlorin-e6 (Ce6) and loaded with the chemotherapeutic drug Paclitaxel. Li et al. exploited an effective drug targeting osteosarcoma. 945 This research examined the use of a peptide-decorated nanogel made from disulfide-crosslinked polypeptides (STP-NG) to improve the intracellular delivery of shikonin (SHK), a medicinal herb extract. The goal is to hinder the progression of osteosarcoma while minimizing any harmful effects on the body. In vitro, the STP-NG/SHK nanogel, which was specifically designed and filled with substances, effectively eliminated osteosarcoma cells by triggering necroptosis that relied on the presence of RIP1 and RIP3.

Combining NPs can also serve as a carrier for various chemotherapy medications to enhance their effectiveness against tumors. In the study conducted by Liu et al. 946 , they successfully developed and examined the therapeutic effectiveness of glycol chitosan nanoparticles loaded with both gambogic acid (GA) and retinoic acid chlorochalcone (RACC) against osteosarcoma. The glycol chitosan nanoparticles (RGNP) loaded with GA/RACC were of nanoscale size and demonstrated a controlled drug release at both pH 7.4 and pH 5.0. Due to the robust positive charge on the surface of RGNP, cancer cells exhibited efficient cellular uptake. Li et al. 933 synthesized a copolymer called mPEG-PαLA by attaching polyethylene glycol (PEG) to poly(α-lipoic acid). This copolymer was designed to act as a nanocarrier that responds to changes in both reduction and pH levels. It was used to carry both paclitaxel and DOX concurrently for the treatment of osteosarcoma. The NP-PTX-DOX sample exhibited an increased release of PTX and DOX when exposed to reducing and acidic conditions.

Other therapy

In addition to chemotherapy, other treatment methods can also apply nanotechnology to deliver the drugs, such as genetic therapy, radiotherapy, immunotherapy and so on. 947 – 951 The efficacy of pharmacological therapy is hindered by the limited penetration of drugs into the bone marrow, mostly attributed to the existence of the bone marrow-blood barrier. Luo et al. presented their findings on the utilization of neutrophils as a means of delivering free medicines and drug NPs specifically to the bone marrow. The study demonstrated the absorption of drug-loaded poly (lactic-co-glycolic acid) NPs by neutrophils and their subsequent transfer through the bone marrow-blood barrier, leading to increased drug levels in the bone marrow. The findings of this study demonstrated that the administration of cabazitaxel by neutrophil transport in a bone metastasis cancer model led to a substantial suppression of tumor growth (Fig. 5 ). 952 Haghiralsadat et al. reported that siRNA, which will not be hardly cleared in the blood, can successfully reach the tumor cells and be released in the acidic environment. 936 Similar results were obtained in the research by Wang et al. 953 As for immunotherapy, it has been reported that all-trans retinoic acid (ATRA), a metabolically active form of vitamin A belonging to the retinoid family, will not change the structure and biological characteristics of the drug, but can promote the drug act on the target rapidly and efficiently by using nanomaterials-based carriers. 954 , 955 Zhang et al. created therapeutic gadolinium-based metal-bisphosphonate NPs dubbed OVA-GdZol NPs that were stabilized by ovalbumin (OVA) and worked as both radiosensitizers and immune adjuvants for osteosarcoma treatment. 956 Fig. 5 Bone marrow-derived neutrophils ingest nanopharmaceuticals containing CTX, transforming into NPs@NEs. These cells return to the bone marrow, where they exert a therapeutic effect on senescent bone metastatic tumors. (Created with BioRender.com) Reproduced with permission from Luo et al. (2023), Copyright 2023 Springer Nature Limited

Cartilage malignancies occur in various parts of the body and tend to be more prevalent as individuals get older. Conventional chondrosarcoma may typically be cured with surgery, particularly when it is at a low histologic grade. However, alternative treatments are pursued when the tumor cannot be removed surgically, which usually happens after several local recurrences or the formation of pulmonary metastases. 957 The palliative use of cisplatin and DOX can sometimes provide therapeutic benefit for those with advanced disease and a favorable performance status. There is few research progress in nanotherapy of chondrosarcoma. According to a publication, chondrosarcoma cells were exposed to an epithelial neuron beam in vitro after the delivery of b-MSNs and exposure to BNCT (boron-neutron capture treatment) beam. This exposure effectively caused DNA damage and subsequent cell death. 958

Ewing sarcoma is a malignant tumor that primarily develops in the bones (especially in the femur, tibia, ribs and pelvis) or soft tissues (particularly in the cervical muscles, thoracic wall, pleural cavities, and gluteal muscle). It mainly affects children, adolescents, and young adults, with approximately 1.5 cases per million individuals in this age group worldwide. 959 Patients having a new diagnosis of Ewing sarcoma are treated with a combination of local control measures (radiation therapy and/or surgery) and multi-agent cytotoxic chemotherapy. 960 Induction chemotherapy is administered prior to local treatment in order to diminish the size of the primary malignancy and inhibit micro-metastatic lesions, as it is anticipated to be present in all patients. 961 Although the nanotherapy for Ewing’s sarcoma has not been extensively studied, it has been proven that the targeted administration and controlled release of SN-38 from gold NPs in Ewing sarcoma cells is highly effective both in in vitro and in vivo studies. 962 Besides, hydrolyzed galactomannan (hGM)-based amphiphilic NPs also showed favorable performance of rapid accumulation in the tumor tissue. 963 Additionally, due to Ewing sarcoma being caused by a fusion oncogene, such as EWSYFli1, a siRNA molecule could be used to reduce its expression. Toub et al. 964 utilized noncationic polyisobutylcyanoacrylate nanocapsules as a safeguard in vivo delivery mechanism for siRNA molecules targeting the Ewing sarcoma oncogene. This method was significantly more effective at inhibiting tumor growth compared to using free siRNA.

Nanomedicine in skin cancers

Malignant melanoma (MM) is the most serious form among skin cancers. This is the fifth most prevalent cancer among both men and women in the United States. 965 Cutaneous squamous cell carcinoma (cSCC) is the second most frequent nonmelanoma skin cancers (NMSCs) after basal cell carcinoma (BCC). 966 The cSCC and BCC account for 99% of NMSCs. 965 , 967 , 968 According to the up-to-date clinical guideline, 969 , 970 the most widely-used radical cure for skin cancers today is still surgery. The other mainstream treatments include cryotherapy, photodynamic therapy, immunotherapy and chemotherapy. However, traditional non-surgery treatments for skin cancers have some troubles in the precise positioning and infiltration through the barrier of skin. Thus, the NP is promising in the application of any kinds of therapeutic tactics except of surgery to overcome the disadvantage of traditional treatments. As for the diagnosis of skin cancer, most of MM and NMSCs depend on dermoscopy and biopsy, which are relatively more available and accurate than other cancer types because of the location on the surface. 971 – 974 In that case, since the dermoscopy and biopsy can meet the demand of diagnosis of skin cancer, limited researches are dedicated in exploring the potential of NP in the area of diagnosis.

Diagnosis

Unlike NMSCs, since there is no single pathological feature to diagnose melanoma, histopathological diagnosis is based on a combination of structural, cytological, and host reaction characteristics. Immunohistochemistry, helpful in distinguishing the melanocytic origin of difficult lesions, and other types of molecules methods are widely applied in the diagnosis of MM, 975 which meet the common requirement with both sensitivity and specificity of above 90%. 976 According to Wang et al., the H 2 O 2 -responsive photoacoustic (PA) imaging modality can also be used in differential diagnosis by different enhanced tumor signals among different skin cancers. In addition, it is recognized that the increasing level of hydrogen peroxide is relevant to the proliferation of tumor cells. Under this hypothesis, Wang et al. managed to develop a probe named intelligent H2O2-responsive ABTS-loaded HRP@Gd nanoprobes (iHRANPs) to determine the position of cancer tissue and distinguish cSCC from malignant melanoma. 977

Treatment

Compared to NMSCs, malignant melanoma is more aggressive and has more opportunity to metastasize, which means it is relatively difficult to treat and leads to a worse prognosis. 978 – 982 As for the malignant melanoma with a limit level of metastasis, surgery can always make a good prognosis. 978 Therefore, the greatest challenge today of malignant melanoma is treatment of metastatic malignant melanoma, 983 , 984 in which nanoparticle material is promising. Similar to NPs application of other tumors, one of the most crucial strategies of malignant melanoma treatment is tackle the TME. Pu et al. 981 designed a NP-based oxidative stress amplifier named APAP@PEG/HMnO 2 to enhance the response of oxidative stress for melanoma therapy. Tyrosinase, over-expressed in malignant melanoma cells, is considered as a special target that can activate the anti-melanoma prodrugs. In that case, APAP@PEG/HMnO 2 is modified to be triggered by tyrosinase so that the non-toxic prodrug acetaminophen (APAP) can be precisely escorted to the position of malignant melanoma. After the accumulation of this NPs, amount of oxygen will be generated by HMnO 2 to interfere the TME at the same time as APAP is released to produce cytotoxic benzoquinone metabolites (AOBQ), which can induce the generation of reactive oxygen species (ROS) and lead to tumor cells apoptosis. A kind of RBC membrane-cloaked NPs called R-RBC@BPtI 280 and an inorganic material NPs named Au@Se-R/A NCs 985 can also accelerate the intracellular ROS overproduction to attack TME and treat malignant melanoma. In addition to the method of ROS, assistant position of PTT or PDT, 977 , 986 – 989 immune therapy 280 , 990 – 993 and gene-related therapy 994 , 995 of NPs are promising in the treatment of metastatic MM as well, even though advanced trials are required.

Although the widely recognized treatment for NMSCs is surgery, many patients have contraindications of operation. Since the lesions of NMSCs cannot be removed easily, the efficacy of surgery largely depends on the individual facts especially the surgical technique. Besides, during the surgery, some normal tissues will be removed as well, which will enlarge the scar and even lead to the psycho-social problems of patients. Photodynamic therapy (PDT) and photothermal therapy (PTT) are both regarded as relatively more stable, precise and efficient therapies than surgery, 996 , 967 which can cooperate with nanomedicine technology in treatment of cSCC. 997 – 1000 Most of the nanomaterial in treatment of skin cancer is for positon or imaging of PDT or PTT. According to Wang et al. 1001 , aminolevulinic acid-loaded PLGA NP (ALA-PLGA NP) can carry 5-ALA, an add-on substance can induce the protoporphyrin IX production in cSCC. This effective and targeting method provides a promising strategy in PDT of cSCC. Beside the application of orientation of phototherapy, NPs can also be applied in the topical drug delivery for skin cancer as well. 1002 – 1004 He et al. designed hybrid peptide-based nanoplatform named Lupbin which is multiple-targeting and can easily penetrate the cell membrane, can carry drugs in cytosol and nucleus to attack tumor cells. 1005

Nanomedicine in other cancers

Diagnosis

Thyroid cancer can be categorized into two groups by cellular origin: (1) follicular epithelial cell derived cancers; (2) parafollicular cell (C cell) derived cancer. Follicular derived cancers consist of papillary, follicular and anaplastic cancers, while C cell-derived cancer is mainly medullar type. Thyroid cancers vary in terms of incidence and lethality, driving the differential diagnosis especially important. Generally, in the past few decades, the incidence of thyroid cancer has been gradually climbing while the mortality rate has been decreasing steadily in most countries. 1006 , 1007 This is partly due to the ever-improving rate of diagnosis and treatment, enabling much earlier detection and better management of the thyroid cancer. Over 95% of thyroid cancers are differentiated cancers (mainly papillary thyroid cancer and follicular thyroid cancer) in which optimal over prognosis are observed. 1008 However, high aggressiveness can be seen in some rarer thyroid cancers like anaplastic thyroid cancer (ATC), which is poorly differentiated, highly metastatic and lacking in normal functions of normal follicular cells, for example, taking in iodine. 1009 Patients show fast-growing neck mass and symptoms like hoarseness, dysphagia and dyspnea and few of them can survive over 6 months upon being diagnosed. 1008 , 1009 Genetical and chromosomal changes can be observed in thyroid cancer cells. Abnormal changes of mitogen-activated protein kinase (MAPK) pathway are believed to be a major indicator for differentiated thyroid cancers (DTC), while RET proto-oncogene mutations for medullary thyroid cancer (MTC) and chromosomal abnormalities along with several mutations such as TP53 and CTNNB1 for ATC. 1008 – 1011 Diagnostic researches of thyroid cancer have been long focused on non-invasive diagnosis. Gold, platinum and iron oxide NPs have been reported to be fabricated as novel diagnostic tools for thyroid malignancies. Omer et al. designed a kind of gold nanobiosensor in the sol-gel/PEG matrix to detect the calcitonin, which is secreted by neuroendocrine C cells, functioning as an excellent biomarker for early diagnosing MTC. 1012 By assessing calcitonin in serum, the method offered a convenient possibility of MTC early diagnosis as well as evaluating therapeutic effects of treatment. A biosensor made by Choi et al., combined platinum NPs with TSH detection antibody-conjugated horseradish peroxidase. 1013 With high sensitivity of assessing TSH level in the serum, they were able to detect a 100-fold lower level compared to the enzyme immunoassay on the market. Contrast agents combined with ligands showed better biocompatibility and targeting ability. 1014 , 1015 Fanfone et al. improved the contrast agent for MRI, by conjugating selected peptides to the vectorized iron oxide NPs. 1015 In vitro experiments showed ideal toxicity and binding specificity with DTC cells, making it a possible candidate as imaging probes in diagnosing thyroid cancer.

Breast cancer is a prevalent malignancy among women, with an increasing prevalence. 1 , 1016 Breast cancer is characterized by the uncontrolled division and proliferation of cells in the breast tissue. Breast cancer contains various forms, which are determined by the origin within breast tissue and the extent of its spread. These varieties include ductal carcinoma in situ, invasive ductal carcinoma, lobular carcinoma in situ, and invasive lobular carcinoma. Breast cancer exhibits various molecular subtypes, including Luminal A, Luminal B, HER2 positive, and triple negative. 1017 , 1018 Nanobiosensors have demonstrated great potential in the detection of a variety of biomarkers, circulating tumor cells, and other unique biomolecules in diagnosis of breast cancer. 1019 – 1023 MicroRNA miR-99a-5p dysregulation has been identified as a reliable indicator of early breast cancer. Garrido-Cano et al. demonstrated a novel nanoporous anodic alumina-based biosensor for breast cancer diagnostics with great sensitivity and selectivity for detecting plasma miR-99a-5p. 1024

Treatment

Treatment strategies normally differ among all subtypes in thyroid cancers. Standard treatment for DTC is usually effective with surgery (lobectomy, total thyroidectomy, with or without lymph node dissection), followed by TSH suppression with L-T or radioactive iodine. 1025 – 1027 However, problems are hiding behind the radioactive therapy and TSH suppression. The purpose of using radioactive iodine is to clear the residual cancer cells in the body after surgery. However, it can increase the systemic exposure to the radioactive agent as well as the chance of second primary malignant tumors. 1028 – 1030 Although the strategy of TSH suppression has been proven effective in reducing the recurrence of DTC, the adverse effects on cardiovascular and skeletal systems as well as the potential of increasing the risk of malignant tumors in other systems cannot be neglected. 1025 , 1031 – 1033 Treatment for MTC is generally surgery followed by observation, and metastatic MTC is managed by kinase inhibitors. For example, vandetanib and cabozantinib also have the limitations on efficacy. 1034 , 1035 Surgical interventions, external radiation therapy and chemoradiation therapy are considered for ATC, yet its high histomorphological abnormalities and biological behaviors promote the management as a challenging work. 1009 , 1036 , 1037 Here, recent advances of nanomedicines utilized in thyroid cancer treatment are focused and discussed.

To improve the therapeutic effects and reduce systemic toxicity of normal treatments, several kinds of nanomedicines have been designed and applied to treat thyroid cancers, including exosomes, 261 , 1038 liposomes, 1039 inorganic NPs (silicon, 883 , 1040 – 1042 carbon, 1043 gold, 1044 , 1045 silver 1046 , 1047 ) and so on. These nanomedicines exhibited many therapeutic priorities compared with the conventional treating protocols, especially in anaplastic thyroid cancer which poses the greatest obstacle in all thyroid cancers. Several progress regarding ATC treatment has been made in the past few years, mainly achieved by precise photothermal ablation improved by the NP modifications, 1048 by combining nanotube-delivered drugs and shock waves to increase the intracellular drug accumulation, 1049 by targeting vascular endothelial growth factor receptor and increase NP accumulation, 883 , 1042 , 1048 by targeted nanoplatform delivery of RNAi agents, 1050 and by targeting cancer cells using NK cell-derived extracellular particles. 1043 All those explorations offer us new ideas of conquering the barriers of ATC treatment.

Nanomedicines can also be helpful assistants for the surgery. Carbon NPs (CNs) were reported to be lymph node tracers in thyroid microcarcinoma surgeries for the purpose of showing lymph nodes and preserving parathyroid glands. Results suggest CNs could be an ideal choice for the aim of tracing and preservation, for it helps retrieve more lymph nodes of metastasis, reduces unwanted parathyroid gland removal, and leads to a shorter recovery duration. 1051 – 1062 However, the significance of the improvement remains controversial. Some insignificant reported negative results in the comparison of lymph nodes removed and parathyroid glands preserved, 1063 while some reported insignificant changes of hypocalcemia incidence (confirmed by a meta-analysis in 2017) 1062 , 1064 – 1066 nor number of metastatic lymph nodes detected. 1065 Since a huge amount of new results are being reported during these years, a new and more comprehensive meta-analyses are in urgent demand to solve the controversy.

The current treatment strategies for breast cancer encompass surgery, chemotherapy, radiotherapy, hormone therapy, and immunotherapy, with adjuvant systemic therapy always required. Nanomedicines are emerging as promising breast cancer therapeutic agents that could correct drugs defects and ensure precise drug distribution. 1067 – 1071 Zhang et al. created the PPD self-assembling dendrimer nanosystem, which was coated with an anti-PD-L1 antibody and used to deliver a small interfering RNA (siRNA) to target PDK1. PPD significantly inhibits both PDK1-induced glycolysis and the PD-1/PD-L1 pathway-related immune response, resulting in strong reduction of tumor development and metastasis in tumor-bearing mice models with no discernible harm. 1072 A promising method for treating breast cancer non-invasively is photothermal therapy (PTT). Nanoparticles with unique properties for penetrating and targeting tumor tissues enhance the efficacy of PTT and have recently attracted increased interest of researchers. 1019 , 1073 – 1075 During anti-tumor nanotherapy, it is frequently discovered that therapeutic NPs have trouble penetrating into the tumor tissue, resulting in disappointing treatment outcomes. The study conducted by Wang et al. provided evidence that the tumor vascular basement membrane, in addition to the endothelial barrier, functioned as a significant mechanical obstacle which firmly trapped NPs within the subendothelial space. In an experimental model of breast cancer in mice, researchers successfully broke the basement membrane barrier and enhanced the efflux of NPs by applying local hyperthermia therapy. 1076

Prospect and challenges

Prospects

Nanomedicine is an emerging area with rapid developments, and being regarded as a promising tactic in solving problems in the diagnosis and treatment of cancer. Cancer cells, especially for solid tumors often highly express some receptors or ligands for the substance-transport and recognition among cells. Scientists can design corresponding targeting strategies based on understanding the intrinsic bio-characteristics of tumors. Nanoparticles designed to target tumor cells can precisely detect malignant tumors in the body, facilitating early diagnosis and accurate localization of cancer. This offers healthcare practitioners more accurate data, which helps in creating customized treatment plans and allows for the implementation of integrated diagnosis and treatment strategies. Nanotechnology’s exceptional performance enables the loading of several materials and the integration of diagnostic and treatment. Therapeutic medications and contrast agents can both be encapsulated in nanoparticles simultaneously to achieve imaging diagnostic and visual therapy effects.

With the developments of material science and computation technology, the nanovector for loading the aimed drugs is also emerging in endlessly, to satisfy the demands of delivering small-molecule-based chemotherapeutic drugs, genes and antibodies, etc. The nano-complex can reach a long-circulation and arrive the tumor site in a positive or passive manner. By integrating the drug carrier with nanoparticles, accurate drug delivery to the tumor site can be achieved, enhancing the medication’s local concentration and minimizing adverse effects on healthy tissues. Cancers are often with specific tumor microenvironment that generates obvious variation in biomarkers, which can be used as the trigger for promoting the drug-release of the nanocarriers upon reaching the tumor lesions. Sophisticated design can normally achieve a controlled drug-release kinetics to favor the need in precise tumor therapy at the aimed time and position. With all the efforts shown above, a fine therapeutic efficacy can be achieved with lower side-effects. Nanotechnology can also be used in photothermal therapy and immunotherapy by using nano materials to treat tumor cells with heat or stimulate the immune system to eliminate malignant cells.

The heterogeneity of tumors should always be considered during the therapeutic procedures in clinic. We should also pay attention to the necessity of pharmacokinetics and toxicology analysis of nanomaterials in vivo, and further optimize the pharmacokinetic effects and strengthen the therapeutic effects. However, the clinical approaches normally display hysteretic effects in combining therapies and diagnoses, which could bring about over-dose of drugs and unexpected unnecessary effects. The real-time distribution of the drugs in vivo is also difficult to be monitored upon being administrated intravenously. Nanotechnology-based vectors, to some extent, are emerging as promising tactics in providing theraonostic information in a spatial-tempo way.

Challenges

It is generally agreed that the tumor microenvironment (TME) accounts for the disappointing results of nanomedicine therapy. 185 , 1077 – 1082 TME, including malignant cells, tumor-associated fibroblasts (CAFs or TAFs), certain kinds of immune cells, and stroma (vessels and extravascular matrix), plays an indispensable role in the medicine resistance of cancer. 1083 Martin et al. 1077 hypothesized that the TME appears to limit drug delivery and immune cell migration through three key steps: immune cell/drug accumulation, distribution, and function. Three key mechanisms implement these effects: abnormal angiogenesis, desmoplasia, and hypoxia. In this case, the “renormalization or reeducation” of the TME, including the normalization of the vasculature to improve perfusion and the mediation of CAFs to reduce the level of ECM (extracellular matrix), is a possible and accessible strategy to optimize the design of nanomedicine, even if the whole mechanism of chemotherapy and immunotherapy resistance is relatively complicated.

Although the active targeting of nano drugs shows great potential in cancer, the clinical application of nano drugs is still unhurried. Firstly, due to safety issues in preclinical and clinical studies, the approval rate of emerging nano-drugs is less than 10%, and biosafety issues have attracted increasing attention. 1067 , 1083 – 1086 It is commonly recognized that the oxidative stress that follow the production of reactive oxygen species, as well as inflammation account for the toxicity of nanoparticles. In vivo, NPs will go through four stages: absorption, distribution, metabolism, elimination. The metabolism and breakdown of NPs is mainly done in the liver and kidneys. It is generally believed that the excretion of NPs primarily occurs through the kidneys in the form of urine, and through the biliary duct in the form of feces. 302 Nonetheless, some studies have indicated that some nanoparticles might not break down or be eliminated, and inadequate elimination may cause the NPs to remain in the body for a long time. 303 , 1087 , 1088 Accumulation of nanocarriers in normal organs could induce physical damage, which refers to the cell damage caused by NPs through the physical obstruction of microcirculation, which triggers a series of toxic reactions, such as cell dysfunction or inflammatory reaction. The physical damage caused by the nanocarrier is mostly due to the nanocarrier’s inability to biodegrade and its ability to aggregate and move freely in bodily tissues, resulting in long-term physical harm. 1089 – 1093 Therefore, the development of fine biodegradable and biocompatible nano-drug carriers is the main direction of nanomaterials research at present.

Secondly, the difficulty in finding an appropriate pre-clinical research model that truly represents the human condition and the lack of validated analytical methods to characterize nanoparticles are also important factors that hinder the development of nano-drugs. 726 , 1094 – 1096 The development of favorable biodegradable and biocompatible nano-drug carriers, the establishment of standardized analytical methods to characterize nanoparticles, and the construction of methods to monitor the safety and efficacy of nano drugs, as well as the understanding of structure-and-property relationship of the nanomedicines will be major challenges in the future. At the same time, with the development of new biological materials and nanotechnology, more effective and safe nanomaterials will be more designed for targeted drug delivery to cancer.

The clinical translation in nanomedicine should always be considered as the ultimate goal. This requests the scientists to seriously tailoring the building materials, size, surficial property, charge in the design, the drug loading/encapsulating efficiency, drug distribution, as well as metabolism and excretion of the vectors during applications. 1096 , 1097 During the clinical translation phase, nanomedicines face various challenges, especially related to the establishment of pharmacokinetic models, the formulation of nanomedicines, and the evaluation of their biological properties. The rational design of physicochemical properties of nanomedicine is critical in allowing nanomedicine immune evasion, tumor extravasation and diffusion, cellular targeting and internalization, and controlled release of therapeutic drugs. Nevertheless, the systematic simultaneous evaluation of the numerous properties of NPs continues to pose difficulties due to the inherent challenge of synthesizing NP libraries with distinct characteristics in a rapid, accurate, and reproducible manner. 1098 Actually, the biocompatibility is currently regarded as one of the bottlenecks in clinical translation. Most nanotechnology-based drug delivery systems can achieve favorable results in the cell and animal models, however, more challenges are still facing upon the clinical II–IV trials as human bodies vary greatly from the animal models. 1099 A classic example is the so-called EPR effect, which is normally observed in animal models and support the mechanism of most nanosystems in accumulating into the tumors. However, few evidences have been found in clinical research about EPR effect in human bodies. These phenomena request us to exploit new and reliable evidences, theory and techniques in developing drug delivery systems.

In summary, employing nanomedicine in treating cancers are still in the ascendant, since nanotechnology possesses multiple advantages and many of which can fit the requirements in tumor treatment. Ideally, the therapeutic nanotechnology-based vectors should be able to specifically deliver the loaded cargos into the tumor, after which the vectors should be bio-degraded with no side effects. Numerous works, including the principle-establishment, material-design, animal model development and the deep understanding of tumors’ biological characteristics, should be undertaken in better utilizing nanotechnology in battling cancers in a more efficient way.

These authors contributed equally: Bilan Wang, Shiqi Hu

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Nos. 82172643, 32222046 and 32371545, China), the Sichuan Science and Technology Program (No. 2023NSFSC1931, China) and the 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (No. ZYJC21022, China).

Author contributions

Conceptualization: X.G., B.W., S.H., and Y.C.; writing—original draft: B.W., S.H., Y.T., J.C., H.W., Y.X., K.W., and J.X.; writing—review and editing: X.G., S.H., and Y.T.; visualization: S.H., Y.C., and X.G.; supervision: Y.C. and X.G.; funding acquisition: Y.C. and X.G. The submitted version was approved by all authors.

Competing interests

The authors declare no competing interests.

References

1. Siegel RL Miller KD Wagle NS Jemal A Cancer statistics, 2023 CA-Cancer J. Clin. 2023 73 17 48 10.3322/caac.21763 36633525 Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA-Cancer J. Clin. 73 , 17–48 (2023). 36633525 10.3322/caac.21763

2. Sung H Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA-Cancer J. Clin. 2021 71 209 249 10.3322/caac.21660 33538338 Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J. Clin. 71 , 209–249 (2021). 33538338 10.3322/caac.21660

3. Siegel RL Miller KD Jemal A Cancer statistics, 2019 CA-Cancer J. Clin 2019 69 7 34 10.3322/caac.21551 30620402 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA-Cancer J. Clin 69 , 7–34 (2019). 30620402 10.3322/caac.21551

4. McGuire S Geneva, Switzerland: world health organization, international agency for research on cancer, WHO press, 2015 Adv. Nutr. 2016 7 418 419 10.3945/an.116.012211 26980827 PMC4785485 McGuire, S. Geneva, Switzerland: world health organization, international agency for research on cancer, WHO press, 2015. Adv. Nutr. 7 , 418–419 (2016). 26980827 10.3945/an.116.012211 PMC4785485

5. Wells JC An analysis of contemporary oncology randomized clinical trials from low/middle-income vs high-income countries JAMA Oncol 2021 7 379 385 10.1001/jamaoncol.2020.7478 33507236 PMC7844695 Wells, J. C. et al. An analysis of contemporary oncology randomized clinical trials from low/middle-income vs high-income countries. JAMA Oncol 7 , 379–385 (2021). 33507236 10.1001/jamaoncol.2020.7478 PMC7844695

6. Pramesh CS Priorities for cancer research in low- and middle-income countries: a global perspective Nat. Med. 2022 28 649 657 10.1038/s41591-022-01738-x 35440716 PMC9108683 Pramesh, C. S. et al. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat. Med. 28 , 649–657 (2022). 35440716 10.1038/s41591-022-01738-x PMC9108683

7. Slomski A Global cancer burden grew from 2010 to 2019 Jama 2022 327 804 35230404 10.1001/jama.2022.2188 Slomski, A. Global cancer burden grew from 2010 to 2019. Jama 327 , 804 (2022). 35230404 10.1001/jama.2022.2188

8. Harbeck N Breast cancer Nat. Rev. Dis. Primers. 2019 5 66 10.1038/s41572-019-0111-2 31548545 Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Primers. 5 , 66 (2019). 31548545 10.1038/s41572-019-0111-2

9. Cives, M. & Strosberg, J. R. Gastroenteropancreatic Neuroendocrine Tumors. CA: Cancer J. Clin . 68 , 471–487 (2018). 10.3322/caac.21493 30295930

10. Cheng L Testicular cancer Nat. Rev. Dis. Primers. 2018 4 29 10.1038/s41572-018-0029-0 30291251 Cheng, L. et al. Testicular cancer. Nat. Rev. Dis. Primers. 4 , 29 (2018). 30291251 10.1038/s41572-018-0029-0

11. Crosbie EJ Endometrial cancer Lancet 2022 399 1412 1428 10.1016/S0140-6736(22)00323-3 35397864 Crosbie, E. J. et al. Endometrial cancer. Lancet 399 , 1412–1428 (2022). 35397864 10.1016/S0140-6736(22)00323-3

12. Leon-Ferre RA Goetz MP Advances in systemic therapies for triple negative breast cancer BMJ 2023 381 e071674 10.1136/bmj-2022-071674 37253507 Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple negative breast cancer. BMJ 381 , e071674 (2023). 37253507 10.1136/bmj-2022-071674

13. Chainitikun S Update on systemic treatment for newly diagnosed inflammatory breast cancer J. Adv. Res. 2021 29 1 12 10.1016/j.jare.2020.08.014 33842000 PMC8020152 Chainitikun, S. et al. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J. Adv. Res. 29 , 1–12 (2021). 33842000 10.1016/j.jare.2020.08.014 PMC8020152

14. Turchan WT Pitroda SP Weichselbaum RR Radiotherapy and immunotherapy combinations in the treatment of patients with metastatic disease: current status and future focus Clin. Cancer Res. 2021 27 5188 5194 10.1158/1078-0432.CCR-21-0145 34140404 Turchan, W. T., Pitroda, S. P. & Weichselbaum, R. R. Radiotherapy and immunotherapy combinations in the treatment of patients with metastatic disease: current status and future focus. Clin. Cancer Res. 27 , 5188–5194 (2021). 34140404 10.1158/1078-0432.CCR-21-0145

15. De Ruysscher D Radiotherapy toxicity Nat. Rev. Dis. Primers. 2019 5 13 10.1038/s41572-019-0064-5 30792503 De Ruysscher, D. et al. Radiotherapy toxicity. Nat. Rev. Dis. Primers. 5 , 13 (2019). 30792503 10.1038/s41572-019-0064-5

16. Schaue D McBride WH Opportunities and challenges of radiotherapy for treating cancer Nat. Rev. Clin. Oncol. 2015 12 527 540 10.1038/nrclinonc.2015.120 26122185 PMC8396062 Schaue, D. & McBride, W. H. Opportunities and challenges of radiotherapy for treating cancer. Nat. Rev. Clin. Oncol. 12 , 527–540 (2015). 26122185 10.1038/nrclinonc.2015.120 PMC8396062

17. Bernier J Hall EJ Giaccia A Radiation oncology: a century of achievements Nat. Rev. Cancer. 2004 4 737 747 10.1038/nrc1451 15343280 Bernier, J., Hall, E. J. & Giaccia, A. Radiation oncology: a century of achievements. Nat. Rev. Cancer. 4 , 737–747 (2004). 15343280 10.1038/nrc1451

18. Citrin DE Recent developments in radiotherapy New Engl. J. Med 2017 377 1065 1075 10.1056/NEJMra1608986 28902591 Citrin, D. E. Recent developments in radiotherapy. New Engl. J. Med 377 , 1065–1075 (2017). 28902591 10.1056/NEJMra1608986

19. Kirby AM Should patients requiring radiotherapy for breast cancer be treated with proton beam therapy? BMJ 2023 381 e072896 10.1136/bmj-2022-072896 37295798 Kirby, A. M. et al. Should patients requiring radiotherapy for breast cancer be treated with proton beam therapy? BMJ 381 , e072896 (2023). 37295798 10.1136/bmj-2022-072896

20. Chandra RA Keane FK Voncken FEM Thomas CR Jr. Contemporary radiotherapy: present and future Lancet 2021 398 171 184 10.1016/S0140-6736(21)00233-6 34166607 Chandra, R. A., Keane, F. K., Voncken, F. E. M. & Thomas, C. R. Jr. Contemporary radiotherapy: present and future. Lancet 398 , 171–184 (2021). 34166607 10.1016/S0140-6736(21)00233-6

21. Yan S Ngoma TA Ngwa W Bortfeld TR Global democratisation of proton radiotherapy Lancet Oncol 2023 24 e245 e254 10.1016/S1470-2045(23)00184-5 37269856 Yan, S., Ngoma, T. A., Ngwa, W. & Bortfeld, T. R. Global democratisation of proton radiotherapy. Lancet Oncol 24 , e245–e254 (2023). 37269856 10.1016/S1470-2045(23)00184-5

22. Banfill K Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions J. Thorac. Oncol. 2021 16 216 227 10.1016/j.jtho.2020.11.002 33278607 PMC7870458 Banfill, K. et al. Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions. J. Thorac. Oncol. 16 , 216–227 (2021). 33278607 10.1016/j.jtho.2020.11.002 PMC7870458

23. Marshall DC Female erectile tissues and sexual dysfunction after pelvic radiotherapy: a scoping review CA: Cancer J. Clin 2022 72 353 359 35298025 10.3322/caac.21726 PMC9262811 Marshall, D. C. et al. Female erectile tissues and sexual dysfunction after pelvic radiotherapy: a scoping review. CA: Cancer J. Clin 72 , 353–359 (2022). 35298025 10.3322/caac.21726 PMC9262811

24. Martin JM Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy Lancet Oncol 2022 23 e534 e543 10.1016/S1470-2045(22)00544-7 36455582 Martin, J. M. et al. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. Lancet Oncol 23 , e534–e543 (2022). 36455582 10.1016/S1470-2045(22)00544-7

25. Fokas E Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives Cancer Treat. Rev. 2023 112 102490 10.1016/j.ctrv.2022.102490 36463667 Fokas, E. et al. Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives. Cancer Treat. Rev. 112 , 102490 (2023). 36463667 10.1016/j.ctrv.2022.102490

26. Wu Y Song Y Wang R Wang T Molecular mechanisms of tumor resistance to radiotherapy Mol. Cancer 2023 22 96 10.1186/s12943-023-01801-2 37322433 PMC10268375 Wu, Y., Song, Y., Wang, R. & Wang, T. Molecular mechanisms of tumor resistance to radiotherapy. Mol. Cancer 22 , 96 (2023). 37322433 10.1186/s12943-023-01801-2 PMC10268375

27. Zhou J Yu G Huang F Supramolecular chemotherapy based on host-guest molecular recognition: a novel strategy in the battle against cancer with a bright future Chem. Soc. Rev. 2017 46 7021 7053 10.1039/C6CS00898D 28980674 Zhou, J., Yu, G. & Huang, F. Supramolecular chemotherapy based on host-guest molecular recognition: a novel strategy in the battle against cancer with a bright future. Chem. Soc. Rev. 46 , 7021–7053 (2017). 28980674 10.1039/C6CS00898D

28. O’Connor MJ Targeting the DNA damage response in cancer Mol. Cell 2015 60 547 560 10.1016/j.molcel.2015.10.040 26590714 O’Connor, M. J. Targeting the DNA damage response in cancer. Mol. Cell 60 , 547–560 (2015). 26590714 10.1016/j.molcel.2015.10.040

29. Herzog BH Devarakonda S Govindan R Overcoming chemotherapy resistance in SCLC J. Thorac. Oncol. 2021 16 2002 2015 10.1016/j.jtho.2021.07.018 34358725 Herzog, B. H., Devarakonda, S. & Govindan, R. Overcoming chemotherapy resistance in SCLC. J. Thorac. Oncol. 16 , 2002–2015 (2021). 34358725 10.1016/j.jtho.2021.07.018

30. Gonzalez-Molina J Chemotherapy as a regulator of extracellular matrix-cell communication: implications in therapy resistance Semin. Cancer Biol. 2022 86 224 236 10.1016/j.semcancer.2022.03.012 35331851 Gonzalez-Molina, J. et al. Chemotherapy as a regulator of extracellular matrix-cell communication: implications in therapy resistance. Semin. Cancer Biol. 86 , 224–236 (2022). 35331851 10.1016/j.semcancer.2022.03.012

31. Blayney DW Schwartzberg L Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review Cancer Treat. Rev. 2022 109 102427 10.1016/j.ctrv.2022.102427 35785754 Blayney, D. W. & Schwartzberg, L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review. Cancer Treat. Rev. 109 , 102427 (2022). 35785754 10.1016/j.ctrv.2022.102427

32. Printezi MI Toxicity and efficacy of chronomodulated chemotherapy: a systematic review Lancet Oncol 2022 23 e129 e143 10.1016/S1470-2045(21)00639-2 35240088 Printezi, M. I. et al. Toxicity and efficacy of chronomodulated chemotherapy: a systematic review. Lancet Oncol 23 , e129–e143 (2022). 35240088 10.1016/S1470-2045(21)00639-2

33. Marchetti C Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments Semin. Cancer Biol. 2021 77 144 166 10.1016/j.semcancer.2021.08.011 34464704 Marchetti, C. et al. Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. Semin. Cancer Biol. 77 , 144–166 (2021). 34464704 10.1016/j.semcancer.2021.08.011

34. Kuderer NM Desai A Lustberg MB Lyman GH Mitigating acute chemotherapy-associated adverse events in patients with cancer Nat. Rev. Clin. Oncol. 2022 19 681 697 10.1038/s41571-022-00685-3 36221000 Kuderer, N. M., Desai, A., Lustberg, M. B. & Lyman, G. H. Mitigating acute chemotherapy-associated adverse events in patients with cancer. Nat. Rev. Clin. Oncol. 19 , 681–697 (2022). 36221000 10.1038/s41571-022-00685-3

35. Jiang D Nanomedicines for renal management: from imaging to treatment Accounts Chem. Res. 2020 53 1869 1880 10.1021/acs.accounts.0c00323 PMC7494607 32786331 Jiang, D. et al. Nanomedicines for renal management: from imaging to treatment. Accounts Chem. Res. 53 , 1869–1880 (2020). 10.1021/acs.accounts.0c00323 PMC7494607 32786331

36. Kopecek J Yang J Polymer nanomedicines Adv. Drug Deliver. Rev. 2020 156 40 64 10.1016/j.addr.2020.07.020 PMC7736172 32735811 Kopecek, J. & Yang, J. Polymer nanomedicines. Adv. Drug Deliver. Rev. 156 , 40–64 (2020). 10.1016/j.addr.2020.07.020 PMC7736172 32735811

37. Lammers T Dexamethasone nanomedicines for COVID-19 Nat. Nanotechnol. 2020 15 622 624 10.1038/s41565-020-0752-z 32747742 PMC7116110 Lammers, T. et al. Dexamethasone nanomedicines for COVID-19. Nat. Nanotechnol. 15 , 622–624 (2020). 32747742 10.1038/s41565-020-0752-z PMC7116110

38. Pelaz B Diverse applications of nanomedicine ACS Nano 2017 11 2313 2381 10.1021/acsnano.6b06040 28290206 PMC5371978 Pelaz, B. et al. Diverse applications of nanomedicine. ACS Nano 11 , 2313–2381 (2017). 28290206 10.1021/acsnano.6b06040 PMC5371978

39. Shi J Kantoff PW Wooster R Farokhzad OC Cancer nanomedicine: progress, challenges and opportunities Nat. Rev. Cancer 2017 17 20 37 10.1038/nrc.2016.108 27834398 PMC5575742 Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17 , 20–37 (2017). 27834398 10.1038/nrc.2016.108 PMC5575742

40. Bhatia SN Chen X Dobrovolskaia MA Lammers T Cancer nanomedicine Nat. Rev. Cancer 2022 22 550 556 10.1038/s41568-022-00496-9 35941223 PMC9358926 Bhatia, S. N., Chen, X., Dobrovolskaia, M. A. & Lammers, T. Cancer nanomedicine. Nat. Rev. Cancer 22 , 550–556 (2022). 35941223 10.1038/s41568-022-00496-9 PMC9358926

41. Kemp JA Kwon YJ Cancer nanotechnology: current status and perspectives Nano Converg 2021 8 34 10.1186/s40580-021-00282-7 34727233 PMC8560887 Kemp, J. A. & Kwon, Y. J. Cancer nanotechnology: current status and perspectives. Nano Converg 8 , 34 (2021). 34727233 10.1186/s40580-021-00282-7 PMC8560887

42. Ferrari M Cancer nanotechnology: opportunities and challenges Nat. Rev. Cancer 2005 5 161 171 10.1038/nrc1566 15738981 Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5 , 161–171 (2005). 15738981 10.1038/nrc1566

43. Wolfram J Ferrari M Clinical cancer nanomedicine Nano Today 2019 25 85 98 10.1016/j.nantod.2019.02.005 31360214 PMC6662733 Wolfram, J. & Ferrari, M. Clinical cancer nanomedicine. Nano Today 25 , 85–98 (2019). 31360214 10.1016/j.nantod.2019.02.005 PMC6662733

44. van der Meel R Smart cancer nanomedicine Nat. Nanotechnol. 2019 14 1007 1017 10.1038/s41565-019-0567-y 31695150 PMC7227032 van der Meel, R. et al. Smart cancer nanomedicine. Nat. Nanotechnol. 14 , 1007–1017 (2019). 31695150 10.1038/s41565-019-0567-y PMC7227032

45. Yang Z Thermal immuno-nanomedicine in cancer Nat. Rev. Clin. Oncol. 2023 20 116 134 10.1038/s41571-022-00717-y 36604531 Yang, Z. et al. Thermal immuno-nanomedicine in cancer. Nat. Rev. Clin. Oncol. 20 , 116–134 (2023). 36604531 10.1038/s41571-022-00717-y

46. Beg S Nanomedicinal strategies as efficient therapeutic interventions for delivery of cancer vaccines Semin. Cancer Biol. 2021 69 43 51 10.1016/j.semcancer.2019.10.005 31618687 Beg, S. et al. Nanomedicinal strategies as efficient therapeutic interventions for delivery of cancer vaccines. Semin. Cancer Biol. 69 , 43–51 (2021). 31618687 10.1016/j.semcancer.2019.10.005

47. Su X Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy Semin. Cancer Biol. 2022 86 929 942 10.1016/j.semcancer.2021.08.003 34375726 Su, X. et al. Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy. Semin. Cancer Biol. 86 , 929–942 (2022). 34375726 10.1016/j.semcancer.2021.08.003

48. Wei G Recent progress in nanomedicine for enhanced cancer chemotherapy Theranostics 2021 11 6370 6392 10.7150/thno.57828 33995663 PMC8120226 Wei, G. et al. Recent progress in nanomedicine for enhanced cancer chemotherapy. Theranostics 11 , 6370–6392 (2021). 33995663 10.7150/thno.57828 PMC8120226

49. Wu W Pu Y Shi J Nanomedicine-enabled chemotherapy-based synergetic cancer treatments J. Nanobiotechnol. 2022 20 4 10.1186/s12951-021-01181-z PMC8725296 34983555 Wu, W., Pu, Y. & Shi, J. Nanomedicine-enabled chemotherapy-based synergetic cancer treatments. J. Nanobiotechnol. 20 , 4 (2022). 10.1186/s12951-021-01181-z PMC8725296 34983555

50. Nevins S Nanotechnology approaches for prevention and treatment of chemotherapy-induced neurotoxicity, neuropathy, and cardiomyopathy in breast and ovarian cancer survivors Small 2023 14 e2300744 10.1002/smll.202300744 PMC10576016 37058079 Nevins, S. et al. Nanotechnology approaches for prevention and treatment of chemotherapy-induced neurotoxicity, neuropathy, and cardiomyopathy in breast and ovarian cancer survivors. Small 14 , e2300744 (2023). 10.1002/smll.202300744 PMC10576016 37058079

51. Bagherifar R Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives J. Nanobiotechnol. 2021 19 110 10.1186/s12951-021-00861-0 PMC8052859 33865432 Bagherifar, R. et al. Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives. J. Nanobiotechnol. 19 , 110 (2021). 10.1186/s12951-021-00861-0 PMC8052859 33865432

52. Lei W Nanocarriers surface engineered with cell membranes for cancer targeted chemotherapy J. Nanobiotechnol. 2022 20 45 10.1186/s12951-022-01251-w PMC8781141 35062958 Lei, W. et al. Nanocarriers surface engineered with cell membranes for cancer targeted chemotherapy. J. Nanobiotechnol. 20 , 45 (2022). 10.1186/s12951-022-01251-w PMC8781141 35062958

53. Ribeiro TP Moreira JA Monteiro FJ Laranjeira MS Nanomaterials in cancer: reviewing the combination of hyperthermia and triggered chemotherapy J. Control. Release 2022 347 89 103 10.1016/j.jconrel.2022.04.045 35513211 Ribeiro, T. P., Moreira, J. A., Monteiro, F. J. & Laranjeira, M. S. Nanomaterials in cancer: reviewing the combination of hyperthermia and triggered chemotherapy. J. Control. Release 347 , 89–103 (2022). 35513211 10.1016/j.jconrel.2022.04.045

54. Ahmad A Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors Semin. Cancer Biol. 2023 89 38 60 10.1016/j.semcancer.2023.01.002 36669712 Ahmad, A. et al. Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors. Semin. Cancer Biol. 89 , 38–60 (2023). 36669712 10.1016/j.semcancer.2023.01.002

55. Gerken LRH Gerdes ME Pruschy M Herrmann IK Prospects of nanoparticle-based radioenhancement for radiotherapy Mater. Horiz. 2023 10 4059 4082 10.1039/D3MH00265A 37555747 PMC10544071 Gerken, L. R. H., Gerdes, M. E., Pruschy, M. & Herrmann, I. K. Prospects of nanoparticle-based radioenhancement for radiotherapy. Mater. Horiz. 10 , 4059–4082 (2023). 37555747 10.1039/D3MH00265A PMC10544071

56. Llop J Lammers T Nanoparticles for cancer diagnosis, radionuclide therapy and theranostics ACS Nano 2021 15 16974 16981 10.1021/acsnano.1c09139 34748314 PMC7612708 Llop, J. & Lammers, T. Nanoparticles for cancer diagnosis, radionuclide therapy and theranostics. ACS Nano 15 , 16974–16981 (2021). 34748314 10.1021/acsnano.1c09139 PMC7612708

57. Su Z Novel nanomedicines to overcome cancer multidrug resistance Drug Resist. Update. 2021 58 100777 10.1016/j.drup.2021.100777 34481195 Su, Z. et al. Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist. Update. 58 , 100777 (2021). 10.1016/j.drup.2021.100777 34481195

58. Zhen W Weichselbaum RR Lin W Nanoparticle-mediated radiotherapy remodels the tumor microenvironment to enhance antitumor efficacy Adv. Mater. 2023 35 e2206370 10.1002/adma.202206370 36524978 PMC10213153 Zhen, W., Weichselbaum, R. R. & Lin, W. Nanoparticle-mediated radiotherapy remodels the tumor microenvironment to enhance antitumor efficacy. Adv. Mater. 35 , e2206370 (2023). 36524978 10.1002/adma.202206370 PMC10213153

59. Blanco E Shen H Ferrari M Principles of nanoparticle design for overcoming biological barriers to drug delivery Nat. Biotechnol. 2015 33 941 951 10.1038/nbt.3330 26348965 PMC4978509 Blanco, E., Shen, H. & Ferrari, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33 , 941–951 (2015). 26348965 10.1038/nbt.3330 PMC4978509

60. Handa M Recent advances in lipid-engineered multifunctional nanophytomedicines for cancer targeting J. Control. Release 2021 340 48 59 10.1016/j.jconrel.2021.10.025 34695523 Handa, M. et al. Recent advances in lipid-engineered multifunctional nanophytomedicines for cancer targeting. J. Control. Release 340 , 48–59 (2021). 34695523 10.1016/j.jconrel.2021.10.025

61. Li S Nanotechnology: breaking the current treatment limits of lung cancer Adv. Healthc. Mater. 2021 10 e2100078 10.1002/adhm.202100078 34019739 Li, S. et al. Nanotechnology: breaking the current treatment limits of lung cancer. Adv. Healthc. Mater. 10 , e2100078 (2021). 34019739 10.1002/adhm.202100078

62. Shi J Votruba AR Farokhzad OC Langer R Nanotechnology in drug delivery and tissue engineering: from discovery to applications Nano Lett 2010 10 3223 3230 10.1021/nl102184c 20726522 PMC2935937 Shi, J., Votruba, A. R., Farokhzad, O. C. & Langer, R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 10 , 3223–3230 (2010). 20726522 10.1021/nl102184c PMC2935937

63. Briolay T Delivery of cancer therapies by synthetic and bio-inspired nanovectors Mol. Cancer 2021 20 55 10.1186/s12943-021-01346-2 33761944 PMC7987750 Briolay, T. et al. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Mol. Cancer 20 , 55 (2021). 33761944 10.1186/s12943-021-01346-2 PMC7987750

64. Peer D Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2007 2 751 760 10.1038/nnano.2007.387 18654426 Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 , 751–760 (2007). 18654426 10.1038/nnano.2007.387

65. Ali ES Targeting cancer cells with nanotherapeutics and nanodiagnostics: current status and future perspectives Semin. Cancer Biol. 2021 69 52 68 10.1016/j.semcancer.2020.01.011 32014609 Ali, E. S. et al. Targeting cancer cells with nanotherapeutics and nanodiagnostics: current status and future perspectives. Semin. Cancer Biol. 69 , 52–68 (2021). 32014609 10.1016/j.semcancer.2020.01.011

66. Klochkov SG Implications of nanotechnology for the treatment of cancer: recent advances Semin. Cancer Biol. 2021 69 190 199 10.1016/j.semcancer.2019.08.028 31446004 Klochkov, S. G. et al. Implications of nanotechnology for the treatment of cancer: recent advances. Semin. Cancer Biol. 69 , 190–199 (2021). 31446004 10.1016/j.semcancer.2019.08.028

67. Jain RK Stylianopoulos T Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 2010 7 653 664 10.1038/nrclinonc.2010.139 20838415 PMC3065247 Jain, R. K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7 , 653–664 (2010). 20838415 10.1038/nrclinonc.2010.139 PMC3065247

68. Izci M Maksoudian C Manshian BB Soenen SJ The use of alternative strategies for enhanced nanoparticle delivery to solid tumors Chem. Rev. 2021 121 1746 1803 10.1021/acs.chemrev.0c00779 33445874 PMC7883342 Izci, M., Maksoudian, C., Manshian, B. B. & Soenen, S. J. The use of alternative strategies for enhanced nanoparticle delivery to solid tumors. Chem. Rev. 121 , 1746–1803 (2021). 33445874 10.1021/acs.chemrev.0c00779 PMC7883342

69. Ikeda-Imafuku M Strategies to improve the EPR effect: a mechanistic perspective and clinical translation J. Control. Release 2022 345 512 536 10.1016/j.jconrel.2022.03.043 35337939 Ikeda-Imafuku, M. et al. Strategies to improve the EPR effect: a mechanistic perspective and clinical translation. J. Control. Release 345 , 512–536 (2022). 35337939 10.1016/j.jconrel.2022.03.043

70. Sun R The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives Adv. Drug Deliver. Rev. 2022 191 114614 10.1016/j.addr.2022.114614 36347432 Sun, R. et al. The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives. Adv. Drug Deliver. Rev. 191 , 114614 (2022). 10.1016/j.addr.2022.114614 36347432

71. Tian H Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies J. Hematol. Oncol. 2022 15 132 10.1186/s13045-022-01320-5 36096856 PMC9469622 Tian, H. et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J. Hematol. Oncol. 15 , 132 (2022). 36096856 10.1186/s13045-022-01320-5 PMC9469622

72. Zi Y Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms Adv. Drug Deliver. Rev. 2022 188 114449 10.1016/j.addr.2022.114449 35835353 Zi, Y. et al. Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Adv. Drug Deliver. Rev. 188 , 114449 (2022). 10.1016/j.addr.2022.114449 35835353

73. Mountzios G Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges Nat. Rev. Clin. Oncol. 2023 20 664 677 10.1038/s41571-023-00794-7 37488229 Mountzios, G. et al. Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat. Rev. Clin. Oncol. 20 , 664–677 (2023). 37488229 10.1038/s41571-023-00794-7

74. Zheng Y The progress of immune checkpoint therapy in primary liver cancer BBA-Rev. Cancer 2021 1876 188638 10.1016/j.bbcan.2021.188638 34688805 Zheng, Y. et al. The progress of immune checkpoint therapy in primary liver cancer. BBA-Rev. Cancer 1876 , 188638 (2021). 10.1016/j.bbcan.2021.188638 34688805

75. Haslam A Prasad V Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs JAMA Netw. Open 2019 2 e192535 10.1001/jamanetworkopen.2019.2535 31050774 PMC6503493 Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2 , e192535 (2019). 31050774 10.1001/jamanetworkopen.2019.2535 PMC6503493

76. Patra JK Nano based drug delivery systems: recent developments and future prospects J. Nanobiotechnol. 2018 16 71 10.1186/s12951-018-0392-8 PMC6145203 30231877 Patra, J. K. et al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol. 16 , 71 (2018). 10.1186/s12951-018-0392-8 PMC6145203 30231877

77. Shakeri S Multifunctional polymeric nanoplatforms for brain diseases diagnosis, therapy and theranostics Biomedicines 2020 8 13 10.3390/biomedicines8010013 31941057 PMC7168063 Shakeri, S. et al. Multifunctional polymeric nanoplatforms for brain diseases diagnosis, therapy and theranostics. Biomedicines 8 , 13 (2020). 31941057 10.3390/biomedicines8010013 PMC7168063

78. Cheng Z Li M Dey R Chen Y Nanomaterials for cancer therapy: current progress and perspectives J. Hematol. Oncol. 2021 14 85 10.1186/s13045-021-01096-0 34059100 PMC8165984 Cheng, Z., Li, M., Dey, R. & Chen, Y. Nanomaterials for cancer therapy: current progress and perspectives. J. Hematol. Oncol. 14 , 85 (2021). 34059100 10.1186/s13045-021-01096-0 PMC8165984

79. Kopeček J Polymer-drug conjugates: origins, progress to date and future directions Adv. Drug Deliver. Rev. 2013 65 49 59 10.1016/j.addr.2012.10.014 PMC3565043 23123294 Kopeček, J. Polymer-drug conjugates: origins, progress to date and future directions. Adv. Drug Deliver. Rev. 65 , 49–59 (2013). 10.1016/j.addr.2012.10.014 PMC3565043 23123294

80. Zaiki Y Iskandar A Wong TW Functionalized chitosan for cancer nano drug delivery Biotechnol. Adv. 2023 67 108200 10.1016/j.biotechadv.2023.108200 37331671 Zaiki, Y., Iskandar, A. & Wong, T. W. Functionalized chitosan for cancer nano drug delivery. Biotechnol. Adv. 67 , 108200 (2023). 37331671 10.1016/j.biotechadv.2023.108200

81. Kou SG Peters L Mucalo M Chitosan: a review of molecular structure, bioactivities and interactions with the human body and micro-organisms Carbohyd. Polym. 2022 282 119132 10.1016/j.carbpol.2022.119132 35123764 Kou, S. G., Peters, L. & Mucalo, M. Chitosan: a review of molecular structure, bioactivities and interactions with the human body and micro-organisms. Carbohyd. Polym. 282 , 119132 (2022). 10.1016/j.carbpol.2022.119132 35123764

82. Sharma AK Arya A Sahoo PK Majumdar DK Overview of biopolymers as carriers of antiphlogistic agents for treatment of diverse ocular inflammations Mat. Sci. Eng. C-Mater. 2016 67 779 791 10.1016/j.msec.2016.05.060 27287177 Sharma, A. K., Arya, A., Sahoo, P. K. & Majumdar, D. K. Overview of biopolymers as carriers of antiphlogistic agents for treatment of diverse ocular inflammations. Mat. Sci. Eng. C-Mater. 67 , 779–791 (2016). 10.1016/j.msec.2016.05.060 27287177

83. Peers S Montembault A Ladavière C Chitosan hydrogels incorporating colloids for sustained drug delivery Carbohyd. Polym. 2022 275 118689 10.1016/j.carbpol.2021.118689 34742416 Peers, S., Montembault, A. & Ladavière, C. Chitosan hydrogels incorporating colloids for sustained drug delivery. Carbohyd. Polym. 275 , 118689 (2022). 10.1016/j.carbpol.2021.118689 34742416

84. Zheng H Tang C Yin C Oral delivery of shRNA based on amino acid modified chitosan for improved antitumor efficacy Biomaterials 2015 70 126 137 10.1016/j.biomaterials.2015.08.024 26310108 Zheng, H., Tang, C. & Yin, C. Oral delivery of shRNA based on amino acid modified chitosan for improved antitumor efficacy. Biomaterials 70 , 126–137 (2015). 26310108 10.1016/j.biomaterials.2015.08.024

85. Liang X Functionalized chitosan as a promising platform for cancer immunotherapy: a review Carbohyd. Polym. 2022 290 119452 10.1016/j.carbpol.2022.119452 35550761 Liang, X. et al. Functionalized chitosan as a promising platform for cancer immunotherapy: a review. Carbohyd. Polym. 290 , 119452 (2022). 10.1016/j.carbpol.2022.119452 35550761

86. Yeh TH Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening Biomaterials 2011 32 6164 6173 10.1016/j.biomaterials.2011.03.056 21641031 Yeh, T. H. et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 32 , 6164–6173 (2011). 21641031 10.1016/j.biomaterials.2011.03.056

87. Kang SH Oral siRNA delivery to treat colorectal liver metastases ACS Nano 2017 11 10417 10429 10.1021/acsnano.7b05547 28902489 Kang, S. H. et al. Oral siRNA delivery to treat colorectal liver metastases. ACS Nano 11 , 10417–10429 (2017). 28902489 10.1021/acsnano.7b05547

88. Tang Y Nanoparticles targeted against cryptococcal pneumonia by interactions between chitosan and its peptide ligand Nano Lett 2018 18 6207 6213 10.1021/acs.nanolett.8b02229 30260652 Tang, Y. et al. Nanoparticles targeted against cryptococcal pneumonia by interactions between chitosan and its peptide ligand. Nano Lett 18 , 6207–6213 (2018). 30260652 10.1021/acs.nanolett.8b02229

89. Carroll EC The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons Immunity 2016 44 597 608 10.1016/j.immuni.2016.02.004 26944200 PMC4852885 Carroll, E. C. et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-dependent induction of type I interferons. Immunity 44 , 597–608 (2016). 26944200 10.1016/j.immuni.2016.02.004 PMC4852885

90. Wang Z Specific photothermal therapy to the tumors with high EphB4 receptor expression Biomaterials 2015 68 32 41 10.1016/j.biomaterials.2015.07.058 26264644 Wang, Z. et al. Specific photothermal therapy to the tumors with high EphB4 receptor expression. Biomaterials 68 , 32–41 (2015). 26264644 10.1016/j.biomaterials.2015.07.058

91. Swierczewska M Polysaccharide-based nanoparticles for theranostic nanomedicine Adv. Drug Deliver. Rev. 2016 99 70 84 10.1016/j.addr.2015.11.015 PMC4798864 26639578 Swierczewska, M. et al. Polysaccharide-based nanoparticles for theranostic nanomedicine. Adv. Drug Deliver. Rev. 99 , 70–84 (2016). 10.1016/j.addr.2015.11.015 PMC4798864 26639578

92. Ou W Plug-and-play nanorization of coarse black phosphorus for targeted chemo-photoimmunotherapy of colorectal cancer ACS Nano 2018 12 10061 10074 10.1021/acsnano.8b04658 30222314 Ou, W. et al. Plug-and-play nanorization of coarse black phosphorus for targeted chemo-photoimmunotherapy of colorectal cancer. ACS Nano 12 , 10061–10074 (2018). 30222314 10.1021/acsnano.8b04658

93. Samadi Pakchin P A novel electrochemical immunosensor for ultrasensitive detection of CA125 in ovarian cancer Biosens. Bioelectron. 2020 153 112029 10.1016/j.bios.2020.112029 31989938 Samadi Pakchin, P. et al. A novel electrochemical immunosensor for ultrasensitive detection of CA125 in ovarian cancer. Biosens. Bioelectron. 153 , 112029 (2020). 31989938 10.1016/j.bios.2020.112029

94. Bai Z Non-enzymatic electrochemical biosensor based on Pt NPs/RGO-CS-Fc nano-hybrids for the detection of hydrogen peroxide in living cells Biosens. Bioelectron. 2016 82 185 194 10.1016/j.bios.2016.04.004 27085950 Bai, Z. et al. Non-enzymatic electrochemical biosensor based on Pt NPs/RGO-CS-Fc nano-hybrids for the detection of hydrogen peroxide in living cells. Biosens. Bioelectron. 82 , 185–194 (2016). 27085950 10.1016/j.bios.2016.04.004

95. Zhang BF Mitochondria apoptosis pathway synergistically activated by hierarchical targeted nanoparticles co-delivering siRNA and lonidamine Biomaterials 2015 61 178 189 10.1016/j.biomaterials.2015.05.027 26004233 Zhang, B. F. et al. Mitochondria apoptosis pathway synergistically activated by hierarchical targeted nanoparticles co-delivering siRNA and lonidamine. Biomaterials 61 , 178–189 (2015). 26004233 10.1016/j.biomaterials.2015.05.027

96. Rong Q Feng F Ma Z Metal ions doped chitosan-poly(acrylic acid) nanospheres: Synthesis and their application in simultaneously electrochemical detection of four markers of pancreatic cancer Biosens. Bioelectron. 2016 75 148 154 10.1016/j.bios.2015.08.041 26318783 Rong, Q., Feng, F. & Ma, Z. Metal ions doped chitosan-poly(acrylic acid) nanospheres: Synthesis and their application in simultaneously electrochemical detection of four markers of pancreatic cancer. Biosens. Bioelectron. 75 , 148–154 (2016). 26318783 10.1016/j.bios.2015.08.041

97. Wang Z Lable-free quadruple signal amplification strategy for sensitive electrochemical p53 gene biosensing Biosens. Bioelectron. 2016 77 157 163 10.1016/j.bios.2015.09.011 26406456 Wang, Z. et al. Lable-free quadruple signal amplification strategy for sensitive electrochemical p53 gene biosensing. Biosens. Bioelectron. 77 , 157–163 (2016). 26406456 10.1016/j.bios.2015.09.011

98. Wang K Iron-oxide-based nanovector for tumor targeted siRNA delivery in an orthotopic hepatocellular carcinoma xenograft mouse model Small 2016 12 477 487 10.1002/smll.201501985 26641029 PMC4829640 Wang, K. et al. Iron-oxide-based nanovector for tumor targeted siRNA delivery in an orthotopic hepatocellular carcinoma xenograft mouse model. Small 12 , 477–487 (2016). 26641029 10.1002/smll.201501985 PMC4829640

99. Xiao B Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles Biomaterials 2015 48 147 160 10.1016/j.biomaterials.2015.01.014 25701040 PMC4339818 Xiao, B. et al. Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. Biomaterials 48 , 147–160 (2015). 25701040 10.1016/j.biomaterials.2015.01.014 PMC4339818

100. Zhang L Gene regulation with carbon-based siRNA conjugates for cancer therapy Biomaterials 2016 104 269 278 10.1016/j.biomaterials.2016.07.015 27472164 Zhang, L. et al. Gene regulation with carbon-based siRNA conjugates for cancer therapy. Biomaterials 104 , 269–278 (2016). 27472164 10.1016/j.biomaterials.2016.07.015

101. Chen Z Enhanced shRNA delivery and ABCG2 silencing by charge-reversible layered nanocarriers Small 2015 11 952 962 10.1002/smll.201401397 25330768 Chen, Z. et al. Enhanced shRNA delivery and ABCG2 silencing by charge-reversible layered nanocarriers. Small 11 , 952–962 (2015). 25330768 10.1002/smll.201401397

102. Ramya AN Emergence of gold-mesoporous silica hybrid nanotheranostics: dox-nncoded, folate targeted chemotherapy with modulation of SERS fingerprinting for apoptosis toward tumor eradication Small 2021 17 e2007852 10.1002/smll.202007852 33442948 Ramya, A. N. et al. Emergence of gold-mesoporous silica hybrid nanotheranostics: dox-nncoded, folate targeted chemotherapy with modulation of SERS fingerprinting for apoptosis toward tumor eradication. Small 17 , e2007852 (2021). 33442948 10.1002/smll.202007852

103. Samadi Pakchin P Ghanbari H Saber R Omidi Y Electrochemical immunosensor based on chitosan-gold nanoparticle/carbon nanotube as a platform and lactate oxidase as a label for detection of CA125 oncomarker Biosens. Bioelectron. 2018 122 68 74 10.1016/j.bios.2018.09.016 30243046 Samadi Pakchin, P., Ghanbari, H., Saber, R. & Omidi, Y. Electrochemical immunosensor based on chitosan-gold nanoparticle/carbon nanotube as a platform and lactate oxidase as a label for detection of CA125 oncomarker. Biosens. Bioelectron. 122 , 68–74 (2018). 30243046 10.1016/j.bios.2018.09.016

104. Chu S Tang C Yin C Effects of mannose density on in vitro and in vivo cellular uptake and RNAi efficiency of polymeric nanoparticles Biomaterials 2015 52 229 239 10.1016/j.biomaterials.2015.02.044 25818429 Chu, S., Tang, C. & Yin, C. Effects of mannose density on in vitro and in vivo cellular uptake and RNAi efficiency of polymeric nanoparticles. Biomaterials 52 , 229–239 (2015). 25818429 10.1016/j.biomaterials.2015.02.044

105. Han L Tang C Yin C Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA Biomaterials 2015 60 42 52 10.1016/j.biomaterials.2015.05.001 25982552 Han, L., Tang, C. & Yin, C. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA. Biomaterials 60 , 42–52 (2015). 25982552 10.1016/j.biomaterials.2015.05.001

106. Wang Y Constructing high effective nano-Mn(3)(PO(4))(2)-chitosan in situ electrochemical detection interface for superoxide anions released from living cell Biosens. Bioelectron. 2019 133 133 140 10.1016/j.bios.2019.03.029 30925362 Wang, Y. et al. Constructing high effective nano-Mn(3)(PO(4))(2)-chitosan in situ electrochemical detection interface for superoxide anions released from living cell. Biosens. Bioelectron. 133 , 133–140 (2019). 30925362 10.1016/j.bios.2019.03.029

107. Li S Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles Nat. Biomed. Eng. 2020 4 732 742 10.1038/s41551-020-0573-2 32572197 Li, S. et al. Combination of tumour-infarction therapy and chemotherapy via the co-delivery of doxorubicin and thrombin encapsulated in tumour-targeted nanoparticles. Nat. Biomed. Eng. 4 , 732–742 (2020). 32572197 10.1038/s41551-020-0573-2

108. Mohammadi Z Eini M Rastegari A Tehrani MR Chitosan as a machine for biomolecule delivery: a review Carbohyd. Polym. 2021 256 117414 10.1016/j.carbpol.2020.117414 33483009 Mohammadi, Z., Eini, M., Rastegari, A. & Tehrani, M. R. Chitosan as a machine for biomolecule delivery: a review. Carbohyd. Polym. 256 , 117414 (2021). 10.1016/j.carbpol.2020.117414 33483009

109. Hu B Recent advances in chitosan-based layer-by-layer biomaterials and their biomedical applications Carbohyd. Polym. 2021 271 118427 10.1016/j.carbpol.2021.118427 34364567 Hu, B. et al. Recent advances in chitosan-based layer-by-layer biomaterials and their biomedical applications. Carbohyd. Polym. 271 , 118427 (2021). 10.1016/j.carbpol.2021.118427 34364567

110. Hamedi H Chitosan based bioadhesives for biomedical applications: a review Carbohyd. Polym. 2022 282 119100 10.1016/j.carbpol.2022.119100 35123739 Hamedi, H. et al. Chitosan based bioadhesives for biomedical applications: a review. Carbohyd. Polym. 282 , 119100 (2022). 10.1016/j.carbpol.2022.119100 35123739

111. Liu Z Chitosan-based hemostatic sponges as new generation hemostatic materials for uncontrolled bleeding emergency: modification, composition, and applications Carbohyd. Polym. 2023 311 120780 10.1016/j.carbpol.2023.120780 37028883 Liu, Z. et al. Chitosan-based hemostatic sponges as new generation hemostatic materials for uncontrolled bleeding emergency: modification, composition, and applications. Carbohyd. Polym. 311 , 120780 (2023). 10.1016/j.carbpol.2023.120780 37028883

112. Mirbagheri MS Chitosan-based electrospun nanofibers for diabetic foot ulcer management; recent advances Carbohyd. Polym. 2023 313 120512 10.1016/j.carbpol.2022.120512 37182929 Mirbagheri, M. S. et al. Chitosan-based electrospun nanofibers for diabetic foot ulcer management; recent advances. Carbohyd. Polym. 313 , 120512 (2023). 10.1016/j.carbpol.2022.120512 37182929

113. Wei X Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response Cell Res 2015 25 237 253 10.1038/cr.2015.9 25613571 PMC4650577 Wei, X. et al. Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response. Cell Res 25 , 237–253 (2015). 25613571 10.1038/cr.2015.9 PMC4650577

114. Tao Y Jakobsson V Chen X Zhang J Exploiting albumin as a versatile carrier for cancer theranostics Accounts Chem. Res. 2023 56 2403 2415 10.1021/acs.accounts.3c00309 37625245 Tao, Y., Jakobsson, V., Chen, X. & Zhang, J. Exploiting albumin as a versatile carrier for cancer theranostics. Accounts Chem. Res. 56 , 2403–2415 (2023). 10.1021/acs.accounts.3c00309 37625245

115. Luo L Perfluorotributylamine-loaded albumin nanoparticles downregulate platelet-derived TGFβ to inhibit tumor metastasis ACS Nano 2023 17 15388 15400 10.1021/acsnano.3c00295 37526429 Luo, L. et al. Perfluorotributylamine-loaded albumin nanoparticles downregulate platelet-derived TGFβ to inhibit tumor metastasis. ACS Nano 17 , 15388–15400 (2023). 37526429 10.1021/acsnano.3c00295

116. Hoogenboezem EN Duvall CL Harnessing albumin as a carrier for cancer therapies Adv. Drug Deliver. Rev. 2018 130 73 89 10.1016/j.addr.2018.07.011 PMC6200408 30012492 Hoogenboezem, E. N. & Duvall, C. L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliver. Rev. 130 , 73–89 (2018). 10.1016/j.addr.2018.07.011 PMC6200408 30012492

117. Tian Y Integration of cell-penetrating peptides with rod-like bionanoparticles: virus-inspired gene-silencing technology Nano Lett 2018 18 5453 5460 10.1021/acs.nanolett.8b01805 30091612 Tian, Y. et al. Integration of cell-penetrating peptides with rod-like bionanoparticles: virus-inspired gene-silencing technology. Nano Lett 18 , 5453–5460 (2018). 30091612 10.1021/acs.nanolett.8b01805

118. Poudel K Photothermally modulatable and structurally disintegratable sub-8-nm Au(1)Ag(9) embedded nanoblocks for combination cancer therapy produced by plug-in assembly ACS Nano 2020 14 11040 11054 10.1021/acsnano.9b09731 32816451 Poudel, K. et al. Photothermally modulatable and structurally disintegratable sub-8-nm Au(1)Ag(9) embedded nanoblocks for combination cancer therapy produced by plug-in assembly. ACS Nano 14 , 11040–11054 (2020). 32816451 10.1021/acsnano.9b09731

119. Li F Novel ultrasmall multifunctional nanodots for dual-modal MR/NIR-II imaging-guided photothermal therapy Biomaterials 2020 256 120219 10.1016/j.biomaterials.2020.120219 32736173 Li, F. et al. Novel ultrasmall multifunctional nanodots for dual-modal MR/NIR-II imaging-guided photothermal therapy. Biomaterials 256 , 120219 (2020). 32736173 10.1016/j.biomaterials.2020.120219

120. Gao G Molecular targeting-mediated mild-temperature photothermal therapy with a smart albumin-based nanodrug Small 2019 15 e1900501 10.1002/smll.201900501 31282114 Gao, G. et al. Molecular targeting-mediated mild-temperature photothermal therapy with a smart albumin-based nanodrug. Small 15 , e1900501 (2019). 31282114 10.1002/smll.201900501

121. Wang L A self-assembled biocompatible nanoplatform for multimodal MR/fluorescence imaging assisted photothermal therapy and prognosis analysis Small 2018 14 e1801612 10.1002/smll.201801612 30084540 Wang, L. et al. A self-assembled biocompatible nanoplatform for multimodal MR/fluorescence imaging assisted photothermal therapy and prognosis analysis. Small 14 , e1801612 (2018). 30084540 10.1002/smll.201801612

122. Tao HY Wang RQ Sheng WJ Zhen YS The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy Int. J. Biol. Macromol. 2021 187 24 34 10.1016/j.ijbiomac.2021.07.080 34284054 Tao, H. Y., Wang, R. Q., Sheng, W. J. & Zhen, Y. S. The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy. Int. J. Biol. Macromol. 187 , 24–34 (2021). 34284054 10.1016/j.ijbiomac.2021.07.080

123. Wang H Engineering antigen as photosensitiser nanocarrier to facilitate ROS triggered immune cascade for photodynamic immunotherapy Biomaterials 2020 244 119964 10.1016/j.biomaterials.2020.119964 32200102 Wang, H. et al. Engineering antigen as photosensitiser nanocarrier to facilitate ROS triggered immune cascade for photodynamic immunotherapy. Biomaterials 244 , 119964 (2020). 32200102 10.1016/j.biomaterials.2020.119964

124. Li Z Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy Sci. Adv. 2020 6 eaaz9240 10.1126/sciadv.aaz9240 32440550 PMC7228744 Li, Z. et al. Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy. Sci. Adv. 6 , eaaz9240 (2020). 32440550 10.1126/sciadv.aaz9240 PMC7228744

125. Yu W Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy Biomaterials 2019 192 128 139 10.1016/j.biomaterials.2018.11.019 30448697 Yu, W. et al. Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy. Biomaterials 192 , 128–139 (2019). 30448697 10.1016/j.biomaterials.2018.11.019

126. Yi X X-rays-optimized delivery of radiolabeled albumin for cancer theranostics Biomaterials 2020 233 119764 10.1016/j.biomaterials.2020.119764 31927252 Yi, X. et al. X-rays-optimized delivery of radiolabeled albumin for cancer theranostics. Biomaterials 233 , 119764 (2020). 31927252 10.1016/j.biomaterials.2020.119764

127. Xie J Graphdiyne nanoradioprotector with efficient free radical scavenging ability for mitigating radiation-induced gastrointestinal tract damage Biomaterials 2020 244 119940 10.1016/j.biomaterials.2020.119940 32200103 Xie, J. et al. Graphdiyne nanoradioprotector with efficient free radical scavenging ability for mitigating radiation-induced gastrointestinal tract damage. Biomaterials 244 , 119940 (2020). 32200103 10.1016/j.biomaterials.2020.119940

128. Lee KJ A novel nanoparticle-based theranostic agent targeting LRP-1 enhances the efficacy of neoadjuvant radiotherapy in colorectal cancer Biomaterials 2020 255 120151 10.1016/j.biomaterials.2020.120151 32505033 Lee, K. J. et al. A novel nanoparticle-based theranostic agent targeting LRP-1 enhances the efficacy of neoadjuvant radiotherapy in colorectal cancer. Biomaterials 255 , 120151 (2020). 32505033 10.1016/j.biomaterials.2020.120151

129. Mao F Ultrasmall biocompatible Bi(2)Se(3) nanodots for multimodal imaging-guided synergistic radiophotothermal therapy against cancer ACS Nano 2016 10 11145 11155 10.1021/acsnano.6b06067 28024338 Mao, F. et al. Ultrasmall biocompatible Bi(2)Se(3) nanodots for multimodal imaging-guided synergistic radiophotothermal therapy against cancer. ACS Nano 10 , 11145–11155 (2016). 28024338 10.1021/acsnano.6b06067

130. Hu H Deciphering albumin-directed drug delivery by imaging Adv. Drug Deliver. Rev. 2022 185 114237 10.1016/j.addr.2022.114237 PMC9117484 35364124 Hu, H. et al. Deciphering albumin-directed drug delivery by imaging. Adv. Drug Deliver. Rev. 185 , 114237 (2022). 10.1016/j.addr.2022.114237 PMC9117484 35364124

131. Tyler B Polylactic acid (PLA) controlled delivery carriers for biomedical applications Adv. Drug Deliver. Rev. 2016 107 163 175 10.1016/j.addr.2016.06.018 27426411 Tyler, B. et al. Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Adv. Drug Deliver. Rev. 107 , 163–175 (2016). 10.1016/j.addr.2016.06.018 27426411

132. Tarangelo A Dixon SJ Nanomedicine: An iron age for cancer therapy Nat. Nanotechnol. 2016 11 921 922 10.1038/nnano.2016.199 27668797 PMC6091215 Tarangelo, A. & Dixon, S. J. Nanomedicine: An iron age for cancer therapy. Nat. Nanotechnol. 11 , 921–922 (2016). 27668797 10.1038/nnano.2016.199 PMC6091215

133. Gigmes D Trimaille T Advances in amphiphilic polylactide/vinyl polymer based nano-assemblies for drug delivery Adv. Colloid Interfac. 2021 294 102483 10.1016/j.cis.2021.102483 34274723 Gigmes, D. & Trimaille, T. Advances in amphiphilic polylactide/vinyl polymer based nano-assemblies for drug delivery. Adv. Colloid Interfac. 294 , 102483 (2021). 10.1016/j.cis.2021.102483 34274723

134. Zhang M Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models Biomaterials 2018 169 1 10 10.1016/j.biomaterials.2018.03.055 29631163 PMC5911411 Zhang, M. et al. Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models. Biomaterials 169 , 1–10 (2018). 29631163 10.1016/j.biomaterials.2018.03.055 PMC5911411

135. Li X Jiang X Microfluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles Adv. Drug Deliver. Rev. 2018 128 101 114 10.1016/j.addr.2017.12.015 29277543 Li, X. & Jiang, X. Microfluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles. Adv. Drug Deliver. Rev. 128 , 101–114 (2018). 10.1016/j.addr.2017.12.015 29277543

136. Wang H Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells Biomaterials 2015 72 74 89 10.1016/j.biomaterials.2015.08.048 26344365 PMC5003084 Wang, H. et al. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials 72 , 74–89 (2015). 26344365 10.1016/j.biomaterials.2015.08.048 PMC5003084

137. Cabral H Miyata K Osada K Kataoka K Block copolymer micelles in nanomedicine applications Chem. Rev. 2018 118 6844 6892 10.1021/acs.chemrev.8b00199 29957926 Cabral, H., Miyata, K., Osada, K. & Kataoka, K. Block copolymer micelles in nanomedicine applications. Chem. Rev. 118 , 6844–6892 (2018). 29957926 10.1021/acs.chemrev.8b00199

138. Luo L Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors ACS Nano 2018 12 7647 7662 10.1021/acsnano.8b00204 30020768 Luo, L. et al. Laser immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors. ACS Nano 12 , 7647–7662 (2018). 30020768 10.1021/acsnano.8b00204

139. Rosalia RA CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses Biomaterials 2015 40 88 97 10.1016/j.biomaterials.2014.10.053 25465442 Rosalia, R. A. et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials 40 , 88–97 (2015). 25465442 10.1016/j.biomaterials.2014.10.053

140. Chen Q Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy Nat. Commun. 2016 7 13193 10.1038/ncomms13193 27767031 PMC5078754 Chen, Q. et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat. Commun. 7 , 13193 (2016). 27767031 10.1038/ncomms13193 PMC5078754

141. Feltrin FDS Agner T Sayer C Lona LMF Curcumin encapsulation in functional PLGA nanoparticles: a promising strategy for cancer therapies Adv. Colloid Interfac. 2022 300 102582 10.1016/j.cis.2021.102582 34953375 Feltrin, F. D. S., Agner, T., Sayer, C. & Lona, L. M. F. Curcumin encapsulation in functional PLGA nanoparticles: a promising strategy for cancer therapies. Adv. Colloid Interfac. 300 , 102582 (2022). 10.1016/j.cis.2021.102582 34953375

142. Zhou S Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy Biomaterials 2020 235 119795 10.1016/j.biomaterials.2020.119795 32014739 Zhou, S. et al. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy. Biomaterials 235 , 119795 (2020). 32014739 10.1016/j.biomaterials.2020.119795

143. Kishimoto TK Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles Nat. Nanotechnol. 2016 11 890 899 10.1038/nnano.2016.135 27479756 Kishimoto, T. K. et al. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat. Nanotechnol. 11 , 890–899 (2016). 27479756 10.1038/nnano.2016.135

144. Mignani S Dendrimers in combination with natural products and analogues as anti-cancer agents Chem. Soc. Rev. 2018 47 514 532 10.1039/C7CS00550D 29154385 Mignani, S. et al. Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem. Soc. Rev. 47 , 514–532 (2018). 29154385 10.1039/C7CS00550D

145. Kannan RM Pitha I Parikh KS A new era in posterior segment ocular drug delivery: translation of systemic, cell-targeted, dendrimer-based therapies Adv. Drug Deliver. Rev. 2023 200 115005 10.1016/j.addr.2023.115005 37419213 Kannan, R. M., Pitha, I. & Parikh, K. S. A new era in posterior segment ocular drug delivery: translation of systemic, cell-targeted, dendrimer-based therapies. Adv. Drug Deliver. Rev. 200 , 115005 (2023). 10.1016/j.addr.2023.115005 37419213

146. Chowdhury S Toth I Stephenson RJ Dendrimers in vaccine delivery: Recent progress and advances Biomaterials 2022 280 121303 10.1016/j.biomaterials.2021.121303 34871877 Chowdhury, S., Toth, I. & Stephenson, R. J. Dendrimers in vaccine delivery: Recent progress and advances. Biomaterials 280 , 121303 (2022). 34871877 10.1016/j.biomaterials.2021.121303

147. Dey AD Dendrimers as nanoscale vectors: unlocking the bars of cancer therapy Semin. Cancer Biol. 2022 86 396 419 10.1016/j.semcancer.2022.06.003 35700939 Dey, A. D. et al. Dendrimers as nanoscale vectors: unlocking the bars of cancer therapy. Semin. Cancer Biol. 86 , 396–419 (2022). 35700939 10.1016/j.semcancer.2022.06.003

148. Li H Polymeric Dendrimers as nanocarrier vectors for neurotheranostics Small 2022 18 e2203629 10.1002/smll.202203629 36084240 Li, H. et al. Polymeric Dendrimers as nanocarrier vectors for neurotheranostics. Small 18 , e2203629 (2022). 36084240 10.1002/smll.202203629

149. Sathe RY Bharatam PV Drug-dendrimer complexes and conjugates: detailed furtherance through theory and experiments Adv. Colloid Interfac. 2022 303 102639 10.1016/j.cis.2022.102639 35339862 Sathe, R. Y. & Bharatam, P. V. Drug-dendrimer complexes and conjugates: detailed furtherance through theory and experiments. Adv. Colloid Interfac. 303 , 102639 (2022). 10.1016/j.cis.2022.102639 35339862

150. Arora V Abourehab MAS Modi G Kesharwani P Dendrimers as prospective nanocarrier for targeted delivery against lung cancer Eur. Polym. J. 2022 180 111635 10.1016/j.eurpolymj.2022.111635 Arora, V., Abourehab, M. A. S., Modi, G. & Kesharwani, P. Dendrimers as prospective nanocarrier for targeted delivery against lung cancer. Eur. Polym. J. 180 , 111635 (2022). 10.1016/j.eurpolymj.2022.111635

151. Bu J An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy Nano Lett 2020 20 4901 4909 10.1021/acs.nanolett.0c00953 32510959 PMC7737517 Bu, J. et al. An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy. Nano Lett 20 , 4901–4909 (2020). 32510959 10.1021/acs.nanolett.0c00953 PMC7737517

152. Bozzuto G Molinari A Liposomes as nanomedical devices Int. J. Nanomed. 2015 10 975 999 10.2147/IJN.S68861 PMC4324542 25678787 Bozzuto, G. & Molinari, A. Liposomes as nanomedical devices. Int. J. Nanomed. 10 , 975–999 (2015). 10.2147/IJN.S68861 PMC4324542 25678787

153. Bangham AD Horne RW Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope J. Mol. Biol. 1964 8 660 668 10.1016/S0022-2836(64)80115-7 14187392 Bangham, A. D. & Horne, R. W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J. Mol. Biol. 8 , 660–668 (1964). 14187392 10.1016/S0022-2836(64)80115-7

154. Shi X Sun K Baker JR Spontaneous formation of functionalized dendrimer-stabilized gold nanoparticles J. Phys. Chem. C 2009 112 8251 8258 10.1021/jp801293a PMC2736051 19727334 Shi, X., Sun, K. & Baker, J. R. Spontaneous formation of functionalized dendrimer-stabilized gold nanoparticles. J. Phys. Chem. C 112 , 8251–8258 (2009). 10.1021/jp801293a PMC2736051 19727334

155. Chen W Goldys EM Deng W Light-induced liposomes for cancer therapeutics Prog. Lipid Res. 2020 79 101052 10.1016/j.plipres.2020.101052 32679153 Chen, W., Goldys, E. M. & Deng, W. Light-induced liposomes for cancer therapeutics. Prog. Lipid Res. 79 , 101052 (2020). 32679153 10.1016/j.plipres.2020.101052

156. Kansız S Elçin YM Advanced liposome and polymersome-based drug delivery systems: Considerations for physicochemical properties, targeting strategies and stimuli-sensitive approaches Adv. Colloid Interfac. 2023 317 102930 10.1016/j.cis.2023.102930 37290380 Kansız, S. & Elçin, Y. M. Advanced liposome and polymersome-based drug delivery systems: Considerations for physicochemical properties, targeting strategies and stimuli-sensitive approaches. Adv. Colloid Interfac. 317 , 102930 (2023). 10.1016/j.cis.2023.102930 37290380

157. Borys N Dewhirst MW Drug development of lyso-thermosensitive liposomal doxorubicin: combining hyperthermia and thermosensitive drug delivery Adv. Drug Deliver. Rev. 2021 178 113985 10.1016/j.addr.2021.113985 34555486 Borys, N. & Dewhirst, M. W. Drug development of lyso-thermosensitive liposomal doxorubicin: combining hyperthermia and thermosensitive drug delivery. Adv. Drug Deliver. Rev. 178 , 113985 (2021). 10.1016/j.addr.2021.113985 34555486

158. Sercombe L Advances and challenges of liposome assisted drug delivery Front. Pharmacol. 2015 6 286 10.3389/fphar.2015.00286 26648870 PMC4664963 Sercombe, L. et al. Advances and challenges of liposome assisted drug delivery. Front. Pharmacol. 6 , 286 (2015). 26648870 10.3389/fphar.2015.00286 PMC4664963

159. Killock D Benefit of nanomedicine confirmed in sAML Nat. Rev. Clin. Oncol. 2018 15 591 30065313 10.1038/s41571-018-0080-5 Killock, D. Benefit of nanomedicine confirmed in sAML. Nat. Rev. Clin. Oncol. 15 , 591 (2018). 30065313 10.1038/s41571-018-0080-5

160. Yingchoncharoen P Kalinowski DS Richardson DR Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come Pharmacol. Rev. 2016 68 701 787 10.1124/pr.115.012070 27363439 PMC4931871 Yingchoncharoen, P., Kalinowski, D. S. & Richardson, D. R. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol. Rev. 68 , 701–787 (2016). 27363439 10.1124/pr.115.012070 PMC4931871

161. Min Y Caster JM Eblan MJ Wang AZ Clinical translation of nanomedicine Chem. Rev. 2015 115 11147 11190 10.1021/acs.chemrev.5b00116 26088284 PMC4607605 Min, Y., Caster, J. M., Eblan, M. J. & Wang, A. Z. Clinical translation of nanomedicine. Chem. Rev. 115 , 11147–11190 (2015). 26088284 10.1021/acs.chemrev.5b00116 PMC4607605

162. Graván P Lipid-core nanoparticles: classification, preparation methods, routes of administration and recent advances in cancer treatment Adv. Colloid Interfac. 2023 314 102871 10.1016/j.cis.2023.102871 36958181 Graván, P. et al. Lipid-core nanoparticles: classification, preparation methods, routes of administration and recent advances in cancer treatment. Adv. Colloid Interfac. 314 , 102871 (2023). 10.1016/j.cis.2023.102871 36958181

163. El Moukhtari SH Lipid nanoparticles for siRNA delivery in cancer treatment J. Control. Release 2023 361 130 146 10.1016/j.jconrel.2023.07.054 37532145 El Moukhtari, S. H. et al. Lipid nanoparticles for siRNA delivery in cancer treatment. J. Control. Release 361 , 130–146 (2023). 37532145 10.1016/j.jconrel.2023.07.054

164. Wang J Zhu M Nie G Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles Adv. Drug Deliver. Rev. 2021 178 113974 10.1016/j.addr.2021.113974 34530015 Wang, J., Zhu, M. & Nie, G. Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles. Adv. Drug Deliver. Rev. 178 , 113974 (2021). 10.1016/j.addr.2021.113974 34530015

165. Zhang W Lipid carriers for mRNA delivery Acta Pharm. Sin. B 2023 13 4105 4126 10.1016/j.apsb.2022.11.026 37799378 PMC10547918 Zhang, W. et al. Lipid carriers for mRNA delivery. Acta Pharm. Sin. B 13 , 4105–4126 (2023). 37799378 10.1016/j.apsb.2022.11.026 PMC10547918

166. Kamoun WS Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models Nat. Biomed. Eng. 2019 3 264 280 10.1038/s41551-019-0385-4 30952988 Kamoun, W. S. et al. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nat. Biomed. Eng. 3 , 264–280 (2019). 30952988 10.1038/s41551-019-0385-4

167. Gouveia MG Polymersome-based protein drug delivery - quo vadis? Chem. Soc. Rev. 2023 52 728 778 10.1039/D2CS00106C 36537575 PMC9890519 Gouveia, M. G. et al. Polymersome-based protein drug delivery - quo vadis? Chem. Soc. Rev. 52 , 728–778 (2023). 36537575 10.1039/D2CS00106C PMC9890519

168. Yuan Y Zhang CJ Liu B A photoactivatable AIE polymer for light-controlled gene delivery: concurrent endo/lysosomal escape and DNA unpacking Angew. Chem. Int. Edit. 2015 54 11419 11423 10.1002/anie.201503640 26094980 Yuan, Y., Zhang, C. J. & Liu, B. A photoactivatable AIE polymer for light-controlled gene delivery: concurrent endo/lysosomal escape and DNA unpacking. Angew. Chem. Int. Edit. 54 , 11419–11423 (2015). 10.1002/anie.201503640 26094980

169. Mura S Nicolas J Couvreur P Stimuli-responsive nanocarriers for drug delivery Nat. Mater. 2013 12 991 1003 10.1038/nmat3776 24150417 Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12 , 991–1003 (2013). 24150417 10.1038/nmat3776

170. Zhang Y Mechanical force-triggered drug delivery Chem. Rev. 2016 116 12536 12563 10.1021/acs.chemrev.6b00369 27680291 Zhang, Y. et al. Mechanical force-triggered drug delivery. Chem. Rev. 116 , 12536–12563 (2016). 27680291 10.1021/acs.chemrev.6b00369

171. Ding Y Application of lipid nanovesicle drug delivery system in cancer immunotherapy J. Nanobiotechnol. 2022 20 214 10.1186/s12951-022-01429-2 PMC9073823 35524277 Ding, Y. et al. Application of lipid nanovesicle drug delivery system in cancer immunotherapy. J. Nanobiotechnol. 20 , 214 (2022). 10.1186/s12951-022-01429-2 PMC9073823 35524277

172. Nel J Functionalized liposomes for targeted breast cancer drug delivery Bioact. Mater. 2023 24 401 437 36632508 10.1016/j.bioactmat.2022.12.027 PMC9812688 Nel, J. et al. Functionalized liposomes for targeted breast cancer drug delivery. Bioact. Mater. 24 , 401–437 (2023). 36632508 10.1016/j.bioactmat.2022.12.027 PMC9812688

173. Sen S Computational studies of micellar and nanoparticle nanomedicines Chem. Soc. Rev. 2018 47 3849 3860 10.1039/C8CS00022K 29645040 Sen, S. et al. Computational studies of micellar and nanoparticle nanomedicines. Chem. Soc. Rev. 47 , 3849–3860 (2018). 29645040 10.1039/C8CS00022K

174. Ghezzi M Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions J. Control. Release 2021 332 312 336 10.1016/j.jconrel.2021.02.031 33652113 Ghezzi, M. et al. Polymeric micelles in drug delivery: an insight of the techniques for their characterization and assessment in biorelevant conditions. J. Control. Release 332 , 312–336 (2021). 33652113 10.1016/j.jconrel.2021.02.031

175. Takeda KM Effect of shear stress on structure and function of polyplex micelles from poly(ethylene glycol)-poly(l-lysine) block copolymers as systemic gene delivery carrier Biomaterials 2017 126 31 38 10.1016/j.biomaterials.2017.02.012 28254691 Takeda, K. M. et al. Effect of shear stress on structure and function of polyplex micelles from poly(ethylene glycol)-poly(l-lysine) block copolymers as systemic gene delivery carrier. Biomaterials 126 , 31–38 (2017). 28254691 10.1016/j.biomaterials.2017.02.012

176. Talelli M Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation Nano Today 2015 10 93 117 10.1016/j.nantod.2015.01.005 25893004 PMC4398985 Talelli, M. et al. Core-crosslinked polymeric micelles: principles, preparation, biomedical applications and clinical translation. Nano Today 10 , 93–117 (2015). 25893004 10.1016/j.nantod.2015.01.005 PMC4398985

177. Zhang Z Ma R Shi L Cooperative macromolecular self-assembly toward polymeric assemblies with multiple and bioactive functions Accounts Chem. Res. 2014 47 1426 1437 10.1021/ar5000264 24694280 Zhang, Z., Ma, R. & Shi, L. Cooperative macromolecular self-assembly toward polymeric assemblies with multiple and bioactive functions. Accounts Chem. Res. 47 , 1426–1437 (2014). 10.1021/ar5000264 24694280

178. Sosnik A Menaker Raskin M Polymeric micelles in mucosal drug delivery: challenges towards clinical translation Biotechnol. Adv. 2015 33 1380 1392 10.1016/j.biotechadv.2015.01.003 25597531 Sosnik, A. & Menaker Raskin, M. Polymeric micelles in mucosal drug delivery: challenges towards clinical translation. Biotechnol. Adv. 33 , 1380–1392 (2015). 25597531 10.1016/j.biotechadv.2015.01.003

179. Chiang YT Yen YW Lo CL Reactive oxygen species and glutathione dual redox-responsive micelles for selective cytotoxicity of cancer Biomaterials 2015 61 150 161 10.1016/j.biomaterials.2015.05.007 26002788 Chiang, Y. T., Yen, Y. W. & Lo, C. L. Reactive oxygen species and glutathione dual redox-responsive micelles for selective cytotoxicity of cancer. Biomaterials 61 , 150–161 (2015). 26002788 10.1016/j.biomaterials.2015.05.007

180. Wilhelm J Wang Z Sumer BD Gao J Exploiting nanoscale cooperativity for precision medicine Adv. Drug Deliver. Rev. 2020 158 63 72 10.1016/j.addr.2020.08.012 PMC7736475 32882321 Wilhelm, J., Wang, Z., Sumer, B. D. & Gao, J. Exploiting nanoscale cooperativity for precision medicine. Adv. Drug Deliver. Rev. 158 , 63–72 (2020). 10.1016/j.addr.2020.08.012 PMC7736475 32882321

181. Knop K Hoogenboom R Fischer D Schubert US Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives Angew. Chem. Int. Edit. 2010 49 6288 6308 10.1002/anie.200902672 20648499 Knop, K., Hoogenboom, R., Fischer, D. & Schubert, U. S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Edit. 49 , 6288–6308 (2010). 10.1002/anie.200902672 20648499

182. Cai Y The in vivo fate of polymeric micelles Adv. Drug Deliver. Rev. 2022 188 114463 10.1016/j.addr.2022.114463 35905947 Cai, Y. et al. The in vivo fate of polymeric micelles. Adv. Drug Deliver. Rev. 188 , 114463 (2022). 10.1016/j.addr.2022.114463 35905947

183. Wei J Clickable and imageable multiblock polymer micelles with magnetically guided and PEG-switched targeting and release property for precise tumor theranosis Biomaterials 2017 145 138 153 10.1016/j.biomaterials.2017.08.005 28863308 Wei, J. et al. Clickable and imageable multiblock polymer micelles with magnetically guided and PEG-switched targeting and release property for precise tumor theranosis. Biomaterials 145 , 138–153 (2017). 28863308 10.1016/j.biomaterials.2017.08.005

184. Miteva M Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers Biomaterials 2015 38 97 107 10.1016/j.biomaterials.2014.10.036 25453977 PMC5477977 Miteva, M. et al. Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers. Biomaterials 38 , 97–107 (2015). 25453977 10.1016/j.biomaterials.2014.10.036 PMC5477977

185. Dai Y Xu C Sun X Chen X Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment Chem. Soc. Rev. 2017 46 3830 3852 10.1039/C6CS00592F 28516983 PMC5521825 Dai, Y., Xu, C., Sun, X. & Chen, X. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem. Soc. Rev. 46 , 3830–3852 (2017). 28516983 10.1039/C6CS00592F PMC5521825

186. Song J Influence of poly(ethylene glycol) molecular architecture on particle assembly and ex vivo particle-immune cell interactions in human blood ACS Nano 2021 15 10025 10038 10.1021/acsnano.1c01642 34009935 Song, J. et al. Influence of poly(ethylene glycol) molecular architecture on particle assembly and ex vivo particle-immune cell interactions in human blood. ACS Nano 15 , 10025–10038 (2021). 34009935 10.1021/acsnano.1c01642

187. Shi D To PEGylate or not to PEGylate: immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives Adv. Drug Deliver. Rev. 2022 180 114079 10.1016/j.addr.2021.114079 PMC8899923 34902516 Shi, D. et al. To PEGylate or not to PEGylate: immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives. Adv. Drug Deliver. Rev. 180 , 114079 (2022). 10.1016/j.addr.2021.114079 PMC8899923 34902516

188. Gabizon A Szebeni J Complement activation: a potential threat on the safety of poly(ethylene glycol)-coated nanomedicines ACS Nano 2020 14 7682 7688 10.1021/acsnano.0c03648 32643376 Gabizon, A. & Szebeni, J. Complement activation: a potential threat on the safety of poly(ethylene glycol)-coated nanomedicines. ACS Nano 14 , 7682–7688 (2020). 32643376 10.1021/acsnano.0c03648

189. Gu X Nanoagents based on poly(ethylene glycol)-b-poly(l-thyroxine) block copolypeptide for enhanced dual-modality imaging and targeted tumor radiotherapy Small 2019 15 e1902577 10.1002/smll.201902577 31539202 Gu, X. et al. Nanoagents based on poly(ethylene glycol)-b-poly(l-thyroxine) block copolypeptide for enhanced dual-modality imaging and targeted tumor radiotherapy. Small 15 , e1902577 (2019). 31539202 10.1002/smll.201902577

190. Wang JL The effect of surface poly(ethylene glycol) length on in vivo drug delivery behaviors of polymeric nanoparticles Biomaterials 2018 182 104 113 10.1016/j.biomaterials.2018.08.022 30114562 Wang, J. L. et al. The effect of surface poly(ethylene glycol) length on in vivo drug delivery behaviors of polymeric nanoparticles. Biomaterials 182 , 104–113 (2018). 30114562 10.1016/j.biomaterials.2018.08.022

191. Karimi M Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems Chem. Soc. Rev. 2016 45 1457 1501 10.1039/C5CS00798D 26776487 PMC4775468 Karimi, M. et al. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem. Soc. Rev. 45 , 1457–1501 (2016). 26776487 10.1039/C5CS00798D PMC4775468

192. Su Z Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor chemoimmunotherapy Small 2020 16 e1906832 10.1002/smll.201906832 31990457 Su, Z. et al. Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor chemoimmunotherapy. Small 16 , e1906832 (2020). 31990457 10.1002/smll.201906832

193. Sun X The blood clearance kinetics and pathway of polymeric micelles in cancer drug delivery ACS Nano 2018 12 6179 6192 10.1021/acsnano.8b02830 29847730 Sun, X. et al. The blood clearance kinetics and pathway of polymeric micelles in cancer drug delivery. ACS Nano 12 , 6179–6192 (2018). 29847730 10.1021/acsnano.8b02830

194. Conde J Oliva N Zhang Y Artzi N Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model Nat. Mater. 2016 15 1128 1138 10.1038/nmat4707 27454043 PMC6594055 Conde, J., Oliva, N., Zhang, Y. & Artzi, N. Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat. Mater. 15 , 1128–1138 (2016). 27454043 10.1038/nmat4707 PMC6594055

195. Cao H Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity Signal Transduct. Tar. 2021 6 426 10.1038/s41392-021-00830-x PMC8674418 34916490 Cao, H. et al. Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. Signal Transduct. Tar. 6 , 426 (2021). 10.1038/s41392-021-00830-x PMC8674418 34916490

196. Zhong R Hydrogels for RNA delivery Nat. Mater. 2023 22 818 831 10.1038/s41563-023-01472-w 36941391 PMC10330049 Zhong, R. et al. Hydrogels for RNA delivery. Nat. Mater. 22 , 818–831 (2023). 36941391 10.1038/s41563-023-01472-w PMC10330049

197. Sepantafar M Engineered hydrogels in cancer therapy and diagnosis Trends Biotechnol 2017 35 1074 1087 10.1016/j.tibtech.2017.06.015 28734545 Sepantafar, M. et al. Engineered hydrogels in cancer therapy and diagnosis. Trends Biotechnol 35 , 1074–1087 (2017). 28734545 10.1016/j.tibtech.2017.06.015

198. Oliva N Conde J Wang K Artzi N Designing hydrogels for on-demand therapy Accounts Chem. Res. 2017 50 669 679 10.1021/acs.accounts.6b00536 PMC6527116 28301139 Oliva, N., Conde, J., Wang, K. & Artzi, N. Designing hydrogels for on-demand therapy. Accounts Chem. Res. 50 , 669–679 (2017). 10.1021/acs.accounts.6b00536 PMC6527116 28301139

199. Piantanida E Alonci G Bertucci A De Cola L Design of nanocomposite injectable hydrogels for minimally invasive surgery Accounts Chem. Res. 2019 52 2101 2112 10.1021/acs.accounts.9b00114 31291090 Piantanida, E., Alonci, G., Bertucci, A. & De Cola, L. Design of nanocomposite injectable hydrogels for minimally invasive surgery. Accounts Chem. Res. 52 , 2101–2112 (2019). 10.1021/acs.accounts.9b00114 31291090

200. Contessotto P Elastin-like recombinamers-based hydrogel modulates post-ischemic remodeling in a non-transmural myocardial infarction in sheep Sci. Transl. Med. 2021 13 eaaz5380 10.1126/scitranslmed.aaz5380 33597263 Contessotto, P. et al. Elastin-like recombinamers-based hydrogel modulates post-ischemic remodeling in a non-transmural myocardial infarction in sheep. Sci. Transl. Med. 13 , eaaz5380 (2021). 33597263 10.1126/scitranslmed.aaz5380

201. Zhu JQ Responsive hydrogels based on triggered click reactions for liver cancer Adv. Mater. 2022 34 e2201651 10.1002/adma.202201651 35583434 Zhu, J. Q. et al. Responsive hydrogels based on triggered click reactions for liver cancer. Adv. Mater. 34 , e2201651 (2022). 35583434 10.1002/adma.202201651

202. Mikhail AS Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer Adv. Drug Deliver. Rev. 2023 202 115083 10.1016/j.addr.2023.115083 PMC11616795 37673217 Mikhail, A. S. et al. Hydrogel drug delivery systems for minimally invasive local immunotherapy of cancer. Adv. Drug Deliver. Rev. 202 , 115083 (2023). 10.1016/j.addr.2023.115083 PMC11616795 37673217

203. Talebian S Self-healing hydrogels: the next paradigm shift in tissue engineering? Adv. Sci. 2019 6 1801664 10.1002/advs.201801664 PMC6702654 31453048 Talebian, S. et al. Self-healing hydrogels: the next paradigm shift in tissue engineering? Adv. Sci. 6 , 1801664 (2019). 10.1002/advs.201801664 PMC6702654 31453048

204. Li P Zhong Y Wang X Hao J Enzyme-regulated healable polymeric hydrogels ACS Central Sci 2020 6 1507 1522 10.1021/acscentsci.0c00768 PMC7517121 32999926 Li, P., Zhong, Y., Wang, X. & Hao, J. Enzyme-regulated healable polymeric hydrogels. ACS Central Sci 6 , 1507–1522 (2020). 10.1021/acscentsci.0c00768 PMC7517121 32999926

205. Mo F DNA hydrogel-based gene editing and drug delivery systems Adv. Drug Deliver. Rev. 2021 168 79 98 10.1016/j.addr.2020.07.018 32712197 Mo, F. et al. DNA hydrogel-based gene editing and drug delivery systems. Adv. Drug Deliver. Rev. 168 , 79–98 (2021). 10.1016/j.addr.2020.07.018 32712197

206. Zhao H Persistent luminescent nanoparticles containing hydrogels for targeted, sustained, and autofluorescence-free tumor metastasis imaging Nano Lett 2020 20 252 260 10.1021/acs.nanolett.9b03755 31793303 Zhao, H. et al. Persistent luminescent nanoparticles containing hydrogels for targeted, sustained, and autofluorescence-free tumor metastasis imaging. Nano Lett 20 , 252–260 (2020). 31793303 10.1021/acs.nanolett.9b03755

207. Yuan P Nanocomposite hydrogel with NIR/magnet/enzyme multiple responsiveness to accurately manipulate local drugs for on-demand tumor therapy Biomaterials 2020 262 120357 10.1016/j.biomaterials.2020.120357 32911253 Yuan, P. et al. Nanocomposite hydrogel with NIR/magnet/enzyme multiple responsiveness to accurately manipulate local drugs for on-demand tumor therapy. Biomaterials 262 , 120357 (2020). 32911253 10.1016/j.biomaterials.2020.120357

208. Jin H Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel ACS Nano 2018 12 3295 3310 10.1021/acsnano.7b08148 29558107 Jin, H. et al. Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel. ACS Nano 12 , 3295–3310 (2018). 29558107 10.1021/acsnano.7b08148

209. Venkatesh V Supramolecular photoactivatable anticancer hydrogels J. Am. Chem. Soc. 2017 139 5656 5659 10.1021/jacs.7b00186 28414222 Venkatesh, V. et al. Supramolecular photoactivatable anticancer hydrogels. J. Am. Chem. Soc. 139 , 5656–5659 (2017). 28414222 10.1021/jacs.7b00186

210. Bencherif SA Injectable cryogel-based whole-cell cancer vaccines Nat. Commun. 2015 6 7556 10.1038/ncomms8556 26265369 PMC4763944 Bencherif, S. A. et al. Injectable cryogel-based whole-cell cancer vaccines. Nat. Commun. 6 , 7556 (2015). 26265369 10.1038/ncomms8556 PMC4763944

211. Ng S Mechanically and chemically defined hydrogel matrices for patient-derived colorectal tumor organoid culture Biomaterials 2019 219 119400 10.1016/j.biomaterials.2019.119400 31398570 Ng, S. et al. Mechanically and chemically defined hydrogel matrices for patient-derived colorectal tumor organoid culture. Biomaterials 219 , 119400 (2019). 31398570 10.1016/j.biomaterials.2019.119400

212. Wang J pH-switchable antimicrobial nanofiber networks of hydrogel eradicate biofilm and rescue stalled healing in chronic wounds ACS Nano 2019 13 11686 11697 10.1021/acsnano.9b05608 31490650 Wang, J. et al. pH-switchable antimicrobial nanofiber networks of hydrogel eradicate biofilm and rescue stalled healing in chronic wounds. ACS Nano 13 , 11686–11697 (2019). 31490650 10.1021/acsnano.9b05608

213. Kunzmann A Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation BBA-Gen. Subjects 2011 1810 361 373 10.1016/j.bbagen.2010.04.007 20435096 Kunzmann, A. et al. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. BBA-Gen. Subjects 1810 , 361–373 (2011). 10.1016/j.bbagen.2010.04.007 20435096

214. Quazi MZ Park N Nanohydrogels: Advanced polymeric nanomaterials in the era of nanotechnology for robust functionalization and cumulative applications Int. J. Mol. Sci. 2022 23 1943 10.3390/ijms23041943 35216058 PMC8875080 Quazi, M. Z. & Park, N. Nanohydrogels: Advanced polymeric nanomaterials in the era of nanotechnology for robust functionalization and cumulative applications. Int. J. Mol. Sci. 23 , 1943 (2022). 35216058 10.3390/ijms23041943 PMC8875080

215. Hajareh Haghighi F Peptide-hydrogel nanocomposites for anti-cancer drug delivery Gels 2023 9 953 10.3390/gels9120953 38131939 PMC10742474 Hajareh Haghighi, F. et al. Peptide-hydrogel nanocomposites for anti-cancer drug delivery. Gels 9 , 953 (2023). 38131939 10.3390/gels9120953 PMC10742474

216. Yuniarsih N Chaerunisaa AY Elamin KM Wathoni N Polymeric nanohydrogel in topical drug delivery system Int. J. Nanomed. 2024 19 2733 2754 10.2147/IJN.S442123 PMC10950079 38505165 Yuniarsih, N., Chaerunisaa, A. Y., Elamin, K. M. & Wathoni, N. Polymeric nanohydrogel in topical drug delivery system. Int. J. Nanomed. 19 , 2733–2754 (2024). 10.2147/IJN.S442123 PMC10950079 38505165

217. Wang F Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy Sci. Adv. 2020 6 eaaz8985 10.1126/sciadv.aaz8985 32490201 PMC7239700 Wang, F. et al. Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. Sci. Adv. 6 , eaaz8985 (2020). 32490201 10.1126/sciadv.aaz8985 PMC7239700

218. Wang F Supramolecular tubustecan hydrogel as chemotherapeutic carrier to improve tumor penetration and local treatment efficacy ACS Nano 2020 14 10083 10094 10.1021/acsnano.0c03286 32806082 Wang, F. et al. Supramolecular tubustecan hydrogel as chemotherapeutic carrier to improve tumor penetration and local treatment efficacy. ACS Nano 14 , 10083–10094 (2020). 32806082 10.1021/acsnano.0c03286

219. Conde J Oliva N Artzi N Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance Proc. Natl. Acad. Sci. USA. 2015 112 E1278 E1287 10.1073/pnas.1421229112 25733851 PMC4371927 Conde, J., Oliva, N. & Artzi, N. Implantable hydrogel embedded dark-gold nanoswitch as a theranostic probe to sense and overcome cancer multidrug resistance. Proc. Natl. Acad. Sci. USA. 112 , E1278–E1287 (2015). 25733851 10.1073/pnas.1421229112 PMC4371927

220. van Niel G D’Angelo G Raposo G Shedding light on the cell biology of extracellular vesicles Nat. Rev. Mol. Cell Bio. 2018 19 213 228 10.1038/nrm.2017.125 29339798 van Niel, G., D’Angelo, G. & Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Bio. 19 , 213–228 (2018). 29339798 10.1038/nrm.2017.125

221. Veerman RE Güçlüler Akpinar G Eldh M Gabrielsson S Immune cell-derived extracellular vesicles - functions and therapeutic applications Trends Mol. Med. 2019 25 382 394 10.1016/j.molmed.2019.02.003 30853173 Veerman, R. E., Güçlüler Akpinar, G., Eldh, M. & Gabrielsson, S. Immune cell-derived extracellular vesicles - functions and therapeutic applications. Trends Mol. Med. 25 , 382–394 (2019). 30853173 10.1016/j.molmed.2019.02.003

222. Kalluri R LeBleu VS The biology, function, and biomedical applications of exosomes Science 2020 367 eaau6977 10.1126/science.aau6977 32029601 PMC7717626 Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367 , eaau6977 (2020). 32029601 10.1126/science.aau6977 PMC7717626

223. Pegtel DM Gould SJ Exosomes Annu. Rev. Biochem. 2019 88 487 514 10.1146/annurev-biochem-013118-111902 31220978 Pegtel, D. M. & Gould, S. J. Exosomes. Annu. Rev. Biochem. 88 , 487–514 (2019). 31220978 10.1146/annurev-biochem-013118-111902

224. Trams EG Lauter CJ Salem N Jr. Heine U Exfoliation of membrane ecto-enzymes in the form of micro-vesicles BBA-Bioenergetics 1981 645 63 70 6266476 10.1016/0005-2736(81)90512-5 Trams, E. G., Lauter, C. J., Salem, N. Jr. & Heine, U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. BBA-Bioenergetics 645 , 63–70 (1981). 6266476 10.1016/0005-2736(81)90512-5

225. Pirisinu M Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation Semin. Cancer Biol. 2020 80 340 355 10.1016/j.semcancer.2020.08.007 32977006 Pirisinu, M. et al. Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation. Semin. Cancer Biol. 80 , 340–355 (2020). 32977006 10.1016/j.semcancer.2020.08.007

226. Yan W Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells Nat. Cell Biol. 2018 20 597 609 10.1038/s41556-018-0083-6 29662176 PMC5920728 Yan, W. et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat. Cell Biol. 20 , 597–609 (2018). 29662176 10.1038/s41556-018-0083-6 PMC5920728

227. Chen G Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response Nature 2018 560 382 386 10.1038/s41586-018-0392-8 30089911 PMC6095740 Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560 , 382–386 (2018). 30089911 10.1038/s41586-018-0392-8 PMC6095740

228. Becker A Extracellular vesicles in cancer: cell-to-cell mediators of metastasis Cancer Cell 2016 30 836 848 10.1016/j.ccell.2016.10.009 27960084 PMC5157696 Becker, A. et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30 , 836–848 (2016). 27960084 10.1016/j.ccell.2016.10.009 PMC5157696

229. Melo SA Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis Cancer Cell 2014 26 707 721 10.1016/j.ccell.2014.09.005 25446899 PMC4254633 Melo, S. A. et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26 , 707–721 (2014). 25446899 10.1016/j.ccell.2014.09.005 PMC4254633

230. Morrissey SM Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming Cell Metab 2021 33 2040 2058.e2010 10.1016/j.cmet.2021.09.002 34559989 PMC8506837 Morrissey, S. M. et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab 33 , 2040–2058.e2010 (2021). 34559989 10.1016/j.cmet.2021.09.002 PMC8506837

231. Qiu S Gastric cancer-derived exosomal miR-519a-3p promotes liver metastasis by inducing intrahepatic M2-like macrophage-mediated angiogenesis J. Exp. Clin. Cancer Res. 2022 41 296 10.1186/s13046-022-02499-8 36217165 PMC9549645 Qiu, S. et al. Gastric cancer-derived exosomal miR-519a-3p promotes liver metastasis by inducing intrahepatic M2-like macrophage-mediated angiogenesis. J. Exp. Clin. Cancer Res. 41 , 296 (2022). 36217165 10.1186/s13046-022-02499-8 PMC9549645

232. Gautam SK Batra SK Jain M Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma Mol. Cancer 2023 22 118 10.1186/s12943-023-01813-y 37488598 PMC10367391 Gautam, S. K., Batra, S. K. & Jain, M. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma. Mol. Cancer 22 , 118 (2023). 37488598 10.1186/s12943-023-01813-y PMC10367391

233. Lee YJ GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer metastasis Dev. Cell 2023 58 320 334.e328 10.1016/j.devcel.2023.01.006 36800996 Lee, Y. J. et al. GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer metastasis. Dev. Cell 58 , 320–334.e328 (2023). 36800996 10.1016/j.devcel.2023.01.006

234. Medhin LB Extracellular vesicles as a liquid biopsy for melanoma: are we there yet? Semin. Cancer Biol. 2023 89 92 98 10.1016/j.semcancer.2023.01.008 36706847 Medhin, L. B. et al. Extracellular vesicles as a liquid biopsy for melanoma: are we there yet? Semin. Cancer Biol. 89 , 92–98 (2023). 36706847 10.1016/j.semcancer.2023.01.008

235. Tran PHL Exosomes and nanoengineering: a match made for precision therapeutics Adv. Mater. 2020 32 e1904040 10.1002/adma.201904040 31531916 Tran, P. H. L. et al. Exosomes and nanoengineering: a match made for precision therapeutics. Adv. Mater. 32 , e1904040 (2020). 31531916 10.1002/adma.201904040

236. Cheng N Recent advances in biosensors for detecting cancer-derived exosomes Trends Biotechnol 2019 37 1236 1254 10.1016/j.tibtech.2019.04.008 31104858 Cheng, N. et al. Recent advances in biosensors for detecting cancer-derived exosomes. Trends Biotechnol 37 , 1236–1254 (2019). 31104858 10.1016/j.tibtech.2019.04.008

237. Pluchino S Smith JA Explicating exosomes: reclassifying the rising stars of intercellular communication Cell 2019 177 225 227 10.1016/j.cell.2019.03.020 30951665 Pluchino, S. & Smith, J. A. Explicating exosomes: reclassifying the rising stars of intercellular communication. Cell 177 , 225–227 (2019). 30951665 10.1016/j.cell.2019.03.020

238. Zhu C Recent advances of aptasensors for exosomes detection Biosens. Bioelectron. 2020 160 112213 10.1016/j.bios.2020.112213 32339150 Zhu, C. et al. Recent advances of aptasensors for exosomes detection. Biosens. Bioelectron. 160 , 112213 (2020). 32339150 10.1016/j.bios.2020.112213

239. Li X Exosomes in cancer: small transporters with big functions Cancer Lett 2018 435 55 65 10.1016/j.canlet.2018.07.037 30071288 Li, X. et al. Exosomes in cancer: small transporters with big functions. Cancer Lett 435 , 55–65 (2018). 30071288 10.1016/j.canlet.2018.07.037

240. Wu H The role and application of small extracellular vesicles in gastric cancer Mol. Cancer 2021 20 71 10.1186/s12943-021-01365-z 33926452 PMC8081769 Wu, H. et al. The role and application of small extracellular vesicles in gastric cancer. Mol. Cancer 20 , 71 (2021). 33926452 10.1186/s12943-021-01365-z PMC8081769

241. Zhao Z Erythrocyte leveraged chemotherapy (ELeCt): nanoparticle assembly on erythrocyte surface to combat lung metastasis Sci. Adv. 2019 5 eaax9250 10.1126/sciadv.aax9250 31763454 PMC6853768 Zhao, Z. et al. Erythrocyte leveraged chemotherapy (ELeCt): nanoparticle assembly on erythrocyte surface to combat lung metastasis. Sci. Adv. 5 , eaax9250 (2019). 31763454 10.1126/sciadv.aax9250 PMC6853768

242. Lunavat TR RNAi delivery by exosome-mimetic nanovesicles - implications for targeting c-Myc in cancer Biomaterials 2016 102 231 238 10.1016/j.biomaterials.2016.06.024 27344366 Lunavat, T. R. et al. RNAi delivery by exosome-mimetic nanovesicles - implications for targeting c-Myc in cancer. Biomaterials 102 , 231–238 (2016). 27344366 10.1016/j.biomaterials.2016.06.024

243. Deng Z Enterobacteria-secreted particles induce production of exosome-like S1P-containing particles by intestinal epithelium to drive Th17-mediated tumorigenesis Nat. Commun. 2015 6 6956 10.1038/ncomms7956 25907800 PMC4410277 Deng, Z. et al. Enterobacteria-secreted particles induce production of exosome-like S1P-containing particles by intestinal epithelium to drive Th17-mediated tumorigenesis. Nat. Commun. 6 , 6956 (2015). 25907800 10.1038/ncomms7956 PMC4410277

244. Barile L Vassalli G Exosomes: therapy delivery tools and biomarkers of diseases Pharmacol. Therapeut. 2017 174 63 78 10.1016/j.pharmthera.2017.02.020 28202367 Barile, L. & Vassalli, G. Exosomes: therapy delivery tools and biomarkers of diseases. Pharmacol. Therapeut. 174 , 63–78 (2017). 10.1016/j.pharmthera.2017.02.020 28202367

245. Witwer KW Wolfram J Extracellular vesicles versus synthetic nanoparticles for drug delivery Nat. Rev. Mater. 2021 6 103 106 10.1038/s41578-020-00277-6 36117545 PMC9481198 Witwer, K. W. & Wolfram, J. Extracellular vesicles versus synthetic nanoparticles for drug delivery. Nat. Rev. Mater. 6 , 103–106 (2021). 36117545 10.1038/s41578-020-00277-6 PMC9481198

246. Lang FM Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas Neuro-oncology 2018 20 380 390 10.1093/neuonc/nox152 29016843 PMC5817945 Lang, F. M. et al. Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. Neuro-oncology 20 , 380–390 (2018). 29016843 10.1093/neuonc/nox152 PMC5817945

247. Sancho-Albero M Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis Nat. Catal. 2019 2 864 872 10.1038/s41929-019-0333-4 31620674 PMC6795537 Sancho-Albero, M. et al. Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis. Nat. Catal. 2 , 864–872 (2019). 31620674 10.1038/s41929-019-0333-4 PMC6795537

248. Zhuang J Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy Nucleic Acids Res 2020 48 8870 8882 10.1093/nar/gkaa683 32810272 PMC7498310 Zhuang, J. et al. Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy. Nucleic Acids Res 48 , 8870–8882 (2020). 32810272 10.1093/nar/gkaa683 PMC7498310

249. Saari H Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery J. Extracell. Vesicles 2020 9 1747206 10.1080/20013078.2020.1747206 32363012 PMC7178890 Saari, H. et al. Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery. J. Extracell. Vesicles 9 , 1747206 (2020). 32363012 10.1080/20013078.2020.1747206 PMC7178890

250. Khalil DN Smith EL Brentjens RJ Wolchok JD The future of cancer treatment: immunomodulation, CARs and combination immunotherapy Nat. Rev. Clin. Oncol. 2016 13 273 290 10.1038/nrclinonc.2016.25 26977780 PMC5551685 Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13 , 273–290 (2016). 26977780 10.1038/nrclinonc.2016.25 PMC5551685

251. Taghikhani A Engineered tumor-derived extracellular vesicles: potentials in cancer immunotherapy Front. Immunol. 2020 11 221 10.3389/fimmu.2020.00221 32210954 PMC7069476 Taghikhani, A. et al. Engineered tumor-derived extracellular vesicles: potentials in cancer immunotherapy. Front. Immunol. 11 , 221 (2020). 32210954 10.3389/fimmu.2020.00221 PMC7069476

252. Wen C Biological roles and potential applications of immune cell-derived extracellular vesicles J. Extracell. Vesicles 2017 6 1400370 10.1080/20013078.2017.1400370 29209467 PMC5706476 Wen, C. et al. Biological roles and potential applications of immune cell-derived extracellular vesicles. J. Extracell. Vesicles 6 , 1400370 (2017). 29209467 10.1080/20013078.2017.1400370 PMC5706476

253. Buzas EI The roles of extracellular vesicles in the immune system Nat. Rev. Immunol. 2023 23 236 250 10.1038/s41577-022-00763-8 35927511 PMC9361922 Buzas, E. I. The roles of extracellular vesicles in the immune system. Nat. Rev. Immunol. 23 , 236–250 (2023). 35927511 10.1038/s41577-022-00763-8 PMC9361922

254. Andre F Malignant effusions and immunogenic tumour-derived exosomes Lancet 2002 360 295 305 10.1016/S0140-6736(02)09552-1 12147373 Andre, F. et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360 , 295–305 (2002). 12147373 10.1016/S0140-6736(02)09552-1

255. Guo X Sui R Piao H Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma J. Nanobiotechnol. 2022 20 383 10.1186/s12951-022-01584-6 PMC9400220 35999601 Guo, X., Sui, R. & Piao, H. Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma. J. Nanobiotechnol. 20 , 383 (2022). 10.1186/s12951-022-01584-6 PMC9400220 35999601

256. Xu Y Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment Theranostics 2022 12 1683 1714 10.7150/thno.67775 35198064 PMC8825588 Xu, Y. et al. Tumor-derived extracellular vesicles as messengers of natural products in cancer treatment. Theranostics 12 , 1683–1714 (2022). 35198064 10.7150/thno.67775 PMC8825588

257. Clancy JW D’Souza-Schorey C Tumor-derived extracellular vesicles: multifunctional entities in the tumor microenvironment Annu. Rev. Pathol.-Mech. 2023 18 205 229 10.1146/annurev-pathmechdis-031521-022116 PMC10410237 36202098 Clancy, J. W. & D’Souza-Schorey, C. Tumor-derived extracellular vesicles: multifunctional entities in the tumor microenvironment. Annu. Rev. Pathol.-Mech. 18 , 205–229 (2023). 10.1146/annurev-pathmechdis-031521-022116 PMC10410237 36202098

258. Kugeratski FG Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker Nat. Cell Biol. 2021 23 631 641 10.1038/s41556-021-00693-y 34108659 PMC9290189 Kugeratski, F. G. et al. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker. Nat. Cell Biol. 23 , 631–641 (2021). 34108659 10.1038/s41556-021-00693-y PMC9290189

259. André F Tumor-derived exosomes: a new source of tumor rejection antigens Vaccine 2002 20 A28 A31 10.1016/S0264-410X(02)00384-5 12477425 André, F. et al. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine 20 , A28–A31 (2002). 12477425 10.1016/S0264-410X(02)00384-5

260. Hazrati A Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications Biomark. Res. 2022 10 30 10.1186/s40364-022-00374-4 35550636 PMC9102350 Hazrati, A. et al. Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications. Biomark. Res. 10 , 30 (2022). 35550636 10.1186/s40364-022-00374-4 PMC9102350

261. Zhu L Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming Biomaterials 2019 190-191 38 50 10.1016/j.biomaterials.2018.10.034 30391801 Zhu, L. et al. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming. Biomaterials 190-191 , 38–50 (2019). 30391801 10.1016/j.biomaterials.2018.10.034

262. Jong AY Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells J. Extracell. Vesicles 2017 6 1294368 10.1080/20013078.2017.1294368 28326171 PMC5345580 Jong, A. Y. et al. Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J. Extracell. Vesicles 6 , 1294368 (2017). 28326171 10.1080/20013078.2017.1294368 PMC5345580

263. Zhang M Conscription of immune cells by light-activatable silencing NK-derived exosome (LASNEO) for synergetic tumor eradication Adv. Sci. 2022 9 e2201135 10.1002/advs.202201135 PMC9353410 35665496 Zhang, M. et al. Conscription of immune cells by light-activatable silencing NK-derived exosome (LASNEO) for synergetic tumor eradication. Adv. Sci. 9 , e2201135 (2022). 10.1002/advs.202201135 PMC9353410 35665496

264. Lu Z Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models J. Hepatol. 2017 67 739 748 10.1016/j.jhep.2017.05.019 28549917 Lu, Z. et al. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J. Hepatol. 67 , 739–748 (2017). 28549917 10.1016/j.jhep.2017.05.019

265. Möller A Lobb RJ The evolving translational potential of small extracellular vesicles in cancer Nat. Rev. Cancer 2020 20 697 709 10.1038/s41568-020-00299-w 32958932 Möller, A. & Lobb, R. J. The evolving translational potential of small extracellular vesicles in cancer. Nat. Rev. Cancer 20 , 697–709 (2020). 32958932 10.1038/s41568-020-00299-w

266. Lai CP Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter ACS Nano 2014 8 483 494 10.1021/nn404945r 24383518 PMC3934350 Lai, C. P. et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 8 , 483–494 (2014). 24383518 10.1021/nn404945r PMC3934350

267. van Niel G Challenges and directions in studying cell-cell communication by extracellular vesicles Nat. Rev. Mol. Cell Bio. 2022 23 369 382 10.1038/s41580-022-00460-3 35260831 van Niel, G. et al. Challenges and directions in studying cell-cell communication by extracellular vesicles. Nat. Rev. Mol. Cell Bio. 23 , 369–382 (2022). 35260831 10.1038/s41580-022-00460-3

268. Parodi A Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery Biomaterials 2017 147 155 168 10.1016/j.biomaterials.2017.09.020 28946131 Parodi, A. et al. Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery. Biomaterials 147 , 155–168 (2017). 28946131 10.1016/j.biomaterials.2017.09.020

269. Fang RH Gao W Zhang L Targeting drugs to tumours using cell membrane-coated nanoparticles Nat. Rev. Clin. Oncol. 2023 20 33 48 10.1038/s41571-022-00699-x 36307534 Fang, R. H., Gao, W. & Zhang, L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat. Rev. Clin. Oncol. 20 , 33–48 (2023). 36307534 10.1038/s41571-022-00699-x

270. Castro F Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments Adv. Drug Deliver. Rev. 2021 170 312 339 10.1016/j.addr.2020.09.001 32946921 Castro, F. et al. Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments. Adv. Drug Deliver. Rev. 170 , 312–339 (2021). 10.1016/j.addr.2020.09.001 32946921

271. Ren X Red blood cell membrane camouflaged magnetic nanoclusters for imaging-guided photothermal therapy Biomaterials 2016 92 13 24 10.1016/j.biomaterials.2016.03.026 27031929 Ren, X. et al. Red blood cell membrane camouflaged magnetic nanoclusters for imaging-guided photothermal therapy. Biomaterials 92 , 13–24 (2016). 27031929 10.1016/j.biomaterials.2016.03.026

272. Parodi A Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions Nat. Nanotechnol. 2013 8 61 68 10.1038/nnano.2012.212 23241654 PMC3751189 Parodi, A. et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8 , 61–68 (2013). 23241654 10.1038/nnano.2012.212 PMC3751189

273. Liu B RBC membrane camouflaged prussian blue nanoparticles for gamabutolin loading and combined chemo/photothermal therapy of breast cancer Biomaterials 2019 217 119301 10.1016/j.biomaterials.2019.119301 31279101 Liu, B. et al. RBC membrane camouflaged prussian blue nanoparticles for gamabutolin loading and combined chemo/photothermal therapy of breast cancer. Biomaterials 217 , 119301 (2019). 31279101 10.1016/j.biomaterials.2019.119301

274. Jiang Q Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors Biomaterials 2019 192 292 308 10.1016/j.biomaterials.2018.11.021 30465973 Jiang, Q. et al. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. Biomaterials 192 , 292–308 (2019). 30465973 10.1016/j.biomaterials.2018.11.021

275. Zhang L Erythrocyte membrane cloaked metal-organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy ACS Nano 2018 12 10201 10211 10.1021/acsnano.8b05200 30265804 Zhang, L. et al. Erythrocyte membrane cloaked metal-organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy. ACS Nano 12 , 10201–10211 (2018). 30265804 10.1021/acsnano.8b05200

276. Wang D Erythrocyte-cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal/chemotherapy of melanoma ACS Nano 2018 12 5241 5252 10.1021/acsnano.7b08355 29800517 Wang, D. et al. Erythrocyte-cancer hybrid membrane camouflaged hollow copper sulfide nanoparticles for prolonged circulation life and homotypic-targeting photothermal/chemotherapy of melanoma. ACS Nano 12 , 5241–5252 (2018). 29800517 10.1021/acsnano.7b08355

277. Jiang Q Red blood cell membrane-camouflaged melanin nanoparticles for enhanced photothermal therapy Biomaterials 2017 143 29 45 10.1016/j.biomaterials.2017.07.027 28756194 Jiang, Q. et al. Red blood cell membrane-camouflaged melanin nanoparticles for enhanced photothermal therapy. Biomaterials 143 , 29–45 (2017). 28756194 10.1016/j.biomaterials.2017.07.027

278. Pei Q Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy ACS Nano 2018 12 1630 1641 10.1021/acsnano.7b08219 29346736 Pei, Q. et al. Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy. ACS Nano 12 , 1630–1641 (2018). 29346736 10.1021/acsnano.7b08219

279. Han X Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy Sci. Adv. 2019 5 eaaw6870 10.1126/sciadv.aaw6870 31681841 PMC6810293 Han, X. et al. Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. Sci. Adv. 5 , eaaw6870 (2019). 31681841 10.1126/sciadv.aaw6870 PMC6810293

280. Liu W Light-triggered biomimetic nanoerythrocyte for tumor-targeted lung metastatic combination therapy of malignant melanoma Small 2018 14 e1801754 10.1002/smll.201801754 30141569 Liu, W. et al. Light-triggered biomimetic nanoerythrocyte for tumor-targeted lung metastatic combination therapy of malignant melanoma. Small 14 , e1801754 (2018). 30141569 10.1002/smll.201801754

281. Palomba R Biomimetic carriers mimicking leukocyte plasma membrane to increase tumor vasculature permeability Sci. Rep.-UK 2016 6 34422 10.1038/srep34422 PMC5050497 27703233 Palomba, R. et al. Biomimetic carriers mimicking leukocyte plasma membrane to increase tumor vasculature permeability. Sci. Rep.-UK 6 , 34422 (2016). 10.1038/srep34422 PMC5050497 27703233

282. Evangelopoulos M Cell source determines the immunological impact of biomimetic nanoparticles Biomaterials 2016 82 168 177 10.1016/j.biomaterials.2015.11.054 26761780 PMC4916497 Evangelopoulos, M. et al. Cell source determines the immunological impact of biomimetic nanoparticles. Biomaterials 82 , 168–177 (2016). 26761780 10.1016/j.biomaterials.2015.11.054 PMC4916497

283. He H Leutusome: a biomimetic nanoplatform integrating plasma membrane components of leukocytes and tumor cells for remarkably enhanced solid tumor homing Nano Lett 2018 18 6164 6174 10.1021/acs.nanolett.8b01892 30207473 PMC6292712 He, H. et al. Leutusome: a biomimetic nanoplatform integrating plasma membrane components of leukocytes and tumor cells for remarkably enhanced solid tumor homing. Nano Lett 18 , 6164–6174 (2018). 30207473 10.1021/acs.nanolett.8b01892 PMC6292712

284. Csányi G Lucas R Annex BH Loaded leukosomes: a smart bomb to halt vascular inflammation Circ Res 2020 126 38 40 10.1161/CIRCRESAHA.119.316249 31895661 PMC7284964 Csányi, G., Lucas, R. & Annex, B. H. Loaded leukosomes: a smart bomb to halt vascular inflammation. Circ Res 126 , 38–40 (2020). 31895661 10.1161/CIRCRESAHA.119.316249 PMC7284964

285. Boada C Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation Circ Res 2020 126 25 37 10.1161/CIRCRESAHA.119.315185 31647755 Boada, C. et al. Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation. Circ Res 126 , 25–37 (2020). 31647755 10.1161/CIRCRESAHA.119.315185

286. Molinaro R Biomimetic proteolipid vesicles for targeting inflamed tissues Nat. Mater. 2016 15 1037 1046 10.1038/nmat4644 27213956 PMC5127392 Molinaro, R. et al. Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat. Mater. 15 , 1037–1046 (2016). 27213956 10.1038/nmat4644 PMC5127392

287. Furman D Chronic inflammation in the etiology of disease across the life span Nat. Med. 2019 25 1822 1832 10.1038/s41591-019-0675-0 31806905 PMC7147972 Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 25 , 1822–1832 (2019). 31806905 10.1038/s41591-019-0675-0 PMC7147972

288. Haemmerle M The platelet lifeline to cancer: challenges and opportunities Cancer Cell 2018 33 965 983 10.1016/j.ccell.2018.03.002 29657130 PMC5997503 Haemmerle, M. et al. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell 33 , 965–983 (2018). 29657130 10.1016/j.ccell.2018.03.002 PMC5997503

289. Lambert AW Pattabiraman DR Weinberg RA Emerging biological principles of metastasis Cell 2017 168 670 691 10.1016/j.cell.2016.11.037 28187288 PMC5308465 Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168 , 670–691 (2017). 28187288 10.1016/j.cell.2016.11.037 PMC5308465

290. Li Z Smart nanotherapeutic targeting of tumor vasculature Accounts Chem. Res. 2019 52 2703 2712 10.1021/acs.accounts.9b00283 31433171 Li, Z. et al. Smart nanotherapeutic targeting of tumor vasculature. Accounts Chem. Res. 52 , 2703–2712 (2019). 10.1021/acs.accounts.9b00283 31433171

291. Xu Y Blockade of platelets using tumor-specific NO-releasing nanoparticles prevents tumor metastasis and reverses tumor immunosuppression ACS Nano 2020 14 9780 9795 10.1021/acsnano.0c01687 32806062 Xu, Y. et al. Blockade of platelets using tumor-specific NO-releasing nanoparticles prevents tumor metastasis and reverses tumor immunosuppression. ACS Nano 14 , 9780–9795 (2020). 32806062 10.1021/acsnano.0c01687

292. Zhuang J Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles Sci. Adv. 2020 6 eaaz6108 10.1126/sciadv.aaz6108 32258408 PMC7101224 Zhuang, J. et al. Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles. Sci. Adv. 6 , eaaz6108 (2020). 32258408 10.1126/sciadv.aaz6108 PMC7101224

293. Jiang Q Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy Small 2020 16 e2001704 10.1002/smll.202001704 32338436 Jiang, Q. et al. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy. Small 16 , e2001704 (2020). 32338436 10.1002/smll.202001704

294. Bao CJ Bioorthogonal engineered virus-like nanoparticles for efficient gene therapy Nano-Micro Lett 2023 15 197 10.1007/s40820-023-01153-y PMC10423197 37572220 Bao, C. J. et al. Bioorthogonal engineered virus-like nanoparticles for efficient gene therapy. Nano-Micro Lett 15 , 197 (2023). 10.1007/s40820-023-01153-y PMC10423197 37572220

295. Alam MM Glycan-modified virus-like particles evoke T helper type 1-like immune responses ACS nano 2020 15 309 321 10.1021/acsnano.0c03023 32790346 PMC8249087 Alam, M. M. et al. Glycan-modified virus-like particles evoke T helper type 1-like immune responses. ACS nano 15 , 309–321 (2020). 32790346 10.1021/acsnano.0c03023 PMC8249087

296. Lee KL Combination of plant virus nanoparticle-based in situ vaccination with chemotherapy potentiates antitumor response Nano Lett 2017 17 4019 4028 10.1021/acs.nanolett.7b00107 28650644 PMC5623935 Lee, K. L. et al. Combination of plant virus nanoparticle-based in situ vaccination with chemotherapy potentiates antitumor response. Nano Lett 17 , 4019–4028 (2017). 28650644 10.1021/acs.nanolett.7b00107 PMC5623935

297. Beatty PH Lewis JD Cowpea mosaic virus nanoparticles for cancer imaging and therapy Adv. Drug Deliver. Rev. 2019 145 130 144 10.1016/j.addr.2019.04.005 31004625 Beatty, P. H. & Lewis, J. D. Cowpea mosaic virus nanoparticles for cancer imaging and therapy. Adv. Drug Deliver. Rev. 145 , 130–144 (2019). 10.1016/j.addr.2019.04.005 31004625

298. Zheng Y Freeze-drying to produce efficacious CPMV virus-like particles Nano Lett 2019 19 2099 2105 10.1021/acs.nanolett.9b00300 30801195 PMC7272238 Zheng, Y. et al. Freeze-drying to produce efficacious CPMV virus-like particles. Nano Lett 19 , 2099–2105 (2019). 30801195 10.1021/acs.nanolett.9b00300 PMC7272238

299. Mohamed Suffian IFB Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo Biomaterials 2017 120 126 138 10.1016/j.biomaterials.2016.12.012 28056402 PMC5300899 Mohamed Suffian, I. F. B. et al. Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo. Biomaterials 120 , 126–138 (2017). 28056402 10.1016/j.biomaterials.2016.12.012 PMC5300899

300. Palomino-Vizcaino G Effect of HPV16 L1 virus-like particles on the aggregation of non-functionalized gold nanoparticles Biosens. Bioelectron. 2018 100 176 183 10.1016/j.bios.2017.09.001 28889068 Palomino-Vizcaino, G. et al. Effect of HPV16 L1 virus-like particles on the aggregation of non-functionalized gold nanoparticles. Biosens. Bioelectron. 100 , 176–183 (2018). 28889068 10.1016/j.bios.2017.09.001

301. Wang C Active delivery of VLPs promotes anti-tumor activity in a mouse ovarian tumor model Small 2020 16 e1907150 10.1002/smll.201907150 32329580 PMC7507763 Wang, C. et al. Active delivery of VLPs promotes anti-tumor activity in a mouse ovarian tumor model. Small 16 , e1907150 (2020). 32329580 10.1002/smll.201907150 PMC7507763

302. Sharifi S Toxicity of nanomaterials Chem. Soc. Rev. 2012 41 2323 2343 10.1039/C1CS15188F 22170510 PMC4703119 Sharifi, S. et al. Toxicity of nanomaterials. Chem. Soc. Rev. 41 , 2323–2343 (2012). 22170510 10.1039/C1CS15188F PMC4703119

303. Li J Toxicity of inorganic nanomaterials in biomedical imaging Biotechnol. Adv. 2014 32 727 743 10.1016/j.biotechadv.2013.12.009 24389087 Li, J. et al. Toxicity of inorganic nanomaterials in biomedical imaging. Biotechnol. Adv. 32 , 727–743 (2014). 24389087 10.1016/j.biotechadv.2013.12.009

304. Hoffmann F Cornelius M Morell J Fröba M Silica-based mesoporous organic-inorganic hybrid materials Angew. Chem. Int. Edit. 2006 45 3216 3251 10.1002/anie.200503075 16676373 Hoffmann, F., Cornelius, M., Morell, J. & Fröba, M. Silica-based mesoporous organic-inorganic hybrid materials. Angew. Chem. Int. Edit. 45 , 3216–3251 (2006). 10.1002/anie.200503075 16676373

305. Haffer S Tiemann M Fröba M Periodic mesoporous organosilica (PMO) materials with uniform spherical core-shell structure Chem.-Eur. J. 2010 16 10447 10452 10.1002/chem.201000643 20648490 Haffer, S., Tiemann, M. & Fröba, M. Periodic mesoporous organosilica (PMO) materials with uniform spherical core-shell structure. Chem.-Eur. J. 16 , 10447–10452 (2010). 20648490 10.1002/chem.201000643

306. Vallet-Regí M Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem. Soc. Rev. 2022 51 5365 5451 10.1039/D1CS00659B 35642539 PMC9252171 Vallet-Regí, M. et al. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem. Soc. Rev. 51 , 5365–5451 (2022). 35642539 10.1039/D1CS00659B PMC9252171

307. Mekaru H Lu J Tamanoi F Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy Adv. Drug Deliver. Rev. 2015 95 40 49 10.1016/j.addr.2015.09.009 PMC4663124 26434537 Mekaru, H., Lu, J. & Tamanoi, F. Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Adv. Drug Deliver. Rev. 95 , 40–49 (2015). 10.1016/j.addr.2015.09.009 PMC4663124 26434537

308. Nguyen TL Choi Y Kim J Mesoporous silica as a versatile platform for cancer immunotherapy Adv. Mater. 2019 31 e1803953 10.1002/adma.201803953 30417454 Nguyen, T. L., Choi, Y. & Kim, J. Mesoporous silica as a versatile platform for cancer immunotherapy. Adv. Mater. 31 , e1803953 (2019). 30417454 10.1002/adma.201803953

309. Yu M Gu Z Ottewell T Yu C Silica-based nanoparticles for therapeutic protein delivery J. Mater. Chem. B 2017 5 3241 3252 10.1039/C7TB00244K 32264391 Yu, M., Gu, Z., Ottewell, T. & Yu, C. Silica-based nanoparticles for therapeutic protein delivery. J. Mater. Chem. B 5 , 3241–3252 (2017). 32264391 10.1039/C7TB00244K

310. Liu J Heat-triggered drug release systems based on mesoporous silica nanoparticles filled with a maghemite core and phase-change molecules as gatekeepers J. Mater. Chem. B 2014 2 59 70 10.1039/C3TB21229G 32261299 Liu, J. et al. Heat-triggered drug release systems based on mesoporous silica nanoparticles filled with a maghemite core and phase-change molecules as gatekeepers. J. Mater. Chem. B 2 , 59–70 (2014). 32261299 10.1039/C3TB21229G

311. Liu J Design of hybrid nanovehicles for remotely triggered drug release: an overview J. Mater. Chem. B 2015 3 6117 6147 10.1039/C5TB00664C 32262732 Liu, J. et al. Design of hybrid nanovehicles for remotely triggered drug release: an overview. J. Mater. Chem. B 3 , 6117–6147 (2015). 32262732 10.1039/C5TB00664C

312. Xu J Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer Nat. Nanotechnol. 2019 14 388 397 10.1038/s41565-019-0381-6 30804480 PMC6449187 Xu, J. et al. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nat. Nanotechnol. 14 , 388–397 (2019). 30804480 10.1038/s41565-019-0381-6 PMC6449187

313. Chen L Multifunctional redox-responsive mesoporous silica nanoparticles for efficient targeting drug delivery and magnetic resonance imaging ACS Appl. Mater. Inter. 2016 8 33829 33841 10.1021/acsami.6b11802 27960384 Chen, L. et al. Multifunctional redox-responsive mesoporous silica nanoparticles for efficient targeting drug delivery and magnetic resonance imaging. ACS Appl. Mater. Inter. 8 , 33829–33841 (2016). 10.1021/acsami.6b11802 27960384

314. Xuan M Magnetic mesoporous silica nanoparticles cloaked by red blood cell membranes: applications in cancer therapy Angew. Chem. Int. Edit. 2018 57 6049 6053 10.1002/anie.201712996 29480962 Xuan, M. et al. Magnetic mesoporous silica nanoparticles cloaked by red blood cell membranes: applications in cancer therapy. Angew. Chem. Int. Edit. 57 , 6049–6053 (2018). 10.1002/anie.201712996 29480962

315. Dogra P Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics Nat. Commun. 2018 9 4551 10.1038/s41467-018-06730-z 30382084 PMC6208419 Dogra, P. et al. Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics. Nat. Commun. 9 , 4551 (2018). 30382084 10.1038/s41467-018-06730-z PMC6208419

316. Lu J Li Z Zink JI Tamanoi F In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification Nanomedicine 2012 8 212 220 10.1016/j.nano.2011.06.002 21703996 PMC3221805 Lu, J., Li, Z., Zink, J. I. & Tamanoi, F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine 8 , 212–220 (2012). 21703996 10.1016/j.nano.2011.06.002 PMC3221805

317. Chen Y Chen H Shi J In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles Adv. Mater. 2013 25 3144 3176 10.1002/adma.201205292 23681931 Chen, Y., Chen, H. & Shi, J. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles. Adv. Mater. 25 , 3144–3176 (2013). 23681931 10.1002/adma.201205292

318. Croissant J Biodegradable ethylene-bis(propyl)disulfide-based periodic mesoporous organosilica nanorods and nanospheres for efficient in-vitro drug delivery Adv. Mater. 2014 26 6174 6180 10.1002/adma.201401931 25042639 Croissant, J. et al. Biodegradable ethylene-bis(propyl)disulfide-based periodic mesoporous organosilica nanorods and nanospheres for efficient in-vitro drug delivery. Adv. Mater. 26 , 6174–6180 (2014). 25042639 10.1002/adma.201401931

319. Lee SJ Enhanced anti-tumor immunotherapy by silica-coated magnetic nanoparticles conjugated with ovalbumin Int. J. Nanomed. 2019 14 8235 8249 10.2147/IJN.S194352 PMC6802490 31802864 Lee, S. J. et al. Enhanced anti-tumor immunotherapy by silica-coated magnetic nanoparticles conjugated with ovalbumin. Int. J. Nanomed. 14 , 8235–8249 (2019). 10.2147/IJN.S194352 PMC6802490 31802864

320. Jafari S Mesoporous silica nanoparticles for therapeutic/diagnostic applications Biomed. Pharmacother. 2019 109 1100 1111 10.1016/j.biopha.2018.10.167 30551360 Jafari, S. et al. Mesoporous silica nanoparticles for therapeutic/diagnostic applications. Biomed. Pharmacother. 109 , 1100–1111 (2019). 30551360 10.1016/j.biopha.2018.10.167

321. Hom C Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells Small 2010 6 1185 1190 10.1002/smll.200901966 20461725 PMC2953950 Hom, C. et al. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small 6 , 1185–1190 (2010). 20461725 10.1002/smll.200901966 PMC2953950

322. Roberts CM Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models Nanomedicine 2017 13 965 976 10.1016/j.nano.2016.11.010 27890656 PMC9004794 Roberts, C. M. et al. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanomedicine 13 , 965–976 (2017). 27890656 10.1016/j.nano.2016.11.010 PMC9004794

323. Singh P Gold nanoparticles in diagnostics and therapeutics for human cancer Int. J. Mol. Sci. 2018 19 1979 10.3390/ijms19071979 29986450 PMC6073740 Singh, P. et al. Gold nanoparticles in diagnostics and therapeutics for human cancer. Int. J. Mol. Sci. 19 , 1979 (2018). 29986450 10.3390/ijms19071979 PMC6073740

324. Moreno-Alcántar G Picchetti P Casini A Gold complexes in anticancer therapy: from new design principles to particle-based delivery systems Angew. Chem. Int. Edit. 2023 62 e202218000 10.1002/anie.202218000 36847211 Moreno-Alcántar, G., Picchetti, P. & Casini, A. Gold complexes in anticancer therapy: from new design principles to particle-based delivery systems. Angew. Chem. Int. Edit. 62 , e202218000 (2023). 10.1002/anie.202218000 36847211

325. Wu T Synthesis and characterization of gold nanoparticles from Abies spectabilis extract and its anticancer activity on bladder cancer T24 cells Artif. Cell. Nanomed. B. 2019 47 512 523 10.1080/21691401.2018.1560305 30810403 Wu, T. et al. Synthesis and characterization of gold nanoparticles from Abies spectabilis extract and its anticancer activity on bladder cancer T24 cells. Artif. Cell. Nanomed. B. 47 , 512–523 (2019). 10.1080/21691401.2018.1560305 30810403

326. Wang L Green synthesis of gold nanoparticles from Scutellaria barbata and its anticancer activity in pancreatic cancer cell (PANC-1) Artif. Cell. Nanomed. B. 2019 47 1617 1627 10.1080/21691401.2019.1594862 31014134 Wang, L. et al. Green synthesis of gold nanoparticles from Scutellaria barbata and its anticancer activity in pancreatic cancer cell (PANC-1). Artif. Cell. Nanomed. B. 47 , 1617–1627 (2019). 10.1080/21691401.2019.1594862 31014134

327. Li L Zhang W Desikan Seshadri VD Cao G Synthesis and characterization of gold nanoparticles from Marsdenia tenacissima and its anticancer activity of liver cancer HepG2 cells Artif. Cell. Nanomed. B. 2019 47 3029 3036 10.1080/21691401.2019.1642902 31328556 Li, L., Zhang, W., Desikan Seshadri, V. D. & Cao, G. Synthesis and characterization of gold nanoparticles from Marsdenia tenacissima and its anticancer activity of liver cancer HepG2 cells. Artif. Cell. Nanomed. B. 47 , 3029–3036 (2019). 10.1080/21691401.2019.1642902 31328556

328. Wang L Synthesis of gold nanoparticles from leaf Panax notoginseng and its anticancer activity in pancreatic cancer PANC-1 cell lines Artif. Cell. Nanomed. B. 2019 47 1216 1223 10.1080/21691401.2019.1593852 30942628 Wang, L. et al. Synthesis of gold nanoparticles from leaf Panax notoginseng and its anticancer activity in pancreatic cancer PANC-1 cell lines. Artif. Cell. Nanomed. B. 47 , 1216–1223 (2019). 10.1080/21691401.2019.1593852 30942628

329. Tian B Gold nanoparticles biosynthesized and functionalized using a hydroxylated tetraterpenoid trigger gene expression changes and apoptosis in cancer cells ACS Appl. Mater. Inter. 2018 10 37353 37363 10.1021/acsami.8b09206 30295457 Tian, B. et al. Gold nanoparticles biosynthesized and functionalized using a hydroxylated tetraterpenoid trigger gene expression changes and apoptosis in cancer cells. ACS Appl. Mater. Inter. 10 , 37353–37363 (2018). 10.1021/acsami.8b09206 30295457

330. Boisselier E Astruc D Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity Chem. Soc. Rev. 2009 38 1759 1782 10.1039/b806051g 19587967 Boisselier, E. & Astruc, D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev. 38 , 1759–1782 (2009). 19587967 10.1039/b806051g

331. Yang Y Colloidal plasmonic gold nanoparticles and gold nanorings: shape-dependent generation of singlet oxygen and their performance in enhanced photodynamic cancer therapy Int. J. Nanomed. 2018 13 2065 2078 10.2147/IJN.S156347 PMC5896663 29670350 Yang, Y. et al. Colloidal plasmonic gold nanoparticles and gold nanorings: shape-dependent generation of singlet oxygen and their performance in enhanced photodynamic cancer therapy. Int. J. Nanomed. 13 , 2065–2078 (2018). 10.2147/IJN.S156347 PMC5896663 29670350

332. Park SJ Protein-nanoparticle interaction: corona formation and conformational changes in proteins on nanoparticles Int. J. Nanomed. 2020 15 5783 5802 10.2147/IJN.S254808 PMC7418457 32821101 Park, S. J. Protein-nanoparticle interaction: corona formation and conformational changes in proteins on nanoparticles. Int. J. Nanomed. 15 , 5783–5802 (2020). 10.2147/IJN.S254808 PMC7418457 32821101

333. Cai R Chen C The crown and the scepter: roles of the protein corona in nanomedicine Adv. Mater. 2019 31 e1805740 10.1002/adma.201805740 30589115 Cai, R. & Chen, C. The crown and the scepter: roles of the protein corona in nanomedicine. Adv. Mater. 31 , e1805740 (2019). 30589115 10.1002/adma.201805740

334. Nguyen VH Lee BJ Protein corona: a new approach for nanomedicine design Int. J. Nanomed. 2017 12 3137 3151 10.2147/IJN.S129300 PMC5402904 28458536 Nguyen, V. H. & Lee, B. J. Protein corona: a new approach for nanomedicine design. Int. J. Nanomed. 12 , 3137–3151 (2017). 10.2147/IJN.S129300 PMC5402904 28458536

335. Kalimuthu K Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells J. Nanobiotechnol. 2018 16 34 10.1186/s12951-018-0362-1 PMC5877385 29602308 Kalimuthu, K. et al. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells. J. Nanobiotechnol. 16 , 34 (2018). 10.1186/s12951-018-0362-1 PMC5877385 29602308

336. Aldahhan R Almohazey D Khan FA Emerging trends in the application of gold nanoformulations in colon cancer diagnosis and treatment Semin. Cancer Biol. 2022 86 1056 1065 10.1016/j.semcancer.2021.11.008 34843989 Aldahhan, R., Almohazey, D. & Khan, F. A. Emerging trends in the application of gold nanoformulations in colon cancer diagnosis and treatment. Semin. Cancer Biol. 86 , 1056–1065 (2022). 34843989 10.1016/j.semcancer.2021.11.008

337. Nejabat M An overview on gold nanorods as versatile nanoparticles in cancer therapy J. Control. Release 2023 354 221 242 10.1016/j.jconrel.2023.01.009 36621644 Nejabat, M. et al. An overview on gold nanorods as versatile nanoparticles in cancer therapy. J. Control. Release 354 , 221–242 (2023). 36621644 10.1016/j.jconrel.2023.01.009

338. Riley RS Day ES Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment WIREs. Nanomed. Nanobi. 2017 9 e1449 10.1002/wnan.1449 PMC5474189 28160445 Riley, R. S. & Day, E. S. Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. WIREs. Nanomed. Nanobi. 9 , e1449 (2017). 10.1002/wnan.1449 PMC5474189 28160445

339. Kesharwani P Gold nanoparticles and gold nanorods in the landscape of cancer therapy Mol. Cancer 2023 22 98 10.1186/s12943-023-01798-8 37344887 PMC10283337 Kesharwani, P. et al. Gold nanoparticles and gold nanorods in the landscape of cancer therapy. Mol. Cancer 22 , 98 (2023). 37344887 10.1186/s12943-023-01798-8 PMC10283337

340. Blackburn JL Ferguson AJ Cho C Grunlan JC Carbon-nanotube-based thermoelectric materials and devices Adv. Mater. 2018 30 1704386 10.1002/adma.201704386 29356158 Blackburn, J. L., Ferguson, A. J., Cho, C. & Grunlan, J. C. Carbon-nanotube-based thermoelectric materials and devices. Adv. Mater. 30 , 1704386 (2018). 10.1002/adma.201704386 29356158

341. Chung S Revia RA Zhang M Graphene quantum dots and their applications in bioimaging, biosensing, and therapy Adv. Mater. 2021 33 e1904362 10.1002/adma.201904362 31833101 PMC7289657 Chung, S., Revia, R. A. & Zhang, M. Graphene quantum dots and their applications in bioimaging, biosensing, and therapy. Adv. Mater. 33 , e1904362 (2021). 31833101 10.1002/adma.201904362 PMC7289657

342. Cheng R Structure and interface modification of carbon dots for electrochemical energy application Small 2021 17 e2102091 10.1002/smll.202102091 34318998 Cheng, R. et al. Structure and interface modification of carbon dots for electrochemical energy application. Small 17 , e2102091 (2021). 34318998 10.1002/smll.202102091

343. Wareing TC Gentile P Phan AN Biomass-based carbon dots: current development and future perspectives ACS Nano 2021 15 15471 15501 10.1021/acsnano.1c03886 34559522 Wareing, T. C., Gentile, P. & Phan, A. N. Biomass-based carbon dots: current development and future perspectives. ACS Nano 15 , 15471–15501 (2021). 34559522 10.1021/acsnano.1c03886

344. Loh KP Clinical applications of carbon nanomaterials in diagnostics and therapy Adv. Mater. 2018 30 e1802368 10.1002/adma.201802368 30133035 Loh, K. P. et al. Clinical applications of carbon nanomaterials in diagnostics and therapy. Adv. Mater. 30 , e1802368 (2018). 30133035 10.1002/adma.201802368

345. Toh TB Lim JJ Chow EK Epigenetics in cancer stem cells Mol. Cancer 2017 16 29 10.1186/s12943-017-0596-9 28148257 PMC5286794 Toh, T. B., Lim, J. J. & Chow, E. K. Epigenetics in cancer stem cells. Mol. Cancer 16 , 29 (2017). 28148257 10.1186/s12943-017-0596-9 PMC5286794

346. Cui X A multifunctional nanodiamond-based nanoplatform for the enhanced mild-temperature photothermal/chemo combination therapy of triple negative breast cancer via an autophagy regulation strategy Nanoscale 2021 13 13375 13389 10.1039/D1NR03161A 34477743 Cui, X. et al. A multifunctional nanodiamond-based nanoplatform for the enhanced mild-temperature photothermal/chemo combination therapy of triple negative breast cancer via an autophagy regulation strategy. Nanoscale 13 , 13375–13389 (2021). 34477743 10.1039/D1NR03161A

347. Liao WS Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite Acta Biomater 2019 86 395 405 10.1016/j.actbio.2019.01.025 30660004 Liao, W. S. et al. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. Acta Biomater 86 , 395–405 (2019). 30660004 10.1016/j.actbio.2019.01.025

348. Wang X Stimuli-responsive nanodiamond-based biosensor for enhanced metastatic tumor site detection SLAS Technol 2018 23 44 56 10.1177/2472630317735497 29020497 Wang, X. et al. Stimuli-responsive nanodiamond-based biosensor for enhanced metastatic tumor site detection. SLAS Technol 23 , 44–56 (2018). 29020497 10.1177/2472630317735497

349. Dykas MM Enhancing image contrast of carbon nanotubes on cellular background using helium ion microscope by varying helium ion fluence J. Microsc.-Oxford 2018 269 14 22 10.1111/jmi.12604 28703381 Dykas, M. M. et al. Enhancing image contrast of carbon nanotubes on cellular background using helium ion microscope by varying helium ion fluence. J. Microsc.-Oxford 269 , 14–22 (2018). 10.1111/jmi.12604 28703381

350. Ackermann J Metternich JT Herbertz S Kruss S Biosensing with fluorescent carbon nanotubes Angew. Chem. Int. Edit. 2022 61 e202112372 10.1002/anie.202112372 PMC9313876 34978752 Ackermann, J., Metternich, J. T., Herbertz, S. & Kruss, S. Biosensing with fluorescent carbon nanotubes. Angew. Chem. Int. Edit. 61 , e202112372 (2022). 10.1002/anie.202112372 PMC9313876 34978752

351. Kim M Detection of ovarian cancer via the spectral fingerprinting of quantum-defect-modified carbon nanotubes in serum by machine learning Nat. Biomed. Eng. 2022 6 267 275 10.1038/s41551-022-00860-y 35301449 PMC9108893 Kim, M. et al. Detection of ovarian cancer via the spectral fingerprinting of quantum-defect-modified carbon nanotubes in serum by machine learning. Nat. Biomed. Eng. 6 , 267–275 (2022). 35301449 10.1038/s41551-022-00860-y PMC9108893

352. Saito N Future prospects for clinical applications of nanocarbons focusing on carbon nanotubes Adv. Sci. 2022 9 e2201214 10.1002/advs.202201214 PMC9404397 35754236 Saito, N. et al. Future prospects for clinical applications of nanocarbons focusing on carbon nanotubes. Adv. Sci. 9 , e2201214 (2022). 10.1002/advs.202201214 PMC9404397 35754236

353. Li J In vitro controlled release of cisplatin from gold-carbon nanobottles via cleavable linkages Int. J. Nanomed. 2015 10 7425 7441 10.2147/IJN.S93810 PMC4687722 26719686 Li, J. et al. In vitro controlled release of cisplatin from gold-carbon nanobottles via cleavable linkages. Int. J. Nanomed. 10 , 7425–7441 (2015). 10.2147/IJN.S93810 PMC4687722 26719686

354. Panwar N Nanocarbons for biology and medicine: sensing, imaging, and drug delivery Chem. Rev. 2019 119 9559 9656 10.1021/acs.chemrev.9b00099 31287663 Panwar, N. et al. Nanocarbons for biology and medicine: sensing, imaging, and drug delivery. Chem. Rev. 119 , 9559–9656 (2019). 31287663 10.1021/acs.chemrev.9b00099

355. Lee JM Performance of screening ultrasonography as an adjunct to screening mammography in women across the spectrum of breast cancer risk JAMA Intern. Med. 2019 179 658 667 10.1001/jamainternmed.2018.8372 30882843 PMC6503561 Lee, J. M. et al. Performance of screening ultrasonography as an adjunct to screening mammography in women across the spectrum of breast cancer risk. JAMA Intern. Med. 179 , 658–667 (2019). 30882843 10.1001/jamainternmed.2018.8372 PMC6503561

356. Siegel RL Colorectal cancer statistics, 2023 CA-Cancer J. Clin 2023 73 233 254 10.3322/caac.21772 36856579 Siegel, R. L. et al. Colorectal cancer statistics, 2023. CA-Cancer J. Clin 73 , 233–254 (2023). 36856579 10.3322/caac.21772

357. Dekker E Colorectal cancer Lancet 2019 394 1467 1480 10.1016/S0140-6736(19)32319-0 31631858 Dekker, E. et al. Colorectal cancer. Lancet 394 , 1467–1480 (2019). 31631858 10.1016/S0140-6736(19)32319-0

358. Bray F Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA-Cancer J. Clin 2018 68 394 424 10.3322/caac.21492 30207593 Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J. Clin 68 , 394–424 (2018). 30207593 10.3322/caac.21492

359. Vogel A Hepatocellular carcinoma Lancet 2022 400 1345 1362 10.1016/S0140-6736(22)01200-4 36084663 Vogel, A. et al. Hepatocellular carcinoma. Lancet 400 , 1345–1362 (2022). 36084663 10.1016/S0140-6736(22)01200-4

360. Vincent A Pancreatic cancer Lancet 2011 378 607 620 10.1016/S0140-6736(10)62307-0 21620466 PMC3062508 Vincent, A. et al. Pancreatic cancer. Lancet 378 , 607–620 (2011). 21620466 10.1016/S0140-6736(10)62307-0 PMC3062508

361. Cronin KA Annual report to the nation on the status of cancer, part I: national cancer statistics Cancer 2018 124 2785 2800 10.1002/cncr.31551 29786848 PMC6033186 Cronin, K. A. et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 124 , 2785–2800 (2018). 29786848 10.1002/cncr.31551 PMC6033186

362. Fang Z Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe 3 O 4 nanoparticles for targeted drug delivery Int. J. Nanomed. 2019 14 5785 5797 10.2147/IJN.S213974 PMC6679701 31440047 Fang, Z. et al. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe 3 O 4 nanoparticles for targeted drug delivery. Int. J. Nanomed. 14 , 5785–5797 (2019). 10.2147/IJN.S213974 PMC6679701 31440047

363. Zhang B Ding C Displacement-type amperometric immunosensing platform for sensitive determination of tumour markers Biosens. Bioelectron. 2016 82 112 118 10.1016/j.bios.2016.03.053 27058441 Zhang, B. & Ding, C. Displacement-type amperometric immunosensing platform for sensitive determination of tumour markers. Biosens. Bioelectron. 82 , 112–118 (2016). 27058441 10.1016/j.bios.2016.03.053

364. Ji T An MMP-2 Responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer ACS Appl. Mater. Inter. 2016 8 3438 3445 10.1021/acsami.5b11619 26759926 Ji, T. et al. An MMP-2 Responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer. ACS Appl. Mater. Inter. 8 , 3438–3445 (2016). 10.1021/acsami.5b11619 26759926

365. Choi J-W Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy J. Control. Release 2015 220 691 703 10.1016/j.jconrel.2015.09.068 26437261 PMC4688183 Choi, J.-W. et al. Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene therapy. J. Control. Release 220 , 691–703 (2015). 26437261 10.1016/j.jconrel.2015.09.068 PMC4688183

366. Jin Y A tantalum oxide-based core/shell nanoparticle for triple-modality image-guided chemo-thermal synergetic therapy of esophageal carcinoma Cancer Lett 2017 397 61 71 10.1016/j.canlet.2017.03.030 28351615 Jin, Y. et al. A tantalum oxide-based core/shell nanoparticle for triple-modality image-guided chemo-thermal synergetic therapy of esophageal carcinoma. Cancer Lett 397 , 61–71 (2017). 28351615 10.1016/j.canlet.2017.03.030

367. Kim SY MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma JAMA Oncol 2017 3 456 463 10.1001/jamaoncol.2016.3147 27657493 PMC5470420 Kim, S. Y. et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol 3 , 456–463 (2017). 27657493 10.1001/jamaoncol.2016.3147 PMC5470420

368. Bibbins-Domingo K Screening for colorectal cancer: US preventive services task force recommendation statement JAMA 2016 315 2564 2575 10.1001/jama.2016.5989 27304597 Bibbins-Domingo, K. et al. Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA 315 , 2564–2575 (2016). 27304597 10.1001/jama.2016.5989

369. Weinberg DS Computed tomography colonography vs colonoscopy for colorectal cancer surveillance after surgery Gastroenterology 2018 154 927 934.e4 10.1053/j.gastro.2017.11.025 29174927 PMC5847443 Weinberg, D. S. et al. Computed tomography colonography vs colonoscopy for colorectal cancer surveillance after surgery. Gastroenterology 154 , 927–934.e4 (2018). 29174927 10.1053/j.gastro.2017.11.025 PMC5847443

370. Bretthauer M Effect of colonoscopy screening on risks of colorectal cancer and related death New Engl. J. Med. 2022 387 1547 1556 10.1056/NEJMoa2208375 36214590 Bretthauer, M. et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. New Engl. J. Med. 387 , 1547–1556 (2022). 36214590 10.1056/NEJMoa2208375

371. Loynachan CN Renal clearable catalytic gold nanoclusters for in vivo disease monitoring Nat. Nanotechnol. 2019 14 883 890 10.1038/s41565-019-0527-6 31477801 PMC7045344 Loynachan, C. N. et al. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring. Nat. Nanotechnol. 14 , 883–890 (2019). 31477801 10.1038/s41565-019-0527-6 PMC7045344

372. Tang B Ultrasensitive, multiplex raman frequency shift immunoassay of liver cancer biomarkers in physiological media ACS Nano 2016 10 871 879 10.1021/acsnano.5b06007 26731464 Tang, B. et al. Ultrasensitive, multiplex raman frequency shift immunoassay of liver cancer biomarkers in physiological media. ACS Nano 10 , 871–879 (2016). 26731464 10.1021/acsnano.5b06007

373. Kim J Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers Sci. Transl. Med. 2017 9 eaah5583 10.1126/scitranslmed.aah5583 28701476 PMC5727893 Kim, J. et al. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci. Transl. Med. 9 , eaah5583 (2017). 28701476 10.1126/scitranslmed.aah5583 PMC5727893

374. Thapa A Carbon nanotube matrix for highly sensitive biosensors to detect pancreatic cancer biomarker CA19-9 ACS Appl. Mater. Inter. 2017 9 25878 25886 10.1021/acsami.7b07384 28696659 Thapa, A. et al. Carbon nanotube matrix for highly sensitive biosensors to detect pancreatic cancer biomarker CA19-9. ACS Appl. Mater. Inter. 9 , 25878–25886 (2017). 10.1021/acsami.7b07384 28696659

375. Liu YJ Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer Biomaterials 2011 32 5167 5176 10.1016/j.biomaterials.2011.03.077 21521627 Liu, Y. J. et al. Gadolinium-loaded polymeric nanoparticles modified with Anti-VEGF as multifunctional MRI contrast agents for the diagnosis of liver cancer. Biomaterials 32 , 5167–5176 (2011). 21521627 10.1016/j.biomaterials.2011.03.077

376. Li H Dendron-grafted polylysine-based dual-modal nanoprobe for ultra-early diagnosis of pancreatic precancerosis via targeting a urokinase-type plasminogen activator receptor Adv. Healthc. Mater. 2018 7 1700912 10.1002/adhm.201700912 29195018 Li, H. et al. Dendron-grafted polylysine-based dual-modal nanoprobe for ultra-early diagnosis of pancreatic precancerosis via targeting a urokinase-type plasminogen activator receptor. Adv. Healthc. Mater. 7 , 1700912 (2018). 10.1002/adhm.201700912 29195018

377. Shi H Magnetic semiconductor Gd-doping CuS nanoparticles as activatable nanoprobes for bimodal imaging and targeted photothermal therapy of gastric tumors Nano Lett 2019 19 937 947 10.1021/acs.nanolett.8b04179 30688465 Shi, H. et al. Magnetic semiconductor Gd-doping CuS nanoparticles as activatable nanoprobes for bimodal imaging and targeted photothermal therapy of gastric tumors. Nano Lett 19 , 937–947 (2019). 30688465 10.1021/acs.nanolett.8b04179

378. Grifantini R Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer J. Control. Release 2018 280 76 86 10.1016/j.jconrel.2018.04.052 29733876 Grifantini, R. et al. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer. J. Control. Release 280 , 76–86 (2018). 29733876 10.1016/j.jconrel.2018.04.052

379. Kinoshita R S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes J. Control. Release 2015 217 1 9 10.1016/j.jconrel.2015.08.036 26302904 Kinoshita, R. et al. S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes. J. Control. Release 217 , 1–9 (2015). 26302904 10.1016/j.jconrel.2015.08.036

380. Du C Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation ACS Nano 2018 12 10785 10796 10.1021/acsnano.8b01573 30407790 Du, C. et al. Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation. ACS Nano 12 , 10785–10796 (2018). 30407790 10.1021/acsnano.8b01573

381. Singh B Combination therapy with doxorubicin-loaded galactosylated poly(ethyleneglycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancer Biomaterials 2017 116 130 144 10.1016/j.biomaterials.2016.11.040 27914985 Singh, B. et al. Combination therapy with doxorubicin-loaded galactosylated poly(ethyleneglycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancer. Biomaterials 116 , 130–144 (2017). 27914985 10.1016/j.biomaterials.2016.11.040

382. Mintz KJ Leblanc RM The use of nanotechnology to combat liver cancer: Progress and perspectives. BBA-Rev Cancer 2021 1876 188621 10.1016/j.bbcan.2021.188621 34454983 Mintz, K. J. & Leblanc, R. M. The use of nanotechnology to combat liver cancer: Progress and perspectives. BBA-Rev . Cancer 1876 , 188621 (2021). 10.1016/j.bbcan.2021.188621 34454983

383. Mulens-Arias V Tumor-selective immune-active mild hyperthermia associated with chemotherapy in colon peritoneal metastasis by photoactivation of fluorouracil-gold nanoparticle complexes ACS Nano 2021 15 3330 3348 10.1021/acsnano.0c10276 33528985 Mulens-Arias, V. et al. Tumor-selective immune-active mild hyperthermia associated with chemotherapy in colon peritoneal metastasis by photoactivation of fluorouracil-gold nanoparticle complexes. ACS Nano 15 , 3330–3348 (2021). 33528985 10.1021/acsnano.0c10276

384. Hou G Hydrazided hyaluronan/cisplatin/indocyanine green coordination nanoprodrug for photodynamic chemotherapy in liver cancer Carbohyd. Polym. 2022 276 118810 10.1016/j.carbpol.2021.118810 34823812 Hou, G. et al. Hydrazided hyaluronan/cisplatin/indocyanine green coordination nanoprodrug for photodynamic chemotherapy in liver cancer. Carbohyd. Polym. 276 , 118810 (2022). 10.1016/j.carbpol.2021.118810 34823812

385. Chen Y Ferritin nanocaged doxorubicin potentiates chemo-immunotherapy against hepatocellular carcinoma via immunogenic cell death Small Methods 2023 7 e2201086 10.1002/smtd.202201086 36446639 Chen, Y. et al. Ferritin nanocaged doxorubicin potentiates chemo-immunotherapy against hepatocellular carcinoma via immunogenic cell death. Small Methods 7 , e2201086 (2023). 36446639 10.1002/smtd.202201086

386. Chen W Cheng C-A Zink JI Spatial, temporal, and dose control of drug delivery using noninvasive magnetic stimulation ACS Nano 2019 13 1292 1308 30633500 10.1021/acsnano.8b06655 Chen, W., Cheng, C.-A. & Zink, J. I. Spatial, temporal, and dose control of drug delivery using noninvasive magnetic stimulation. ACS Nano 13 , 1292–1308 (2019). 30633500 10.1021/acsnano.8b06655

387. Cervello M Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: in vitro and in vivo evaluation J. Control. Release 2017 266 47 56 10.1016/j.jconrel.2017.09.014 28917533 Cervello, M. et al. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: in vitro and in vivo evaluation. J. Control. Release 266 , 47–56 (2017). 28917533 10.1016/j.jconrel.2017.09.014

388. He X Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic cancer therapy Adv. Sci. 2018 5 1701070 10.1002/advs.201701070 PMC5979633 29876225 He, X. et al. Sequentially triggered nanoparticles with tumor penetration and intelligent drug release for pancreatic cancer therapy. Adv. Sci. 5 , 1701070 (2018). 10.1002/advs.201701070 PMC5979633 29876225

389. Sun Y In vitro and in vivo evaluation of a novel estrogen-targeted PEGylated oxaliplatin liposome for gastric cancer Int. J. Nanomed. 2021 16 8279 8303 10.2147/IJN.S340180 PMC8712509 34992365 Sun, Y. et al. In vitro and in vivo evaluation of a novel estrogen-targeted PEGylated oxaliplatin liposome for gastric cancer. Int. J. Nanomed. 16 , 8279–8303 (2021). 10.2147/IJN.S340180 PMC8712509 34992365

390. Yu Y Butyrate modification promotes intestinal absorption and hepatic cancer cells targeting of ferroptosis inducer loaded nanoparticle for enhanced hepatocellular carcinoma therapy Small 2023 19 e2301149 10.1002/smll.202301149 37165608 Yu, Y. et al. Butyrate modification promotes intestinal absorption and hepatic cancer cells targeting of ferroptosis inducer loaded nanoparticle for enhanced hepatocellular carcinoma therapy. Small 19 , e2301149 (2023). 37165608 10.1002/smll.202301149

391. Xu M Hollow mesoporous ruthenium nanoparticles conjugated bispecific antibody for targeted anti-colorectal cancer response of combination therapy Nanoscale 2019 11 9661 9678 10.1039/C9NR01904A 31065660 Xu, M. et al. Hollow mesoporous ruthenium nanoparticles conjugated bispecific antibody for targeted anti-colorectal cancer response of combination therapy. Nanoscale 11 , 9661–9678 (2019). 31065660 10.1039/C9NR01904A

392. Shao D Janus “nano-bullets” for magnetic targeting liver cancer chemotherapy Biomaterials 2016 100 118 133 10.1016/j.biomaterials.2016.05.030 27258482 Shao, D. et al. Janus “nano-bullets” for magnetic targeting liver cancer chemotherapy. Biomaterials 100 , 118–133 (2016). 27258482 10.1016/j.biomaterials.2016.05.030

393. de Lázaro I Mooney DJ Obstacles and opportunities in a forward vision for cancer nanomedicine Nat. Mater. 2021 20 1469 1479 10.1038/s41563-021-01047-7 34226688 de Lázaro, I. & Mooney, D. J. Obstacles and opportunities in a forward vision for cancer nanomedicine. Nat. Mater. 20 , 1469–1479 (2021). 34226688 10.1038/s41563-021-01047-7

394. Guo J Yu Z Das M Huang L Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis ACS Nano 2020 14 5075 5089 10.1021/acsnano.0c01676 32283007 Guo, J., Yu, Z., Das, M. & Huang, L. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano 14 , 5075–5089 (2020). 32283007 10.1021/acsnano.0c01676

395. Tarannum M Vivero-Escoto JL Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment Adv. Drug Deliver. Rev. 2022 187 114357 10.1016/j.addr.2022.114357 35605679 Tarannum, M. & Vivero-Escoto, J. L. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv. Drug Deliver. Rev. 187 , 114357 (2022). 10.1016/j.addr.2022.114357 35605679

396. Liu X Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer ACS Nano 2019 13 38 53 10.1021/acsnano.8b06164 30525443 PMC6554030 Liu, X. et al. Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer. ACS Nano 13 , 38–53 (2019). 30525443 10.1021/acsnano.8b06164 PMC6554030

397. Li L In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy ACS Nano 2010 4 6874 6882 10.1021/nn100918a 20973487 Li, L. et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 4 , 6874–6882 (2010). 20973487 10.1021/nn100918a

398. Zhang JM iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy Nanomed.-Nanotechnol. 2016 12 1303 1311 10.1016/j.nano.2016.01.017 26964482 Zhang, J. M. et al. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. Nanomed.-Nanotechnol. 12 , 1303–1311 (2016). 10.1016/j.nano.2016.01.017 26964482

399. Qin SK RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma Future Oncol 2019 15 1811 1822 10.2217/fon-2019-0097 30969136 Qin, S. K. et al. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol 15 , 1811–1822 (2019). 30969136 10.2217/fon-2019-0097

400. Lozano E Causes of hOCT1-dependent cholangiocarcinoma resistance to sorafenib and sensitization by tumor-selective gene therapy Hepatology 2019 70 1246 1261 10.1002/hep.30656 30972782 Lozano, E. et al. Causes of hOCT1-dependent cholangiocarcinoma resistance to sorafenib and sensitization by tumor-selective gene therapy. Hepatology 70 , 1246–1261 (2019). 30972782 10.1002/hep.30656

401. Von Hoff DD Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine New Engl. J. Med. 2013 369 1691 1703 10.1056/NEJMoa1304369 24131140 PMC4631139 Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl. J. Med. 369 , 1691–1703 (2013). 24131140 10.1056/NEJMoa1304369 PMC4631139

402. Chen X Codelivery nanosystem targeting the deep microenvironment of pancreatic cancer Nano Lett 2019 19 3527 3534 10.1021/acs.nanolett.9b00374 31058513 Chen, X. et al. Codelivery nanosystem targeting the deep microenvironment of pancreatic cancer. Nano Lett 19 , 3527–3534 (2019). 31058513 10.1021/acs.nanolett.9b00374

403. Chen B Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system J. Control. Release 2016 241 68 80 10.1016/j.jconrel.2016.09.014 27641831 Chen, B. et al. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system. J. Control. Release 241 , 68–80 (2016). 27641831 10.1016/j.jconrel.2016.09.014

404. Zhang X Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy Int. J. Nanomed. 2019 14 2733 2751 10.2147/IJN.S198747 PMC6503337 31118608 Zhang, X. et al. Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy. Int. J. Nanomed. 14 , 2733–2751 (2019). 10.2147/IJN.S198747 PMC6503337 31118608

405. Han X Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem Nat. Commun. 2018 9 3390 10.1038/s41467-018-05906-x 30139933 PMC6107580 Han, X. et al. Reversal of pancreatic desmoplasia by re-educating stellate cells with a tumour microenvironment-activated nanosystem. Nat. Commun. 9 , 3390 (2018). 30139933 10.1038/s41467-018-05906-x PMC6107580

406. Abu-Rustum NR Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology J. Natl. Compr. Canc. Ne. 2019 17 1374 1391 10.6004/jnccn.2019.0053 31693991 Abu-Rustum, N. R. et al. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Ne. 17 , 1374–1391 (2019). 10.6004/jnccn.2019.0053 31693991

407. Pi F Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression Nat. Nanotechnol. 2018 13 82 89 10.1038/s41565-017-0012-z 29230043 PMC5762263 Pi, F. et al. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat. Nanotechnol. 13 , 82–89 (2018). 29230043 10.1038/s41565-017-0012-z PMC5762263

408. Kim JH Suppression of tumor growth in H-ras12V liver cancer mice by delivery of programmed cell death protein 4 using galactosylated poly(ethylene glycol)-chitosan-graft-spermine Biomaterials 2012 33 1894 1902 10.1016/j.biomaterials.2011.11.024 22153867 Kim, J. H. et al. Suppression of tumor growth in H-ras12V liver cancer mice by delivery of programmed cell death protein 4 using galactosylated poly(ethylene glycol)-chitosan-graft-spermine. Biomaterials 33 , 1894–1902 (2012). 22153867 10.1016/j.biomaterials.2011.11.024

409. Liu M An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy Biomaterials 2012 33 2240 2250 10.1016/j.biomaterials.2011.11.082 22177837 Liu, M. et al. An oligopeptide ligand-mediated therapeutic gene nanocomplex for liver cancer-targeted therapy. Biomaterials 33 , 2240–2250 (2012). 22177837 10.1016/j.biomaterials.2011.11.082

410. Lei Y Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer Nat. Commun. 2017 8 15130 10.1038/ncomms15130 28440296 PMC5414062 Lei, Y. et al. Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. Nat. Commun. 8 , 15130 (2017). 28440296 10.1038/ncomms15130 PMC5414062

411. Karakasheva TA IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment Cancer Res 2018 78 4957 4970 10.1158/0008-5472.CAN-17-2268 29976575 PMC6125177 Karakasheva, T. A. et al. IL-6 mediates cross-talk between tumor cells and activated fibroblasts in the tumor microenvironment. Cancer Res 78 , 4957–4970 (2018). 29976575 10.1158/0008-5472.CAN-17-2268 PMC6125177

412. Salimifard S Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression Life Sci 2020 260 118423 10.1016/j.lfs.2020.118423 32941896 Salimifard, S. et al. Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression. Life Sci 260 , 118423 (2020). 32941896 10.1016/j.lfs.2020.118423

413. Katlinski KV Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment Cancer Cell 2017 31 194 207 10.1016/j.ccell.2017.01.004 28196594 PMC5313042 Katlinski, K. V. et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31 , 194–207 (2017). 28196594 10.1016/j.ccell.2017.01.004 PMC5313042

414. Nam J Cancer nanomedicine for combination cancer immunotherapy Nat. Rev. Mater. 2019 4 398 414 10.1038/s41578-019-0108-1 Nam, J. et al. Cancer nanomedicine for combination cancer immunotherapy. Nat. Rev. Mater. 4 , 398–414 (2019). 10.1038/s41578-019-0108-1

415. Ji G Manipulating liver bile acid signaling by nanodelivery of bile acid receptor modulators for liver cancer immunotherapy Nano Lett 2021 21 6781 6791 10.1021/acs.nanolett.1c01360 34382807 Ji, G. et al. Manipulating liver bile acid signaling by nanodelivery of bile acid receptor modulators for liver cancer immunotherapy. Nano Lett 21 , 6781–6791 (2021). 34382807 10.1021/acs.nanolett.1c01360

416. Hu X The application of nanoparticles in immunotherapy for hepatocellular carcinoma J. Control. Release 2023 355 85 108 10.1016/j.jconrel.2023.01.051 36708880 Hu, X. et al. The application of nanoparticles in immunotherapy for hepatocellular carcinoma. J. Control. Release 355 , 85–108 (2023). 36708880 10.1016/j.jconrel.2023.01.051

417. Liu H Xie Z Zheng M Carbon dots and tumor antigen conjugates as nanovaccines for elevated cancer immunotherapy Small 2023 19 e2206683 10.1002/smll.202206683 36978241 Liu, H., Xie, Z. & Zheng, M. Carbon dots and tumor antigen conjugates as nanovaccines for elevated cancer immunotherapy. Small 19 , e2206683 (2023). 36978241 10.1002/smll.202206683

418. O’Neill LAJ Golenbock D Bowie AG The history of toll-like receptors - redefining innate immunity Nat. Rev. Immunol. 2013 13 453 460 10.1038/nri3446 23681101 O’Neill, L. A. J., Golenbock, D. & Bowie, A. G. The history of toll-like receptors - redefining innate immunity. Nat. Rev. Immunol. 13 , 453–460 (2013). 23681101 10.1038/nri3446

419. Naumann K Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100 Clin. Dev. Immunol. 2013 2013 283649 10.1155/2013/283649 24454470 PMC3878805 Naumann, K. et al. Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100. Clin. Dev. Immunol. 2013 , 283649 (2013). 24454470 10.1155/2013/283649 PMC3878805

420. Wei X Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy J. Control. Release 2019 313 42 53 10.1016/j.jconrel.2019.09.021 31629039 Wei, X. et al. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy. J. Control. Release 313 , 42–53 (2019). 31629039 10.1016/j.jconrel.2019.09.021

421. Sun H Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives Biomark. Res. 2022 10 89 10.1186/s40364-022-00436-7 36476317 PMC9727882 Sun, H. et al. Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomark. Res. 10 , 89 (2022). 36476317 10.1186/s40364-022-00436-7 PMC9727882

422. Ni Q Zhang F Liu Y A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer Sci. Adv. 2020 6 1 12 10.1126/sciadv.aaw6071 PMC7080439 32206706 Ni, Q., Zhang, F. & Liu, Y. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci. Adv. 6 , 1–12 (2020). 10.1126/sciadv.aaw6071 PMC7080439 32206706

423. Li X Wang X Ito A Tsuji NM A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity Nat. Commun. 2020 11 3858 10.1038/s41467-020-17637-z 32737343 PMC7395732 Li, X., Wang, X., Ito, A. & Tsuji, N. M. A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity. Nat. Commun. 11 , 3858 (2020). 32737343 10.1038/s41467-020-17637-z PMC7395732

424. Gasparri AM Boosting interleukin-12 antitumor activity and synergism with immunotherapy by targeted delivery with isoDGR-tagged nanogold Small 2019 15 e1903462 10.1002/smll.201903462 31523920 Gasparri, A. M. et al. Boosting interleukin-12 antitumor activity and synergism with immunotherapy by targeted delivery with isoDGR-tagged nanogold. Small 15 , e1903462 (2019). 31523920 10.1002/smll.201903462

425. Zhang Y Li N Suh H Irvine DJ Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity Nat. Commun. 2018 9 6 10.1038/s41467-017-02251-3 29295974 PMC5750237 Zhang, Y., Li, N., Suh, H. & Irvine, D. J. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat. Commun. 9 , 6 (2018). 29295974 10.1038/s41467-017-02251-3 PMC5750237

426. Barberio AE Cancer cell coating nanoparticles for optimal tumor-specific cytokine delivery ACS Nano 2020 14 11238 11253 10.1021/acsnano.0c03109 32692155 PMC7530125 Barberio, A. E. et al. Cancer cell coating nanoparticles for optimal tumor-specific cytokine delivery. ACS Nano 14 , 11238–11253 (2020). 32692155 10.1021/acsnano.0c03109 PMC7530125

427. Xu Q Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12 Biomaterials 2012 33 3909 3918 10.1016/j.biomaterials.2012.02.014 22374455 Xu, Q. et al. Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12. Biomaterials 33 , 3909–3918 (2012). 22374455 10.1016/j.biomaterials.2012.02.014

428. Guimarães PPG Nanoparticles for immune cytokine trail-based cancer therapy ACS Nano 2018 12 912 931 10.1021/acsnano.7b05876 29378114 PMC5834400 Guimarães, P. P. G. et al. Nanoparticles for immune cytokine trail-based cancer therapy. ACS Nano 12 , 912–931 (2018). 29378114 10.1021/acsnano.7b05876 PMC5834400

429. Mitchell MJ Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis Nat. Commun. 2017 8 14179 10.1038/ncomms14179 28317839 PMC5364380 Mitchell, M. J. et al. Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis. Nat. Commun. 8 , 14179 (2017). 28317839 10.1038/ncomms14179 PMC5364380

430. McHugh MD Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells Biomaterials 2015 59 172 181 10.1016/j.biomaterials.2015.04.003 25974747 PMC5997248 McHugh, M. D. et al. Paracrine co-delivery of TGF-β and IL-2 using CD4-targeted nanoparticles for induction and maintenance of regulatory T cells. Biomaterials 59 , 172–181 (2015). 25974747 10.1016/j.biomaterials.2015.04.003 PMC5997248

431. Kienzle A Dendritic mesoporous silica nanoparticles for pH-stimuli-responsive drug delivery of TNF-alpha Adv. Healthc. Mater. 2017 6 1700012 10.1002/adhm.201700012 28557249 Kienzle, A. et al. Dendritic mesoporous silica nanoparticles for pH-stimuli-responsive drug delivery of TNF-alpha. Adv. Healthc. Mater. 6 , 1700012 (2017). 10.1002/adhm.201700012 28557249

432. Liu X Powerful anti-colon cancer effect of modified nanoparticle-mediated IL-15 immunogene therapy through activation of the host immune system Theranostics 2018 8 3490 3503 10.7150/thno.24157 30026861 PMC6037032 Liu, X. et al. Powerful anti-colon cancer effect of modified nanoparticle-mediated IL-15 immunogene therapy through activation of the host immune system. Theranostics 8 , 3490–3503 (2018). 30026861 10.7150/thno.24157 PMC6037032

433. Zhang J Nanoformulated codelivery of quercetin and alantolactone promotes an antitumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer ACS Nano 2019 13 12511 12524 10.1021/acsnano.9b02875 31664821 Zhang, J. et al. Nanoformulated codelivery of quercetin and alantolactone promotes an antitumor response through synergistic immunogenic cell death for microsatellite-stable colorectal cancer. ACS Nano 13 , 12511–12524 (2019). 31664821 10.1021/acsnano.9b02875

434. Goodwin TJ Huang L Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis Vaccine 2017 35 2550 2557 10.1016/j.vaccine.2017.03.067 28385609 PMC5448460 Goodwin, T. J. & Huang, L. Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis. Vaccine 35 , 2550–2557 (2017). 28385609 10.1016/j.vaccine.2017.03.067 PMC5448460

435. Brown ZJ Greten TF Heinrich B Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy Hepatology 2019 70 1437 1442 10.1002/hep.30633 30927283 Brown, Z. J., Greten, T. F. & Heinrich, B. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology 70 , 1437–1442 (2019). 30927283 10.1002/hep.30633

436. Li G Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice Gastroenterology 2018 154 1024 1036 10.1053/j.gastro.2017.10.050 29408569 PMC5908238 Li, G. et al. Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice. Gastroenterology 154 , 1024–1036 (2018). 29408569 10.1053/j.gastro.2017.10.050 PMC5908238

437. Yu X Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis Nat. Commun. 2019 10 574 10.1038/s41467-019-08538-x 30718511 PMC6361944 Yu, X. et al. Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis. Nat. Commun. 10 , 574 (2019). 30718511 10.1038/s41467-019-08538-x PMC6361944

438. Li M Remodeling tumor immune microenvironment via targeted blockade of PI3K-gamma and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy J. Control. Release 2020 321 23 35 10.1016/j.jconrel.2020.02.011 32035193 Li, M. et al. Remodeling tumor immune microenvironment via targeted blockade of PI3K-gamma and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy. J. Control. Release 321 , 23–35 (2020). 32035193 10.1016/j.jconrel.2020.02.011

439. Zhang J Photothermal and gene therapy combined with immunotherapy to gastric cancer by the gold nanoshell-based system J. Nanobiotechnol. 2019 17 80 10.1186/s12951-019-0515-x PMC6612092 31277667 Zhang, J. et al. Photothermal and gene therapy combined with immunotherapy to gastric cancer by the gold nanoshell-based system. J. Nanobiotechnol. 17 , 80 (2019). 10.1186/s12951-019-0515-x PMC6612092 31277667

440. Feng J Multifunctional siRNA-laden hybrid nanoplatform for noninvasive PA/IR dual-modal imaging-guided enhanced photogenetherapy ACS Appl. Mater. Inter. 2020 12 22613 22623 10.1021/acsami.0c04533 32338491 Feng, J. et al. Multifunctional siRNA-laden hybrid nanoplatform for noninvasive PA/IR dual-modal imaging-guided enhanced photogenetherapy. ACS Appl. Mater. Inter. 12 , 22613–22623 (2020). 10.1021/acsami.0c04533 32338491

441. Lee S-Y A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy Biomaterials 2016 86 92 105 10.1016/j.biomaterials.2016.01.068 26896610 Lee, S.-Y. et al. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy. Biomaterials 86 , 92–105 (2016). 26896610 10.1016/j.biomaterials.2016.01.068

442. Guo J Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma Mol. Cancer 2021 20 10 10.1186/s12943-020-01297-0 33407548 PMC7786897 Guo, J. et al. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Mol. Cancer 20 , 10 (2021). 33407548 10.1186/s12943-020-01297-0 PMC7786897

443. Li SL Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy Biomaterials 2020 234 119760 10.1016/j.biomaterials.2020.119760 31945619 Li, S. L. et al. Redox-responsive polyprodrug nanoparticles for targeted siRNA delivery and synergistic liver cancer therapy. Biomaterials 234 , 119760 (2020). 31945619 10.1016/j.biomaterials.2020.119760

444. Jun Y Leukocyte-mediated combined targeted chemo and gene therapy for esophageal cancer ACS Appl. Mater. Inter. 2020 12 47330 47341 10.1021/acsami.0c15419 32997489 Jun, Y. et al. Leukocyte-mediated combined targeted chemo and gene therapy for esophageal cancer. ACS Appl. Mater. Inter. 12 , 47330–47341 (2020). 10.1021/acsami.0c15419 32997489

445. Gomez S Combining epigenetic and immune therapy to overcome cancer resistance Semin. Cancer Biol. 2020 65 99 113 10.1016/j.semcancer.2019.12.019 31877341 PMC7308208 Gomez, S. et al. Combining epigenetic and immune therapy to overcome cancer resistance. Semin. Cancer Biol. 65 , 99–113 (2020). 31877341 10.1016/j.semcancer.2019.12.019 PMC7308208

446. Liao W KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer Cancer Cell 2019 35 559 572 10.1016/j.ccell.2019.02.008 30905761 PMC6467776 Liao, W. et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35 , 559–572 (2019). 30905761 10.1016/j.ccell.2019.02.008 PMC6467776

447. Wang D Cabalag CS Clemons NJ DuBois RN Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer Gastroenterology 2021 161 1813 1829 10.1053/j.gastro.2021.09.059 34606846 Wang, D., Cabalag, C. S., Clemons, N. J. & DuBois, R. N. Cyclooxygenases and prostaglandins in tumor immunology and microenvironment of gastrointestinal cancer. Gastroenterology 161 , 1813–1829 (2021). 34606846 10.1053/j.gastro.2021.09.059

448. Xiang X Wang J Lu D Xu X Targeting tumor-associated macrophages to synergize tumor immunotherapy Signal Transduct. Tar. 2021 6 75 10.1038/s41392-021-00484-9 PMC7900181 33619259 Xiang, X., Wang, J., Lu, D. & Xu, X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct. Tar. 6 , 75 (2021). 10.1038/s41392-021-00484-9 PMC7900181 33619259

449. Bai R The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies Mol. Cancer 2022 21 177 10.1186/s12943-022-01645-2 36071472 PMC9454207 Bai, R. et al. The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Mol. Cancer 21 , 177 (2022). 36071472 10.1186/s12943-022-01645-2 PMC9454207

450. Cassetta L Pollard JW A timeline of tumour-associated macrophage biology Nat. Rev. Cancer 2023 23 238 257 10.1038/s41568-022-00547-1 36792751 Cassetta, L. & Pollard, J. W. A timeline of tumour-associated macrophage biology. Nat. Rev. Cancer 23 , 238–257 (2023). 36792751 10.1038/s41568-022-00547-1

451. Liu X Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer Nature 2020 588 693 698 10.1038/s41586-020-2911-7 33177715 PMC7770056 Liu, X. et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature 588 , 693–698 (2020). 33177715 10.1038/s41586-020-2911-7 PMC7770056

452. Song Y Tang C Yin C Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells Biomaterials 2018 185 117 132 10.1016/j.biomaterials.2018.09.017 30241030 Song, Y., Tang, C. & Yin, C. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Biomaterials 185 , 117–132 (2018). 30241030 10.1016/j.biomaterials.2018.09.017

453. Liu X Powerful anticolon tumor effect of targeted gene immunotherapy using folate-modified nanoparticle delivery of CCL19 to activate the immune system ACS Central Sci 2019 5 277 289 10.1021/acscentsci.8b00688 PMC6396391 30834316 Liu, X. et al. Powerful anticolon tumor effect of targeted gene immunotherapy using folate-modified nanoparticle delivery of CCL19 to activate the immune system. ACS Central Sci 5 , 277–289 (2019). 10.1021/acscentsci.8b00688 PMC6396391 30834316

454. Chen Y Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy Nat. Nanotechnol. 2023 18 193 204 10.1038/s41565-022-01266-2 36424448 PMC9974593 Chen, Y. et al. Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy. Nat. Nanotechnol. 18 , 193–204 (2023). 36424448 10.1038/s41565-022-01266-2 PMC9974593

455. Dmitrieva-Posocco O Cell-type-specific responses to interleukin-1 control microbial invasion and tumor-elicited inflammation in colorectal cancer Immunity 2019 50 166 180.e167 10.1016/j.immuni.2018.11.015 30650375 PMC6490968 Dmitrieva-Posocco, O. et al. Cell-type-specific responses to interleukin-1 control microbial invasion and tumor-elicited inflammation in colorectal cancer. Immunity 50 , 166–180.e167 (2019). 30650375 10.1016/j.immuni.2018.11.015 PMC6490968

456. Lasry A Zinger A Ben-Neriah Y Inflammatory networks underlying colorectal cancer Nat. Immunol. 2016 17 230 240 10.1038/ni.3384 26882261 Lasry, A., Zinger, A. & Ben-Neriah, Y. Inflammatory networks underlying colorectal cancer. Nat. Immunol. 17 , 230–240 (2016). 26882261 10.1038/ni.3384

457. Iida N Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment Science 2013 342 967 970 10.1126/science.1240527 24264989 PMC6709532 Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342 , 967–970 (2013). 24264989 10.1126/science.1240527 PMC6709532

458. Simpson RC Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome Nat. Med. 2022 28 2344 2352 10.1038/s41591-022-01965-2 36138151 Simpson, R. C. et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat. Med. 28 , 2344–2352 (2022). 36138151 10.1038/s41591-022-01965-2

459. Wong CC Yu J Gut microbiota in colorectal cancer development and therapy Nat. Rev. Clin. Oncol. 2023 20 429 452 10.1038/s41571-023-00766-x 37169888 Wong, C. C. & Yu, J. Gut microbiota in colorectal cancer development and therapy. Nat. Rev. Clin. Oncol. 20 , 429–452 (2023). 37169888 10.1038/s41571-023-00766-x

460. Jiang H Nanocatalytic bacteria disintegration reverses immunosuppression of colorectal cancer Natl. Sci. Rev. 2022 9 nwac169 10.1093/nsr/nwac169 36381212 PMC9647001 Jiang, H. et al. Nanocatalytic bacteria disintegration reverses immunosuppression of colorectal cancer. Natl. Sci. Rev. 9 , nwac169 (2022). 36381212 10.1093/nsr/nwac169 PMC9647001

461. Song W Anselmo AC Huang L Nanotechnology intervention of the microbiome for cancer therapy Nat. Nanotechnol. 2019 14 1093 1103 10.1038/s41565-019-0589-5 31802032 Song, W., Anselmo, A. C. & Huang, L. Nanotechnology intervention of the microbiome for cancer therapy. Nat. Nanotechnol. 14 , 1093–1103 (2019). 31802032 10.1038/s41565-019-0589-5

462. Song W Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis Adv. Mater. 2018 30 e1805007 10.1002/adma.201805007 30387230 PMC6580426 Song, W. et al. Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis. Adv. Mater. 30 , e1805007 (2018). 30387230 10.1002/adma.201805007 PMC6580426

463. Huang K-W Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer Sci. Adv. 2020 6 eaax5032 10.1126/sciadv.aax5032 31998834 PMC6962042 Huang, K.-W. et al. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Sci. Adv. 6 , eaax5032 (2020). 31998834 10.1126/sciadv.aax5032 PMC6962042

464. Lu H Cancer phototherapy with nano-bacteria biohybrids J. Control. Release 2023 360 133 148 10.1016/j.jconrel.2023.06.009 37315693 Lu, H. et al. Cancer phototherapy with nano-bacteria biohybrids. J. Control. Release 360 , 133–148 (2023). 37315693 10.1016/j.jconrel.2023.06.009

465. Deng S Application of nanotechnology in the early diagnosis and comprehensive treatment of gastrointestinal cancer J. Nanobiotechnol. 2022 20 415 10.1186/s12951-022-01613-4 PMC9479390 36109734 Deng, S. et al. Application of nanotechnology in the early diagnosis and comprehensive treatment of gastrointestinal cancer. J. Nanobiotechnol. 20 , 415 (2022). 10.1186/s12951-022-01613-4 PMC9479390 36109734

466. Li X Lee S Yoon J Supramolecular photosensitizers rejuvenate photodynamic therapy Chem. Soc. Rev. 2018 47 1174 1188 10.1039/C7CS00594F 29334090 Li, X., Lee, S. & Yoon, J. Supramolecular photosensitizers rejuvenate photodynamic therapy. Chem. Soc. Rev. 47 , 1174–1188 (2018). 29334090 10.1039/C7CS00594F

467. Agostinis P Photodynamic therapy of cancer: an update CA-Cancer J. Clin 2011 61 250 281 10.3322/caac.20114 21617154 PMC3209659 Agostinis, P. et al. Photodynamic therapy of cancer: an update. CA-Cancer J. Clin 61 , 250–281 (2011). 21617154 10.3322/caac.20114 PMC3209659

468. Zhou Z Song J Nie L Chen X Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy Chem. Soc. Rev. 2016 45 6597 6626 10.1039/C6CS00271D 27722328 PMC5118097 Zhou, Z., Song, J., Nie, L. & Chen, X. Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy. Chem. Soc. Rev. 45 , 6597–6626 (2016). 27722328 10.1039/C6CS00271D PMC5118097

469. Xie J Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies Chem. Soc. Rev. 2021 50 9152 9201 10.1039/D0CS01370F 34223847 Xie, J. et al. Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies. Chem. Soc. Rev. 50 , 9152–9201 (2021). 34223847 10.1039/D0CS01370F

470. Shanmugam V Selvakumar S Yeh C-S Near-infrared light-responsive nanomaterials in cancer therapeutics Chem. Soc. Rev. 2014 43 6254 6287 10.1039/C4CS00011K 24811160 Shanmugam, V., Selvakumar, S. & Yeh, C.-S. Near-infrared light-responsive nanomaterials in cancer therapeutics. Chem. Soc. Rev. 43 , 6254–6287 (2014). 24811160 10.1039/C4CS00011K

471. Idris NM In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers Nat. Med. 2012 18 1580 1585 10.1038/nm.2933 22983397 Idris, N. M. et al. In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers. Nat. Med. 18 , 1580–1585 (2012). 22983397 10.1038/nm.2933

472. Mao B Cyclic cRGDfk peptide and Chlorin e6 functionalized silk fibroin nanoparticles for targeted drug delivery and photodynamic therapy Biomaterials 2018 161 306 320 10.1016/j.biomaterials.2018.01.045 29427926 Mao, B. et al. Cyclic cRGDfk peptide and Chlorin e6 functionalized silk fibroin nanoparticles for targeted drug delivery and photodynamic therapy. Biomaterials 161 , 306–320 (2018). 29427926 10.1016/j.biomaterials.2018.01.045

473. Wang H DNAzyme-loaded metal-organic frameworks (MOFs) for self-sufficient gene therapy Angew. Chem. Int. Edit. 2019 58 7380 7384 10.1002/anie.201902714 30916460 Wang, H. et al. DNAzyme-loaded metal-organic frameworks (MOFs) for self-sufficient gene therapy. Angew. Chem. Int. Edit. 58 , 7380–7384 (2019). 10.1002/anie.201902714 30916460

474. Guo R Engineered nanomaterials for synergistic photo-immunotherapy Biomaterials 2022 282 121425 10.1016/j.biomaterials.2022.121425 35217344 Guo, R. et al. Engineered nanomaterials for synergistic photo-immunotherapy. Biomaterials 282 , 121425 (2022). 35217344 10.1016/j.biomaterials.2022.121425

475. Liu J Tumor-microenvironment-activatable polymer nano-immunomodulator for precision cancer photoimmunotherapy Adv. Mater. 2022 34 e2106654 10.1002/adma.202106654 34854147 Liu, J. et al. Tumor-microenvironment-activatable polymer nano-immunomodulator for precision cancer photoimmunotherapy. Adv. Mater. 34 , e2106654 (2022). 34854147 10.1002/adma.202106654

476. Zhang C Metal coordination micelles for anti-cancer treatment by gene-editing and phototherapy J. Control. Release 2023 357 210 221 10.1016/j.jconrel.2023.03.042 36972864 Zhang, C. et al. Metal coordination micelles for anti-cancer treatment by gene-editing and phototherapy. J. Control. Release 357 , 210–221 (2023). 36972864 10.1016/j.jconrel.2023.03.042

477. Guo Z Zhu AT Fang RH Zhang L Recent developments in nanoparticle-based photo-immunotherapy for cancer treatment Small Methods 2023 7 e2300252 10.1002/smtd.202300252 36960932 PMC10192221 Guo, Z., Zhu, A. T., Fang, R. H. & Zhang, L. Recent developments in nanoparticle-based photo-immunotherapy for cancer treatment. Small Methods 7 , e2300252 (2023). 36960932 10.1002/smtd.202300252 PMC10192221

478. Qiu Y Nano ultrasound contrast agent for synergistic chemo-photothermal therapy and enhanced immunotherapy against liver cancer and metastasis Adv. Sci. 2023 10 e2300878 10.1002/advs.202300878 PMC10375134 37162268 Qiu, Y. et al. Nano ultrasound contrast agent for synergistic chemo-photothermal therapy and enhanced immunotherapy against liver cancer and metastasis. Adv. Sci. 10 , e2300878 (2023). 10.1002/advs.202300878 PMC10375134 37162268

479. Yan J Application of phototherapeutic-based nanoparticles in colorectal cancer Int. J. Biol. Sci. 2021 17 1361 1381 10.7150/ijbs.58773 33867852 PMC8040477 Yan, J. et al. Application of phototherapeutic-based nanoparticles in colorectal cancer. Int. J. Biol. Sci. 17 , 1361–1381 (2021). 33867852 10.7150/ijbs.58773 PMC8040477

480. Hu X Supramolecular prodrug nanovectors for active tumor targeting and combination immunotherapy of colorectal cancer Adv. Sci. 2020 7 1903332 10.1002/advs.201903332 PMC7175291 32328426 Hu, X. et al. Supramolecular prodrug nanovectors for active tumor targeting and combination immunotherapy of colorectal cancer. Adv. Sci. 7 , 1903332 (2020). 10.1002/advs.201903332 PMC7175291 32328426

481. Gao D Lo P-C Polymeric micelles encapsulating pH-responsive doxorubicin prodrug and glutathione-activated zinc(II) phthalocyanine for combined chemotherapy and photodynamic therapy J. Control. Release 2018 282 46 61 10.1016/j.jconrel.2018.04.030 29673646 Gao, D. & Lo, P.-C. Polymeric micelles encapsulating pH-responsive doxorubicin prodrug and glutathione-activated zinc(II) phthalocyanine for combined chemotherapy and photodynamic therapy. J. Control. Release 282 , 46–61 (2018). 29673646 10.1016/j.jconrel.2018.04.030

482. Yuan Z Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles Mol. Ther. 2021 29 2931 2948 10.1016/j.ymthe.2021.05.017 34023507 PMC8530932 Yuan, Z. et al. Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles. Mol. Ther. 29 , 2931–2948 (2021). 34023507 10.1016/j.ymthe.2021.05.017 PMC8530932

483. Liu H Metal-organic framework-mediated multifunctional nanoparticles for combined chemo-photothermal therapy and enhanced immunotherapy against colorectal cancer Acta Biomater 2022 144 132 141 10.1016/j.actbio.2022.03.023 35307591 Liu, H. et al. Metal-organic framework-mediated multifunctional nanoparticles for combined chemo-photothermal therapy and enhanced immunotherapy against colorectal cancer. Acta Biomater 144 , 132–141 (2022). 35307591 10.1016/j.actbio.2022.03.023

484. Pavitra E Engineered nanoparticles for imaging and drug delivery in colorectal cancer Semin. Cancer Biol. 2021 69 293 306 10.1016/j.semcancer.2019.06.017 31260733 Pavitra, E. et al. Engineered nanoparticles for imaging and drug delivery in colorectal cancer. Semin. Cancer Biol. 69 , 293–306 (2021). 31260733 10.1016/j.semcancer.2019.06.017

485. Zhu J-Y Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes Nano Lett 2016 16 5895 5901 10.1021/acs.nanolett.6b02786 27513184 Zhu, J.-Y. et al. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett 16 , 5895–5901 (2016). 27513184 10.1021/acs.nanolett.6b02786

486. Zhang P The dual-response-single-amplification fluorescent nanomachine for tumor imaging and gastric cancer diagnosis ACS Nano 2023 17 16553 16564 10.1021/acsnano.3c02148 37527488 Zhang, P. et al. The dual-response-single-amplification fluorescent nanomachine for tumor imaging and gastric cancer diagnosis. ACS Nano 17 , 16553–16564 (2023). 37527488 10.1021/acsnano.3c02148

487. Sun L Nanoengineered neutrophils as a cellular sonosensitizer for visual sonodynamic therapy of malignant tumors Adv. Mater. 2022 34 e2109969 10.1002/adma.202109969 35174915 Sun, L. et al. Nanoengineered neutrophils as a cellular sonosensitizer for visual sonodynamic therapy of malignant tumors. Adv. Mater. 34 , e2109969 (2022). 35174915 10.1002/adma.202109969

488. Ma X Nanoprobe-based molecular imaging for tumor stratification Chem. Soc. Rev. 2023 52 6447 6496 10.1039/D3CS00063J 37615588 Ma, X. et al. Nanoprobe-based molecular imaging for tumor stratification. Chem. Soc. Rev. 52 , 6447–6496 (2023). 37615588 10.1039/D3CS00063J

489. Jing B Extracellular vesicles-based pre-targeting strategy enables multi-modal imaging of orthotopic colon cancer and image-guided surgery J. Nanobiotechnol. 2021 19 151 10.1186/s12951-021-00888-3 PMC8141172 34022897 Jing, B. et al. Extracellular vesicles-based pre-targeting strategy enables multi-modal imaging of orthotopic colon cancer and image-guided surgery. J. Nanobiotechnol. 19 , 151 (2021). 10.1186/s12951-021-00888-3 PMC8141172 34022897

490. Luo X Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer Int. J. Nanomed. 2017 12 5331 5343 10.2147/IJN.S137245 PMC5536232 28794626 Luo, X. et al. Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer. Int. J. Nanomed. 12 , 5331–5343 (2017). 10.2147/IJN.S137245 PMC5536232 28794626

491. Zhang LY Dual drug delivery and sequential release by amphiphilic Janus nanoparticles for liver cancer theranostics Biomaterials 2018 181 113 125 10.1016/j.biomaterials.2018.07.060 30081302 Zhang, L. Y. et al. Dual drug delivery and sequential release by amphiphilic Janus nanoparticles for liver cancer theranostics. Biomaterials 181 , 113–125 (2018). 30081302 10.1016/j.biomaterials.2018.07.060

492. Zeng C Cancer diagnosis and imaging-guided photothermal therapy using a dual-modality nanoparticle ACS Appl. Mater. Inter. 2016 8 29232 29241 10.1021/acsami.6b06883 27731621 Zeng, C. et al. Cancer diagnosis and imaging-guided photothermal therapy using a dual-modality nanoparticle. ACS Appl. Mater. Inter. 8 , 29232–29241 (2016). 10.1021/acsami.6b06883 27731621

493. Chen W Cancer statistics in China, 2015 CA-Cancer J. Clin 2016 66 115 132 10.3322/caac.21338 26808342 Chen, W. et al. Cancer statistics in China, 2015. CA-Cancer J. Clin 66 , 115–132 (2016). 26808342 10.3322/caac.21338

494. de Groot PM Wu CC Carter BW Munden RF The epidemiology of lung cancer Transl. Lung Cancer Res 2018 7 220 233 10.21037/tlcr.2018.05.06 30050761 PMC6037963 de Groot, P. M., Wu, C. C., Carter, B. W. & Munden, R. F. The epidemiology of lung cancer. Transl. Lung Cancer Res 7 , 220–233 (2018). 30050761 10.21037/tlcr.2018.05.06 PMC6037963

495. Thai AA Lung cancer Lancet 2021 398 535 554 10.1016/S0140-6736(21)00312-3 34273294 Thai, A. A. et al. Lung cancer. Lancet 398 , 535–554 (2021). 34273294 10.1016/S0140-6736(21)00312-3

496. Larsen JE Minna JD Molecular biology of lung cancer: clinical implications Clin. Chest Med. 2011 32 703 740 10.1016/j.ccm.2011.08.003 22054881 PMC3367865 Larsen, J. E. & Minna, J. D. Molecular biology of lung cancer: clinical implications. Clin. Chest Med. 32 , 703–740 (2011). 22054881 10.1016/j.ccm.2011.08.003 PMC3367865

497. MacKinnon AC Kopatz J Sethi T The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies Brit. Med. Bull. 2010 95 47 61 10.1093/bmb/ldq023 20643690 MacKinnon, A. C., Kopatz, J. & Sethi, T. The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies. Brit. Med. Bull. 95 , 47–61 (2010). 20643690 10.1093/bmb/ldq023

498. Herbst RS Morgensztern D Boshoff C The biology and management of non-small cell lung cancer Nature 2018 553 446 454 10.1038/nature25183 29364287 Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553 , 446–454 (2018). 29364287 10.1038/nature25183

499. Burki TK Developments in lung cancer biology in never-smokers Lancet Oncol 2021 22 1363 10.1016/S1470-2045(21)00532-5 34509183 Burki, T. K. Developments in lung cancer biology in never-smokers. Lancet Oncol 22 , 1363 (2021). 34509183 10.1016/S1470-2045(21)00532-5

500. Mottaghitalab F New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment J. Control. Release 2019 295 250 267 10.1016/j.jconrel.2019.01.009 30639691 Mottaghitalab, F. et al. New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment. J. Control. Release 295 , 250–267 (2019). 30639691 10.1016/j.jconrel.2019.01.009

501. Woodman C Vundu G George A Wilson CM Applications and strategies in nanodiagnosis and nanotherapy in lung cancer Semin. Cancer Biol. 2021 69 349 364 10.1016/j.semcancer.2020.02.009 32088362 Woodman, C., Vundu, G., George, A. & Wilson, C. M. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Semin. Cancer Biol. 69 , 349–364 (2021). 32088362 10.1016/j.semcancer.2020.02.009

502. Yenerall P Kittler R Minna J Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy Cancer Cell 2021 39 1455 1457 10.1016/j.ccell.2021.10.012 34752753 PMC9241337 Yenerall, P., Kittler, R. & Minna, J. Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy. Cancer Cell 39 , 1455–1457 (2021). 34752753 10.1016/j.ccell.2021.10.012 PMC9241337

503. Billiet C Postoperative radiotherapy for lung cancer: Is it worth the controversy? Cancer Treat. Rev. 2016 51 10 18 10.1016/j.ctrv.2016.10.001 27788387 Billiet, C. et al. Postoperative radiotherapy for lung cancer: Is it worth the controversy? Cancer Treat. Rev. 51 , 10–18 (2016). 27788387 10.1016/j.ctrv.2016.10.001

504. Olaussen KA Postel-Vinay S Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape Ann. Oncol. 2016 27 2004 2016 10.1093/annonc/mdw321 27502726 Olaussen, K. A. & Postel-Vinay, S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann. Oncol. 27 , 2004–2016 (2016). 27502726 10.1093/annonc/mdw321

505. Grønberg BH High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial Lancet Oncol 2021 22 321 331 10.1016/S1470-2045(20)30742-7 33662285 Grønberg, B. H. et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol 22 , 321–331 (2021). 33662285 10.1016/S1470-2045(20)30742-7

506. Higgins KA Puri S Gray JE Systemic and radiation therapy approaches for locally advanced non-small-cell lung cancer J. Clin. Oncol. 2022 40 576 585 10.1200/JCO.21.01707 34985931 Higgins, K. A., Puri, S. & Gray, J. E. Systemic and radiation therapy approaches for locally advanced non-small-cell lung cancer. J. Clin. Oncol. 40 , 576–585 (2022). 34985931 10.1200/JCO.21.01707

507. Mittal V The microenvironment of lung cancer and therapeutic implications Adv. Exp. Med. Biol. 2016 890 75 110 10.1007/978-3-319-24932-2_5 26703800 Mittal, V. et al. The microenvironment of lung cancer and therapeutic implications. Adv. Exp. Med. Biol. 890 , 75–110 (2016). 26703800 10.1007/978-3-319-24932-2_5

508. Deb D Moore AC Roy UB The 2021 global lung cancer therapy landscape J. Thorac. Oncol. 2022 17 931 936 10.1016/j.jtho.2022.03.018 35489693 Deb, D., Moore, A. C. & Roy, U. B. The 2021 global lung cancer therapy landscape. J. Thorac. Oncol. 17 , 931–936 (2022). 35489693 10.1016/j.jtho.2022.03.018

509. Criner GJ Interventional bronchoscopy Am. J. Resp. Crit. Care. 2020 202 29 50 10.1164/rccm.201907-1292SO 32023078 Criner, G. J. et al. Interventional bronchoscopy. Am. J. Resp. Crit. Care. 202 , 29–50 (2020). 10.1164/rccm.201907-1292SO 32023078

510. Xu C AuGd integrated nanoprobes for optical/MRI/CT triple-modal in vivo tumor imaging Nanoscale 2017 9 4620 4628 10.1039/C7NR01064H 28323295 Xu, C. et al. AuGd integrated nanoprobes for optical/MRI/CT triple-modal in vivo tumor imaging. Nanoscale 9 , 4620–4628 (2017). 28323295 10.1039/C7NR01064H

511. Megyesfalvi Z Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions CA-Cancer J. Clin 2023 73 620 652 10.3322/caac.21785 37329269 Megyesfalvi, Z. et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA-Cancer J. Clin 73 , 620–652 (2023). 37329269 10.3322/caac.21785

512. Seijo LM Biomarkers in lung cancer screening: achievements, promises, and challenges J. Thorac. Oncol. 2019 14 343 357 10.1016/j.jtho.2018.11.023 30529598 PMC6494979 Seijo, L. M. et al. Biomarkers in lung cancer screening: achievements, promises, and challenges. J. Thorac. Oncol. 14 , 343–357 (2019). 30529598 10.1016/j.jtho.2018.11.023 PMC6494979

513. Le-Rademacher J Biomarker clinical trials in lung cancer: design, logistics, challenges, and practical considerations J. Thorac. Oncol. 2018 13 1625 1637 10.1016/j.jtho.2018.08.2019 30194034 Le-Rademacher, J. et al. Biomarker clinical trials in lung cancer: design, logistics, challenges, and practical considerations. J. Thorac. Oncol. 13 , 1625–1637 (2018). 30194034 10.1016/j.jtho.2018.08.2019

514. Cryer AM Thorley AJ Nanotechnology in the diagnosis and treatment of lung cancer Pharmacol. Therapeut. 2019 198 189 205 10.1016/j.pharmthera.2019.02.010 30796927 Cryer, A. M. & Thorley, A. J. Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacol. Therapeut. 198 , 189–205 (2019). 10.1016/j.pharmthera.2019.02.010 30796927

515. Liu J Zwitterionic gadolinium(III)-complexed dendrimer-entrapped gold nanoparticles for enhanced computed tomography/magnetic resonance imaging of lung cancer metastasis ACS Appl. Mater. Inter. 2019 11 15212 15221 10.1021/acsami.8b21679 30964632 Liu, J. et al. Zwitterionic gadolinium(III)-complexed dendrimer-entrapped gold nanoparticles for enhanced computed tomography/magnetic resonance imaging of lung cancer metastasis. ACS Appl. Mater. Inter. 11 , 15212–15221 (2019). 10.1021/acsami.8b21679 30964632

516. Ramanathan S Gopinath SCB Md Arshad MK Poopalan P Multidimensional (0D-3D) nanostructures for lung cancer biomarker analysis: comprehensive assessment on current diagnostics Biosens. Bioelectron. 2019 141 111434 10.1016/j.bios.2019.111434 31238281 Ramanathan, S., Gopinath, S. C. B., Md Arshad, M. K. & Poopalan, P. Multidimensional (0D-3D) nanostructures for lung cancer biomarker analysis: comprehensive assessment on current diagnostics. Biosens. Bioelectron. 141 , 111434 (2019). 31238281 10.1016/j.bios.2019.111434

517. Hu C Role of exosomal microRNAs in lung cancer biology and clinical applications Cell Proliferat 2020 53 e12828 10.1111/cpr.12828 PMC7309943 32391938 Hu, C. et al. Role of exosomal microRNAs in lung cancer biology and clinical applications. Cell Proliferat 53 , e12828 (2020). 10.1111/cpr.12828 PMC7309943 32391938

518. Paramanantham A Extracellular vesicle (EVs) associated non-coding RNAs in lung cancer and therapeutics Int. J. Mol. Sci. 2022 23 13637 10.3390/ijms232113637 36362424 PMC9655370 Paramanantham, A. et al. Extracellular vesicle (EVs) associated non-coding RNAs in lung cancer and therapeutics. Int. J. Mol. Sci. 23 , 13637 (2022). 36362424 10.3390/ijms232113637 PMC9655370

519. Shin H Early-stage lung cancer diagnosis by deep learning-based spectroscopic analysis of circulating exosomes ACS Nano 2020 14 5435 5444 10.1021/acsnano.9b09119 32286793 Shin, H. et al. Early-stage lung cancer diagnosis by deep learning-based spectroscopic analysis of circulating exosomes. ACS Nano 14 , 5435–5444 (2020). 32286793 10.1021/acsnano.9b09119

520. Wu J Shen Z Exosomal miRNAs as biomarkers for diagnostic and prognostic in lung cancer Cancer Med.-US 2020 9 6909 6922 10.1002/cam4.3379 PMC7541138 32779402 Wu, J. & Shen, Z. Exosomal miRNAs as biomarkers for diagnostic and prognostic in lung cancer. Cancer Med.-US 9 , 6909–6922 (2020). 10.1002/cam4.3379 PMC7541138 32779402

521. Fan Y High-sensitive and multiplex biosensing assay of NSCLC-derived exosomes via different recognition sites based on SPRi array Biosens. Bioelectron. 2020 154 112066 10.1016/j.bios.2020.112066 32056961 Fan, Y. et al. High-sensitive and multiplex biosensing assay of NSCLC-derived exosomes via different recognition sites based on SPRi array. Biosens. Bioelectron. 154 , 112066 (2020). 32056961 10.1016/j.bios.2020.112066

522. Tao Y Exploration of serum exosomal lncRNA TBILA and AGAP2-AS1 as promising biomarkers for diagnosis of non-small cell lung cancer Int. J. Biol. Sci. 2020 16 471 482 10.7150/ijbs.39123 32015683 PMC6990900 Tao, Y. et al. Exploration of serum exosomal lncRNA TBILA and AGAP2-AS1 as promising biomarkers for diagnosis of non-small cell lung cancer. Int. J. Biol. Sci. 16 , 471–482 (2020). 32015683 10.7150/ijbs.39123 PMC6990900

523. Niu L Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer Cancer Sci 2019 110 433 442 10.1111/cas.13862 30407700 PMC6317937 Niu, L. et al. Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer. Cancer Sci 110 , 433–442 (2019). 30407700 10.1111/cas.13862 PMC6317937

524. Jin X Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing Clin. Cancer Res. 2017 23 5311 5319 10.1158/1078-0432.CCR-17-0577 28606918 Jin, X. et al. Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin. Cancer Res. 23 , 5311–5319 (2017). 28606918 10.1158/1078-0432.CCR-17-0577

525. Yang Y An immuno-biochip selectively captures tumor-derived exosomes and detects exosomal RNAs for cancer diagnosis ACS Appl. Mater. Inter. 2018 10 43375 43386 10.1021/acsami.8b13971 PMC8628516 30451486 Yang, Y. et al. An immuno-biochip selectively captures tumor-derived exosomes and detects exosomal RNAs for cancer diagnosis. ACS Appl. Mater. Inter. 10 , 43375–43386 (2018). 10.1021/acsami.8b13971 PMC8628516 30451486

526. Liu F The exosome total isolation chip ACS Nano 2017 11 10712 10723 10.1021/acsnano.7b04878 29090896 PMC5983373 Liu, F. et al. The exosome total isolation chip. ACS Nano 11 , 10712–10723 (2017). 29090896 10.1021/acsnano.7b04878 PMC5983373

527. Lee LJ Extracellular mRNA detected by tethered lipoplex nanoparticle biochip for lung adenocarcinoma detection Am. J. Resp. Crit. Care. 2016 193 1431 1433 10.1164/rccm.201511-2129LE PMC4910892 27304243 Lee, L. J. et al. Extracellular mRNA detected by tethered lipoplex nanoparticle biochip for lung adenocarcinoma detection. Am. J. Resp. Crit. Care. 193 , 1431–1433 (2016). 10.1164/rccm.201511-2129LE PMC4910892 27304243

528. Wan Y Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer Ann. Oncol. 2018 29 2379 2383 10.1093/annonc/mdy458 30339193 PMC6311950 Wan, Y. et al. Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer. Ann. Oncol. 29 , 2379–2383 (2018). 30339193 10.1093/annonc/mdy458 PMC6311950

529. Castellanos-Rizaldos E Exosome-based detection of EGFR T790M in plasma from non-small cell lung cancer patients Clin. Cancer Res. 2018 24 2944 2950 10.1158/1078-0432.CCR-17-3369 29535126 Castellanos-Rizaldos, E. et al. Exosome-based detection of EGFR T790M in plasma from non-small cell lung cancer patients. Clin. Cancer Res. 24 , 2944–2950 (2018). 29535126 10.1158/1078-0432.CCR-17-3369

530. Krug AK Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma Ann. Oncol. 2018 29 700 706 10.1093/annonc/mdx765 29216356 PMC5889041 Krug, A. K. et al. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Ann. Oncol. 29 , 700–706 (2018). 29216356 10.1093/annonc/mdx765 PMC5889041

531. Shoja Y Kermanpur A Karimzadeh F Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode Biosens. Bioelectron. 2018 113 108 115 10.1016/j.bios.2018.04.013 29753165 Shoja, Y., Kermanpur, A. & Karimzadeh, F. Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode. Biosens. Bioelectron. 113 , 108–115 (2018). 29753165 10.1016/j.bios.2018.04.013

532. Divya KP Carbon dots stabilized silver-lipid nano hybrids for sensitive label free DNA detection Biosens. Bioelectron. 2019 133 48 54 10.1016/j.bios.2019.03.027 30909012 Divya, K. P. et al. Carbon dots stabilized silver-lipid nano hybrids for sensitive label free DNA detection. Biosens. Bioelectron. 133 , 48–54 (2019). 30909012 10.1016/j.bios.2019.03.027

533. Zhang Y Highly sensitive photoelectric detection and imaging enhanced by the pyro-phototronic effect based on a photoinduced dynamic schottky effect in 4H-SiC Adv. Mater. 2022 34 e2204363 10.1002/adma.202204363 35817411 Zhang, Y. et al. Highly sensitive photoelectric detection and imaging enhanced by the pyro-phototronic effect based on a photoinduced dynamic schottky effect in 4H-SiC. Adv. Mater. 34 , e2204363 (2022). 35817411 10.1002/adma.202204363

534. Li Q Design and synthesis of SERS materials for in vivo molecular imaging and biosensing Adv. Sci. 2023 10 e2202051 10.1002/advs.202202051 PMC10015885 36683237 Li, Q. et al. Design and synthesis of SERS materials for in vivo molecular imaging and biosensing. Adv. Sci. 10 , e2202051 (2023). 10.1002/advs.202202051 PMC10015885 36683237

535. Shin H Correlation between cancerous exosomes and protein markers based on surface-enhanced raman spectroscopy (SERS) and principal component analysis (PCA) ACS Sensors 2018 3 2637 2643 10.1021/acssensors.8b01047 30381940 Shin, H. et al. Correlation between cancerous exosomes and protein markers based on surface-enhanced raman spectroscopy (SERS) and principal component analysis (PCA). ACS Sensors 3 , 2637–2643 (2018). 30381940 10.1021/acssensors.8b01047

536. Wu Y Affibody-modified Gd@C-dots with efficient renal clearance for enhanced MRI of EGFR expression in non-small-cell lung cancer Int. J. Nanomed. 2020 15 4691 4703 10.2147/IJN.S244172 PMC7335283 32636625 Wu, Y. et al. Affibody-modified Gd@C-dots with efficient renal clearance for enhanced MRI of EGFR expression in non-small-cell lung cancer. Int. J. Nanomed. 15 , 4691–4703 (2020). 10.2147/IJN.S244172 PMC7335283 32636625

537. Wu L Local intratracheal delivery of perfluorocarbon nanoparticles to lung cancer demonstrated with magnetic resonance multimodal imaging Theranostics 2018 8 563 574 10.7150/thno.21466 29290827 PMC5743567 Wu, L. et al. Local intratracheal delivery of perfluorocarbon nanoparticles to lung cancer demonstrated with magnetic resonance multimodal imaging. Theranostics 8 , 563–574 (2018). 29290827 10.7150/thno.21466 PMC5743567

538. Feng Y Renal-clearable peptide-functionalized Ba2GdF7 nanoparticles for positive tumor-targeting dual-mode bioimaging ACS Appl. Mater. Inter. 2018 10 25511 25518 10.1021/acsami.8b07129 29989405 Feng, Y. et al. Renal-clearable peptide-functionalized Ba2GdF7 nanoparticles for positive tumor-targeting dual-mode bioimaging. ACS Appl. Mater. Inter. 10 , 25511–25518 (2018). 10.1021/acsami.8b07129 29989405

539. Chen J Multifunctional gold nanocomposites designed for targeted CT/MR/optical trimodal imaging of human non-small cell lung cancer cells Nanoscale 2016 8 13568 13573 10.1039/C6NR03143A 27381000 Chen, J. et al. Multifunctional gold nanocomposites designed for targeted CT/MR/optical trimodal imaging of human non-small cell lung cancer cells. Nanoscale 8 , 13568–13573 (2016). 27381000 10.1039/C6NR03143A

540. Rogalla S Intraoperative molecular imaging in lung cancer: the state of the art and the future Mol. Ther. 2018 26 338 341 10.1016/j.ymthe.2018.01.013 29398484 PMC5835150 Rogalla, S. et al. Intraoperative molecular imaging in lung cancer: the state of the art and the future. Mol. Ther. 26 , 338–341 (2018). 29398484 10.1016/j.ymthe.2018.01.013 PMC5835150

541. Chen Y Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti-metastasis activity and reduce side effects Acta Pharm. Sin. B 2020 10 1106 1121 10.1016/j.apsb.2019.10.011 32642416 PMC7332658 Chen, Y. et al. Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti-metastasis activity and reduce side effects. Acta Pharm. Sin. B 10 , 1106–1121 (2020). 32642416 10.1016/j.apsb.2019.10.011 PMC7332658

542. Yu OHY Suissa S Metformin and cancer: solutions to a real-world evidence failure Diabetes Care 2023 46 904 912 10.2337/dci22-0047 37185680 Yu, O. H. Y. & Suissa, S. Metformin and cancer: solutions to a real-world evidence failure. Diabetes Care 46 , 904–912 (2023). 37185680 10.2337/dci22-0047

543. Foretz M Guigas B Viollet B Metformin: update on mechanisms of action and repurposing potential Nat. Rev. Endocrinol. 2023 19 460 476 10.1038/s41574-023-00833-4 37130947 PMC10153049 Foretz, M., Guigas, B. & Viollet, B. Metformin: update on mechanisms of action and repurposing potential. Nat. Rev. Endocrinol. 19 , 460–476 (2023). 37130947 10.1038/s41574-023-00833-4 PMC10153049

544. Xiong Y Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer J. Control. Release 2016 244 63 73 10.1016/j.jconrel.2016.11.005 27840166 PMC5515375 Xiong, Y. et al. Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J. Control. Release 244 , 63–73 (2016). 27840166 10.1016/j.jconrel.2016.11.005 PMC5515375

545. Cong Y Dual drug backboned shattering polymeric theranostic nanomedicine for synergistic eradication of patient-derived lung cancer Adv. Mater. 2018 30 1706220 10.1002/adma.201706220 29349918 Cong, Y. et al. Dual drug backboned shattering polymeric theranostic nanomedicine for synergistic eradication of patient-derived lung cancer. Adv. Mater. 30 , 1706220 (2018). 10.1002/adma.201706220 29349918

546. Xu C Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy J. Control. Release 2019 295 153 163 10.1016/j.jconrel.2018.12.013 30586598 Xu, C. et al. Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy. J. Control. Release 295 , 153–163 (2019). 30586598 10.1016/j.jconrel.2018.12.013

547. Remon J Small cell lung cancer: a slightly less orphan disease after immunotherapy Ann. Oncol. 2021 32 698 709 10.1016/j.annonc.2021.02.025 33737119 Remon, J. et al. Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann. Oncol. 32 , 698–709 (2021). 33737119 10.1016/j.annonc.2021.02.025

548. Wan X Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer ACS Nano 2018 12 2426 2439 10.1021/acsnano.7b07878 29533606 PMC5960350 Wan, X. et al. Drug combination synergy in worm-like polymeric micelles improves treatment outcome for small cell and non-small cell lung cancer. ACS Nano 12 , 2426–2439 (2018). 29533606 10.1021/acsnano.7b07878 PMC5960350

549. Zhu R pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer Acta Biomater 2016 29 320 332 10.1016/j.actbio.2015.10.029 26485164 Zhu, R. et al. pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer. Acta Biomater 29 , 320–332 (2016). 26485164 10.1016/j.actbio.2015.10.029

550. de Langen AJ Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial Lancet 2023 401 733 746 10.1016/S0140-6736(23)00221-0 36764316 de Langen, A. J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet 401 , 733–746 (2023). 36764316 10.1016/S0140-6736(23)00221-0

551. Wu J Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer J. Control. Release 2017 259 76 82 10.1016/j.jconrel.2016.12.024 28027947 Wu, J. et al. Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer. J. Control. Release 259 , 76–82 (2017). 28027947 10.1016/j.jconrel.2016.12.024

552. Han H Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy Asian J. Pharm. Sci. 2022 17 35 52 10.1016/j.ajps.2021.06.001 35261643 PMC8888143 Han, H. et al. Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy. Asian J. Pharm. Sci. 17 , 35–52 (2022). 35261643 10.1016/j.ajps.2021.06.001 PMC8888143

553. Soni N Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles J. Colloid. Interf. Sci. 2016 481 107 116 10.1016/j.jcis.2016.07.020 27459173 Soni, N. et al. Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles. J. Colloid. Interf. Sci. 481 , 107–116 (2016). 10.1016/j.jcis.2016.07.020 27459173

554. Cai X pH-sensitive ZnO quantum dots-doxorubicin nanoparticles for lung cancer targeted drug delivery ACS Appl. Mater. Inter. 2016 8 22442 22450 10.1021/acsami.6b04933 27463610 Cai, X. et al. pH-sensitive ZnO quantum dots-doxorubicin nanoparticles for lung cancer targeted drug delivery. ACS Appl. Mater. Inter. 8 , 22442–22450 (2016). 10.1021/acsami.6b04933 27463610

555. Zhang Z Construction of a supramolecular drug-drug delivery system for non-small-cell lung cancer therapy ACS Appl. Mater. Inter. 2017 9 29505 29514 10.1021/acsami.7b07565 28809468 Zhang, Z. et al. Construction of a supramolecular drug-drug delivery system for non-small-cell lung cancer therapy. ACS Appl. Mater. Inter. 9 , 29505–29514 (2017). 10.1021/acsami.7b07565 28809468

556. Conte C Enhanced uptake in 2D- and 3D- lung cancer cell models of redox responsive PEGylated nanoparticles with sensitivity to reducing extra- and intracellular environments J. Control. Release 2018 277 126 141 10.1016/j.jconrel.2018.03.011 29534890 Conte, C. et al. Enhanced uptake in 2D- and 3D- lung cancer cell models of redox responsive PEGylated nanoparticles with sensitivity to reducing extra- and intracellular environments. J. Control. Release 277 , 126–141 (2018). 29534890 10.1016/j.jconrel.2018.03.011

557. Mottaghitalab F Targeted delivery system based on gemcitabine-loaded silk fibroin nanoparticles for lung cancer therapy ACS Appl. Mater. Inter. 2017 9 31600 31611 10.1021/acsami.7b10408 28836425 Mottaghitalab, F. et al. Targeted delivery system based on gemcitabine-loaded silk fibroin nanoparticles for lung cancer therapy. ACS Appl. Mater. Inter. 9 , 31600–31611 (2017). 10.1021/acsami.7b10408 28836425

558. Meng Y Bai R Cui J Precision targeted therapy for EGFR mutation-positive NSCLC: dilemmas and coping strategies Thorac. Cancer 2023 14 1121 1134 10.1111/1759-7714.14858 37005552 PMC10151140 Meng, Y., Bai, R. & Cui, J. Precision targeted therapy for EGFR mutation-positive NSCLC: dilemmas and coping strategies. Thorac. Cancer 14 , 1121–1134 (2023). 37005552 10.1111/1759-7714.14858 PMC10151140

559. Saravanakumar K Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy Carbohyd. Polym. 2020 245 116407 10.1016/j.carbpol.2020.116407 32718591 Saravanakumar, K. et al. Dual stimuli-responsive release of aptamer AS1411 decorated erlotinib loaded chitosan nanoparticles for non-small-cell lung carcinoma therapy. Carbohyd. Polym. 245 , 116407 (2020). 10.1016/j.carbpol.2020.116407 32718591

560. Cryer AM Tyrosine kinase inhibitor gold nanoconjugates for the treatment of non-small cell lung cancer ACS Appl. Mater. Inter. 2019 11 16336 16346 10.1021/acsami.9b02986 30986026 Cryer, A. M. et al. Tyrosine kinase inhibitor gold nanoconjugates for the treatment of non-small cell lung cancer. ACS Appl. Mater. Inter. 11 , 16336–16346 (2019). 10.1021/acsami.9b02986 30986026

561. Villadolid J Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance Transl. Lung Cancer Res 2015 4 576 583 26629426 10.3978/j.issn.2218-6751.2015.10.01 PMC4630529 Villadolid, J. et al. Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance. Transl. Lung Cancer Res 4 , 576–583 (2015). 26629426 10.3978/j.issn.2218-6751.2015.10.01 PMC4630529

562. Jeannot V Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer J. Control. Release 2018 275 117 128 10.1016/j.jconrel.2018.02.024 29474960 Jeannot, V. et al. Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer. J. Control. Release 275 , 117–128 (2018). 29474960 10.1016/j.jconrel.2018.02.024

563. Yang Y PLGA porous microspheres dry powders for codelivery of afatinib-loaded solid lipid nanoparticles and paclitaxel: novel therapy for EGFR tyrosine kinase inhibitors resistant nonsmall cell lung cancer Adv. Healthc. Mater. 2019 8 e1900965 10.1002/adhm.201900965 31664795 Yang, Y. et al. PLGA porous microspheres dry powders for codelivery of afatinib-loaded solid lipid nanoparticles and paclitaxel: novel therapy for EGFR tyrosine kinase inhibitors resistant nonsmall cell lung cancer. Adv. Healthc. Mater. 8 , e1900965 (2019). 31664795 10.1002/adhm.201900965

564. Wu P Cell membrane based biomimetic nanocomposites for targeted therapy of drug resistant EGFR-mutated lung cancer Nanoscale 2019 11 19520 19528 10.1039/C9NR05791A 31573595 Wu, P. et al. Cell membrane based biomimetic nanocomposites for targeted therapy of drug resistant EGFR-mutated lung cancer. Nanoscale 11 , 19520–19528 (2019). 31573595 10.1039/C9NR05791A

565. Roy A Selective targeting and therapy of metastatic and multidrug resistant tumors using a long circulating podophyllotoxin nanoparticle Biomaterials 2017 137 11 22 10.1016/j.biomaterials.2017.05.019 28528299 PMC5516947 Roy, A. et al. Selective targeting and therapy of metastatic and multidrug resistant tumors using a long circulating podophyllotoxin nanoparticle. Biomaterials 137 , 11–22 (2017). 28528299 10.1016/j.biomaterials.2017.05.019 PMC5516947

566. Cheng W TPGS-functionalized polydopamine-modified mesoporous silica as drug nanocarriers for enhanced lung cancer chemotherapy against multidrug resistance Small 2017 13 1700623 10.1002/smll.201700623 28594473 Cheng, W. et al. TPGS-functionalized polydopamine-modified mesoporous silica as drug nanocarriers for enhanced lung cancer chemotherapy against multidrug resistance. Small 13 , 1700623 (2017). 10.1002/smll.201700623 28594473

567. Yu H Paclitaxel-loaded core-shell magnetic nanoparticles and cold atmospheric plasma inhibit non-small cell lung cancer growth ACS Appl. Mater. Inter. 2018 10 43462 43471 10.1021/acsami.8b16487 30375840 Yu, H. et al. Paclitaxel-loaded core-shell magnetic nanoparticles and cold atmospheric plasma inhibit non-small cell lung cancer growth. ACS Appl. Mater. Inter. 10 , 43462–43471 (2018). 10.1021/acsami.8b16487 30375840

568. Yamada Y Power of mitochondrial drug delivery systems to produce innovative nanomedicines Adv. Drug Deliver. Rev. 2020 154–155 187 209 10.1016/j.addr.2020.09.010 32987095 Yamada, Y. et al. Power of mitochondrial drug delivery systems to produce innovative nanomedicines. Adv. Drug Deliver. Rev. 154–155 , 187–209 (2020). 10.1016/j.addr.2020.09.010 32987095

569. Song J Mitochondrial targeting nanodrugs self-assembled from 9-O-octadecyl substituted berberine derivative for cancer treatment by inducing mitochondrial apoptosis pathways J. Control. Release 2019 294 27 42 10.1016/j.jconrel.2018.11.014 30445003 Song, J. et al. Mitochondrial targeting nanodrugs self-assembled from 9-O-octadecyl substituted berberine derivative for cancer treatment by inducing mitochondrial apoptosis pathways. J. Control. Release 294 , 27–42 (2019). 30445003 10.1016/j.jconrel.2018.11.014

570. Sun Y Mitochondria-targeted hydroxyapatite nanoparticles for selective growth inhibition of lung cancer in vitro and in vivo ACS Appl. Mater. Inter. 2016 8 25680 25690 10.1021/acsami.6b06094 27602785 Sun, Y. et al. Mitochondria-targeted hydroxyapatite nanoparticles for selective growth inhibition of lung cancer in vitro and in vivo. ACS Appl. Mater. Inter. 8 , 25680–25690 (2016). 10.1021/acsami.6b06094 27602785

571. Lee KT Catalase-modulated heterogeneous Fenton reaction for selective cancer cell eradication: SnFe 2 O 4 nanocrystals as an effective reagent for treating lung cancer cells ACS Appl. Mater. Inter. 2017 9 1273 1279 10.1021/acsami.6b13529 28006093 Lee, K. T. et al. Catalase-modulated heterogeneous Fenton reaction for selective cancer cell eradication: SnFe 2 O 4 nanocrystals as an effective reagent for treating lung cancer cells. ACS Appl. Mater. Inter. 9 , 1273–1279 (2017). 10.1021/acsami.6b13529 28006093

572. Sun Y FePt-Cys nanoparticles induce ROS-dependent cell toxicity, and enhance chemo-radiation sensitivity of NSCLC cells in vivo and in vitro Cancer Lett 2018 418 27 40 10.1016/j.canlet.2018.01.024 29331422 Sun, Y. et al. FePt-Cys nanoparticles induce ROS-dependent cell toxicity, and enhance chemo-radiation sensitivity of NSCLC cells in vivo and in vitro. Cancer Lett 418 , 27–40 (2018). 29331422 10.1016/j.canlet.2018.01.024

573. Khan P RNA-based therapies: a cog in the wheel of lung cancer defense Mol. Cancer 2021 20 54 10.1186/s12943-021-01338-2 33740988 PMC7977189 Khan, P. et al. RNA-based therapies: a cog in the wheel of lung cancer defense. Mol. Cancer 20 , 54 (2021). 33740988 10.1186/s12943-021-01338-2 PMC7977189

574. Raguraman R Drug delivery approaches for HuR-targeted therapy for lung cancer Adv. Drug Deliver. Rev. 2022 180 114068 10.1016/j.addr.2021.114068 PMC8724414 34822926 Raguraman, R. et al. Drug delivery approaches for HuR-targeted therapy for lung cancer. Adv. Drug Deliver. Rev. 180 , 114068 (2022). 10.1016/j.addr.2021.114068 PMC8724414 34822926

575. Kubczak M Nanoparticles for local delivery of siRNA in lung therapy Adv. Drug Deliver. Rev. 2021 179 114038 10.1016/j.addr.2021.114038 34742826 Kubczak, M. et al. Nanoparticles for local delivery of siRNA in lung therapy. Adv. Drug Deliver. Rev. 179 , 114038 (2021). 10.1016/j.addr.2021.114038 34742826

576. Yan Y Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells Proc. Natl. Acad. Sci. USA 2016 113 E5702 E5710 10.1073/pnas.1606886113 27621434 PMC5047169 Yan, Y. et al. Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells. Proc. Natl. Acad. Sci. USA 113 , E5702–E5710 (2016). 27621434 10.1073/pnas.1606886113 PMC5047169

577. Shi M Stimuli-responsive release and efficient siRNA delivery in non-small cell lung cancer by a poly(l-histidine)-based multifunctional nanoplatform J. Mater. Chem. B 2020 8 1616 1628 10.1039/C9TB02764E 32010914 Shi, M. et al. Stimuli-responsive release and efficient siRNA delivery in non-small cell lung cancer by a poly(l-histidine)-based multifunctional nanoplatform. J. Mater. Chem. B 8 , 1616–1628 (2020). 32010914 10.1039/C9TB02764E

578. Kim T Croce CM MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies Exp. Mol. Med. 2023 55 1314 1321 10.1038/s12276-023-01050-9 37430087 PMC10394030 Kim, T. & Croce, C. M. MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies. Exp. Mol. Med. 55 , 1314–1321 (2023). 37430087 10.1038/s12276-023-01050-9 PMC10394030

579. Sun Z Effect of exosomal miRNA on cancer biology and clinical applications Mol. Cancer 2018 17 147 10.1186/s12943-018-0897-7 30309355 PMC6182840 Sun, Z. et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol. Cancer 17 , 147 (2018). 30309355 10.1186/s12943-018-0897-7 PMC6182840

580. Kim T Croce CM MicroRNA and ER stress in cancer Semin. Cancer Biol. 2021 75 3 14 10.1016/j.semcancer.2020.12.025 33422566 Kim, T. & Croce, C. M. MicroRNA and ER stress in cancer. Semin. Cancer Biol. 75 , 3–14 (2021). 33422566 10.1016/j.semcancer.2020.12.025

581. Moro M Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models J. Control. Release 2019 308 44 56 10.1016/j.jconrel.2019.07.006 31299263 Moro, M. et al. Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J. Control. Release 308 , 44–56 (2019). 31299263 10.1016/j.jconrel.2019.07.006

582. Peng Y Zhu X Qiu L Electroneutral composite polymersomes self-assembled by amphiphilic polyphosphazenes for effective miR-200c in vivo delivery to inhibit drug resistant lung cancer Biomaterials 2016 106 1 12 10.1016/j.biomaterials.2016.08.001 27541441 Peng, Y., Zhu, X. & Qiu, L. Electroneutral composite polymersomes self-assembled by amphiphilic polyphosphazenes for effective miR-200c in vivo delivery to inhibit drug resistant lung cancer. Biomaterials 106 , 1–12 (2016). 27541441 10.1016/j.biomaterials.2016.08.001

583. Perepelyuk M Maher C Lakshmikuttyamma A Shoyele SA Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins Int. J. Nanomed. 2016 11 3533 3544 10.2147/IJN.S110488 PMC4970448 27555773 Perepelyuk, M., Maher, C., Lakshmikuttyamma, A. & Shoyele, S. A. Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins. Int. J. Nanomed. 11 , 3533–3544 (2016). 10.2147/IJN.S110488 PMC4970448 27555773

584. Kong N Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition Sci. Transl. Med. 2019 11 eaaw1565 10.1126/scitranslmed.aaw1565 31852795 PMC7024563 Kong, N. et al. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci. Transl. Med. 11 , eaaw1565 (2019). 31852795 10.1126/scitranslmed.aaw1565 PMC7024563

585. Ji P MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer Oncogene 2003 22 8031 8041 10.1038/sj.onc.1206928 12970751 Ji, P. et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22 , 8031–8041 (2003). 12970751 10.1038/sj.onc.1206928

586. Gong N Teng X Li J Liang X-J Antisense oligonucleotide-conjugated nanostructure-targeting lncRNA MALAT1 inhibits cancer metastasis ACS Appl. Mater. Inter. 2019 11 37 42 10.1021/acsami.8b18288 30548064 Gong, N., Teng, X., Li, J. & Liang, X.-J. Antisense oligonucleotide-conjugated nanostructure-targeting lncRNA MALAT1 inhibits cancer metastasis. ACS Appl. Mater. Inter. 11 , 37–42 (2019). 10.1021/acsami.8b18288 30548064

587. Ji D An engineered influenza virus to deliver antigens for lung cancer vaccination Nat. Biotechnol. 2024 42 518 528 10.1038/s41587-023-01796-7 37231262 Ji, D. et al. An engineered influenza virus to deliver antigens for lung cancer vaccination. Nat. Biotechnol. 42 , 518–528 (2024). 37231262 10.1038/s41587-023-01796-7

588. Perry JL Pulmonary delivery of nanoparticle-bound toll-like receptor 9 agonist for the treatment of metastatic lung cancer ACS Nano 2020 14 7200 7215 10.1021/acsnano.0c02207 32463690 PMC7531260 Perry, J. L. et al. Pulmonary delivery of nanoparticle-bound toll-like receptor 9 agonist for the treatment of metastatic lung cancer. ACS Nano 14 , 7200–7215 (2020). 32463690 10.1021/acsnano.0c02207 PMC7531260

589. Park G LDR-induced miR-30a and miR-30b target the PAI-1 pathway to control adverse effects of NSCLC radiotherapy Mol. Ther. 2019 27 342 354 10.1016/j.ymthe.2018.10.015 30424954 PMC6369577 Park, G. et al. LDR-induced miR-30a and miR-30b target the PAI-1 pathway to control adverse effects of NSCLC radiotherapy. Mol. Ther. 27 , 342–354 (2019). 30424954 10.1016/j.ymthe.2018.10.015 PMC6369577

590. Song G Emerging nanotechnology and advanced materials for cancer radiation therapy Adv. Mater. 2017 29 1700996 10.1002/adma.201700996 28643452 Song, G. et al. Emerging nanotechnology and advanced materials for cancer radiation therapy. Adv. Mater. 29 , 1700996 (2017). 10.1002/adma.201700996 28643452

591. Chen MH Hafnium-doped hydroxyapatite nanoparticles with ionizing radiation for lung cancer treatment Acta Biomater 2016 37 165 173 10.1016/j.actbio.2016.04.004 27060620 Chen, M. H. et al. Hafnium-doped hydroxyapatite nanoparticles with ionizing radiation for lung cancer treatment. Acta Biomater 37 , 165–173 (2016). 27060620 10.1016/j.actbio.2016.04.004

592. Reda M PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer Cancer Lett 2019 467 9 18 10.1016/j.canlet.2019.09.014 31563561 PMC6927399 Reda, M. et al. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. Cancer Lett 467 , 9–18 (2019). 31563561 10.1016/j.canlet.2019.09.014 PMC6927399

593. Zheng Y Cloutier P Hunting DJ Sanche L Radiosensitization by gold nanoparticles: comparison of DNA damage induced by low and high-energy electrons J. Biomed. Nanotechnol. 2008 4 1 5 10.1166/jbn.2008.3282 Zheng, Y., Cloutier, P., Hunting, D. J. & Sanche, L. Radiosensitization by gold nanoparticles: comparison of DNA damage induced by low and high-energy electrons. J. Biomed. Nanotechnol. 4 , 1–5 (2008). 10.1166/jbn.2008.3282

594. Wu H Reactive oxygen species acts as executor in radiation enhancement and autophagy inducing by AgNPs Biomaterials 2016 101 1 9 10.1016/j.biomaterials.2016.05.031 27254247 Wu, H. et al. Reactive oxygen species acts as executor in radiation enhancement and autophagy inducing by AgNPs. Biomaterials 101 , 1–9 (2016). 27254247 10.1016/j.biomaterials.2016.05.031

595. Wen N Is the autophagy a friend or foe in the silver nanoparticles associated radiotherapy for glioma ? Biomaterials 2015 62 47 57 10.1016/j.biomaterials.2015.05.033 26022979 Wen, N. et al. Is the autophagy a friend or foe in the silver nanoparticles associated radiotherapy for glioma ? Biomaterials 62 , 47–57 (2015). 26022979 10.1016/j.biomaterials.2015.05.033

596. Boca SC Chitosan-coated triangular silver nanoparticles as a novel class of biocompatible, highly effective photothermal transducers for in vitro cancer cell therapy Cancer Lett 2011 311 131 140 10.1016/j.canlet.2011.06.022 21840122 Boca, S. C. et al. Chitosan-coated triangular silver nanoparticles as a novel class of biocompatible, highly effective photothermal transducers for in vitro cancer cell therapy. Cancer Lett 311 , 131–140 (2011). 21840122 10.1016/j.canlet.2011.06.022

597. Gao Shi Nanoparticles encapsulating nitrosylated maytansine to enhance radiation therapy ACS Nano 2020 14 1468 1481 10.1021/acsnano.9b05976 31939662 Gao, Shi et al. Nanoparticles encapsulating nitrosylated maytansine to enhance radiation therapy. ACS Nano 14 , 1468–1481 (2020). 31939662 10.1021/acsnano.9b05976

598. Brown JM Wilson WR Exploiting tumour hypoxia in cancer treatment Nat. Rev. Cancer 2004 4 437 447 10.1038/nrc1367 15170446 Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4 , 437–447 (2004). 15170446 10.1038/nrc1367

599. Song X Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies Nano Lett 2016 16 6145 6153 10.1021/acs.nanolett.6b02365 27622835 Song, X. et al. Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies. Nano Lett 16 , 6145–6153 (2016). 27622835 10.1021/acs.nanolett.6b02365

600. Bradley JD Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study Lancet Oncol 2015 16 187 199 10.1016/S1470-2045(14)71207-0 25601342 PMC4419359 Bradley, J. D. et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16 , 187–199 (2015). 25601342 10.1016/S1470-2045(14)71207-0 PMC4419359

601. Cao W Gu Y Meineck M Xu H The combination of chemotherapy and radiotherapy towards more efficient drug delivery Chem.-Asian J. 2014 9 48 57 10.1002/asia.201301294 24347066 Cao, W., Gu, Y., Meineck, M. & Xu, H. The combination of chemotherapy and radiotherapy towards more efficient drug delivery. Chem.-Asian J. 9 , 48–57 (2014). 24347066 10.1002/asia.201301294

602. Curran WJ Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 JNCI-J. Natl. Cancer I. 2011 103 1452 1460 10.1093/jnci/djr325 PMC3186782 21903745 Curran, W. J. et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. JNCI-J. Natl. Cancer I. 103 , 1452–1460 (2011). 10.1093/jnci/djr325 PMC3186782 21903745

603. Ma M Bi 2 S 3 -embedded mesoporous silica nanoparticles for efficient drug delivery and interstitial radiotherapy sensitization Biomaterials 2015 37 447 455 10.1016/j.biomaterials.2014.10.001 25453972 Ma, M. et al. Bi 2 S 3 -embedded mesoporous silica nanoparticles for efficient drug delivery and interstitial radiotherapy sensitization. Biomaterials 37 , 447–455 (2015). 25453972 10.1016/j.biomaterials.2014.10.001

604. Kinoshita T A novel laser fiberscope for simultaneous imaging and phototherapy of peripheral lung cancer Chest 2019 156 571 578 10.1016/j.chest.2019.04.010 31034817 Kinoshita, T. et al. A novel laser fiberscope for simultaneous imaging and phototherapy of peripheral lung cancer. Chest 156 , 571–578 (2019). 31034817 10.1016/j.chest.2019.04.010

605. Li S Rational design of conjugated small molecules for superior photothermal theranostics in the NIR-II biowindow Adv. Mater. 2020 32 e2001146 10.1002/adma.202001146 32627868 Li, S. et al. Rational design of conjugated small molecules for superior photothermal theranostics in the NIR-II biowindow. Adv. Mater. 32 , e2001146 (2020). 32627868 10.1002/adma.202001146

606. Liu B Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer Acta Biomater 2019 99 307 319 10.1016/j.actbio.2019.08.046 31513911 Liu, B. et al. Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer. Acta Biomater 99 , 307–319 (2019). 31513911 10.1016/j.actbio.2019.08.046

607. Gu X CuS nanoparticles as a photodynamic nanoswitch for abrogating bypass signaling to overcome gefitinib resistance Nano Lett 2019 19 3344 3352 10.1021/acs.nanolett.9b01065 30974946 Gu, X. et al. CuS nanoparticles as a photodynamic nanoswitch for abrogating bypass signaling to overcome gefitinib resistance. Nano Lett 19 , 3344–3352 (2019). 30974946 10.1021/acs.nanolett.9b01065

608. Jin CS An integrated nanotechnology-enabled transbronchial image-guided intervention strategy for peripheral lung cancer Cancer Res 2016 76 5870 5880 10.1158/0008-5472.CAN-15-3196 27543602 PMC5050138 Jin, C. S. et al. An integrated nanotechnology-enabled transbronchial image-guided intervention strategy for peripheral lung cancer. Cancer Res 76 , 5870–5880 (2016). 27543602 10.1158/0008-5472.CAN-15-3196 PMC5050138

609. Yuan ZQ Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor J. Control. Release 2017 268 198 211 10.1016/j.jconrel.2017.10.025 29061511 Yuan, Z. Q. et al. Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor. J. Control. Release 268 , 198–211 (2017). 29061511 10.1016/j.jconrel.2017.10.025

610. Jin M Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes Int. J. Nanomed. 2018 13 2405 2426 10.2147/IJN.S161426 PMC5916383 29719390 Jin, M. et al. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes. Int. J. Nanomed. 13 , 2405–2426 (2018). 10.2147/IJN.S161426 PMC5916383 29719390

611. Yang Y Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally via a multi-functional polymer micelle J. Control. Release 2018 287 103 120 10.1016/j.jconrel.2018.08.028 30144476 Yang, Y. et al. Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally via a multi-functional polymer micelle. J. Control. Release 287 , 103–120 (2018). 30144476 10.1016/j.jconrel.2018.08.028

612. Zhang Q Chemoimmunological cascade cancer therapy using fluorine assembly nanomedicine ACS Nano 2023 17 7498 7510 10.1021/acsnano.2c12600 37011376 Zhang, Q. et al. Chemoimmunological cascade cancer therapy using fluorine assembly nanomedicine. ACS Nano 17 , 7498–7510 (2023). 37011376 10.1021/acsnano.2c12600

613. Nascimento AV Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles Acta Biomater 2017 47 71 80 10.1016/j.actbio.2016.09.045 27697601 PMC5110398 Nascimento, A. V. et al. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Acta Biomater 47 , 71–80 (2017). 27697601 10.1016/j.actbio.2016.09.045 PMC5110398

614. Gu L Deng ZJ Roy S Hammond PT A combination RNAi-chemotherapy layer-by-layer nanoparticle for systemic targeting of KRAS/P53 with cisplatin to treat non-small cell lung cancer Clin. Cancer Res. 2017 23 7312 7323 10.1158/1078-0432.CCR-16-2186 28912139 PMC5712246 Gu, L., Deng, Z. J., Roy, S. & Hammond, P. T. A combination RNAi-chemotherapy layer-by-layer nanoparticle for systemic targeting of KRAS/P53 with cisplatin to treat non-small cell lung cancer. Clin. Cancer Res. 23 , 7312–7323 (2017). 28912139 10.1158/1078-0432.CCR-16-2186 PMC5712246

615. Li F Co-delivery of VEGF siRNA and etoposide for enhanced anti-angiogenesis and anti-proliferation effect via multi-functional nanoparticles for orthotopic non-small cell lung cancer treatment Theranostics 2019 9 5886 5898 10.7150/thno.32416 31534526 PMC6735374 Li, F. et al. Co-delivery of VEGF siRNA and etoposide for enhanced anti-angiogenesis and anti-proliferation effect via multi-functional nanoparticles for orthotopic non-small cell lung cancer treatment. Theranostics 9 , 5886–5898 (2019). 31534526 10.7150/thno.32416 PMC6735374

616. Li S Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system Theranostics 2018 8 2621 2633 10.7150/thno.24469 29774063 PMC5956997 Li, S. et al. Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system. Theranostics 8 , 2621–2633 (2018). 29774063 10.7150/thno.24469 PMC5956997

617. Sacko K Thangavel K Shoyele SA Codelivery of genistein and miRNA-29b to A549 cells using aptamer-hybrid nanoparticle bioconjugates Nanomaterials-Basel 2019 9 1052 10.3390/nano9071052 31340494 PMC6669731 Sacko, K., Thangavel, K. & Shoyele, S. A. Codelivery of genistein and miRNA-29b to A549 cells using aptamer-hybrid nanoparticle bioconjugates. Nanomaterials-Basel 9 , 1052 (2019). 31340494 10.3390/nano9071052 PMC6669731

618. Garbuzenko OB Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy Theranostics 2019 9 8362 8376 10.7150/thno.39816 31754402 PMC6857061 Garbuzenko, O. B. et al. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics 9 , 8362–8376 (2019). 31754402 10.7150/thno.39816 PMC6857061

619. Yue C ROS-responsive mitochondria-targeting blended nanoparticles: chemo- and photodynamic synergistic therapy for lung cancer with on-demand drug release upon irradiation with a single light source Theranostics 2016 6 2352 2366 10.7150/thno.15433 27877240 PMC5118600 Yue, C. et al. ROS-responsive mitochondria-targeting blended nanoparticles: chemo- and photodynamic synergistic therapy for lung cancer with on-demand drug release upon irradiation with a single light source. Theranostics 6 , 2352–2366 (2016). 27877240 10.7150/thno.15433 PMC5118600

620. Yue C Near-infrared light triggered ROS-activated theranostic platform based on Ce6-CPT-UCNPs for simultaneous fluorescence imaging and chemo-photodynamic combined therapy Theranostics 2016 6 456 469 10.7150/thno.14101 26941840 PMC4775857 Yue, C. et al. Near-infrared light triggered ROS-activated theranostic platform based on Ce6-CPT-UCNPs for simultaneous fluorescence imaging and chemo-photodynamic combined therapy. Theranostics 6 , 456–469 (2016). 26941840 10.7150/thno.14101 PMC4775857

621. Xia F pH-responsive gold nanoclusters-based nanoprobes for lung cancer targeted near-infrared fluorescence imaging and chemo-photodynamic therapy Acta Biomater 2018 68 308 319 10.1016/j.actbio.2017.12.034 29292171 Xia, F. et al. pH-responsive gold nanoclusters-based nanoprobes for lung cancer targeted near-infrared fluorescence imaging and chemo-photodynamic therapy. Acta Biomater 68 , 308–319 (2018). 29292171 10.1016/j.actbio.2017.12.034

622. Zhong X NaCeF4:Gd,Tb scintillator as an X-ray responsive photosensitizer for multimodal imaging-guided synchronous radio/radiodynamic therapy Nano Lett 2019 19 8234 8244 10.1021/acs.nanolett.9b03682 31576757 Zhong, X. et al. NaCeF4:Gd,Tb scintillator as an X-ray responsive photosensitizer for multimodal imaging-guided synchronous radio/radiodynamic therapy. Nano Lett 19 , 8234–8244 (2019). 31576757 10.1021/acs.nanolett.9b03682

623. Song W Enhanced immunotherapy based on photodynamic therapy for both primary and lung metastasis tumor eradication ACS Nano 2018 12 1978 1989 10.1021/acsnano.7b09112 29420012 Song, W. et al. Enhanced immunotherapy based on photodynamic therapy for both primary and lung metastasis tumor eradication. ACS Nano 12 , 1978–1989 (2018). 29420012 10.1021/acsnano.7b09112

624. Zhang Y Construction of DOX-APC co-loaded BiOI@CuS NPs for safe and highly effective CT imaging and chemo-photothermal therapy of lung cancer J. Mater. Chem. B 2019 7 7176 10.1039/C9TB01874C 31651926 Zhang, Y. et al. Construction of DOX-APC co-loaded BiOI@CuS NPs for safe and highly effective CT imaging and chemo-photothermal therapy of lung cancer. J. Mater. Chem. B 7 , 7176 (2019). 31651926 10.1039/C9TB01874C

625. Hirsch FR Lung cancer: current therapies and new targeted treatments Lancet 2017 389 299 311 10.1016/S0140-6736(16)30958-8 27574741 Hirsch, F. R. et al. Lung cancer: current therapies and new targeted treatments. Lancet 389 , 299–311 (2017). 27574741 10.1016/S0140-6736(16)30958-8

626. Gioux S Choi HS Frangioni JV Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation Mol. Imaging 2010 9 237 255 10.2310/7290.2010.00034 20868625 PMC3105445 Gioux, S., Choi, H. S. & Frangioni, J. V. Image-guided surgery using invisible near-infrared light: fundamentals of clinical translation. Mol. Imaging 9 , 237–255 (2010). 20868625 10.2310/7290.2010.00034 PMC3105445

627. Lee S Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo Nano Lett 2009 9 4412 4416 10.1021/nl902709m 19842672 PMC3618996 Lee, S. et al. Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo. Nano Lett 9 , 4412–4416 (2009). 19842672 10.1021/nl902709m PMC3618996

628. Hirche C An experimental study to evaluate the fluobeam 800 imaging system for fluorescence-guided lymphatic imaging and sentinel node biopsy Surg. Innov. 2013 20 516 523 10.1177/1553350612468962 23275469 Hirche, C. et al. An experimental study to evaluate the fluobeam 800 imaging system for fluorescence-guided lymphatic imaging and sentinel node biopsy. Surg. Innov. 20 , 516–523 (2013). 23275469 10.1177/1553350612468962

629. On KC Tumor-targeting glycol chitosan nanoparticles for image-guided surgery of rabbit orthotopic VX2 lung cancer Pharmaceutics 2020 12 621 10.3390/pharmaceutics12070621 32635231 PMC7407595 On, K. C. et al. Tumor-targeting glycol chitosan nanoparticles for image-guided surgery of rabbit orthotopic VX2 lung cancer. Pharmaceutics 12 , 621 (2020). 32635231 10.3390/pharmaceutics12070621 PMC7407595

630. Ostrom QT CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019 Neuro-Oncology 2022 24 v1 v95 10.1093/neuonc/noac202 36196752 PMC9533228 Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro-Oncology 24 , v1–v95 (2022). 36196752 10.1093/neuonc/noac202 PMC9533228

631. Louis DN The 2016 world health organization classification of tumors of the central nervous system: a summary Acta Neuropathol 2016 131 803 820 10.1007/s00401-016-1545-1 27157931 Louis, D. N. et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131 , 803–820 (2016). 27157931 10.1007/s00401-016-1545-1

632. Abdul KU WINDOW consortium: a path towards increased therapy efficacy against glioblastoma Drug Resist. Update. 2018 40 17 24 10.1016/j.drup.2018.10.001 30439622 Abdul, K. U. et al. WINDOW consortium: a path towards increased therapy efficacy against glioblastoma. Drug Resist. Update. 40 , 17–24 (2018). 10.1016/j.drup.2018.10.001 30439622

633. Valiente M Towards personalizing radiotherapy for brain metastasis Nat. Med. 2022 28 643 644 10.1038/s41591-022-01776-5 35411078 Valiente, M. Towards personalizing radiotherapy for brain metastasis. Nat. Med. 28 , 643–644 (2022). 35411078 10.1038/s41591-022-01776-5

634. Zhang L Zhao D Applications of nanoparticles for brain cancer imaging and therapy J. Biomed. Nanotechnol. 2014 10 1713 1731 10.1166/jbn.2014.1896 25992438 Zhang, L. & Zhao, D. Applications of nanoparticles for brain cancer imaging and therapy. J. Biomed. Nanotechnol. 10 , 1713–1731 (2014). 25992438 10.1166/jbn.2014.1896

635. Tang W Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics Chem. Soc. Rev. 2019 48 2967 3014 10.1039/C8CS00805A 31089607 Tang, W. et al. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem. Soc. Rev. 48 , 2967–3014 (2019). 31089607 10.1039/C8CS00805A

636. Zhao W Construction of nanomaterials as contrast agents or probes for glioma imaging J. Nanobiotechnol. 2021 19 125 10.1186/s12951-021-00866-9 PMC8091158 33941206 Zhao, W. et al. Construction of nanomaterials as contrast agents or probes for glioma imaging. J. Nanobiotechnol. 19 , 125 (2021). 10.1186/s12951-021-00866-9 PMC8091158 33941206

637. Qiao R Magnetic iron oxide nanoparticles for brain imaging and drug delivery Adv. Drug Deliver. Rev. 2023 197 114822 10.1016/j.addr.2023.114822 37086918 Qiao, R. et al. Magnetic iron oxide nanoparticles for brain imaging and drug delivery. Adv. Drug Deliver. Rev. 197 , 114822 (2023). 10.1016/j.addr.2023.114822 37086918

638. Hou S Pretargeted positron emission tomography imaging that employs supramolecular nanoparticles with in vivo bioorthogonal chemistry ACS Nano 2016 10 1417 1424 10.1021/acsnano.5b06860 26731174 PMC4893318 Hou, S. et al. Pretargeted positron emission tomography imaging that employs supramolecular nanoparticles with in vivo bioorthogonal chemistry. ACS Nano 10 , 1417–1424 (2016). 26731174 10.1021/acsnano.5b06860 PMC4893318

639. Karimian-Jazi K Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM) Theranostics 2020 10 1873 1883 10.7150/thno.38659 32042342 PMC6993231 Karimian-Jazi, K. et al. Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM). Theranostics 10 , 1873–1883 (2020). 32042342 10.7150/thno.38659 PMC6993231

640. Zhang L Multifunctional nanotheranostics for near infrared optical imaging-guided treatment of brain tumors Adv. Drug Deliver. Rev. 2022 190 114536 10.1016/j.addr.2022.114536 36108792 Zhang, L. et al. Multifunctional nanotheranostics for near infrared optical imaging-guided treatment of brain tumors. Adv. Drug Deliver. Rev. 190 , 114536 (2022). 10.1016/j.addr.2022.114536 36108792

641. Reichel D Near infrared fluorescent nanoplatform for targeted intraoperative resection and chemotherapeutic treatment of glioblastoma ACS Nano 2020 14 8392 8408 10.1021/acsnano.0c02509 32551496 PMC7438253 Reichel, D. et al. Near infrared fluorescent nanoplatform for targeted intraoperative resection and chemotherapeutic treatment of glioblastoma. ACS Nano 14 , 8392–8408 (2020). 32551496 10.1021/acsnano.0c02509 PMC7438253

642. Kanda T High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material Radiology 2014 270 834 841 10.1148/radiol.13131669 24475844 Kanda, T. et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270 , 834–841 (2014). 24475844 10.1148/radiol.13131669

643. Bjornmalm M Bridging bio-nano science and cancer nanomedicine ACS Nano 2017 11 9594 9613 10.1021/acsnano.7b04855 28926225 Bjornmalm, M. et al. Bridging bio-nano science and cancer nanomedicine. ACS Nano 11 , 9594–9613 (2017). 28926225 10.1021/acsnano.7b04855

644. Hasan I Recent progress in nanomedicines for imaging and therapy of brain tumors Biomater. Sci.-UK 2023 11 1270 1310 10.1039/D2BM01572B 36648496 Hasan, I. et al. Recent progress in nanomedicines for imaging and therapy of brain tumors. Biomater. Sci.-UK 11 , 1270–1310 (2023). 10.1039/D2BM01572B 36648496

645. Yasaswi PS Shetty K Yadav KS Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy J. Control. Release 2021 336 549 571 10.1016/j.jconrel.2021.07.003 34229001 Yasaswi, P. S., Shetty, K. & Yadav, K. S. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. J. Control. Release 336 , 549–571 (2021). 34229001 10.1016/j.jconrel.2021.07.003

646. Agarwal S Chlorotoxin modified morusin-PLGA nanoparticles for targeted glioblastoma therapy J. Mater. Chem. B 2019 7 5896 5919 10.1039/C9TB01131E 31423502 Agarwal, S. et al. Chlorotoxin modified morusin-PLGA nanoparticles for targeted glioblastoma therapy. J. Mater. Chem. B 7 , 5896–5919 (2019). 31423502 10.1039/C9TB01131E

647. Choudhury H Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends Drug Deliv. Transl. Res. 2018 8 1545 1563 10.1007/s13346-018-0552-2 29916012 Choudhury, H. et al. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv. Transl. Res. 8 , 1545–1563 (2018). 29916012 10.1007/s13346-018-0552-2

648. Zhang B LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma Biomaterials 2013 34 9171 9182 10.1016/j.biomaterials.2013.08.039 24008043 Zhang, B. et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials 34 , 9171–9182 (2013). 24008043 10.1016/j.biomaterials.2013.08.039

649. Israel LL Signature effects of vector-guided systemic nano bioconjugate delivery across blood-brain barrier of normal, Alzheimer’s, and tumor mouse models ACS Nano 2022 16 11815 11832 10.1021/acsnano.1c10034 35961653 PMC9413444 Israel, L. L. et al. Signature effects of vector-guided systemic nano bioconjugate delivery across blood-brain barrier of normal, Alzheimer’s, and tumor mouse models. ACS Nano 16 , 11815–11832 (2022). 35961653 10.1021/acsnano.1c10034 PMC9413444

650. Fan K Magnetoferritin nanoparticles for targeting and visualizing tumour tissues Nat. Nanotechnol. 2012 7 459 464 10.1038/nnano.2012.90 22706697 Fan, K. et al. Magnetoferritin nanoparticles for targeting and visualizing tumour tissues. Nat. Nanotechnol. 7 , 459–464 (2012). 22706697 10.1038/nnano.2012.90

651. Liu W Target delivering paclitaxel by ferritin heavy chain nanocages for glioma treatment J. Control. Release 2020 323 191 202 10.1016/j.jconrel.2019.12.010 31838201 Liu, W. et al. Target delivering paclitaxel by ferritin heavy chain nanocages for glioma treatment. J. Control. Release 323 , 191–202 (2020). 31838201 10.1016/j.jconrel.2019.12.010

652. Zhao Y Bioengineered magnetoferritin nanoprobes for single-dose nuclear-magnetic resonance tumor imaging ACS Nano 2016 10 4184 4191 10.1021/acsnano.5b07408 26959856 Zhao, Y. et al. Bioengineered magnetoferritin nanoprobes for single-dose nuclear-magnetic resonance tumor imaging. ACS Nano 10 , 4184–4191 (2016). 26959856 10.1021/acsnano.5b07408

653. Fan K Ferritin nanocarrier traverses the blood brain barrier and kills glioma ACS Nano 2018 12 4105 4115 10.1021/acsnano.7b06969 29608290 Fan, K. et al. Ferritin nanocarrier traverses the blood brain barrier and kills glioma. ACS Nano 12 , 4105–4115 (2018). 29608290 10.1021/acsnano.7b06969

654. Sabra S Agwa MM Lactoferrin, a unique molecule with diverse therapeutical and nanotechnological applications Int. J. Biol. Macromol. 2020 164 1046 1060 10.1016/j.ijbiomac.2020.07.167 32707283 PMC7374128 Sabra, S. & Agwa, M. M. Lactoferrin, a unique molecule with diverse therapeutical and nanotechnological applications. Int. J. Biol. Macromol. 164 , 1046–1060 (2020). 32707283 10.1016/j.ijbiomac.2020.07.167 PMC7374128

655. Zhai M Glioma targeting peptide modified apoferritin nanocage Drug Deliv 2018 25 1013 1024 10.1080/10717544.2018.1464082 29726297 PMC6058491 Zhai, M. et al. Glioma targeting peptide modified apoferritin nanocage. Drug Deliv 25 , 1013–1024 (2018). 29726297 10.1080/10717544.2018.1464082 PMC6058491

656. Di Mauro PP Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma Int. J. Pharmaceut. 2018 553 169 185 10.1016/j.ijpharm.2018.10.022 30321641 Di Mauro, P. P. et al. Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma. Int. J. Pharmaceut. 553 , 169–185 (2018). 10.1016/j.ijpharm.2018.10.022 30321641

657. Xu HL Glioma-targeted superparamagnetic iron oxide nanoparticles as drug-carrying vehicles for theranostic effects Nanoscale 2016 8 14222 14236 10.1039/C6NR02448C 27396404 Xu, H. L. et al. Glioma-targeted superparamagnetic iron oxide nanoparticles as drug-carrying vehicles for theranostic effects. Nanoscale 8 , 14222–14236 (2016). 27396404 10.1039/C6NR02448C

658. Tapeinos C Battaglini M Ciofani G Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases J. Control. Release 2017 264 306 332 10.1016/j.jconrel.2017.08.033 28844756 PMC6701993 Tapeinos, C., Battaglini, M. & Ciofani, G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control. Release 264 , 306–332 (2017). 28844756 10.1016/j.jconrel.2017.08.033 PMC6701993

659. Norouzi M Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles Sci. Rep.-UK 2020 10 11292 10.1038/s41598-020-68017-y PMC7347880 32647151 Norouzi, M. et al. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles. Sci. Rep.-UK 10 , 11292 (2020). 10.1038/s41598-020-68017-y PMC7347880 32647151

660. Zhang X Virion-like membrane-breaking nanoparticles with tumor-activated cell-and-tissue dual-penetration conquer impermeable cancer Adv. Mater. 2018 30 e1707240 10.1002/adma.201707240 29774608 Zhang, X. et al. Virion-like membrane-breaking nanoparticles with tumor-activated cell-and-tissue dual-penetration conquer impermeable cancer. Adv. Mater. 30 , e1707240 (2018). 29774608 10.1002/adma.201707240

661. Edwardson TGW Hilvert D Virus-inspired function in engineered protein cages J. Am. Chem. Soc. 2019 141 9432 9443 10.1021/jacs.9b03705 31117660 Edwardson, T. G. W. & Hilvert, D. Virus-inspired function in engineered protein cages. J. Am. Chem. Soc. 141 , 9432–9443 (2019). 31117660 10.1021/jacs.9b03705

662. Qiao C Rabies virus-inspired metal-organic frameworks (MOFs) for targeted imaging and chemotherapy of glioma Angew. Chem. Int. Edit. 2020 59 16982 16988 10.1002/anie.202007474 32608558 Qiao, C. et al. Rabies virus-inspired metal-organic frameworks (MOFs) for targeted imaging and chemotherapy of glioma. Angew. Chem. Int. Edit. 59 , 16982–16988 (2020). 10.1002/anie.202007474 32608558

663. Chatterjee S Nontoxic, double-deletion-mutant rabies viral vectors for retrograde targeting of projection neurons Nat. Neurosci. 2018 21 638 646 10.1038/s41593-018-0091-7 29507411 PMC6503322 Chatterjee, S. et al. Nontoxic, double-deletion-mutant rabies viral vectors for retrograde targeting of projection neurons. Nat. Neurosci. 21 , 638–646 (2018). 29507411 10.1038/s41593-018-0091-7 PMC6503322

664. Kozielski KL Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo Biomaterials 2019 209 79 87 10.1016/j.biomaterials.2019.04.020 31026613 PMC7122460 Kozielski, K. L. et al. Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo. Biomaterials 209 , 79–87 (2019). 31026613 10.1016/j.biomaterials.2019.04.020 PMC7122460

665. Kuang Y T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting Int. J. Pharmaceut. 2013 454 11 20 10.1016/j.ijpharm.2013.07.019 23867728 Kuang, Y. et al. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int. J. Pharmaceut. 454 , 11–20 (2013). 10.1016/j.ijpharm.2013.07.019 23867728

666. Kumthekar P A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma Sci. Transl. Med. 2021 13 eabb3945 10.1126/scitranslmed.abb3945 33692132 PMC8272521 Kumthekar, P. et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci. Transl. Med. 13 , eabb3945 (2021). 33692132 10.1126/scitranslmed.abb3945 PMC8272521

667. Kim SS Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide Nucleic Acids Res 2018 46 1424 1440 10.1093/nar/gkx1221 29202181 PMC5815062 Kim, S. S. et al. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res 46 , 1424–1440 (2018). 29202181 10.1093/nar/gkx1221 PMC5815062

668. Chen W Glackin CA Horwitz MA Zink JI Nanomachines and other caps on mesoporous silica nanoparticles for drug delivery Accounts Chem. Res. 2019 52 1531 1542 10.1021/acs.accounts.9b00116 31082188 Chen, W., Glackin, C. A., Horwitz, M. A. & Zink, J. I. Nanomachines and other caps on mesoporous silica nanoparticles for drug delivery. Accounts Chem. Res. 52 , 1531–1542 (2019). 10.1021/acs.accounts.9b00116 31082188

669. Dong Y A dual targeting dendrimer-mediated siRNA delivery system for effective gene silencing in cancer therapy J. Am. Chem. Soc. 2018 140 16264 16274 10.1021/jacs.8b10021 30346764 Dong, Y. et al. A dual targeting dendrimer-mediated siRNA delivery system for effective gene silencing in cancer therapy. J. Am. Chem. Soc. 140 , 16264–16274 (2018). 30346764 10.1021/jacs.8b10021

670. Yoo YJ Lee CH Park SH Lim YT Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy J. Control. Release 2022 343 564 583 10.1016/j.jconrel.2022.01.047 35124126 Yoo, Y. J., Lee, C. H., Park, S. H. & Lim, Y. T. Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy. J. Control. Release 343 , 564–583 (2022). 35124126 10.1016/j.jconrel.2022.01.047

671. Zhou P Delivery siRNA with a novel gene vector for glioma therapy by targeting Gli1 Int. J. Nanomed. 2018 13 4781 4793 10.2147/IJN.S164364 PMC6118331 30214189 Zhou, P. et al. Delivery siRNA with a novel gene vector for glioma therapy by targeting Gli1. Int. J. Nanomed. 13 , 4781–4793 (2018). 10.2147/IJN.S164364 PMC6118331 30214189

672. Van Woensel M Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy Sci. Rep.-UK 2017 7 1217 10.1038/s41598-017-01279-1 PMC5430862 28450700 Van Woensel, M. et al. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Sci. Rep.-UK 7 , 1217 (2017). 10.1038/s41598-017-01279-1 PMC5430862 28450700

673. Xu X ROS-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy Adv. Mater. 2017 29 1700141 10.1002/adma.201700141 PMC5681219 28681981 Xu, X. et al. ROS-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy. Adv. Mater. 29 , 1700141 (2017). 10.1002/adma.201700141 PMC5681219 28681981

674. Song CC Oxidation-accelerated hydrolysis of the ortho ester-containing acid-labile polymers ACS Macro Lett 2013 2 273 277 10.1021/mz4000392 35581896 Song, C. C. et al. Oxidation-accelerated hydrolysis of the ortho ester-containing acid-labile polymers. ACS Macro Lett 2 , 273–277 (2013). 35581896 10.1021/mz4000392

675. Zheng M ROS-responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy Adv. Mater. 2019 31 e1903277 10.1002/adma.201903277 31348581 Zheng, M. et al. ROS-responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy. Adv. Mater. 31 , e1903277 (2019). 31348581 10.1002/adma.201903277

676. Kamran N Immunosuppressive myeloid cells’ blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy Mol. Ther. 2017 25 232 248 10.1016/j.ymthe.2016.10.003 28129117 PMC5363306 Kamran, N. et al. Immunosuppressive myeloid cells’ blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. Mol. Ther. 25 , 232–248 (2017). 28129117 10.1016/j.ymthe.2016.10.003 PMC5363306

677. Weiss T Immunocytokines are a promising immunotherapeutic approach against glioblastoma Sci. Transl. Med. 2020 12 eabb2311 10.1126/scitranslmed.abb2311 33028706 Weiss, T. et al. Immunocytokines are a promising immunotherapeutic approach against glioblastoma. Sci. Transl. Med. 12 , eabb2311 (2020). 33028706 10.1126/scitranslmed.abb2311

678. Khasraw M Reardon DA Weller M Sampson JH PD-1 inhibitors: do they have a future in the treatment of glioblastoma? Clin. Cancer Res. 2020 26 5287 5296 10.1158/1078-0432.CCR-20-1135 32527943 PMC7682636 Khasraw, M., Reardon, D. A., Weller, M. & Sampson, J. H. PD-1 inhibitors: do they have a future in the treatment of glioblastoma? Clin. Cancer Res. 26 , 5287–5296 (2020). 32527943 10.1158/1078-0432.CCR-20-1135 PMC7682636

679. Majd N de Groot J Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma Expert Opin. Pharmaco. 2019 20 1609 1624 10.1080/14656566.2019.1621840 31264484 Majd, N. & de Groot, J. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. Expert Opin. Pharmaco. 20 , 1609–1624 (2019). 10.1080/14656566.2019.1621840 31264484

680. Ostrom QT CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012 Neuro-Oncology 2015 17 iv1 iv62 10.1093/neuonc/nov189 26511214 PMC4623240 Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology 17 , iv1–iv62 (2015). 26511214 10.1093/neuonc/nov189 PMC4623240

681. Chen C Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy Sci. Transl. Med. 2022 14 eabn1128 10.1126/scitranslmed.abn1128 35921473 Chen, C. et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci. Transl. Med. 14 , eabn1128 (2022). 35921473 10.1126/scitranslmed.abn1128

682. Janjua TI Frontiers in the treatment of glioblastoma: past, present and emerging Adv. Drug Deliver. Rev. 2021 171 108 138 10.1016/j.addr.2021.01.012 33486006 Janjua, T. I. et al. Frontiers in the treatment of glioblastoma: past, present and emerging. Adv. Drug Deliver. Rev. 171 , 108–138 (2021). 10.1016/j.addr.2021.01.012 33486006

683. Galstyan A Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy Nat. Commun. 2019 10 3850 10.1038/s41467-019-11719-3 31462642 PMC6713723 Galstyan, A. et al. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat. Commun. 10 , 3850 (2019). 31462642 10.1038/s41467-019-11719-3 PMC6713723

684. Karinaga R Galactose-PEG dual conjugation of beta-(1->3)-D-glucan schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptake Biomaterials 2006 27 1626 1635 10.1016/j.biomaterials.2005.08.023 16174528 Karinaga, R. et al. Galactose-PEG dual conjugation of beta-(1->3)-D-glucan schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptake. Biomaterials 27 , 1626–1635 (2006). 16174528 10.1016/j.biomaterials.2005.08.023

685. Kobiyama K Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist Proc. Natl. Acad. Sci. USA 2014 111 3086 3091 10.1073/pnas.1319268111 24516163 PMC3939924 Kobiyama, K. et al. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. Proc. Natl. Acad. Sci. USA 111 , 3086–3091 (2014). 24516163 10.1073/pnas.1319268111 PMC3939924

686. Tiwari RK Repolarization of glioblastoma macrophage cells using non-agonistic Dectin-1 ligand encapsulating TLR-9 agonist: plausible role in regenerative medicine against brain tumor Int. J. Neurosci. 2021 131 591 598 10.1080/00207454.2020.1750393 32250189 Tiwari, R. K. et al. Repolarization of glioblastoma macrophage cells using non-agonistic Dectin-1 ligand encapsulating TLR-9 agonist: plausible role in regenerative medicine against brain tumor. Int. J. Neurosci. 131 , 591–598 (2021). 32250189 10.1080/00207454.2020.1750393

687. Xie R Hsp70-targeting and size-tunable nanoparticles combine with PD-1 checkpoint blockade to treat glioma Small 2023 19 2300570 10.1002/smll.202300570 37222118 Xie, R. et al. Hsp70-targeting and size-tunable nanoparticles combine with PD-1 checkpoint blockade to treat glioma. Small 19 , 2300570 (2023). 10.1002/smll.202300570 37222118

688. Ursu R Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study Eur. J. Cancer. 2017 73 30 37 10.1016/j.ejca.2016.12.003 28142059 Ursu, R. et al. Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study. Eur. J. Cancer. 73 , 30–37 (2017). 28142059 10.1016/j.ejca.2016.12.003

689. Jordan M Waxman DJ CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model Cancer Lett 2016 373 88 96 10.1016/j.canlet.2015.11.029 26655275 PMC4761486 Jordan, M. & Waxman, D. J. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Lett 373 , 88–96 (2016). 26655275 10.1016/j.canlet.2015.11.029 PMC4761486

690. Fan H Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice Clin. Cancer Res. 2012 18 5628 5638 10.1158/1078-0432.CCR-12-1911 22904105 PMC3483143 Fan, H. et al. Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice. Clin. Cancer Res. 18 , 5628–5638 (2012). 22904105 10.1158/1078-0432.CCR-12-1911 PMC3483143

691. Lollo G Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma Int. J. Pharmaceut. 2015 495 972 980 10.1016/j.ijpharm.2015.09.062 26428632 Lollo, G. et al. Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. Int. J. Pharmaceut. 495 , 972–980 (2015). 10.1016/j.ijpharm.2015.09.062 26428632

692. Zhao D Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity Clin. Cancer Res. 2011 17 771 782 10.1158/1078-0432.CCR-10-2444 21088258 PMC3041854 Zhao, D. et al. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin. Cancer Res. 17 , 771–782 (2011). 21088258 10.1158/1078-0432.CCR-10-2444 PMC3041854

693. Gille A CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects Arterioscl. Throm. Vas. 2014 34 2106 2114 10.1161/ATVBAHA.114.303720 24969776 Gille, A. et al. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscl. Throm. Vas. 34 , 2106–2114 (2014). 10.1161/ATVBAHA.114.303720 24969776

694. Kadiyala P High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme ACS Nano 2019 13 1365 1384 30721028 10.1021/acsnano.8b06842 PMC6484828 Kadiyala, P. et al. High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano 13 , 1365–1384 (2019). 30721028 10.1021/acsnano.8b06842 PMC6484828

695. Alexander BM Cloughesy TF Adult glioblastoma J. Clin. Oncol. 2017 35 2402 2409 10.1200/JCO.2017.73.0119 28640706 Alexander, B. M. & Cloughesy, T. F. Adult glioblastoma. J. Clin. Oncol. 35 , 2402–2409 (2017). 28640706 10.1200/JCO.2017.73.0119

696. Fan W Yung B Huang P Chen X Nanotechnology for multimodal synergistic cancer therapy Chem. Rev. 2017 117 13566 13638 10.1021/acs.chemrev.7b00258 29048884 Fan, W., Yung, B., Huang, P. & Chen, X. Nanotechnology for multimodal synergistic cancer therapy. Chem. Rev. 117 , 13566–13638 (2017). 29048884 10.1021/acs.chemrev.7b00258

697. Modrek AS Bayin NS Placantonakis DG Brain stem cells as the cell of origin in glioma World J. Stem Cells 2014 6 43 52 10.4252/wjsc.v6.i1.43 24567787 PMC3927013 Modrek, A. S., Bayin, N. S. & Placantonakis, D. G. Brain stem cells as the cell of origin in glioma. World J. Stem Cells 6 , 43–52 (2014). 24567787 10.4252/wjsc.v6.i1.43 PMC3927013

698. Chen X Mechanosensitive brain tumor cells construct blood-tumor barrier to mask chemosensitivity Neuron 2023 111 30 48.e14 10.1016/j.neuron.2022.10.007 36323321 Chen, X. et al. Mechanosensitive brain tumor cells construct blood-tumor barrier to mask chemosensitivity. Neuron 111 , 30–48.e14 (2023). 36323321 10.1016/j.neuron.2022.10.007

699. Lu-Emerson C Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma J. Clin. Oncol. 2015 33 1197 1213 10.1200/JCO.2014.55.9575 25713439 PMC4517055 Lu-Emerson, C. et al. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J. Clin. Oncol. 33 , 1197–1213 (2015). 25713439 10.1200/JCO.2014.55.9575 PMC4517055

700. Venkatesh HS Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma Neuro-Oncology 2012 14 315 325 10.1093/neuonc/nor209 22156546 PMC3280799 Venkatesh, H. S. et al. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro-Oncology 14 , 315–325 (2012). 22156546 10.1093/neuonc/nor209 PMC3280799

701. Viswanathan A 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma Eur. J. Med. Chem. 2019 166 291 303 10.1016/j.ejmech.2019.01.021 30731398 Viswanathan, A. et al. 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma. Eur. J. Med. Chem. 166 , 291–303 (2019). 30731398 10.1016/j.ejmech.2019.01.021

702. Agarwal S Muniyandi P Maekawa T Kumar DS Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: a nanotechnological approach Int. J. Pharmaceut. 2018 551 339 361 10.1016/j.ijpharm.2018.09.033 30236647 Agarwal, S., Muniyandi, P., Maekawa, T. & Kumar, D. S. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: a nanotechnological approach. Int. J. Pharmaceut. 551 , 339–361 (2018). 10.1016/j.ijpharm.2018.09.033 30236647

703. Furnari FB Cloughesy TF Cavenee WK Mischel PS Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma Nat. Rev. Cancer 2015 15 302 310 10.1038/nrc3918 25855404 PMC4875778 Furnari, F. B., Cloughesy, T. F., Cavenee, W. K. & Mischel, P. S. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat. Rev. Cancer 15 , 302–310 (2015). 25855404 10.1038/nrc3918 PMC4875778

704. Nehra M Nanobiotechnology-assisted therapies to manage brain cancer in personalized manner J. Control. Release 2021 338 224 243 10.1016/j.jconrel.2021.08.027 34418523 Nehra, M. et al. Nanobiotechnology-assisted therapies to manage brain cancer in personalized manner. J. Control. Release 338 , 224–243 (2021). 34418523 10.1016/j.jconrel.2021.08.027

705. Daneman R Prat A The blood-brain barrier CSH Perspect. Biol. 2015 7 a020412 10.1101/cshperspect.a020412 PMC4292164 25561720 Daneman, R. & Prat, A. The blood-brain barrier. CSH Perspect. Biol. 7 , a020412 (2015). 10.1101/cshperspect.a020412 PMC4292164 25561720

706. Shergalis A Current challenges and opportunities in treating glioblastoma Pharmacol. Rev. 2018 70 412 445 10.1124/pr.117.014944 29669750 PMC5907910 Shergalis, A. et al. Current challenges and opportunities in treating glioblastoma. Pharmacol. Rev. 70 , 412–445 (2018). 29669750 10.1124/pr.117.014944 PMC5907910

707. van Tellingen O Overcoming the blood-brain tumor barrier for effective glioblastoma treatment Drug Resist. Update. 2015 19 1 12 10.1016/j.drup.2015.02.002 25791797 van Tellingen, O. et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist. Update. 19 , 1–12 (2015). 10.1016/j.drup.2015.02.002 25791797

708. Galea I The blood-brain barrier in systemic infection and inflammation Cell. Mol. Immunol. 2021 18 2489 2501 10.1038/s41423-021-00757-x 34594000 PMC8481764 Galea, I. The blood-brain barrier in systemic infection and inflammation. Cell. Mol. Immunol. 18 , 2489–2501 (2021). 34594000 10.1038/s41423-021-00757-x PMC8481764

709. Rathi S The influence of the blood-brain barrier in the treatment of brain tumours J. Intern Med. 2022 292 3 30 10.1111/joim.13440 35040235 Rathi, S. et al. The influence of the blood-brain barrier in the treatment of brain tumours. J. Intern Med. 292 , 3–30 (2022). 35040235 10.1111/joim.13440

710. Terstappen GC Meyer AH Bell RD Zhang W Strategies for delivering therapeutics across the blood-brain barrier Nat. Rev. Drug Discov. 2021 20 362 383 10.1038/s41573-021-00139-y 33649582 Terstappen, G. C., Meyer, A. H., Bell, R. D. & Zhang, W. Strategies for delivering therapeutics across the blood-brain barrier. Nat. Rev. Drug Discov. 20 , 362–383 (2021). 33649582 10.1038/s41573-021-00139-y

711. Golombek SK Tumor targeting via EPR: strategies to enhance patient responses Adv. Drug Deliver. Rev. 2018 130 17 38 10.1016/j.addr.2018.07.007 PMC6130746 30009886 Golombek, S. K. et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv. Drug Deliver. Rev. 130 , 17–38 (2018). 10.1016/j.addr.2018.07.007 PMC6130746 30009886

712. Deeken JF Loscher W The blood-brain barrier and cancer: transporters, treatment, and Trojan horses Clin. Cancer Res. 2007 13 1663 1674 10.1158/1078-0432.CCR-06-2854 17363519 Deeken, J. F. & Loscher, W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13 , 1663–1674 (2007). 17363519 10.1158/1078-0432.CCR-06-2854

713. Han L Jiang C Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies Acta Pharm. Sin. B 2021 11 2306 2325 10.1016/j.apsb.2020.11.023 34522589 PMC8424230 Han, L. & Jiang, C. Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies. Acta Pharm. Sin. B 11 , 2306–2325 (2021). 34522589 10.1016/j.apsb.2020.11.023 PMC8424230

714. Robey RW Revisiting the role of ABC transporters in multidrug-resistant cancer Nat. Rev. Cancer 2018 18 452 464 10.1038/s41568-018-0005-8 29643473 PMC6622180 Robey, R. W. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 18 , 452–464 (2018). 29643473 10.1038/s41568-018-0005-8 PMC6622180

715. Arvanitis CD Ferraro GB Jain RK The blood-brain barrier and blood-tumour barrier in brain tumours and metastases Nat. Rev. Cancer 2020 20 26 41 10.1038/s41568-019-0205-x 31601988 PMC8246629 Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20 , 26–41 (2020). 31601988 10.1038/s41568-019-0205-x PMC8246629

716. Wolf KJ Dissecting and rebuilding the glioblastoma microenvironment with engineered materials Nat. Rev. Mater. 2019 4 651 668 10.1038/s41578-019-0135-y 32647587 PMC7347297 Wolf, K. J. et al. Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. Nat. Rev. Mater. 4 , 651–668 (2019). 32647587 10.1038/s41578-019-0135-y PMC7347297

717. Yi Y Glioblastoma stem-like cells: characteristics, microenvironment, and therapy Front. Pharmacol. 2016 7 477 10.3389/fphar.2016.00477 28003805 PMC5141588 Yi, Y. et al. Glioblastoma stem-like cells: characteristics, microenvironment, and therapy. Front. Pharmacol. 7 , 477 (2016). 28003805 10.3389/fphar.2016.00477 PMC5141588

718. Rape A Ananthanarayanan B Kumar S Engineering strategies to mimic the glioblastoma microenvironment Adv. Drug Deliver. Rev. 2014 79-80 172 183 10.1016/j.addr.2014.08.012 PMC4258440 25174308 Rape, A., Ananthanarayanan, B. & Kumar, S. Engineering strategies to mimic the glioblastoma microenvironment. Adv. Drug Deliver. Rev. 79-80 , 172–183 (2014). 10.1016/j.addr.2014.08.012 PMC4258440 25174308

719. Bikfalvi A Challenges in glioblastoma research: focus on the tumor microenvironment Trends Cancer 2023 9 9 27 10.1016/j.trecan.2022.09.005 36400694 Bikfalvi, A. et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends Cancer 9 , 9–27 (2023). 36997420 10.1016/j.trecan.2022.09.005

720. Qiu Q Nanobiotechnology-based treatment strategies for malignant relapsed glioma J. Control. Release 2023 358 681 705 10.1016/j.jconrel.2023.05.016 37196900 Qiu, Q. et al. Nanobiotechnology-based treatment strategies for malignant relapsed glioma. J. Control. Release 358 , 681–705 (2023). 37196900 10.1016/j.jconrel.2023.05.016

721. Poon CC Sarkar S Yong VW Kelly JJP Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis Brain 2017 140 1548 1560 10.1093/brain/aww355 28334886 Poon, C. C., Sarkar, S., Yong, V. W. & Kelly, J. J. P. Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. Brain 140 , 1548–1560 (2017). 28334886 10.1093/brain/aww355

722. Quail DF Joyce JA The microenvironmental landscape of brain tumors Cancer Cell 2017 31 326 341 10.1016/j.ccell.2017.02.009 28292436 PMC5424263 Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31 , 326–341 (2017). 28292436 10.1016/j.ccell.2017.02.009 PMC5424263

723. Haas L Obenauf AC Allies or enemies-the multifaceted role of myeloid cells in the tumor microenvironment Front. Immunol. 2019 10 2746 10.3389/fimmu.2019.02746 31849950 PMC6892746 Haas, L. & Obenauf, A. C. Allies or enemies-the multifaceted role of myeloid cells in the tumor microenvironment. Front. Immunol. 10 , 2746 (2019). 31849950 10.3389/fimmu.2019.02746 PMC6892746

724. Kiss M Myeloid cell heterogeneity in cancer: not a single cell alike Cell. Immunol. 2018 330 188 201 10.1016/j.cellimm.2018.02.008 29482836 Kiss, M. et al. Myeloid cell heterogeneity in cancer: not a single cell alike. Cell. Immunol. 330 , 188–201 (2018). 29482836 10.1016/j.cellimm.2018.02.008

725. Poh AR Ernst M Targeting macrophages in cancer: from bench to bedside Front. Oncol. 2018 8 49 10.3389/fonc.2018.00049 29594035 PMC5858529 Poh, A. R. & Ernst, M. Targeting macrophages in cancer: from bench to bedside. Front. Oncol. 8 , 49 (2018). 29594035 10.3389/fonc.2018.00049 PMC5858529

726. Strepkos D Insights in the immunobiology of glioblastoma J. Mol. Med. 2020 98 1 10 10.1007/s00109-019-01835-4 31650201 Strepkos, D. et al. Insights in the immunobiology of glioblastoma. J. Mol. Med. 98 , 1–10 (2020). 31650201 10.1007/s00109-019-01835-4

727. Matias D Microglia/astrocytes-glioblastoma crosstalk: crucial molecular mechanisms and microenvironmental factors Front. Cell. Neurosci. 2018 12 235 10.3389/fncel.2018.00235 30123112 PMC6086063 Matias, D. et al. Microglia/astrocytes-glioblastoma crosstalk: crucial molecular mechanisms and microenvironmental factors. Front. Cell. Neurosci. 12 , 235 (2018). 30123112 10.3389/fncel.2018.00235 PMC6086063

728. Platten M Bunse L Wick W Bunse T Concepts in glioma immunotherapy Cancer Immunol. Immun. 2016 65 1269 1275 10.1007/s00262-016-1874-x PMC11029493 27460064 Platten, M., Bunse, L., Wick, W. & Bunse, T. Concepts in glioma immunotherapy. Cancer Immunol. Immun. 65 , 1269–1275 (2016). 10.1007/s00262-016-1874-x PMC11029493 27460064

729. Bai Y Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy Int. J. Pharmaceut. 2019 570 118636 10.1016/j.ijpharm.2019.118636 31446027 Bai, Y. et al. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy. Int. J. Pharmaceut. 570 , 118636 (2019). 10.1016/j.ijpharm.2019.118636 31446027

730. Tang W Correction to acidity/reducibility dual-responsive hollow mesoporous organosilica nanoplatforms for tumor-specific self-assembly and synergistic therapy ACS Nano 2019 13 6125 10.1021/acsnano.9b03387 31082190 Tang, W. et al. Correction to acidity/reducibility dual-responsive hollow mesoporous organosilica nanoplatforms for tumor-specific self-assembly and synergistic therapy. ACS Nano 13 , 6125 (2019). 31082190 10.1021/acsnano.9b03387

731. Xie J Nanomaterial-based blood-brain-barrier (BBB) crossing strategies Biomaterials 2019 224 119491 10.1016/j.biomaterials.2019.119491 31546096 PMC6915305 Xie, J. et al. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials 224 , 119491 (2019). 31546096 10.1016/j.biomaterials.2019.119491 PMC6915305

732. Sethi B Recent advances in drug delivery and targeting to the brain J. Control. Release 2022 350 668 687 10.1016/j.jconrel.2022.08.051 36057395 PMC9884093 Sethi, B. et al. Recent advances in drug delivery and targeting to the brain. J. Control. Release 350 , 668–687 (2022). 36057395 10.1016/j.jconrel.2022.08.051 PMC9884093

733. Akhter MH Molecular targets and nanoparticulate systems designed for the improved therapeutic intervention in glioblastoma multiforme Drug Res 2021 71 122 137 10.1055/a-1296-7870 33167048 Akhter, M. H. et al. Molecular targets and nanoparticulate systems designed for the improved therapeutic intervention in glioblastoma multiforme. Drug Res 71 , 122–137 (2021). 10.1055/a-1296-7870 33167048

734. Lundy DJ Inducing a transient increase in blood-brain barrier permeability for improved liposomal drug therapy of glioblastoma multiforme ACS Nano 2019 13 97 113 10.1021/acsnano.8b03785 30532951 Lundy, D. J. et al. Inducing a transient increase in blood-brain barrier permeability for improved liposomal drug therapy of glioblastoma multiforme. ACS Nano 13 , 97–113 (2019). 30532951 10.1021/acsnano.8b03785

735. Ssenyonga N Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries Lancet Child Adolesc 2022 6 409 431 10.1016/S2352-4642(22)00095-5 35468327 Ssenyonga, N. et al. Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. Lancet Child Adolesc 6 , 409–431 (2022). 10.1016/S2352-4642(22)00095-5 35468327

736. Deshantri AK Nanomedicines for the treatment of hematological malignancies J. Control. Release 2018 287 194 215 10.1016/j.jconrel.2018.08.034 30165140 Deshantri, A. K. et al. Nanomedicines for the treatment of hematological malignancies. J. Control. Release 287 , 194–215 (2018). 30165140 10.1016/j.jconrel.2018.08.034

737. Gu W Polymeric nanomedicines targeting hematological malignancies J. Control. Release 2021 337 571 588 10.1016/j.jconrel.2021.08.001 34364920 Gu, W. et al. Polymeric nanomedicines targeting hematological malignancies. J. Control. Release 337 , 571–588 (2021). 34364920 10.1016/j.jconrel.2021.08.001

738. Li J Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies J. Hematol. Oncol. 2023 16 65 10.1186/s13045-023-01460-2 37353849 PMC10290401 Li, J. et al. Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies. J. Hematol. Oncol. 16 , 65 (2023). 37353849 10.1186/s13045-023-01460-2 PMC10290401

739. Belov L Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples J. Extracell. Vesicles 2016 5 25355 10.3402/jev.v5.25355 27086589 PMC4834364 Belov, L. et al. Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. J. Extracell. Vesicles 5 , 25355 (2016). 27086589 10.3402/jev.v5.25355 PMC4834364

740. Huang L A dual-signal amplification platform for sensitive fluorescence biosensing of leukemia-derived exosomes Nanoscale 2018 10 20289 20295 10.1039/C8NR07720G 30371719 Huang, L. et al. A dual-signal amplification platform for sensitive fluorescence biosensing of leukemia-derived exosomes. Nanoscale 10 , 20289–20295 (2018). 30371719 10.1039/C8NR07720G

741. Ensafi AA Amini M Rezaei B Talebi M A novel diagnostic biosensor for distinguishing immunoglobulin mutated and unmutated types of chronic lymphocytic leukemia Biosens. Bioelectron. 2016 77 409 415 10.1016/j.bios.2015.09.063 26436328 Ensafi, A. A., Amini, M., Rezaei, B. & Talebi, M. A novel diagnostic biosensor for distinguishing immunoglobulin mutated and unmutated types of chronic lymphocytic leukemia. Biosens. Bioelectron. 77 , 409–415 (2016). 26436328 10.1016/j.bios.2015.09.063

742. Wen S Plasmonic Au nanostar Raman probes coupling with highly ordered TiO2/Au nanotube arrays as the reliable SERS sensing platform for chronic myeloid leukemia drug evaluation Biosens. Bioelectron. 2018 117 260 266 10.1016/j.bios.2018.06.001 29909197 Wen, S. et al. Plasmonic Au nanostar Raman probes coupling with highly ordered TiO2/Au nanotube arrays as the reliable SERS sensing platform for chronic myeloid leukemia drug evaluation. Biosens. Bioelectron. 117 , 260–266 (2018). 29909197 10.1016/j.bios.2018.06.001

743. Silberstein J Tuchman S Grant SJ What is multiple myeloma? JAMA 2022 327 497 10.1001/jama.2021.25306 35103765 Silberstein, J., Tuchman, S. & Grant, S. J. What is multiple myeloma? JAMA 327 , 497 (2022). 35103765 10.1001/jama.2021.25306

744. Brigle K Rogers B Pathobiology and diagnosis of multiple myeloma Semin. Oncol. Nurs. 2017 33 225 236 10.1016/j.soncn.2017.05.012 28688533 Brigle, K. & Rogers, B. Pathobiology and diagnosis of multiple myeloma. Semin. Oncol. Nurs. 33 , 225–236 (2017). 28688533 10.1016/j.soncn.2017.05.012

745. Cowan AJ Diagnosis and management of multiple myeloma: a review JAMA 2022 327 464 477 10.1001/jama.2022.0003 35103762 Cowan, A. J. et al. Diagnosis and management of multiple myeloma: a review. JAMA 327 , 464–477 (2022). 35103762 10.1001/jama.2022.0003

746. Detappe A Bustoros M Mouhieddine TH Ghoroghchian PP Advancements in nanomedicine for multiple myeloma Trends Mol. Med. 2018 24 560 574 10.1016/j.molmed.2018.04.005 29773319 Detappe, A., Bustoros, M., Mouhieddine, T. H. & Ghoroghchian, P. P. Advancements in nanomedicine for multiple myeloma. Trends Mol. Med. 24 , 560–574 (2018). 29773319 10.1016/j.molmed.2018.04.005

747. Detappe A Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma Nanoscale 2019 11 20485 20496 10.1039/C9NR06512A 31650133 Detappe, A. et al. Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma. Nanoscale 11 , 20485–20496 (2019). 31650133 10.1039/C9NR06512A

748. Dutta R Real-time detection of circulating tumor cells in living animals using functionalized large gold nanorods Nano Lett 2019 19 2334 2342 10.1021/acs.nanolett.8b05005 30895796 Dutta, R. et al. Real-time detection of circulating tumor cells in living animals using functionalized large gold nanorods. Nano Lett 19 , 2334–2342 (2019). 30895796 10.1021/acs.nanolett.8b05005

749. Long S Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma Talanta 2019 200 288 292 10.1016/j.talanta.2019.03.067 31036186 Long, S. et al. Nanoporous silica coupled MALDI-TOF MS detection of Bence-Jones proteins in human urine for diagnosis of multiple myeloma. Talanta 200 , 288–292 (2019). 31036186 10.1016/j.talanta.2019.03.067

750. Di Noto G Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling of multiple myeloma-derived exosomes Biosens. Bioelectron. 2016 77 518 524 10.1016/j.bios.2015.09.061 26469728 Di Noto, G. et al. Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling of multiple myeloma-derived exosomes. Biosens. Bioelectron. 77 , 518–524 (2016). 26469728 10.1016/j.bios.2015.09.061

751. Iaccino E Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes Mol. Cancer 2017 16 159 10.1186/s12943-017-0730-8 29029605 PMC5640902 Iaccino, E. et al. Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes. Mol. Cancer 16 , 159 (2017). 29029605 10.1186/s12943-017-0730-8 PMC5640902

752. Tang R Osteotropic radiolabeled nanophotosensitizer for imaging and treating multiple myeloma ACS Nano 2020 14 4255 4264 10.1021/acsnano.9b09618 32223222 PMC7295119 Tang, R. et al. Osteotropic radiolabeled nanophotosensitizer for imaging and treating multiple myeloma. ACS Nano 14 , 4255–4264 (2020). 32223222 10.1021/acsnano.9b09618 PMC7295119

753. Tatar AS Nanomedicine approaches in acute lymphoblastic leukemia J. Control. Release 2016 238 123 138 10.1016/j.jconrel.2016.07.035 27460684 Tatar, A. S. et al. Nanomedicine approaches in acute lymphoblastic leukemia. J. Control. Release 238 , 123–138 (2016). 27460684 10.1016/j.jconrel.2016.07.035

754. Armitage JO Gascoyne RD Lunning MA Cavalli F Non-Hodgkin lymphoma Lancet 2017 390 298 310 10.1016/S0140-6736(16)32407-2 28153383 Armitage, J. O., Gascoyne, R. D., Lunning, M. A. & Cavalli, F. Non-Hodgkin lymphoma. Lancet 390 , 298–310 (2017). 28153383 10.1016/S0140-6736(16)32407-2

755. Wildes TM Stirewalt DL Medeiros B Hurria A Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic J. Natl. Compr. Canc. Ne. 2014 12 128 136 10.6004/jnccn.2014.0010 PMC4010196 24453296 Wildes, T. M., Stirewalt, D. L., Medeiros, B. & Hurria, A. Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. J. Natl. Compr. Canc. Ne. 12 , 128–136 (2014). 10.6004/jnccn.2014.0010 PMC4010196 24453296

756. Lumish M How we treat mature B-cell neoplasms (indolent B-cell lymphomas) J. Hematol. Oncol. 2021 14 5 10.1186/s13045-020-01018-6 33407745 PMC7789477 Lumish, M. et al. How we treat mature B-cell neoplasms (indolent B-cell lymphomas). J. Hematol. Oncol. 14 , 5 (2021). 33407745 10.1186/s13045-020-01018-6 PMC7789477

757. Xie Y CAR-T cells for cancer immunotherapy Chinese Chem. Lett. 2023 34 108202 10.1016/j.cclet.2023.108202 Xie, Y. et al. CAR-T cells for cancer immunotherapy. Chinese Chem. Lett. 34 , 108202 (2023). 10.1016/j.cclet.2023.108202

758. Pallares V An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination J. Hematol. Oncol. 2020 13 36 10.1186/s13045-020-00863-9 32295630 PMC7160905 Pallares, V. et al. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. J. Hematol. Oncol. 13 , 36 (2020). 32295630 10.1186/s13045-020-00863-9 PMC7160905

759. Peng Y Smart human-serum-albumin-As 2 O 3 nanodrug with self-amplified folate receptor-targeting ability for chronic myeloid leukemia treatment Angew. Chem. Int. Edit. 2017 56 10845 10849 10.1002/anie.201701366 PMC5912668 28686804 Peng, Y. et al. Smart human-serum-albumin-As 2 O 3 nanodrug with self-amplified folate receptor-targeting ability for chronic myeloid leukemia treatment. Angew. Chem. Int. Edit. 56 , 10845–10849 (2017). 10.1002/anie.201701366 PMC5912668 28686804

760. Yasinska IM Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates Nanoscale 2018 10 5827 5833 10.1039/C7NR09436A 29538473 Yasinska, I. M. et al. Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates. Nanoscale 10 , 5827–5833 (2018). 29538473 10.1039/C7NR09436A

761. Lei Y DNA nanotriangle-scaffolded activatable aptamer probe with ultralow background and robust stability for cancer theranostics Theranostics 2018 8 4062 4071 10.7150/thno.24683 30128036 PMC6096399 Lei, Y. et al. DNA nanotriangle-scaffolded activatable aptamer probe with ultralow background and robust stability for cancer theranostics. Theranostics 8 , 4062–4071 (2018). 30128036 10.7150/thno.24683 PMC6096399

762. Bellavia D Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth Theranostics 2017 7 1333 1345 10.7150/thno.17092 28435469 PMC5399597 Bellavia, D. et al. Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth. Theranostics 7 , 1333–1345 (2017). 28435469 10.7150/thno.17092 PMC5399597

763. Halley PD Daunorubicin-loaded DNA origami nanostructures circumvent drug-resistance mechanisms in a leukemia model Small 2016 12 308 320 10.1002/smll.201502118 26583570 PMC4879968 Halley, P. D. et al. Daunorubicin-loaded DNA origami nanostructures circumvent drug-resistance mechanisms in a leukemia model. Small 12 , 308–320 (2016). 26583570 10.1002/smll.201502118 PMC4879968

764. Zong S Black phosphorus-based drug nanocarrier for targeted and synergetic chemophotothermal therapy of acute lymphoblastic leukemia ACS Appl. Mater. Inter. 2019 11 5896 5902 10.1021/acsami.8b22563 30668091 Zong, S. et al. Black phosphorus-based drug nanocarrier for targeted and synergetic chemophotothermal therapy of acute lymphoblastic leukemia. ACS Appl. Mater. Inter. 11 , 5896–5902 (2019). 10.1021/acsami.8b22563 30668091

765. Boto C Prolonged intracellular accumulation of light-inducible nanoparticles in leukemia cells allows their remote activation Nat. Commun. 2017 8 15204 10.1038/ncomms15204 28492285 PMC5437273 Boto, C. et al. Prolonged intracellular accumulation of light-inducible nanoparticles in leukemia cells allows their remote activation. Nat. Commun. 8 , 15204 (2017). 28492285 10.1038/ncomms15204 PMC5437273

766. Xiong F Superparamagnetic anisotropic nano-assemblies with longer blood circulation in vivo: a highly efficient drug delivery carrier for leukemia therapy Nanoscale 2016 8 17085 17089 10.1039/C6NR05781K 27714144 Xiong, F. et al. Superparamagnetic anisotropic nano-assemblies with longer blood circulation in vivo: a highly efficient drug delivery carrier for leukemia therapy. Nanoscale 8 , 17085–17089 (2016). 27714144 10.1039/C6NR05781K

767. Zhao Q Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma J. Nanobiotechnol. 2021 19 179 10.1186/s12951-021-00922-4 PMC8201715 34120620 Zhao, Q. et al. Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma. J. Nanobiotechnol. 19 , 179 (2021). 10.1186/s12951-021-00922-4 PMC8201715 34120620

768. Liu C Tang C Yin C Co-delivery of doxorubicin and siRNA by all-trans retinoic acid conjugated chitosan-based nanocarriers for multiple synergistic antitumor efficacy Carbohyd. Polym. 2022 283 119097 10.1016/j.carbpol.2022.119097 35153031 Liu, C., Tang, C. & Yin, C. Co-delivery of doxorubicin and siRNA by all-trans retinoic acid conjugated chitosan-based nanocarriers for multiple synergistic antitumor efficacy. Carbohyd. Polym. 283 , 119097 (2022). 10.1016/j.carbpol.2022.119097 35153031

769. Srivastava P Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles J. Mater. Chem. B 2020 8 1411 1421 10.1039/C9TB02628B 31974541 Srivastava, P. et al. Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles. J. Mater. Chem. B 8 , 1411–1421 (2020). 31974541 10.1039/C9TB02628B

770. Zhao N Zeng Z Zu Y Self-assembled aptamer-nanomedicine for targeted chemotherapy and gene therapy Small 2018 14 1702103 10.1002/smll.201702103 PMC5857619 29205808 Zhao, N., Zeng, Z. & Zu, Y. Self-assembled aptamer-nanomedicine for targeted chemotherapy and gene therapy. Small 14 , 1702103 (2018). 10.1002/smll.201702103 PMC5857619 29205808

771. Goswami U Transferrin-copper nanocluster-doxorubicin nanoparticles as targeted theranostic cancer nanodrug ACS Appl. Mater. Inter. 2018 10 3282 3294 10.1021/acsami.7b15165 29278317 Goswami, U. et al. Transferrin-copper nanocluster-doxorubicin nanoparticles as targeted theranostic cancer nanodrug. ACS Appl. Mater. Inter. 10 , 3282–3294 (2018). 10.1021/acsami.7b15165 29278317

772. Srivastava P ATP-decorated mesoporous silica for biomineralization of calcium carbonate and P2 purinergic receptor-mediated antitumor activity against aggressive lymphoma ACS Appl. Mater. Inter. 2018 10 6917 6929 10.1021/acsami.7b18729 29392934 Srivastava, P. et al. ATP-decorated mesoporous silica for biomineralization of calcium carbonate and P2 purinergic receptor-mediated antitumor activity against aggressive lymphoma. ACS Appl. Mater. Inter. 10 , 6917–6929 (2018). 10.1021/acsami.7b18729 29392934

773. Xiao K Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma Nanoscale 2018 10 8207 8216 10.1039/C8NR00680F 29682647 PMC5980239 Xiao, K. et al. Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma. Nanoscale 10 , 8207–8216 (2018). 29682647 10.1039/C8NR00680F PMC5980239

774. Guo D Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: high loading capacity, increased stability, and improved anticancer efficacy Biomaterials 2017 141 161 175 10.1016/j.biomaterials.2017.06.041 28688287 PMC5557385 Guo, D. et al. Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: high loading capacity, increased stability, and improved anticancer efficacy. Biomaterials 141 , 161–175 (2017). 28688287 10.1016/j.biomaterials.2017.06.041 PMC5557385

775. Sedlacek, O. et al. Poly(2-ethyl-2-oxazoline) conjugates with doxorubicin for cancer therapy: In vitro and in vivo evaluation and direct comparison to poly[N-(2-hydroxypropyl)methacrylamide] analogues. Biomaterials 146 , 1–12 (2017). 10.1016/j.biomaterials.2017.09.003 28892751

776. Au KM High-performance concurrent chemo-immuno-radiotherapy for the treatment of hematologic cancer through selective high-affinity ligand antibody mimic-functionalized doxorubicin-encapsulated nanoparticles ACS Central Sci 2019 5 122 144 10.1021/acscentsci.8b00746 PMC6346391 30693332 Au, K. M. et al. High-performance concurrent chemo-immuno-radiotherapy for the treatment of hematologic cancer through selective high-affinity ligand antibody mimic-functionalized doxorubicin-encapsulated nanoparticles. ACS Central Sci 5 , 122–144 (2019). 10.1021/acscentsci.8b00746 PMC6346391 30693332

777. Nigro A Bortezomib-loaded mesoporous silica nanoparticles selectively alter metabolism and induce death in multiple myeloma cells Cancers 2020 12 2709 10.3390/cancers12092709 32967380 PMC7565423 Nigro, A. et al. Bortezomib-loaded mesoporous silica nanoparticles selectively alter metabolism and induce death in multiple myeloma cells. Cancers 12 , 2709 (2020). 32967380 10.3390/cancers12092709 PMC7565423

778. Lee ALZ Injectable coacervate hydrogel for delivery of anticancer drug-loaded nanoparticles in vivo ACS Appl. Mater. Inter. 2018 10 13274 13282 10.1021/acsami.7b14319 29595244 Lee, A. L. Z. et al. Injectable coacervate hydrogel for delivery of anticancer drug-loaded nanoparticles in vivo. ACS Appl. Mater. Inter. 10 , 13274–13282 (2018). 10.1021/acsami.7b14319 29595244

779. de la Puente P Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma J. Control. Release 2018 270 158 176 10.1016/j.jconrel.2017.11.045 29196043 PMC6056271 de la Puente, P. et al. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. J. Control. Release 270 , 158–176 (2018). 29196043 10.1016/j.jconrel.2017.11.045 PMC6056271

780. Hu Q Engineered nanoplatelets for enhanced treatment of multiple myeloma and thrombus Adv. Mater. 2016 28 9573 9580 10.1002/adma.201603463 27626769 PMC5283718 Hu, Q. et al. Engineered nanoplatelets for enhanced treatment of multiple myeloma and thrombus. Adv. Mater. 28 , 9573–9580 (2016). 27626769 10.1002/adma.201603463 PMC5283718

781. Swami A Engineered nanomedicine for myeloma and bone microenvironment targeting Proc. Natl. Acad. Sci. USA 2014 111 10287 10292 10.1073/pnas.1401337111 24982170 PMC4104924 Swami, A. et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc. Natl. Acad. Sci. USA 111 , 10287–10292 (2014). 24982170 10.1073/pnas.1401337111 PMC4104924

782. Ashley JD Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo J. Control. Release 2014 196 113 121 10.1016/j.jconrel.2014.10.005 25312543 Ashley, J. D. et al. Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. J. Control. Release 196 , 113–121 (2014). 25312543 10.1016/j.jconrel.2014.10.005

783. Ashley JD Dual carfilzomib and doxorubicin-loaded liposomal nanoparticles for synergistic efficacy in multiple myeloma Mol. Cancer Ther. 2016 15 1452 1459 10.1158/1535-7163.MCT-15-0867 27196779 Ashley, J. D. et al. Dual carfilzomib and doxorubicin-loaded liposomal nanoparticles for synergistic efficacy in multiple myeloma. Mol. Cancer Ther. 15 , 1452–1459 (2016). 27196779 10.1158/1535-7163.MCT-15-0867

784. Wang M Zhao J Jiang H Wang X Tumor-targeted nano-delivery system of therapeutic RNA Mater. Horiz. 2022 9 1111 1140 10.1039/D1MH01969D 35134106 Wang, M., Zhao, J., Jiang, H. & Wang, X. Tumor-targeted nano-delivery system of therapeutic RNA. Mater. Horiz. 9 , 1111–1140 (2022). 35134106 10.1039/D1MH01969D

785. Liu Y Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy Biomater. Sci.-UK 2018 6 1592 1603 10.1039/C8BM00263K 29725684 Liu, Y. et al. Systemic delivery of CRISPR/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy. Biomater. Sci.-UK 6 , 1592–1603 (2018). 10.1039/C8BM00263K 29725684

786. Hong CA Viral/nonviral chimeric nanoparticles to synergistically suppress leukemia proliferation via simultaneous gene transduction and silencing ACS Nano 2016 10 8705 8714 10.1021/acsnano.6b04155 27472284 PMC5602606 Hong, C. A. et al. Viral/nonviral chimeric nanoparticles to synergistically suppress leukemia proliferation via simultaneous gene transduction and silencing. ACS Nano 10 , 8705–8714 (2016). 27472284 10.1021/acsnano.6b04155 PMC5602606

787. Vinhas R Fernandes AR Baptista PV Gold nanoparticles for BCR-ABL1 gene silencing: improving tyrosine kinase inhibitor efficacy in chronic myeloid leukemia Mol. Ther.-Nucl. Acids 2017 7 408 416 10.1016/j.omtn.2017.05.003 PMC5436101 28624216 Vinhas, R., Fernandes, A. R. & Baptista, P. V. Gold nanoparticles for BCR-ABL1 gene silencing: improving tyrosine kinase inhibitor efficacy in chronic myeloid leukemia. Mol. Ther.-Nucl. Acids 7 , 408–416 (2017). 10.1016/j.omtn.2017.05.003 PMC5436101 28624216

788. Smith TT In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers Nat. Nanotechnol. 2017 12 813 820 10.1038/nnano.2017.57 28416815 PMC5646367 Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12 , 813–820 (2017). 28416815 10.1038/nnano.2017.57 PMC5646367

789. Billingsley MM Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering Nano Lett 2020 20 1578 1589 10.1021/acs.nanolett.9b04246 31951421 PMC7313236 Billingsley, M. M. et al. Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett 20 , 1578–1589 (2020). 31951421 10.1021/acs.nanolett.9b04246 PMC7313236

790. Kedmi R A modular platform for targeted RNAi therapeutics Nat. Nanotechnol. 2018 13 214 219 10.1038/s41565-017-0043-5 29379205 Kedmi, R. et al. A modular platform for targeted RNAi therapeutics. Nat. Nanotechnol. 13 , 214–219 (2018). 29379205 10.1038/s41565-017-0043-5

791. Knapp CM He J Lister J Whitehead KA Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma Bioeng. Transl. Med. 2018 3 138 147 10.1002/btm2.10088 30065968 PMC6063866 Knapp, C. M., He, J., Lister, J. & Whitehead, K. A. Lipid nanoparticle siRNA cocktails for the treatment of mantle cell lymphoma. Bioeng. Transl. Med. 3 , 138–147 (2018). 30065968 10.1002/btm2.10088 PMC6063866

792. Fenton OS Synthesis and biological evaluation of Ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes Adv. Mater. 2017 29 1606944 10.1002/adma.201606944 28681930 Fenton, O. S. et al. Synthesis and biological evaluation of Ionizable lipid materials for the in vivo delivery of messenger RNA to B lymphocytes. Adv. Mater. 29 , 1606944 (2017). 10.1002/adma.201606944 28681930

793. Zilkowski I Nanogels enable efficient miRNA delivery and target gene downregulation in transfection-resistant multiple myeloma cells Biomacromolecules 2019 20 916 926 10.1021/acs.biomac.8b01553 30571914 Zilkowski, I. et al. Nanogels enable efficient miRNA delivery and target gene downregulation in transfection-resistant multiple myeloma cells. Biomacromolecules 20 , 916–926 (2019). 30571914 10.1021/acs.biomac.8b01553

794. Park M Anti-FLT3 nanoparticles for acute myeloid leukemia: preclinical pharmacology and pharmacokinetics J. Control. Release 2020 324 317 329 10.1016/j.jconrel.2020.05.021 32428520 PMC7473778 Park, M. et al. Anti-FLT3 nanoparticles for acute myeloid leukemia: preclinical pharmacology and pharmacokinetics. J. Control. Release 324 , 317–329 (2020). 32428520 10.1016/j.jconrel.2020.05.021 PMC7473778

795. Jiang X Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles Cancer Res 2016 76 4470 4480 10.1158/0008-5472.CAN-15-2949 27280396 PMC4970973 Jiang, X. et al. Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res 76 , 4470–4480 (2016). 27280396 10.1158/0008-5472.CAN-15-2949 PMC4970973

796. Niu F Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy Biomaterials 2018 167 132 142 10.1016/j.biomaterials.2018.03.025 29571049 PMC5889738 Niu, F. et al. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy. Biomaterials 167 , 132–142 (2018). 29571049 10.1016/j.biomaterials.2018.03.025 PMC5889738

797. Choi KY Binary targeting of siRNA to hematologic cancer cells in vivo using layer-by-layer nanoparticles Adv. Funct. Mater. 2019 29 1900018 10.1002/adfm.201900018 31839764 PMC6910249 Choi, K. Y. et al. Binary targeting of siRNA to hematologic cancer cells in vivo using layer-by-layer nanoparticles. Adv. Funct. Mater. 29 , 1900018 (2019). 31839764 10.1002/adfm.201900018 PMC6910249

798. Dorrance AM Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia Leukemia 2015 29 2143 2153 10.1038/leu.2015.139 26055302 PMC4633325 Dorrance, A. M. et al. Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia 29 , 2143–2153 (2015). 26055302 10.1038/leu.2015.139 PMC4633325

799. Zong H In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche Leukemia 2016 30 1582 1586 10.1038/leu.2015.343 26669973 PMC4911325 Zong, H. et al. In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche. Leukemia 30 , 1582–1586 (2016). 26669973 10.1038/leu.2015.343 PMC4911325

800. Zhao Q Smart biomimetic nanocomposites mediate mitochondrial outcome through aerobic glycolysis reprogramming: a promising treatment for lymphoma ACS Appl. Mater. Inter. 2020 12 22687 22701 10.1021/acsami.0c05763 32330381 Zhao, Q. et al. Smart biomimetic nanocomposites mediate mitochondrial outcome through aerobic glycolysis reprogramming: a promising treatment for lymphoma. ACS Appl. Mater. Inter. 12 , 22687–22701 (2020). 10.1021/acsami.0c05763 32330381

801. Au KM Wang AZ Park SI Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin’s lymphoma Sci. Adv. 2020 6 eaaz9798 10.1126/sciadv.aaz9798 32270047 PMC7112753 Au, K. M., Wang, A. Z. & Park, S. I. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin’s lymphoma. Sci. Adv. 6 , eaaz9798 (2020). 32270047 10.1126/sciadv.aaz9798 PMC7112753

802. Huang YH Decoration of anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma Cancers 2019 11 248 10.3390/cancers11020248 30791634 PMC6407065 Huang, Y. H. et al. Decoration of anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma. Cancers 11 , 248 (2019). 30791634 10.3390/cancers11020248 PMC6407065

803. Irvine DJ Dane EL Enhancing cancer immunotherapy with nanomedicine Nat. Rev. Immunol. 2020 20 321 334 10.1038/s41577-019-0269-6 32005979 PMC7536618 Irvine, D. J. & Dane, E. L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 20 , 321–334 (2020). 32005979 10.1038/s41577-019-0269-6 PMC7536618

804. Zhang Y Chen J Shi L Ma F Polymeric nanoparticle-based nanovaccines for cancer immunotherapy Mater. Horiz. 2023 10 361 392 10.1039/D2MH01358D 36541078 Zhang, Y., Chen, J., Shi, L. & Ma, F. Polymeric nanoparticle-based nanovaccines for cancer immunotherapy. Mater. Horiz. 10 , 361–392 (2023). 36541078 10.1039/D2MH01358D

805. Johnson DT Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy Leukemia 2022 36 994 1005 10.1038/s41375-021-01432-w 34845316 PMC8979812 Johnson, D. T. et al. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia 36 , 994–1005 (2022). 34845316 10.1038/s41375-021-01432-w PMC8979812

806. Alhallak K Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy Leukemia 2021 35 2346 2357 10.1038/s41375-021-01127-2 33479469 PMC8292428 Alhallak, K. et al. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia 35 , 2346–2357 (2021). 33479469 10.1038/s41375-021-01127-2 PMC8292428

807. Verbeke R Broadening the message: a nanovaccine co-loaded with messenger RNA and alpha-GalCer induces antitumor immunity through conventional and natural killer T cells ACS Nano 2019 13 1655 1669 30742405 10.1021/acsnano.8b07660 Verbeke, R. et al. Broadening the message: a nanovaccine co-loaded with messenger RNA and alpha-GalCer induces antitumor immunity through conventional and natural killer T cells. ACS Nano 13 , 1655–1669 (2019). 30742405 10.1021/acsnano.8b07660

808. Da Silva CG Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines Biomaterials 2019 220 119417 10.1016/j.biomaterials.2019.119417 31419588 Da Silva, C. G. et al. Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccines. Biomaterials 220 , 119417 (2019). 31419588 10.1016/j.biomaterials.2019.119417

809. Sasso MS Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy Biomaterials 2016 96 47 62 10.1016/j.biomaterials.2016.04.010 27135716 Sasso, M. S. et al. Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. Biomaterials 96 , 47–62 (2016). 27135716 10.1016/j.biomaterials.2016.04.010

810. Gavilán H Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer Chem. Soc. Rev. 2021 50 11614 11667 10.1039/D1CS00427A 34661212 Gavilán, H. et al. Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer. Chem. Soc. Rev. 50 , 11614–11667 (2021). 34661212 10.1039/D1CS00427A

811. Al Faruque H Targeted removal of leukemia cells from the circulating system by whole-body magnetic hyperthermia in mice Nanoscale 2020 12 2773 2786 10.1039/C9NR06730B 31957767 Al Faruque, H. et al. Targeted removal of leukemia cells from the circulating system by whole-body magnetic hyperthermia in mice. Nanoscale 12 , 2773–2786 (2020). 31957767 10.1039/C9NR06730B

812. Peuler K Dimmitt N Lin CC Clickable modular polysaccharide nanoparticles for selective cell-targeting Carbohyd. Polym. 2020 234 115901 10.1016/j.carbpol.2020.115901 PMC7579774 32070522 Peuler, K., Dimmitt, N. & Lin, C. C. Clickable modular polysaccharide nanoparticles for selective cell-targeting. Carbohyd. Polym. 234 , 115901 (2020). 10.1016/j.carbpol.2020.115901 PMC7579774 32070522

813. Jin Y Anti-leukemia activities of selenium nanoparticles embedded in nanotube consisted of triple-helix beta-d-glucan Carbohyd. Polym. 2020 240 116329 10.1016/j.carbpol.2020.116329 32475588 Jin, Y. et al. Anti-leukemia activities of selenium nanoparticles embedded in nanotube consisted of triple-helix beta-d-glucan. Carbohyd. Polym. 240 , 116329 (2020). 10.1016/j.carbpol.2020.116329 32475588

814. Trujillo-Alonso V FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels Nat. Nanotechnol. 2019 14 616 622 10.1038/s41565-019-0406-1 30911166 PMC6554053 Trujillo-Alonso, V. et al. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat. Nanotechnol. 14 , 616–622 (2019). 30911166 10.1038/s41565-019-0406-1 PMC6554053

815. Shen N HDL-AuNPs-BMS nanoparticle conjugates as molecularly targeted therapy for leukemia ACS Appl. Mater. Inter. 2018 10 14454 14462 10.1021/acsami.8b01696 29668254 Shen, N. et al. HDL-AuNPs-BMS nanoparticle conjugates as molecularly targeted therapy for leukemia. ACS Appl. Mater. Inter. 10 , 14454–14462 (2018). 10.1021/acsami.8b01696 29668254

816. Durfee PN Mesoporous silica nanoparticle-supported lipid bilayers (protocells) for active targeting and delivery to individual leukemia cells ACS Nano 2016 10 8325 8345 10.1021/acsnano.6b02819 27419663 Durfee, P. N. et al. Mesoporous silica nanoparticle-supported lipid bilayers (protocells) for active targeting and delivery to individual leukemia cells. ACS Nano 10 , 8325–8345 (2016). 27419663 10.1021/acsnano.6b02819

817. Au KM Bespoke pretargeted nanoradioimmunotherapy for the treatment of non-Hodgkin lymphoma ACS Nano 2018 12 1544 1563 10.1021/acsnano.7b08122 29361211 PMC6713228 Au, K. M. et al. Bespoke pretargeted nanoradioimmunotherapy for the treatment of non-Hodgkin lymphoma. ACS Nano 12 , 1544–1563 (2018). 29361211 10.1021/acsnano.7b08122 PMC6713228

818. Zuo H Platelet-mimicking nanoparticles co-loaded with W(18)O(49) and metformin alleviate tumor hypoxia for enhanced photodynamic therapy and photothermal therapy Acta Biomater 2018 80 296 307 10.1016/j.actbio.2018.09.017 30223092 Zuo, H. et al. Platelet-mimicking nanoparticles co-loaded with W(18)O(49) and metformin alleviate tumor hypoxia for enhanced photodynamic therapy and photothermal therapy. Acta Biomater 80 , 296–307 (2018). 30223092 10.1016/j.actbio.2018.09.017

819. Zheng B Persistent luminescent nanocarrier as an accurate tracker in vivo for near infrared-remote selectively triggered photothermal therapy ACS Appl. Mater. Inter. 2016 8 21603 21611 10.1021/acsami.6b07642 27491888 Zheng, B. et al. Persistent luminescent nanocarrier as an accurate tracker in vivo for near infrared-remote selectively triggered photothermal therapy. ACS Appl. Mater. Inter. 8 , 21603–21611 (2016). 10.1021/acsami.6b07642 27491888

820. Ackley J Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma Cancers 2021 13 4787 10.3390/cancers13194787 34638271 PMC8507631 Ackley, J. et al. Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma. Cancers 13 , 4787 (2021). 34638271 10.3390/cancers13194787 PMC8507631

821. Stefanick JF Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro J. Control. Release 2019 311-312 190 200 10.1016/j.jconrel.2019.08.033 31473250 Stefanick, J. F. et al. Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro. J. Control. Release 311-312 , 190–200 (2019). 31473250 10.1016/j.jconrel.2019.08.033

822. Stefanick JF Omstead DT Kiziltepe T Bilgicer B Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity Nanoscale 2019 11 4414 4427 10.1039/C8NR09431D 30801591 Stefanick, J. F., Omstead, D. T., Kiziltepe, T. & Bilgicer, B. Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity. Nanoscale 11 , 4414–4427 (2019). 30801591 10.1039/C8NR09431D

823. Kiziltepe T Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo Blood Cancer J 2012 2 e64 10.1038/bcj.2012.10 22829966 PMC3346680 Kiziltepe, T. et al. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J 2 , e64 (2012). 22829966 10.1038/bcj.2012.10 PMC3346680

824. Kotagiri N Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer Nat. Commun. 2018 9 275 10.1038/s41467-017-02758-9 29348537 PMC5773683 Kotagiri, N. et al. Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer. Nat. Commun. 9 , 275 (2018). 29348537 10.1038/s41467-017-02758-9 PMC5773683

825. Bae J BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8(+) cytotoxic T lymphocytes against multiple myeloma: clinical applications Leukemia 2020 34 210 223 10.1038/s41375-019-0540-7 31427721 PMC7297141 Bae, J. et al. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8(+) cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia 34 , 210–223 (2020). 31427721 10.1038/s41375-019-0540-7 PMC7297141

826. Bai C Modular design of Bi-specific nanoplatform engaged in malignant lymphoma immunotherapy Nanoscale 2020 12 18418 18428 10.1039/D0NR04450D 32941572 Bai, C. et al. Modular design of Bi-specific nanoplatform engaged in malignant lymphoma immunotherapy. Nanoscale 12 , 18418–18428 (2020). 32941572 10.1039/D0NR04450D

827. Etrych T Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging J. Control. Release 2018 289 44 55 10.1016/j.jconrel.2018.09.018 30248447 Etrych, T. et al. Effective doxorubicin-based nano-therapeutics for simultaneous malignant lymphoma treatment and lymphoma growth imaging. J. Control. Release 289 , 44–55 (2018). 30248447 10.1016/j.jconrel.2018.09.018

828. De Ninno A High-throughput label-free characterization of viable, necrotic and apoptotic human lymphoma cells in a coplanar-electrode microfluidic impedance chip Biosens. Bioelectron. 2020 150 111887 10.1016/j.bios.2019.111887 31780405 De Ninno, A. et al. High-throughput label-free characterization of viable, necrotic and apoptotic human lymphoma cells in a coplanar-electrode microfluidic impedance chip. Biosens. Bioelectron. 150 , 111887 (2020). 31780405 10.1016/j.bios.2019.111887

829. Hsu CC Chou PT Zare RN Imaging of proteins in tissue samples using nanospray desorption electrospray Ionization mass spectrometry Anal. Chem. 2015 87 11171 11175 10.1021/acs.analchem.5b03389 26509582 Hsu, C. C., Chou, P. T. & Zare, R. N. Imaging of proteins in tissue samples using nanospray desorption electrospray Ionization mass spectrometry. Anal. Chem. 87 , 11171–11175 (2015). 26509582 10.1021/acs.analchem.5b03389

830. Lee JR Longitudinal multiplexed measurement of quantitative proteomic signatures in mouse lymphoma models using magneto-nanosensors Theranostics 2018 8 1389 1398 10.7150/thno.20706 29507628 PMC5835944 Lee, J. R. et al. Longitudinal multiplexed measurement of quantitative proteomic signatures in mouse lymphoma models using magneto-nanosensors. Theranostics 8 , 1389–1398 (2018). 29507628 10.7150/thno.20706 PMC5835944

831. Li X Label-free optofluidic nanobiosensor enables real-time analysis of single-cell cytokine secretion Small 2018 14 e1800698 10.1002/smll.201800698 29806234 Li, X. et al. Label-free optofluidic nanobiosensor enables real-time analysis of single-cell cytokine secretion. Small 14 , e1800698 (2018). 29806234 10.1002/smll.201800698

832. Zeng Q Inhibition of REDD1 sensitizes bladder urothelial carcinoma to paclitaxel by inhibiting autophagy Clin. Cancer Res. 2018 24 445 459 10.1158/1078-0432.CCR-17-0419 29084921 Zeng, Q. et al. Inhibition of REDD1 sensitizes bladder urothelial carcinoma to paclitaxel by inhibiting autophagy. Clin. Cancer Res. 24 , 445–459 (2018). 29084921 10.1158/1078-0432.CCR-17-0419

833. Liu Y Paclitaxel/chitosan nanosupensions provide enhanced intravesical bladder cancer therapy with sustained and prolonged delivery of paclitaxel ACS Appl. Bio Mater 2018 1 1992 2001 10.1021/acsabm.8b00501 34996261 Liu, Y. et al. Paclitaxel/chitosan nanosupensions provide enhanced intravesical bladder cancer therapy with sustained and prolonged delivery of paclitaxel. ACS Appl. Bio Mater 1 , 1992–2001 (2018). 34996261 10.1021/acsabm.8b00501

834. Antoni S Bladder cancer incidence and mortality: a global overview and recent trends Eur. Urol. 2017 71 96 108 10.1016/j.eururo.2016.06.010 27370177 Antoni, S. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol. 71 , 96–108 (2017). 27370177 10.1016/j.eururo.2016.06.010

835. Xiong Q Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer Cell Death Dis 2020 11 366 10.1038/s41419-020-2554-5 32409654 PMC7224387 Xiong, Q. et al. Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer. Cell Death Dis 11 , 366 (2020). 32409654 10.1038/s41419-020-2554-5 PMC7224387

836. Nadal R Bellmunt J Management of metastatic bladder cancer Cancer Treat. Rev. 2019 76 10 21 10.1016/j.ctrv.2019.04.002 31030123 Nadal, R. & Bellmunt, J. Management of metastatic bladder cancer. Cancer Treat. Rev. 76 , 10–21 (2019). 31030123 10.1016/j.ctrv.2019.04.002

837. Moch H The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours Eur. Urol. 2016 70 93 105 10.1016/j.eururo.2016.02.029 26935559 Moch, H. et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur. Urol. 70 , 93–105 (2016). 26935559 10.1016/j.eururo.2016.02.029

838. Ferlay J Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int. J. Cancer 2015 136 E359 E386 10.1002/ijc.29210 25220842 Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 , E359–E386 (2015). 25220842 10.1002/ijc.29210

839. Jayson GC Kohn EC Kitchener HC Ledermann JA Ovarian cancer Lancet 2014 384 1376 1388 10.1016/S0140-6736(13)62146-7 24767708 Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet 384 , 1376–1388 (2014). 24767708 10.1016/S0140-6736(13)62146-7

840. DeSantis CE Breast cancer statistics, 2019 CA-Cancer J. Clin 2019 69 438 451 10.3322/caac.21583 31577379 DeSantis, C. E. et al. Breast cancer statistics, 2019. CA-Cancer J. Clin 69 , 438–451 (2019). 31577379 10.3322/caac.21583

841. Adeel M Self-therapeutic cobalt hydroxide nanosheets (Co(OH)(2) NS) for ovarian cancer therapy ACS Omega 2021 6 28611 28619 10.1021/acsomega.1c03010 34746556 PMC8567285 Adeel, M. et al. Self-therapeutic cobalt hydroxide nanosheets (Co(OH)(2) NS) for ovarian cancer therapy. ACS Omega 6 , 28611–28619 (2021). 34746556 10.1021/acsomega.1c03010 PMC8567285

842. Moss SM Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial Lancet Oncol 2015 16 1123 1132 10.1016/S1470-2045(15)00128-X 26206144 Moss, S. M. et al. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol 16 , 1123–1132 (2015). 26206144 10.1016/S1470-2045(15)00128-X

843. Arasu VA Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk J. Clin. Oncol. 2019 37 954 963 10.1200/JCO.18.00378 30625040 PMC6494266 Arasu, V. A. et al. Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk. J. Clin. Oncol. 37 , 954–963 (2019). 30625040 10.1200/JCO.18.00378 PMC6494266

844. Comstock CE Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening JAMA 2020 323 746 756 10.1001/jama.2020.0572 32096852 PMC7276668 Comstock, C. E. et al. Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening. JAMA 323 , 746–756 (2020). 32096852 10.1001/jama.2020.0572 PMC7276668

845. Wang P NIR-II nanoprobes in-vivo assembly to improve image-guided surgery for metastatic ovarian cancer Nat. Commun. 2018 9 2898 10.1038/s41467-018-05113-8 30042434 PMC6057964 Wang, P. et al. NIR-II nanoprobes in-vivo assembly to improve image-guided surgery for metastatic ovarian cancer. Nat. Commun. 9 , 2898 (2018). 30042434 10.1038/s41467-018-05113-8 PMC6057964

846. Zhao Y Enhancing prostate-cancer-specific MRI by genetic amplified nanoparticle tumor homing Adv. Mater. 2019 31 e1900928 10.1002/adma.201900928 31183895 Zhao, Y. et al. Enhancing prostate-cancer-specific MRI by genetic amplified nanoparticle tumor homing. Adv. Mater. 31 , e1900928 (2019). 31183895 10.1002/adma.201900928

847. Wei X Multiplexed detection strategy for bladder cancer microRNAs based on photonic crystal barcodes Anal. Chem. 2020 92 6121 6127 10.1021/acs.analchem.0c00630 32227890 Wei, X. et al. Multiplexed detection strategy for bladder cancer microRNAs based on photonic crystal barcodes. Anal. Chem. 92 , 6121–6127 (2020). 32227890 10.1021/acs.analchem.0c00630

848. Usuba W Circulating miRNA panels for specific and early detection in bladder cancer Cancer Sci 2019 110 408 419 10.1111/cas.13856 30382619 PMC6317958 Usuba, W. et al. Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci 110 , 408–419 (2019). 30382619 10.1111/cas.13856 PMC6317958

849. Enokida H Yoshino H Matsushita R Nakagawa M The role of microRNAs in bladder cancer Investig. Clin. Urol. 2016 57 S60 S76 10.4111/icu.2016.57.S1.S60 27326409 PMC4910767 Enokida, H., Yoshino, H., Matsushita, R. & Nakagawa, M. The role of microRNAs in bladder cancer. Investig. Clin. Urol. 57 , S60–S76 (2016). 27326409 10.4111/icu.2016.57.S1.S60 PMC4910767

850. Moura SL Martin CG Marti M Pividori MI Electrochemical immunosensing of nanovesicles as biomarkers for breast cancer Biosens. Bioelectron. 2020 150 111882 10.1016/j.bios.2019.111882 31786017 Moura, S. L., Martin, C. G., Marti, M. & Pividori, M. I. Electrochemical immunosensing of nanovesicles as biomarkers for breast cancer. Biosens. Bioelectron. 150 , 111882 (2020). 31786017 10.1016/j.bios.2019.111882

851. Dorayappan KDP Wallbillich JJ Cohn DE Selvendiran K The biological significance and clinical applications of exosomes in ovarian cancer Gynecol. Oncol. 2016 142 199 205 10.1016/j.ygyno.2016.03.036 27058839 PMC4917458 Dorayappan, K. D. P., Wallbillich, J. J., Cohn, D. E. & Selvendiran, K. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol. Oncol. 142 , 199–205 (2016). 27058839 10.1016/j.ygyno.2016.03.036 PMC4917458

852. Jeong S Integrated magneto-electrochemical sensor for exosome analysis ACS Nano 2016 10 1802 1809 10.1021/acsnano.5b07584 26808216 PMC4802494 Jeong, S. et al. Integrated magneto-electrochemical sensor for exosome analysis. ACS Nano 10 , 1802–1809 (2016). 26808216 10.1021/acsnano.5b07584 PMC4802494

853. Boschi F Malatesta M Nanoparticle-based techniques for bladder cancer imaging: a review Int. J. Mol. Sci. 2023 24 3812 10.3390/ijms24043812 36835222 PMC9965346 Boschi, F. & Malatesta, M. Nanoparticle-based techniques for bladder cancer imaging: a review. Int. J. Mol. Sci. 24 , 3812 (2023). 36835222 10.3390/ijms24043812 PMC9965346

854. Yang Y Illuminating platinum transportation while maximizing therapeutic efficacy by gold nanoclusters via simultaneous near-infrared-I/II imaging and glutathione scavenging ACS Nano 2020 14 13536 13547 10.1021/acsnano.0c05541 32924505 Yang, Y. et al. Illuminating platinum transportation while maximizing therapeutic efficacy by gold nanoclusters via simultaneous near-infrared-I/II imaging and glutathione scavenging. ACS Nano 14 , 13536–13547 (2020). 32924505 10.1021/acsnano.0c05541

855. Ouyang J Nanoaggregate probe for breast cancer metastasis through multispectral optoacoustic tomography and aggregation-induced NIR-I/II fluorescence imaging Angew. Chem. Int. Edit. 2020 59 10111 10121 10.1002/anie.201913149 31733015 Ouyang, J. et al. Nanoaggregate probe for breast cancer metastasis through multispectral optoacoustic tomography and aggregation-induced NIR-I/II fluorescence imaging. Angew. Chem. Int. Edit. 59 , 10111–10121 (2020). 10.1002/anie.201913149 31733015

856. Zhu S Near-infrared-II molecular dyes for cancer imaging and surgery Adv. Mater. 2019 31 e1900321 10.1002/adma.201900321 31025403 PMC6555689 Zhu, S. et al. Near-infrared-II molecular dyes for cancer imaging and surgery. Adv. Mater. 31 , e1900321 (2019). 31025403 10.1002/adma.201900321 PMC6555689

857. Li J One-pot preparation of hydrophilic manganese oxide nanoparticles as T(1) nano-contrast agent for molecular magnetic resonance imaging of renal carcinoma in vitro and in vivo Biosens. Bioelectron. 2018 102 1 8 10.1016/j.bios.2017.10.047 29101783 Li, J. et al. One-pot preparation of hydrophilic manganese oxide nanoparticles as T(1) nano-contrast agent for molecular magnetic resonance imaging of renal carcinoma in vitro and in vivo. Biosens. Bioelectron. 102 , 1–8 (2018). 29101783 10.1016/j.bios.2017.10.047

858. Dell’Oglio P Hybrid indocyanine green-(99m)Tc-nanocolloid for single-photon emission computed tomography and combined radio- and fluorescence-guided sentinel node biopsy in penile cancer: results of 740 inguinal basins assessed at a single institution Eur. Urol. 2020 78 865 872 10.1016/j.eururo.2020.09.007 32950298 Dell’Oglio, P. et al. Hybrid indocyanine green-(99m)Tc-nanocolloid for single-photon emission computed tomography and combined radio- and fluorescence-guided sentinel node biopsy in penile cancer: results of 740 inguinal basins assessed at a single institution. Eur. Urol. 78 , 865–872 (2020). 32950298 10.1016/j.eururo.2020.09.007

859. Liu X Coordination of nanoconjugation with an antigen/antibody for efficient detection of gynecological tumors J. Anal. Methods Chem. 2020 2020 6528572 10.1155/2020/6528572 32309010 PMC7149363 Liu, X. et al. Coordination of nanoconjugation with an antigen/antibody for efficient detection of gynecological tumors. J. Anal. Methods Chem. 2020 , 6528572 (2020). 32309010 10.1155/2020/6528572 PMC7149363

860. Guo S Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy Nat. Commun. 2020 11 972 10.1038/s41467-020-14780-5 32080195 PMC7033104 Guo, S. et al. Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. Nat. Commun. 11 , 972 (2020). 32080195 10.1038/s41467-020-14780-5 PMC7033104

861. Tassinari D Treatment of metastatic, castration-resistant, docetaxel-resistant prostate cancer: a systematic review of literature with a network meta-analysis of randomized clinical trials Rev. Recent Clin. Tria. 2018 13 226 237 10.2174/1574887113666180404120540 29623850 Tassinari, D. et al. Treatment of metastatic, castration-resistant, docetaxel-resistant prostate cancer: a systematic review of literature with a network meta-analysis of randomized clinical trials. Rev. Recent Clin. Tria. 13 , 226–237 (2018). 10.2174/1574887113666180404120540 29623850

862. O’Neill AJ Characterisation and manipulation of docetaxel resistant prostate cancer cell lines Mol. Cancer 2011 10 126 10.1186/1476-4598-10-126 21982118 PMC3203088 O’Neill, A. J. et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol. Cancer 10 , 126 (2011). 21982118 10.1186/1476-4598-10-126 PMC3203088

863. Nagesh PKB Cross-linked polyphenol-based drug nano-self-assemblies engineered to blockade prostate cancer senescence ACS Appl. Mater. Inter. 2019 11 38537 38554 10.1021/acsami.9b14738 PMC8020616 31553876 Nagesh, P. K. B. et al. Cross-linked polyphenol-based drug nano-self-assemblies engineered to blockade prostate cancer senescence. ACS Appl. Mater. Inter. 11 , 38537–38554 (2019). 10.1021/acsami.9b14738 PMC8020616 31553876

864. Luo K Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo J. Control. Release 2020 326 25 37 10.1016/j.jconrel.2020.06.005 32531414 Luo, K. et al. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo. J. Control. Release 326 , 25–37 (2020). 32531414 10.1016/j.jconrel.2020.06.005

865. Her S Jaffray DA Allen C Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements Adv. Drug Deliver. Rev. 2017 109 84 101 10.1016/j.addr.2015.12.012 26712711 Her, S., Jaffray, D. A. & Allen, C. Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements. Adv. Drug Deliver. Rev. 109 , 84–101 (2017). 10.1016/j.addr.2015.12.012 26712711

866. Luo D Targeted radiosensitizers for MR-Guided radiation therapy of prostate cancer Nano Lett 2020 20 7159 7167 10.1021/acs.nanolett.0c02487 32845644 PMC9109254 Luo, D. et al. Targeted radiosensitizers for MR-Guided radiation therapy of prostate cancer. Nano Lett 20 , 7159–7167 (2020). 32845644 10.1021/acs.nanolett.0c02487 PMC9109254

867. Barker HE Paget JT Khan AA Harrington KJ The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence Nat. Rev. Cancer 2015 15 409 425 10.1038/nrc3958 26105538 PMC4896389 Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15 , 409–425 (2015). 26105538 10.1038/nrc3958 PMC4896389

868. Huo D Hypoxia-targeting, tumor microenvironment responsive nanocluster bomb for radical-enhanced radiotherapy ACS Nano 2017 11 10159 10174 10.1021/acsnano.7b04737 28992409 Huo, D. et al. Hypoxia-targeting, tumor microenvironment responsive nanocluster bomb for radical-enhanced radiotherapy. ACS Nano 11 , 10159–10174 (2017). 28992409 10.1021/acsnano.7b04737

869. Hua JT Chen S He HH Landscape of noncoding RNA in prostate cancer Trends Genet 2019 35 840 851 10.1016/j.tig.2019.08.004 31623872 Hua, J. T., Chen, S. & He, H. H. Landscape of noncoding RNA in prostate cancer. Trends Genet 35 , 840–851 (2019). 31623872 10.1016/j.tig.2019.08.004

870. Chen S Widespread and functional RNA circularization in localized prostate cancer Cell 2019 176 831 843.e822 10.1016/j.cell.2019.01.025 30735634 Chen, S. et al. Widespread and functional RNA circularization in localized prostate cancer. Cell 176 , 831–843.e822 (2019). 30735634 10.1016/j.cell.2019.01.025

871. Anderson DM A micropeptide encoded by a putative long noncoding RNA regulates muscle performance Cell 2015 160 595 606 10.1016/j.cell.2015.01.009 25640239 PMC4356254 Anderson, D. M. et al. A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell 160 , 595–606 (2015). 25640239 10.1016/j.cell.2015.01.009 PMC4356254

872. Xu YH Deng JL Wang G Zhu YS Long non-coding RNAs in prostate cancer: Functional roles and clinical implications Cancer Lett 2019 464 37 55 10.1016/j.canlet.2019.08.010 31465841 Xu, Y. H., Deng, J. L., Wang, G. & Zhu, Y. S. Long non-coding RNAs in prostate cancer: Functional roles and clinical implications. Cancer Lett 464 , 37–55 (2019). 31465841 10.1016/j.canlet.2019.08.010

873. Springer AD Dowdy SF GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics Nucleic Acid Ther 2018 28 109 118 10.1089/nat.2018.0736 29792572 PMC5994659 Springer, A. D. & Dowdy, S. F. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther 28 , 109–118 (2018). 29792572 10.1089/nat.2018.0736 PMC5994659

874. Liang C Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy Nat. Med. 2015 21 288 294 10.1038/nm.3791 25665179 PMC5508976 Liang, C. et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat. Med. 21 , 288–294 (2015). 25665179 10.1038/nm.3791 PMC5508976

875. Cox AD Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 2014 13 828 851 10.1038/nrd4389 25323927 PMC4355017 Cox, A. D. et al. Drugging the undruggable RAS: mission possible? Nat. Rev. Drug Discov. 13 , 828–851 (2014). 25323927 10.1038/nrd4389 PMC4355017

876. Chen Z Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo Biomaterials 2016 81 125 134 10.1016/j.biomaterials.2015.11.022 26731576 Chen, Z. et al. Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo. Biomaterials 81 , 125–134 (2016). 26731576 10.1016/j.biomaterials.2015.11.022

877. Ashrafizadeh M Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer Bioengineering-Basel 2020 7 91 10.3390/bioengineering7030091 32784981 PMC7552721 Ashrafizadeh, M. et al. Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer. Bioengineering-Basel 7 , 91 (2020). 32784981 10.3390/bioengineering7030091 PMC7552721

878. Wei J The inhibition of human bladder cancer growth by calcium carbonate/CaIP6 nanocomposite particles delivering AIB1 siRNA Biomaterials 2013 34 1246 1254 10.1016/j.biomaterials.2012.09.068 23127333 Wei, J. et al. The inhibition of human bladder cancer growth by calcium carbonate/CaIP6 nanocomposite particles delivering AIB1 siRNA. Biomaterials 34 , 1246–1254 (2013). 23127333 10.1016/j.biomaterials.2012.09.068

879. Dong Y Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy J. Control. Release 2020 322 416 425 10.1016/j.jconrel.2020.04.003 32247806 Dong, Y. et al. Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy. J. Control. Release 322 , 416–425 (2020). 32247806 10.1016/j.jconrel.2020.04.003

880. Liu J Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite nanotubes Sci. Adv. 2019 5 eaaw6499 10.1126/sciadv.aaw6499 31579820 PMC6760933 Liu, J. et al. Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite nanotubes. Sci. Adv. 5 , eaaw6499 (2019). 31579820 10.1126/sciadv.aaw6499 PMC6760933

881. Van de Vyver T Cationic amphiphilic drugs boost the lysosomal escape of small nucleic acid therapeutics in a nanocarrier-dependent manner ACS Nano 2020 14 4774 4791 10.1021/acsnano.0c00666 32250113 Van de Vyver, T. et al. Cationic amphiphilic drugs boost the lysosomal escape of small nucleic acid therapeutics in a nanocarrier-dependent manner. ACS Nano 14 , 4774–4791 (2020). 32250113 10.1021/acsnano.0c00666

882. Ganguly D Cancer-associated fibroblasts: versatile players in the tumor microenvironment Cancers 2020 12 2652 10.3390/cancers12092652 32957515 PMC7564346 Ganguly, D. et al. Cancer-associated fibroblasts: versatile players in the tumor microenvironment. Cancers 12 , 2652 (2020). 32957515 10.3390/cancers12092652 PMC7564346

883. Huang Z beta2AR-HIF-1alpha-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells BMC Cancer 2019 19 1142 10.1186/s12885-019-6301-1 31771535 PMC6878637 Huang, Z. et al. beta2AR-HIF-1alpha-CXCL12 signaling of osteoblasts activated by isoproterenol promotes migration and invasion of prostate cancer cells. BMC Cancer 19 , 1142 (2019). 31771535 10.1186/s12885-019-6301-1 PMC6878637

884. Duda DG CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res. 2011 17 2074 2080 10.1158/1078-0432.CCR-10-2636 21349998 PMC3079023 Duda, D. G. et al. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin. Cancer Res. 17 , 2074–2080 (2011). 21349998 10.1158/1078-0432.CCR-10-2636 PMC3079023

885. Lang J Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem ACS Nano 2019 13 12357 12371 10.1021/acsnano.9b04857 31545587 Lang, J. et al. Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. ACS Nano 13 , 12357–12371 (2019). 31545587 10.1021/acsnano.9b04857

886. Shukla S Wang C Beiss V Steinmetz NF Antibody response against cowpea mosaic viral nanoparticles improves in situ vaccine efficacy in ovarian cancer ACS Nano 2020 14 2994 3003 10.1021/acsnano.9b07865 32133838 PMC8085886 Shukla, S., Wang, C., Beiss, V. & Steinmetz, N. F. Antibody response against cowpea mosaic viral nanoparticles improves in situ vaccine efficacy in ovarian cancer. ACS Nano 14 , 2994–3003 (2020). 32133838 10.1021/acsnano.9b07865 PMC8085886

887. Jafari S Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer Cell. Mol. Life Sci. 2020 77 3693 3710 10.1007/s00018-020-03459-1 32006051 PMC11104895 Jafari, S. et al. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. Cell. Mol. Life Sci. 77 , 3693–3710 (2020). 32006051 10.1007/s00018-020-03459-1 PMC11104895

888. Harris E Immunotherapeutics for the treatment of prostate cancer: a patent landscape based on key therapeutic mechanisms of actions Pharm. Pat. Anal. 2018 7 47 57 10.4155/ppa-2017-0029 29227196 Harris, E. Immunotherapeutics for the treatment of prostate cancer: a patent landscape based on key therapeutic mechanisms of actions. Pharm. Pat. Anal. 7 , 47–57 (2018). 29227196 10.4155/ppa-2017-0029

889. Wang H Mooney DJ Biomaterial-assisted targeted modulation of immune cells in cancer treatment Nat. Mater. 2018 17 761 772 10.1038/s41563-018-0147-9 30104668 Wang, H. & Mooney, D. J. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat. Mater. 17 , 761–772 (2018). 30104668 10.1038/s41563-018-0147-9

890. Mangadlao JD Prostate-specific membrane antigen targeted gold nanoparticles for theranostics of prostate cancer ACS Nano 2018 12 3714 3725 10.1021/acsnano.8b00940 29641905 PMC6392200 Mangadlao, J. D. et al. Prostate-specific membrane antigen targeted gold nanoparticles for theranostics of prostate cancer. ACS Nano 12 , 3714–3725 (2018). 29641905 10.1021/acsnano.8b00940 PMC6392200

891. Maeda H Polymer therapeutics and the EPR effect J. Drug Target. 2017 25 781 785 10.1080/1061186X.2017.1365878 28988499 Maeda, H. Polymer therapeutics and the EPR effect. J. Drug Target. 25 , 781–785 (2017). 28988499 10.1080/1061186X.2017.1365878

892. Rauscher, I. et al. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging 16 , 14 (2016). 10.1186/s40644-016-0072-6 PMC4898465 27277843

893. Tesch ME Gelmon KA Targeting HER2 in breast cancer: latest developments on treatment sequencing and the introduction of biosimilars Drugs 2020 80 1811 1830 10.1007/s40265-020-01411-y 33021725 Tesch, M. E. & Gelmon, K. A. Targeting HER2 in breast cancer: latest developments on treatment sequencing and the introduction of biosimilars. Drugs 80 , 1811–1830 (2020). 33021725 10.1007/s40265-020-01411-y

894. Dong Y Inhibition of HER2-positive breast cancer growth by blocking the HER2 signaling pathway with HER2-glycan-imprinted nanoparticles Angew. Chem. Int. Edit. 2019 58 10621 10625 10.1002/anie.201904860 31166063 Dong, Y. et al. Inhibition of HER2-positive breast cancer growth by blocking the HER2 signaling pathway with HER2-glycan-imprinted nanoparticles. Angew. Chem. Int. Edit. 58 , 10621–10625 (2019). 10.1002/anie.201904860 31166063

895. Choi H Cho SH Hahn SK Urease-powered polydopamine nanomotors for intravesical therapy of bladder diseases ACS Nano 2020 14 6683 6692 10.1021/acsnano.9b09726 32491832 Choi, H., Cho, S. H. & Hahn, S. K. Urease-powered polydopamine nanomotors for intravesical therapy of bladder diseases. ACS Nano 14 , 6683–6692 (2020). 32491832 10.1021/acsnano.9b09726

896. Peng F A peptide functionalized nanomotor as an efficient cell penetrating tool Chem. Commun. 2017 53 1088 1091 10.1039/C6CC09169E 28044164 Peng, F. et al. A peptide functionalized nanomotor as an efficient cell penetrating tool. Chem. Commun. 53 , 1088–1091 (2017). 10.1039/C6CC09169E 28044164

897. Hortelao AC Targeting 3D bladder cancer spheroids with urease-powered nanomotors ACS Nano 2019 13 429 439 10.1021/acsnano.8b06610 30588798 Hortelao, A. C. et al. Targeting 3D bladder cancer spheroids with urease-powered nanomotors. ACS Nano 13 , 429–439 (2019). 30588798 10.1021/acsnano.8b06610

898. Pitt JM Resistance Mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors Immunity 2016 44 1255 1269 10.1016/j.immuni.2016.06.001 27332730 Pitt, J. M. et al. Resistance Mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44 , 1255–1269 (2016). 27332730 10.1016/j.immuni.2016.06.001

899. Kalbasi A Ribas A Tumour-intrinsic resistance to immune checkpoint blockade Nat. Rev. Immunol. 2020 20 25 39 10.1038/s41577-019-0218-4 31570880 PMC8499690 Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20 , 25–39 (2020). 31570880 10.1038/s41577-019-0218-4 PMC8499690

900. Binnewies M Understanding the tumor immune microenvironment (TIME) for effective therapy Nat. Med. 2018 24 541 550 10.1038/s41591-018-0014-x 29686425 PMC5998822 Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24 , 541–550 (2018). 29686425 10.1038/s41591-018-0014-x PMC5998822

901. Choi B Sequential MR image-guided local immune checkpoint blockade cancer immunotherapy using ferumoxytol capped ultralarge pore mesoporous silica carriers after standard chemotherapy Small 2019 15 e1904378 10.1002/smll.201904378 31697036 PMC7027959 Choi, B. et al. Sequential MR image-guided local immune checkpoint blockade cancer immunotherapy using ferumoxytol capped ultralarge pore mesoporous silica carriers after standard chemotherapy. Small 15 , e1904378 (2019). 31697036 10.1002/smll.201904378 PMC7027959

902. Zhang Q Photoactivatable prodrug-backboned polymeric nanoparticles for efficient light-controlled gene delivery and synergistic treatment of platinum-resistant ovarian cancer Nano Lett 2020 20 3039 3049 10.1021/acs.nanolett.9b04981 32250633 Zhang, Q. et al. Photoactivatable prodrug-backboned polymeric nanoparticles for efficient light-controlled gene delivery and synergistic treatment of platinum-resistant ovarian cancer. Nano Lett 20 , 3039–3049 (2020). 32250633 10.1021/acs.nanolett.9b04981

903. Biermann JS NCCN guidelines insights: bone cancer, version 2.2017 J. Natl. Compr. Canc. Ne. 2017 15 155 167 10.6004/jnccn.2017.0017 28188186 Biermann, J. S. et al. NCCN guidelines insights: bone cancer, version 2.2017. J. Natl. Compr. Canc. Ne. 15 , 155–167 (2017). 10.6004/jnccn.2017.0017 28188186

904. Bernstein M Ewing’s sarcoma family of tumors: current management Oncologist 2006 11 503 519 10.1634/theoncologist.11-5-503 16720851 Bernstein, M. et al. Ewing’s sarcoma family of tumors: current management. Oncologist 11 , 503–519 (2006). 16720851 10.1634/theoncologist.11-5-503

905. Subbiah V Ewing’s sarcoma: standard and experimental treatment options Curr. Treat. Option. On. 2009 10 126 140 10.1007/s11864-009-0104-6 19533369 Subbiah, V. et al. Ewing’s sarcoma: standard and experimental treatment options. Curr. Treat. Option. On. 10 , 126–140 (2009). 10.1007/s11864-009-0104-6 19533369

906. Gill J Gorlick R Advancing therapy for osteosarcoma Nat. Rev. Clin. Oncol. 2021 18 609 624 10.1038/s41571-021-00519-8 34131316 Gill, J. & Gorlick, R. Advancing therapy for osteosarcoma. Nat. Rev. Clin. Oncol. 18 , 609–624 (2021). 34131316 10.1038/s41571-021-00519-8

907. Kager L Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols J. Clin. Oncol. 2003 21 2011 2018 10.1200/JCO.2003.08.132 12743156 Kager, L. et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 21 , 2011–2018 (2003). 12743156 10.1200/JCO.2003.08.132

908. Messerschmitt PJ Osteosarcoma J. Am. Acad. Orthop. Sur. 2009 17 515 527 10.5435/00124635-200908000-00005 19652033 Messerschmitt, P. J. et al. Osteosarcoma. J. Am. Acad. Orthop. Sur. 17 , 515–527 (2009). 10.5435/00124635-200908000-00005 19652033

909. Klein MJ Siegal GP Osteosarcoma: anatomic and histologic variants Am. J. Clin. Pathol. 2006 125 555 581 10.1309/UC6KQHLD9LV2KENN 16627266 Klein, M. J. & Siegal, G. P. Osteosarcoma: anatomic and histologic variants. Am. J. Clin. Pathol. 125 , 555–581 (2006). 16627266 10.1309/UC6KQHLD9LV2KENN

910. Beird HC Osteosarcoma Nat. Rev. Dis. Primers 2022 8 77 10.1038/s41572-022-00409-y 36481668 Beird, H. C. et al. Osteosarcoma. Nat. Rev. Dis. Primers 8 , 77 (2022). 36481668 10.1038/s41572-022-00409-y

911. Wang H The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy J. Hematol. Oncol. 2022 15 140 10.1186/s13045-022-01365-6 36209102 PMC9547461 Wang, H. et al. The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy. J. Hematol. Oncol. 15 , 140 (2022). 36209102 10.1186/s13045-022-01365-6 PMC9547461

912. Sapiano A Extraskeletal osteosarcoma of primary retroperitoneal origin Lancet Oncol 2023 24 e284 10.1016/S1470-2045(23)00155-9 37269859 Sapiano, A. et al. Extraskeletal osteosarcoma of primary retroperitoneal origin. Lancet Oncol 24 , e284 (2023). 37269859 10.1016/S1470-2045(23)00155-9

913. Whelan JS Davis LE Osteosarcoma, chondrosarcoma, and chordoma J. Clin. Oncol. 2018 36 188 193 10.1200/JCO.2017.75.1743 29220289 Whelan, J. S. & Davis, L. E. Osteosarcoma, chondrosarcoma, and chordoma. J. Clin. Oncol. 36 , 188–193 (2018). 29220289 10.1200/JCO.2017.75.1743

914. Strauss SJ Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up Ann. Oncol. 2021 32 1520 1536 10.1016/j.annonc.2021.08.1995 34500044 Strauss, S. J. et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 32 , 1520–1536 (2021). 34500044 10.1016/j.annonc.2021.08.1995

915. Meng X Negative CT contrast agents for the diagnosis of malignant osteosarcoma Adv. Sci. 2019 6 1901214 10.1002/advs.201901214 PMC6891899 31832312 Meng, X. et al. Negative CT contrast agents for the diagnosis of malignant osteosarcoma. Adv. Sci. 6 , 1901214 (2019). 10.1002/advs.201901214 PMC6891899 31832312

916. Xu Z Noninvasive multimodal imaging of osteosarcoma and lymph nodes using a (99m)Tc-labeled biomineralization nanoprobe Anal. Chem. 2018 90 4529 4534 10.1021/acs.analchem.7b04925 29504754 Xu, Z. et al. Noninvasive multimodal imaging of osteosarcoma and lymph nodes using a (99m)Tc-labeled biomineralization nanoprobe. Anal. Chem. 90 , 4529–4534 (2018). 29504754 10.1021/acs.analchem.7b04925

917. Lu Y Enhancing osteosarcoma killing and CT imaging using ultrahigh drug loading and NIR-responsive bismuth sulfide@Mesoporous silica nanoparticles Adv. Healthc. Mater. 2018 7 e1800602 10.1002/adhm.201800602 30102469 PMC6504251 Lu, Y. et al. Enhancing osteosarcoma killing and CT imaging using ultrahigh drug loading and NIR-responsive bismuth sulfide@Mesoporous silica nanoparticles. Adv. Healthc. Mater. 7 , e1800602 (2018). 30102469 10.1002/adhm.201800602 PMC6504251

918. Estanqueiro M Amaral MH Conceição J Sousa Lobo JM Nanotechnological carriers for cancer chemotherapy: the state of the art Colloid. Surface. B. 2015 126 631 648 10.1016/j.colsurfb.2014.12.041 25591851 Estanqueiro, M., Amaral, M. H., Conceição, J. & Sousa Lobo, J. M. Nanotechnological carriers for cancer chemotherapy: the state of the art. Colloid. Surface. B. 126 , 631–648 (2015). 10.1016/j.colsurfb.2014.12.041 25591851

919. Ordikhani F Targeted nanomedicines for the treatment of bone disease and regeneration Med. Res. Rev. 2021 41 1221 1254 10.1002/med.21759 33347711 Ordikhani, F. et al. Targeted nanomedicines for the treatment of bone disease and regeneration. Med. Res. Rev. 41 , 1221–1254 (2021). 33347711 10.1002/med.21759

920. Wang Y Chemotherapy-sensitized in situ vaccination for malignant osteosarcoma enabled by bioinspired calcium phosphonate nanoagents ACS Nano 2023 17 6247 6260 10.1021/acsnano.2c09685 36961255 Wang, Y. et al. Chemotherapy-sensitized in situ vaccination for malignant osteosarcoma enabled by bioinspired calcium phosphonate nanoagents. ACS Nano 17 , 6247–6260 (2023). 36961255 10.1021/acsnano.2c09685

921. Maleki Dana P Chitosan applications in studying and managing osteosarcoma Int. J. Biol. Macromol. 2021 169 321 329 10.1016/j.ijbiomac.2020.12.058 33310094 Maleki Dana, P. et al. Chitosan applications in studying and managing osteosarcoma. Int. J. Biol. Macromol. 169 , 321–329 (2021). 33310094 10.1016/j.ijbiomac.2020.12.058

922. Wang S Improving bioavailability of hydrophobic prodrugs through supramolecular nanocarriers based on recombinant proteins for osteosarcoma treatment Angew. Chem. Int. Edit. 2021 60 11252 11256 10.1002/anie.202101938 33650286 Wang, S. et al. Improving bioavailability of hydrophobic prodrugs through supramolecular nanocarriers based on recombinant proteins for osteosarcoma treatment. Angew. Chem. Int. Edit. 60 , 11252–11256 (2021). 10.1002/anie.202101938 33650286

923. Lu KH Curcumin and its analogs and carriers: potential therapeutic strategies for human osteosarcoma Int. J. Biol. Sci. 2023 19 1241 1265 10.7150/ijbs.80590 36923933 PMC10008701 Lu, K. H. et al. Curcumin and its analogs and carriers: potential therapeutic strategies for human osteosarcoma. Int. J. Biol. Sci. 19 , 1241–1265 (2023). 36923933 10.7150/ijbs.80590 PMC10008701

924. Pereira-Silva M Nanomedicine in osteosarcoma therapy: micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies Eur. J. Pharm. Biopharm. 2020 148 88 106 10.1016/j.ejpb.2019.10.013 31958514 Pereira-Silva, M. et al. Nanomedicine in osteosarcoma therapy: micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies. Eur. J. Pharm. Biopharm. 148 , 88–106 (2020). 31958514 10.1016/j.ejpb.2019.10.013

925. Tian H Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment Bone Res 2023 11 11 10.1038/s41413-023-00246-z 36849442 PMC9971189 Tian, H. et al. Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment. Bone Res 11 , 11 (2023). 36849442 10.1038/s41413-023-00246-z PMC9971189

926. Shi P Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics J. Nanobiotechnol. 2023 21 103 10.1186/s12951-023-01826-1 PMC10031984 36944946 Shi, P. et al. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. J. Nanobiotechnol. 21 , 103 (2023). 10.1186/s12951-023-01826-1 PMC10031984 36944946

927. Zhang Y Self-stabilized hyaluronate nanogel for intracellular codelivery of doxorubicin and cisplatin to osteosarcoma Adv. Sci. 2018 5 1700821 10.1002/advs.201700821 PMC5980114 29876208 Zhang, Y. et al. Self-stabilized hyaluronate nanogel for intracellular codelivery of doxorubicin and cisplatin to osteosarcoma. Adv. Sci. 5 , 1700821 (2018). 10.1002/advs.201700821 PMC5980114 29876208

928. Yin F Reduction-responsive polypeptide nanomedicines significantly inhibit progression of orthotopic osteosarcoma Nanomed. Nanotechnol. 2020 23 102085 10.1016/j.nano.2019.102085 31442580 Yin, F. et al. Reduction-responsive polypeptide nanomedicines significantly inhibit progression of orthotopic osteosarcoma. Nanomed. Nanotechnol. 23 , 102085 (2020). 10.1016/j.nano.2019.102085 31442580

929. Wei H A nanodrug consisting of doxorubicin and exosome derived from mesenchymal stem cells for osteosarcoma treatment in vitro Int. J. Nanomed. 2019 14 8603 8610 10.2147/IJN.S218988 PMC6830377 31802872 Wei, H. et al. A nanodrug consisting of doxorubicin and exosome derived from mesenchymal stem cells for osteosarcoma treatment in vitro. Int. J. Nanomed. 14 , 8603–8610 (2019). 10.2147/IJN.S218988 PMC6830377 31802872

930. Wang L Wang W Rui Z Zhou D The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system Drug Deliv 2016 23 3200 3208 10.3109/10717544.2016.1162875 26987435 Wang, L., Wang, W., Rui, Z. & Zhou, D. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system. Drug Deliv 23 , 3200–3208 (2016). 26987435 10.3109/10717544.2016.1162875

931. Pei P Composite-dissolving microneedle patches for chemotherapy and photothermal therapy in superficial tumor treatment Biomater. Sci.-UK 2018 6 1414 1423 10.1039/C8BM00005K 29595852 Pei, P. et al. Composite-dissolving microneedle patches for chemotherapy and photothermal therapy in superficial tumor treatment. Biomater. Sci.-UK 6 , 1414–1423 (2018). 10.1039/C8BM00005K 29595852

932. Liang B Multifunctional bone cement for synergistic magnetic hyperthermia ablation and chemotherapy of osteosarcoma Mat. Sci. Eng. C-Mater. 2020 108 110460 10.1016/j.msec.2019.110460 31923975 Liang, B. et al. Multifunctional bone cement for synergistic magnetic hyperthermia ablation and chemotherapy of osteosarcoma. Mat. Sci. Eng. C-Mater. 108 , 110460 (2020). 10.1016/j.msec.2019.110460 31923975

933. Li Y Hou H Zhang P Zhang Z Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy Drug Deliv 2020 27 1044 1053 10.1080/10717544.2020.1785049 32633576 PMC7470123 Li, Y., Hou, H., Zhang, P. & Zhang, Z. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy. Drug Deliv 27 , 1044–1053 (2020). 32633576 10.1080/10717544.2020.1785049 PMC7470123

934. Li K Calcium-mineralized polypeptide nanoparticle for intracellular drug delivery in osteosarcoma chemotherapy Bioact. Mater. 2020 5 721 731 32596554 10.1016/j.bioactmat.2020.04.010 PMC7298657 Li, K. et al. Calcium-mineralized polypeptide nanoparticle for intracellular drug delivery in osteosarcoma chemotherapy. Bioact. Mater. 5 , 721–731 (2020). 32596554 10.1016/j.bioactmat.2020.04.010 PMC7298657

935. Jalili NA Injectable nanoengineered stimuli-responsive hydrogels for on-demand and localized therapeutic delivery Nanoscale 2017 9 15379 15389 10.1039/C7NR02327H 28975171 PMC5702913 Jalili, N. A. et al. Injectable nanoengineered stimuli-responsive hydrogels for on-demand and localized therapeutic delivery. Nanoscale 9 , 15379–15389 (2017). 28975171 10.1039/C7NR02327H PMC5702913

936. Haghiralsadat F Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance Int. J. Nanomed. 2018 13 3853 3866 10.2147/IJN.S150017 PMC6039070 30013340 Haghiralsadat, F. et al. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance. Int. J. Nanomed. 13 , 3853–3866 (2018). 10.2147/IJN.S150017 PMC6039070 30013340

937. Gurunathan S Jeyaraj M Kang MH Kim JH Tangeretin-assisted platinum nanoparticles enhance the apoptotic properties of doxorubicin: combination therapy for osteosarcoma treatment Nanomaterials-Basel 2019 9 1089 10.3390/nano9081089 31362420 PMC6723885 Gurunathan, S., Jeyaraj, M., Kang, M. H. & Kim, J. H. Tangeretin-assisted platinum nanoparticles enhance the apoptotic properties of doxorubicin: combination therapy for osteosarcoma treatment. Nanomaterials-Basel 9 , 1089 (2019). 31362420 10.3390/nano9081089 PMC6723885

938. Gonzalez-Fernandez Y Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma Cancer Lett 2018 430 193 200 10.1016/j.canlet.2018.05.030 29802930 Gonzalez-Fernandez, Y. et al. Oral administration of edelfosine encapsulated lipid nanoparticles causes regression of lung metastases in pre-clinical models of osteosarcoma. Cancer Lett 430 , 193–200 (2018). 29802930 10.1016/j.canlet.2018.05.030

939. Gonzalez-Fernandez Y Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells Cancer Lett 2017 388 262 268 10.1016/j.canlet.2016.12.012 27998763 Gonzalez-Fernandez, Y. et al. Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells. Cancer Lett 388 , 262–268 (2017). 27998763 10.1016/j.canlet.2016.12.012

940. Gu W Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma Drug Deliv 2019 26 918 927 10.1080/10717544.2019.1662513 31526064 PMC6758616 Gu, W. et al. Albumin-bioinspired iridium oxide nanoplatform with high photothermal conversion efficiency for synergistic chemo-photothermal of osteosarcoma. Drug Deliv 26 , 918–927 (2019). 31526064 10.1080/10717544.2019.1662513 PMC6758616

941. Jiang J IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma J. Control. Release 2022 350 460 470 10.1016/j.jconrel.2022.08.048 36041590 Jiang, J. et al. IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma. J. Control. Release 350 , 460–470 (2022). 36041590 10.1016/j.jconrel.2022.08.048

942. Hsu HK Development and in vitro evaluation of linear PEI-shelled heparin/berberine nanoparticles in human osteosarcoma U-2 OS cells Molecules 2018 23 3122 10.3390/molecules23123121 30487471 PMC6320921 Hsu, H. K. et al. Development and in vitro evaluation of linear PEI-shelled heparin/berberine nanoparticles in human osteosarcoma U-2 OS cells. Molecules 23 , 3122 (2018). 30487471 10.3390/molecules23123121 PMC6320921

943. Li S Xiong Y Zhang X Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcoma Biomed. Pharmacother. 2017 90 872 879 10.1016/j.biopha.2017.04.004 28449430 Li, S., Xiong, Y. & Zhang, X. Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcoma. Biomed. Pharmacother. 90 , 872–879 (2017). 28449430 10.1016/j.biopha.2017.04.004

944. Martella E Functionalized keratin as nanotechnology-based drug delivery system for the pharmacological treatment of osteosarcoma Int. J. Mol. Sci. 2018 19 3670 10.3390/ijms19113670 30463350 PMC6274803 Martella, E. et al. Functionalized keratin as nanotechnology-based drug delivery system for the pharmacological treatment of osteosarcoma. Int. J. Mol. Sci. 19 , 3670 (2018). 30463350 10.3390/ijms19113670 PMC6274803

945. Li S Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis Theranostics 2018 8 1361 1375 10.7150/thno.18299 29507626 PMC5835942 Li, S. et al. Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics 8 , 1361–1375 (2018). 29507626 10.7150/thno.18299 PMC5835942

946. Liu L Qi XJ Zhong ZK Zhang EN Nanomedicine-based combination of gambogic acid and retinoic acid chlorochalcone for enhanced anticancer efficacy in osteosarcoma Biomed. Pharmacother. 2016 83 79 84 10.1016/j.biopha.2016.06.001 27470553 Liu, L., Qi, X. J., Zhong, Z. K. & Zhang, E. N. Nanomedicine-based combination of gambogic acid and retinoic acid chlorochalcone for enhanced anticancer efficacy in osteosarcoma. Biomed. Pharmacother. 83 , 79–84 (2016). 27470553 10.1016/j.biopha.2016.06.001

947. Chen C Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs Cancer Lett 2021 500 1 10 10.1016/j.canlet.2020.12.024 33359211 Chen, C. et al. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett 500 , 1–10 (2021). 33359211 10.1016/j.canlet.2020.12.024

948. Du C D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy Biomaterials 2021 269 120642 10.1016/j.biomaterials.2020.120642 33440291 Du, C. et al. D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy. Biomaterials 269 , 120642 (2021). 33440291 10.1016/j.biomaterials.2020.120642

949. Zeng WN Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma J. Nanobiotechnol. 2021 19 79 10.1186/s12951-021-00831-6 PMC7980640 33740998 Zeng, W. N. et al. Mitochondria-targeting graphene oxide nanocomposites for fluorescence imaging-guided synergistic phototherapy of drug-resistant osteosarcoma. J. Nanobiotechnol. 19 , 79 (2021). 10.1186/s12951-021-00831-6 PMC7980640 33740998

950. Liu K Photothermal-triggered immunogenic nanotherapeutics for optimizing osteosarcoma therapy by synergizing innate and adaptive immunity Biomaterials 2022 282 121383 10.1016/j.biomaterials.2022.121383 35074635 Liu, K. et al. Photothermal-triggered immunogenic nanotherapeutics for optimizing osteosarcoma therapy by synergizing innate and adaptive immunity. Biomaterials 282 , 121383 (2022). 35074635 10.1016/j.biomaterials.2022.121383

951. Luo T Biodegradable FePS(3) nanoplatform for efficient treatment of osteosarcoma by combination of gene and NIR-II photothermal therapy J. Nanobiotechnol. 2023 21 224 10.1186/s12951-023-01961-9 PMC10347837 37443019 Luo, T. et al. Biodegradable FePS(3) nanoplatform for efficient treatment of osteosarcoma by combination of gene and NIR-II photothermal therapy. J. Nanobiotechnol. 21 , 224 (2023). 10.1186/s12951-023-01961-9 PMC10347837 37443019

952. Luo Z Neutrophil hitchhiking for drug delivery to the bone marrow Nat. Nanotechnol. 2023 18 647 656 10.1038/s41565-023-01374-7 37081080 Luo, Z. et al. Neutrophil hitchhiking for drug delivery to the bone marrow. Nat. Nanotechnol. 18 , 647–656 (2023). 37081080 10.1038/s41565-023-01374-7

953. Wang F Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy Int. J. Nanomed. 2018 13 857 875 10.2147/IJN.S147747 PMC5811182 29467575 Wang, F. et al. Nanoscale polysaccharide derivative as an AEG-1 siRNA carrier for effective osteosarcoma therapy. Int. J. Nanomed. 13 , 857–875 (2018). 10.2147/IJN.S147747 PMC5811182 29467575

954. Gui K Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells Biomed. Pharmacother. 2019 111 751 764 10.1016/j.biopha.2018.11.118 30612000 Gui, K. et al. Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells. Biomed. Pharmacother. 111 , 751–764 (2019). 30612000 10.1016/j.biopha.2018.11.118

955. Panagi M Pilavaki P Constantinidou A Stylianopoulos T Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness Theranostics 2022 12 6106 6129 10.7150/thno.72800 36168619 PMC9475460 Panagi, M., Pilavaki, P., Constantinidou, A. & Stylianopoulos, T. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. Theranostics 12 , 6106–6129 (2022). 36168619 10.7150/thno.72800 PMC9475460

956. Zhang S Gadolinium-bisphosphonate nanoparticle-based low-dose radioimmunotherapy for osteosarcoma ACS Biomater. Sci. Eng. 2022 8 5329 5337 10.1021/acsbiomaterials.2c00880 36383732 Zhang, S. et al. Gadolinium-bisphosphonate nanoparticle-based low-dose radioimmunotherapy for osteosarcoma. ACS Biomater. Sci. Eng. 8 , 5329–5337 (2022). 36383732 10.1021/acsbiomaterials.2c00880

957. Amary MF IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours J. Pathol. 2011 224 334 343 10.1002/path.2913 21598255 Amary, M. F. et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J. Pathol. 224 , 334–343 (2011). 21598255 10.1002/path.2913

958. Vares G Functionalized mesoporous silica nanoparticles for innovative boron-neutron capture therapy of resistant cancers Nanomed. Nanotechnol. 2020 27 102195 10.1016/j.nano.2020.102195 32278101 Vares, G. et al. Functionalized mesoporous silica nanoparticles for innovative boron-neutron capture therapy of resistant cancers. Nanomed. Nanotechnol. 27 , 102195 (2020). 10.1016/j.nano.2020.102195 32278101

959. Pappo AS Dirksen U Rhabdomyosarcoma, Ewing sarcoma, and other round cell sarcomas J. Clin. Oncol. 2018 36 168 179 10.1200/JCO.2017.74.7402 29220292 Pappo, A. S. & Dirksen, U. Rhabdomyosarcoma, Ewing sarcoma, and other round cell sarcomas. J. Clin. Oncol. 36 , 168–179 (2018). 29220292 10.1200/JCO.2017.74.7402

960. Slotkin EK Tap WD Towards a new era in the treatment of Ewing sarcoma Lancet 2022 400 1488 1489 10.1016/S0140-6736(22)02081-5 36522196 Slotkin, E. K. & Tap, W. D. Towards a new era in the treatment of Ewing sarcoma. Lancet 400 , 1488–1489 (2022). 36522196 10.1016/S0140-6736(22)02081-5

961. Grunewald TGP Ewing sarcoma Nat. Rev. Dis. Primers 2018 4 5 10.1038/s41572-018-0003-x 29977059 Grunewald, T. G. P. et al. Ewing sarcoma. Nat. Rev. Dis. Primers 4 , 5 (2018). 29977059 10.1038/s41572-018-0003-x

962. Naumann JA SN-38 conjugated gold nanoparticles activated by Ewing sarcoma specific mRNAs exhibit in vitro and in vivo efficacy Bioconjugate Chem 2018 29 1111 1118 10.1021/acs.bioconjchem.7b00774 PMC7278042 29412642 Naumann, J. A. et al. SN-38 conjugated gold nanoparticles activated by Ewing sarcoma specific mRNAs exhibit in vitro and in vivo efficacy. Bioconjugate Chem 29 , 1111–1118 (2018). 10.1021/acs.bioconjchem.7b00774 PMC7278042 29412642

963. Zaritski A Selective accumulation of galactomannan amphiphilic nanomaterials in pediatric solid tumor xenografts correlates with GLUT1 gene expression ACS Appl. Mater. Inter. 2019 11 38483 38496 10.1021/acsami.9b12682 31537060 Zaritski, A. et al. Selective accumulation of galactomannan amphiphilic nanomaterials in pediatric solid tumor xenografts correlates with GLUT1 gene expression. ACS Appl. Mater. Inter. 11 , 38483–38496 (2019). 10.1021/acsami.9b12682 31537060

964. Toub N Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma Pharm. Res. 2006 23 892 900 10.1007/s11095-006-9901-9 16715379 Toub, N. et al. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm. Res. 23 , 892–900 (2006). 16715379 10.1007/s11095-006-9901-9

965. Que SKT Zwald FO Schmults CD Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging J. Am. Acad. Dermatol. 2018 78 237 247 10.1016/j.jaad.2017.08.059 29332704 Que, S. K. T., Zwald, F. O. & Schmults, C. D. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J. Am. Acad. Dermatol. 78 , 237–247 (2018). 29332704 10.1016/j.jaad.2017.08.059

966. Winge MCG Advances in cutaneous squamous cell carcinoma Nat. Rev. Cancer 2023 23 430 449 10.1038/s41568-023-00583-5 37286893 Winge, M. C. G. et al. Advances in cutaneous squamous cell carcinoma. Nat. Rev. Cancer 23 , 430–449 (2023). 37286893 10.1038/s41568-023-00583-5

967. Keyal U Bhatta AK Zhang G Wang XL Present and future perspectives of photodynamic therapy for cutaneous squamous cell carcinoma J. Am. Acad. Dermatol. 2019 80 765 773 10.1016/j.jaad.2018.10.042 30393093 Keyal, U., Bhatta, A. K., Zhang, G. & Wang, X. L. Present and future perspectives of photodynamic therapy for cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol. 80 , 765–773 (2019). 30393093 10.1016/j.jaad.2018.10.042

968. Aslam AM Patel AN Facial cutaneous squamous cell carcinoma BMJ 2016 352 i1513 10.1136/bmj.i1513 27032668 Aslam, A. M. & Patel, A. N. Facial cutaneous squamous cell carcinoma. BMJ 352 , i1513 (2016). 27032668 10.1136/bmj.i1513

969. Zwald F Recommendations for solid organ transplantation for transplant candidates with a pretransplant diagnosis of cutaneous squamous cell carcinoma, merkel cell carcinoma and melanoma: a consensus opinion from the international transplant skin cancer collaborative (ITSCC) Am. J. Transplant. 2016 16 407 413 10.1111/ajt.13593 26820755 Zwald, F. et al. Recommendations for solid organ transplantation for transplant candidates with a pretransplant diagnosis of cutaneous squamous cell carcinoma, merkel cell carcinoma and melanoma: a consensus opinion from the international transplant skin cancer collaborative (ITSCC). Am. J. Transplant. 16 , 407–413 (2016). 26820755 10.1111/ajt.13593

970. Schmults CD NCCN guidelines® insights: squamous cell skin cancer, version 1.2022 J. Natl. Compr. Canc. Ne. 2021 19 1382 1394 10.6004/jnccn.2021.0059 34902824 Schmults, C. D. et al. NCCN guidelines® insights: squamous cell skin cancer, version 1.2022. J. Natl. Compr. Canc. Ne. 19 , 1382–1394 (2021). 10.6004/jnccn.2021.0059 34902824

971. Waldman A Schmults C Cutaneous squamous cell carcinoma Hematol. Oncol. Clin. N. 2019 33 1 12 10.1016/j.hoc.2018.08.001 30497667 Waldman, A. & Schmults, C. Cutaneous squamous cell carcinoma. Hematol. Oncol. Clin. N. 33 , 1–12 (2019). 10.1016/j.hoc.2018.08.001 30497667

972. Yu Z Early melanoma diagnosis with sequential dermoscopic images IEEE T. Med. Imaging 2022 41 633 646 10.1109/TMI.2021.3120091 34648437 Yu, Z. et al. Early melanoma diagnosis with sequential dermoscopic images. IEEE T. Med. Imaging 41 , 633–646 (2022). 10.1109/TMI.2021.3120091 34648437

973. Skudalski L Waldman R Kerr PE Grant-Kels JM Melanoma: how and when to consider clinical diagnostic technologies J. Am. Acad. Dermatol. 2022 86 503 512 10.1016/j.jaad.2021.06.901 34915058 Skudalski, L., Waldman, R., Kerr, P. E. & Grant-Kels, J. M. Melanoma: how and when to consider clinical diagnostic technologies. J. Am. Acad. Dermatol. 86 , 503–512 (2022). 34915058 10.1016/j.jaad.2021.06.901

974. Pellacani G Argenziano G New insights from non-invasive imaging: from prospection of skin photodamages to training with mobile application J. Eur. Acad. Dermatol. 2022 36 38 50 10.1111/jdv.18197 PMC9328152 35738810 Pellacani, G. & Argenziano, G. New insights from non-invasive imaging: from prospection of skin photodamages to training with mobile application. J. Eur. Acad. Dermatol. 36 , 38–50 (2022). 10.1111/jdv.18197 PMC9328152 35738810

975. Long GV Cutaneous melanoma Lancet 2023 402 485 502 10.1016/S0140-6736(23)00821-8 37499671 Long, G. V. et al. Cutaneous melanoma. Lancet 402 , 485–502 (2023). 37499671 10.1016/S0140-6736(23)00821-8

976. Clarke LE Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma J. Cutan. Pathol. 2015 42 244 252 10.1111/cup.12475 25727210 PMC6681167 Clarke, L. E. et al. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J. Cutan. Pathol. 42 , 244–252 (2015). 25727210 10.1111/cup.12475 PMC6681167

977. Wang P Differential diagnosis and precision therapy of two typical malignant cutaneous tumors leveraging their tumor microenvironment: a photomedicine strategy ACS Nano 2019 13 11168 11180 10.1021/acsnano.9b04070 31585038 Wang, P. et al. Differential diagnosis and precision therapy of two typical malignant cutaneous tumors leveraging their tumor microenvironment: a photomedicine strategy. ACS Nano 13 , 11168–11180 (2019). 31585038 10.1021/acsnano.9b04070

978. Knackstedt T Knackstedt RW Couto R Gastman B Malignant melanoma: diagnostic and management update Plast. Reconstr. Surg. 2018 142 202e 216e 10.1097/PRS.0000000000004571 30045186 Knackstedt, T., Knackstedt, R. W., Couto, R. & Gastman, B. Malignant melanoma: diagnostic and management update. Plast. Reconstr. Surg. 142 , 202e–216e (2018). 30045186 10.1097/PRS.0000000000004571

979. Kozyra P Krasowska D Pitucha M New potential agents for malignant melanoma treatment-most recent studies 2020-2022 Int. J. Mol. Sci. 2022 23 6084 10.3390/ijms23116084 35682764 PMC9180979 Kozyra, P., Krasowska, D. & Pitucha, M. New potential agents for malignant melanoma treatment-most recent studies 2020-2022. Int. J. Mol. Sci. 23 , 6084 (2022). 35682764 10.3390/ijms23116084 PMC9180979

980. Luo L Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma Biomaterials 2019 223 119464 10.1016/j.biomaterials.2019.119464 31525691 Luo, L. et al. Engineered nano-immunopotentiators efficiently promote cancer immunotherapy for inhibiting and preventing lung metastasis of melanoma. Biomaterials 223 , 119464 (2019). 31525691 10.1016/j.biomaterials.2019.119464

981. Pu Y Tyrosinase-activated prodrug nanomedicine as oxidative stress amplifier for melanoma-specific treatment Biomaterials 2020 259 120329 10.1016/j.biomaterials.2020.120329 32836058 Pu, Y. et al. Tyrosinase-activated prodrug nanomedicine as oxidative stress amplifier for melanoma-specific treatment. Biomaterials 259 , 120329 (2020). 32836058 10.1016/j.biomaterials.2020.120329

982. Suman S Markovic SN Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis Trends Immunol 2023 44 724 743 10.1016/j.it.2023.07.002 37573226 PMC10528107 Suman, S. & Markovic, S. N. Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis. Trends Immunol 44 , 724–743 (2023). 37573226 10.1016/j.it.2023.07.002 PMC10528107

983. Skudalski L Waldman R Kerr PE Grant-Kels JM Melanoma: an update on systemic therapies J. Am. Acad. Dermatol. 2022 86 515 524 10.1016/j.jaad.2021.09.075 34915056 Skudalski, L., Waldman, R., Kerr, P. E. & Grant-Kels, J. M. Melanoma: an update on systemic therapies. J. Am. Acad. Dermatol. 86 , 515–524 (2022). 34915056 10.1016/j.jaad.2021.09.075

984. Shalhout SZ Kaufman HL Emerick KS Miller DM Immunotherapy for nonmelanoma skin cancer: facts and hopes Clin. Cancer Res. 2022 28 2211 2220 10.1158/1078-0432.CCR-21-2971 35121622 Shalhout, S. Z., Kaufman, H. L., Emerick, K. S. & Miller, D. M. Immunotherapy for nonmelanoma skin cancer: facts and hopes. Clin. Cancer Res. 28 , 2211–2220 (2022). 35121622 10.1158/1078-0432.CCR-21-2971

985. Chang Y Designing core-shell gold and selenium nanocomposites for cancer radiochemotherapy ACS Nano 2017 11 4848 4858 10.1021/acsnano.7b01346 28460158 Chang, Y. et al. Designing core-shell gold and selenium nanocomposites for cancer radiochemotherapy. ACS Nano 11 , 4848–4858 (2017). 28460158 10.1021/acsnano.7b01346

986. Jiang BP Poly(N-phenylglycine)-based nanoparticles as highly effective and targeted near-infrared photothermal therapy/photodynamic therapeutic agents for malignant melanoma Small 2017 13 1602496 10.1002/smll.201602496 27982516 Jiang, B. P. et al. Poly(N-phenylglycine)-based nanoparticles as highly effective and targeted near-infrared photothermal therapy/photodynamic therapeutic agents for malignant melanoma. Small 13 , 1602496 (2017). 10.1002/smll.201602496 27982516

987. Carvajal RD Advances in the clinical management of uveal melanoma Nat. Rev. Clin. Oncol. 2023 20 99 115 10.1038/s41571-022-00714-1 36600005 Carvajal, R. D. et al. Advances in the clinical management of uveal melanoma. Nat. Rev. Clin. Oncol. 20 , 99–115 (2023). 36600005 10.1038/s41571-022-00714-1

988. Li X Research progress of microneedles in the treatment of melanoma J. Control. Release 2022 348 631 647 10.1016/j.jconrel.2022.06.021 35718209 Li, X. et al. Research progress of microneedles in the treatment of melanoma. J. Control. Release 348 , 631–647 (2022). 35718209 10.1016/j.jconrel.2022.06.021

989. Zhao J Novel strategies in melanoma treatment using silver nanoparticles Cancer Lett 2023 561 216148 10.1016/j.canlet.2023.216148 36990267 Zhao, J. et al. Novel strategies in melanoma treatment using silver nanoparticles. Cancer Lett 561 , 216148 (2023). 36990267 10.1016/j.canlet.2023.216148

990. Moy AJ Tunnell JW Combinatorial immunotherapy and nanoparticle mediated hyperthermia Adv. Drug Deliver. Rev. 2017 114 175 183 10.1016/j.addr.2017.06.008 28625829 Moy, A. J. & Tunnell, J. W. Combinatorial immunotherapy and nanoparticle mediated hyperthermia. Adv. Drug Deliver. Rev. 114 , 175–183 (2017). 10.1016/j.addr.2017.06.008 28625829

991. Bhave P Management of cutaneous melanoma in Australia: a narrative review Med. J. Australia 2023 218 426 431 10.5694/mja2.51910 37120760 Bhave, P. et al. Management of cutaneous melanoma in Australia: a narrative review. Med. J. Australia 218 , 426–431 (2023). 37120760 10.5694/mja2.51910

992. Zhi D Microneedles for gene and drug delivery in skin cancer therapy J. Control. Release 2021 335 158 177 10.1016/j.jconrel.2021.05.009 33984344 Zhi, D. et al. Microneedles for gene and drug delivery in skin cancer therapy. J. Control. Release 335 , 158–177 (2021). 33984344 10.1016/j.jconrel.2021.05.009

993. Xiao Q Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator Acta Pharm. Sin. B 2023 13 3503 3517 10.1016/j.apsb.2022.07.012 37655330 PMC10465872 Xiao, Q. et al. Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator. Acta Pharm. Sin. B 13 , 3503–3517 (2023). 37655330 10.1016/j.apsb.2022.07.012 PMC10465872

994. Kristensen LS Spatial expression analyses of the putative oncogene ciRS-7 in cancer reshape the microRNA sponge theory Nat. Commun. 2020 11 4551 10.1038/s41467-020-18355-2 32917870 PMC7486402 Kristensen, L. S. et al. Spatial expression analyses of the putative oncogene ciRS-7 in cancer reshape the microRNA sponge theory. Nat. Commun. 11 , 4551 (2020). 32917870 10.1038/s41467-020-18355-2 PMC7486402

995. Liu Q Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy Biomaterials 2020 258 120275 10.1016/j.biomaterials.2020.120275 32798741 Liu, Q. et al. Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR/Cas9-based cancer immunotherapy. Biomaterials 258 , 120275 (2020). 32798741 10.1016/j.biomaterials.2020.120275

996. Zeng L Advancements in nanoparticle-based treatment approaches for skin cancer therapy Mol. Cancer 2023 22 10 10.1186/s12943-022-01708-4 36635761 PMC9835394 Zeng, L. et al. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol. Cancer 22 , 10 (2023). 36635761 10.1186/s12943-022-01708-4 PMC9835394

997. Akhtar N Khan RA Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions’ Prog. Lipid Res. 2016 64 192 230 10.1016/j.plipres.2016.08.005 27697511 Akhtar, N. & Khan, R. A. Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions’. Prog. Lipid Res. 64 , 192–230 (2016). 27697511 10.1016/j.plipres.2016.08.005

998. Feng L Near-infrared light activation of quenched liposomal Ce6 for synergistic cancer phototherapy with effective skin protection Biomaterials 2017 127 13 24 10.1016/j.biomaterials.2016.11.027 28279918 Feng, L. et al. Near-infrared light activation of quenched liposomal Ce6 for synergistic cancer phototherapy with effective skin protection. Biomaterials 127 , 13–24 (2017). 28279918 10.1016/j.biomaterials.2016.11.027

999. Tham HP Microneedle-assisted topical delivery of photodynamically active mesoporous formulation for combination therapy of deep-seated melanoma ACS Nano 2018 12 11936 11948 10.1021/acsnano.8b03007 30444343 Tham, H. P. et al. Microneedle-assisted topical delivery of photodynamically active mesoporous formulation for combination therapy of deep-seated melanoma. ACS Nano 12 , 11936–11948 (2018). 30444343 10.1021/acsnano.8b03007

1000. Algarin YA Jambusaria-Pahlajani A Ruiz E Patel VA Advances in topical treatments of cutaneous malignancies Am. J. Clin. Dermatol. 2023 24 69 80 10.1007/s40257-022-00731-x 36169917 Algarin, Y. A., Jambusaria-Pahlajani, A., Ruiz, E. & Patel, V. A. Advances in topical treatments of cutaneous malignancies. Am. J. Clin. Dermatol. 24 , 69–80 (2023). 36169917 10.1007/s40257-022-00731-x

1001. Wang X Treating cutaneous squamous cell carcinoma using 5-aminolevulinic acid polylactic-co-glycolic acid nanoparticle-mediated photodynamic therapy in a mouse model Int. J. Nanomed. 2015 10 347 355 10.2147/IJN.S71245 PMC4293366 25609949 Wang, X. et al. Treating cutaneous squamous cell carcinoma using 5-aminolevulinic acid polylactic-co-glycolic acid nanoparticle-mediated photodynamic therapy in a mouse model. Int. J. Nanomed. 10 , 347–355 (2015). 10.2147/IJN.S71245 PMC4293366 25609949

1002. Borgheti-Cardoso LN Nanotechnology approaches in the current therapy of skin cancer Adv. Drug Deliver. Rev. 2020 153 109 136 10.1016/j.addr.2020.02.005 32113956 Borgheti-Cardoso, L. N. et al. Nanotechnology approaches in the current therapy of skin cancer. Adv. Drug Deliver. Rev. 153 , 109–136 (2020). 10.1016/j.addr.2020.02.005 32113956

1003. Kaur H Kesharwani P Advanced nanomedicine approaches applied for treatment of skin carcinoma J. Control. Release 2021 337 589 611 10.1016/j.jconrel.2021.08.003 34364919 Kaur, H. & Kesharwani, P. Advanced nanomedicine approaches applied for treatment of skin carcinoma. J. Control. Release 337 , 589–611 (2021). 34364919 10.1016/j.jconrel.2021.08.003

1004. Khan NH Skin cancer biology and barriers to treatment: recent applications of polymeric micro/nanostructures J. Adv. Res. 2022 36 223 247 10.1016/j.jare.2021.06.014 35127174 PMC8799916 Khan, N. H. et al. Skin cancer biology and barriers to treatment: recent applications of polymeric micro/nanostructures. J. Adv. Res. 36 , 223–247 (2022). 35127174 10.1016/j.jare.2021.06.014 PMC8799916

1005. He W Turning a luffa protein into a self-assembled biodegradable nanoplatform for multitargeted cancer therapy ACS Nano 2018 12 11664 11677 10.1021/acsnano.8b07079 30335959 He, W. et al. Turning a luffa protein into a self-assembled biodegradable nanoplatform for multitargeted cancer therapy. ACS Nano 12 , 11664–11677 (2018). 30335959 10.1021/acsnano.8b07079

1006. La Vecchia C Thyroid cancer mortality and incidence: a global overview Int. J. Cancer 2015 136 2187 2195 10.1002/ijc.29251 25284703 La Vecchia, C. et al. Thyroid cancer mortality and incidence: a global overview. Int. J. Cancer 136 , 2187–2195 (2015). 25284703 10.1002/ijc.29251

1007. Miranda-Filho A Thyroid cancer incidence trends by histology in 25 countries: a population-based study Lancet Diabetes Endo 2021 9 225 234 10.1016/S2213-8587(21)00027-9 33662333 Miranda-Filho, A. et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endo 9 , 225–234 (2021). 10.1016/S2213-8587(21)00027-9 33662333

1008. Cabanillas ME McFadden DG Durante C Thyroid cancer Lancet 2016 388 2783 2795 10.1016/S0140-6736(16)30172-6 27240885 Cabanillas, M. E., McFadden, D. G. & Durante, C. Thyroid cancer. Lancet 388 , 2783–2795 (2016). 27240885 10.1016/S0140-6736(16)30172-6

1009. Molinaro E Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies Nat. Rev. Endocrinol. 2017 13 644 660 10.1038/nrendo.2017.76 28707679 Molinaro, E. et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 13 , 644–660 (2017). 28707679 10.1038/nrendo.2017.76

1010. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159 , 676–690 (2014). 10.1016/j.cell.2014.09.050 PMC4243044 25417114

1011. Landa I Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers J. Clin. Invest. 2016 126 1052 1066 10.1172/JCI85271 26878173 PMC4767360 Landa, I. et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 126 , 1052–1066 (2016). 26878173 10.1172/JCI85271 PMC4767360

1012. Omer WE Highly efficient gold nano-flower optical biosensor doped in a sol-Gel/PEG matrix for the determination of a calcitonin biomarker in different serum samples ACS Omega 2020 5 5629 5637 10.1021/acsomega.9b02833 32226838 PMC7097903 Omer, W. E. et al. Highly efficient gold nano-flower optical biosensor doped in a sol-Gel/PEG matrix for the determination of a calcitonin biomarker in different serum samples. ACS Omega 5 , 5629–5637 (2020). 32226838 10.1021/acsomega.9b02833 PMC7097903

1013. Choi G Kim E Park E Lee JH A cost-effective chemiluminescent biosensor capable of early diagnosing cancer using a combination of magnetic beads and platinum nanoparticles Talanta 2017 162 38 45 10.1016/j.talanta.2016.09.061 27837844 Choi, G., Kim, E., Park, E. & Lee, J. H. A cost-effective chemiluminescent biosensor capable of early diagnosing cancer using a combination of magnetic beads and platinum nanoparticles. Talanta 162 , 38–45 (2017). 27837844 10.1016/j.talanta.2016.09.061

1014. Hu Z Qin J Li T Guo J Thyroid cancer MR molecular imaging via SHP2-targeted nanoparticles Int. J. Nanomed. 2019 14 7365 7373 10.2147/IJN.S201358 PMC6751334 31686812 Hu, Z., Qin, J., Li, T. & Guo, J. Thyroid cancer MR molecular imaging via SHP2-targeted nanoparticles. Int. J. Nanomed. 14 , 7365–7373 (2019). 10.2147/IJN.S201358 PMC6751334 31686812

1015. Fanfone D Toward a new and noninvasive diagnostic method of papillary thyroid cancer by using peptide vectorized contrast agents targeted to galectin-1 Med. Oncol. 2017 34 184 10.1007/s12032-017-1042-y 28986753 Fanfone, D. et al. Toward a new and noninvasive diagnostic method of papillary thyroid cancer by using peptide vectorized contrast agents targeted to galectin-1. Med. Oncol. 34 , 184 (2017). 28986753 10.1007/s12032-017-1042-y

1016. Giaquinto AN Breast cancer statistics, 2022 CA-Cancer J. Clin 2022 72 524 541 10.3322/caac.21754 36190501 Giaquinto, A. N. et al. Breast cancer statistics, 2022. CA-Cancer J. Clin 72 , 524–541 (2022). 36190501 10.3322/caac.21754

1017. Kitsios K Sharifi S Mahmoudi M Nanomedicine technologies for diagnosis and treatment of breast cancer ACS Pharmacol. Transl. 2023 6 671 682 10.1021/acsptsci.3c00044 PMC10186357 37200812 Kitsios, K., Sharifi, S. & Mahmoudi, M. Nanomedicine technologies for diagnosis and treatment of breast cancer. ACS Pharmacol. Transl. 6 , 671–682 (2023). 10.1021/acsptsci.3c00044 PMC10186357 37200812

1018. Nolan E Lindeman GJ Visvader JE Deciphering breast cancer: from biology to the clinic Cell 2023 186 1708 1728 10.1016/j.cell.2023.01.040 36931265 Nolan, E., Lindeman, G. J. & Visvader, J. E. Deciphering breast cancer: from biology to the clinic. Cell 186 , 1708–1728 (2023). 36931265 10.1016/j.cell.2023.01.040

1019. Ashkarran AA Impact of nanomedicine in women’s metastatic breast cancer Small 2023 3 e2301385 10.1002/smll.202301385 PMC10693652 37269217 Ashkarran, A. A. et al. Impact of nanomedicine in women’s metastatic breast cancer. Small 3 , e2301385 (2023). 10.1002/smll.202301385 PMC10693652 37269217

1020. Nasrollahpour H Nanotechnology-based electrochemical biosensors for monitoring breast cancer biomarkers Med. Res. Rev. 2023 43 464 569 10.1002/med.21931 36464910 Nasrollahpour, H. et al. Nanotechnology-based electrochemical biosensors for monitoring breast cancer biomarkers. Med. Res. Rev. 43 , 464–569 (2023). 36464910 10.1002/med.21931

1021. Lee Y Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis Mol. Cancer 2023 22 33 10.1186/s12943-023-01741-x 36797736 PMC9933347 Lee, Y. et al. Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis. Mol. Cancer 22 , 33 (2023). 36797736 10.1186/s12943-023-01741-x PMC9933347

1022. Mohammadpour-Haratbar A Zare Y Rhee KY Electrochemical biosensors based on polymer nanocomposites for detecting breast cancer: recent progress and future prospects Adv. Colloid Interfac. 2022 309 102795 10.1016/j.cis.2022.102795 36242876 Mohammadpour-Haratbar, A., Zare, Y. & Rhee, K. Y. Electrochemical biosensors based on polymer nanocomposites for detecting breast cancer: recent progress and future prospects. Adv. Colloid Interfac. 309 , 102795 (2022). 10.1016/j.cis.2022.102795 36242876

1023. Chauhan P Surface-enhanced Raman scattering biosensors for detection of oncomiRs in breast cancer Drug Discov. Today 2022 27 2121 2136 10.1016/j.drudis.2022.04.016 35460892 Chauhan, P. et al. Surface-enhanced Raman scattering biosensors for detection of oncomiRs in breast cancer. Drug Discov. Today 27 , 2121–2136 (2022). 35460892 10.1016/j.drudis.2022.04.016

1024. Garrido-Cano I Nanoporous anodic alumina-based sensor for miR-99a-5p detection as an effective early breast cancer diagnostic tool ACS Sensors 2021 6 1022 1029 10.1021/acssensors.0c02222 33599490 Garrido-Cano, I. et al. Nanoporous anodic alumina-based sensor for miR-99a-5p detection as an effective early breast cancer diagnostic tool. ACS Sensors 6 , 1022–1029 (2021). 33599490 10.1021/acssensors.0c02222

1025. Biondi B Wartofsky L Treatment with thyroid hormone Endocr. Rev. 2014 35 433 512 10.1210/er.2013-1083 24433025 Biondi, B. & Wartofsky, L. Treatment with thyroid hormone. Endocr. Rev. 35 , 433–512 (2014). 24433025 10.1210/er.2013-1083

1026. Chen DW Thyroid cancer Lancet 2023 401 1531 1544 10.1016/S0140-6736(23)00020-X 37023783 Chen, D. W. et al. Thyroid cancer. Lancet 401 , 1531–1544 (2023). 37023783 10.1016/S0140-6736(23)00020-X

1027. Haugen BR Sherman SI Evolving approaches to patients with advanced differentiated thyroid cancer Endocr. Rev. 2013 34 439 455 10.1210/er.2012-1038 23575762 PMC3660715 Haugen, B. R. & Sherman, S. I. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr. Rev. 34 , 439–455 (2013). 23575762 10.1210/er.2012-1038 PMC3660715

1028. Van Nostrand D The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer Thyroid 2009 19 1381 1391 10.1089/thy.2009.1611 20001720 Van Nostrand, D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid 19 , 1381–1391 (2009). 20001720 10.1089/thy.2009.1611

1029. Kebebew E Treatment for advanced and metastatic thyroid cancer refractory to standard treatment—we need to know the when, what, and who JAMA Oncol 2022 8 250 251 10.1001/jamaoncol.2021.6247 34913944 Kebebew, E. Treatment for advanced and metastatic thyroid cancer refractory to standard treatment—we need to know the when, what, and who. JAMA Oncol 8 , 250–251 (2022). 34913944 10.1001/jamaoncol.2021.6247

1030. Liu Y Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy Drug Resist. Update. 2023 68 100939 10.1016/j.drup.2023.100939 36806005 Liu, Y. et al. Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy. Drug Resist. Update. 68 , 100939 (2023). 10.1016/j.drup.2023.100939 36806005

1031. Cellini M Skeletal health in patients with differentiated thyroid carcinoma J. Endocrinol. Invest. 2021 44 431 442 10.1007/s40618-020-01359-6 32696339 Cellini, M. et al. Skeletal health in patients with differentiated thyroid carcinoma. J. Endocrinol. Invest. 44 , 431–442 (2021). 32696339 10.1007/s40618-020-01359-6

1032. Lee EK Cardiovascular outcomes in thyroid cancer patients treated with thyroidectomy: a meta-analysis J. Clin. Endocr. Metab. 2021 106 3644 3654 34347085 10.1210/clinem/dgab576 Lee, E. K. et al. Cardiovascular outcomes in thyroid cancer patients treated with thyroidectomy: a meta-analysis. J. Clin. Endocr. Metab. 106 , 3644–3654 (2021). 34347085 10.1210/clinem/dgab576

1033. Walker MD Shane E Hypercalcemia: a review JAMA 2022 328 1624 1636 10.1001/jama.2022.18331 36282253 Walker, M. D. & Shane, E. Hypercalcemia: a review. JAMA 328 , 1624–1636 (2022). 36282253 10.1001/jama.2022.18331

1034. Bible KC Ryder M Evolving molecularly targeted therapies for advanced-stage thyroid cancers Nat. Rev. Clin. Oncol. 2016 13 403 416 10.1038/nrclinonc.2016.19 26925962 Bible, K. C. & Ryder, M. Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat. Rev. Clin. Oncol. 13 , 403–416 (2016). 26925962 10.1038/nrclinonc.2016.19

1035. Naoum GE Morkos M Kim B Arafat W Novel targeted therapies and immunotherapy for advanced thyroid cancers Mol. Cancer 2018 17 51 10.1186/s12943-018-0786-0 29455653 PMC5817719 Naoum, G. E., Morkos, M., Kim, B. & Arafat, W. Novel targeted therapies and immunotherapy for advanced thyroid cancers. Mol. Cancer 17 , 51 (2018). 29455653 10.1186/s12943-018-0786-0 PMC5817719

1036. Saini S Therapeutic advances in anaplastic thyroid cancer: a current perspective Mol. Cancer 2018 17 154 10.1186/s12943-018-0903-0 30352606 PMC6198524 Saini, S. et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol. Cancer 17 , 154 (2018). 30352606 10.1186/s12943-018-0903-0 PMC6198524

1037. Tiedje V Fagin JA Therapeutic breakthroughs for metastatic thyroid cancer Nat. Rev. Endocrinol. 2020 16 77 78 10.1038/s41574-019-0307-2 31819229 PMC7470005 Tiedje, V. & Fagin, J. A. Therapeutic breakthroughs for metastatic thyroid cancer. Nat. Rev. Endocrinol. 16 , 77–78 (2020). 31819229 10.1038/s41574-019-0307-2 PMC7470005

1038. Zhu L Novel alternatives to extracellular vesicle-based immunotherapy - exosome mimetics derived from natural killer cells Artif. Cell. Nanomed. B. 2018 46 S166 s179 10.1080/21691401.2018.1489824 30092165 Zhu, L. et al. Novel alternatives to extracellular vesicle-based immunotherapy - exosome mimetics derived from natural killer cells. Artif. Cell. Nanomed. B. 46 , S166–s179 (2018). 10.1080/21691401.2018.1489824 30092165

1039. Cristiano MC Anticancer activity of all-trans retinoic acid-loaded liposomes on human thyroid carcinoma cells Colloid. Surface. B 2017 150 408 416 10.1016/j.colsurfb.2016.10.052 27829536 Cristiano, M. C. et al. Anticancer activity of all-trans retinoic acid-loaded liposomes on human thyroid carcinoma cells. Colloid. Surface. B 150 , 408–416 (2017). 10.1016/j.colsurfb.2016.10.052 27829536

1040. Li S Zhang D Sheng S Sun H Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles Int. J. Nanomed. 2017 12 5993 6003 10.2147/IJN.S137335 PMC5573063 28860762 Li, S., Zhang, D., Sheng, S. & Sun, H. Targeting thyroid cancer with acid-triggered release of doxorubicin from silicon dioxide nanoparticles. Int. J. Nanomed. 12 , 5993–6003 (2017). 10.2147/IJN.S137335 PMC5573063 28860762

1041. Yu T Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy J. Photoch. Photobio. B 2019 197 111534 10.1016/j.jphotobiol.2019.111534 31279897 Yu, T. et al. Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy. J. Photoch. Photobio. B 197 , 111534 (2019). 10.1016/j.jphotobiol.2019.111534 31279897

1042. Wang C Effect of mesoporous silica nanoparticles co-loading with 17-AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2 Oncol. Rep. 2020 43 1491 1502 10.1007/s12094-019-02283-9 32323855 PMC7108023 Wang, C. et al. Effect of mesoporous silica nanoparticles co-loading with 17-AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2. Oncol. Rep. 43 , 1491–1502 (2020). 32323855 10.1007/s12094-019-02283-9 PMC7108023

1043. Dotan I Engineering multi-walled carbon nanotube therapeutic bionanofluids to selectively target papillary thyroid cancer cells PLoS ONE 2016 11 e0149723 10.1371/journal.pone.0149723 26901566 PMC4762941 Dotan, I. et al. Engineering multi-walled carbon nanotube therapeutic bionanofluids to selectively target papillary thyroid cancer cells. PLoS ONE 11 , e0149723 (2016). 26901566 10.1371/journal.pone.0149723 PMC4762941

1044. Zhang Q Small-sized gold nanoparticles inhibit the proliferation and invasion of SW579 cells Mol. Med. Rep. 2015 12 8313 8319 10.3892/mmr.2015.4433 26499332 Zhang, Q. et al. Small-sized gold nanoparticles inhibit the proliferation and invasion of SW579 cells. Mol. Med. Rep. 12 , 8313–8319 (2015). 26499332 10.3892/mmr.2015.4433

1045. Yu T NIR triggered PLGA coated Au-TiO(2) core loaded CPT-11 nanoparticles for human papillary thyroid carcinoma therapy Drug Deliv 2020 27 855 863 10.1080/10717544.2020.1775723 32515668 PMC8216437 Yu, T. et al. NIR triggered PLGA coated Au-TiO(2) core loaded CPT-11 nanoparticles for human papillary thyroid carcinoma therapy. Drug Deliv 27 , 855–863 (2020). 32515668 10.1080/10717544.2020.1775723 PMC8216437

1046. Yang J Pseudomonas aeruginosa synthesized silver nanoparticles inhibit cell proliferation and induce ROS mediated apoptosis in thyroid cancer cell line (TPC1) Artif. Cell. Nanomed. B. 2020 48 800 809 10.1080/21691401.2019.1687495 32432484 Yang, J. et al. Pseudomonas aeruginosa synthesized silver nanoparticles inhibit cell proliferation and induce ROS mediated apoptosis in thyroid cancer cell line (TPC1). Artif. Cell. Nanomed. B. 48 , 800–809 (2020). 10.1080/21691401.2019.1687495 32432484

1047. Li H Highly selective anchoring silver nanoclusters on MOF/SOF heterostructured framework for efficient adsorption of radioactive iodine from aqueous solution Chemosphere 2020 252 126448 10.1016/j.chemosphere.2020.126448 32203781 Li, H. et al. Highly selective anchoring silver nanoclusters on MOF/SOF heterostructured framework for efficient adsorption of radioactive iodine from aqueous solution. Chemosphere 252 , 126448 (2020). 32203781 10.1016/j.chemosphere.2020.126448

1048. Wang Q A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics Acta Biomater 2020 102 367 383 10.1016/j.actbio.2019.11.043 31778831 Wang, Q. et al. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics. Acta Biomater 102 , 367–383 (2020). 31778831 10.1016/j.actbio.2019.11.043

1049. Marano F Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model Endocr.-Relat. Cancer 2017 24 275 286 10.1530/ERC-17-0045 28487350 Marano, F. et al. Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model. Endocr.-Relat. Cancer 24 , 275–286 (2017). 28487350 10.1530/ERC-17-0045

1050. Liu Y Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer Proc. Natl. Acad. Sci. USA 2016 113 7750 7755 10.1073/pnas.1605841113 27342857 PMC4948349 Liu, Y. et al. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer. Proc. Natl. Acad. Sci. USA 113 , 7750–7755 (2016). 27342857 10.1073/pnas.1605841113 PMC4948349

1051. Xu Z The role of carbon nanoparticles in guiding central neck dissection and protecting the parathyroid in transoral vestibular endoscopic thyroidectomy for thyroid cancer Videosurgery Miniinv 2020 15 455 461 10.5114/wiitm.2019.89658 PMC7457188 32904573 Xu, Z. et al. The role of carbon nanoparticles in guiding central neck dissection and protecting the parathyroid in transoral vestibular endoscopic thyroidectomy for thyroid cancer. Videosurgery Miniinv 15 , 455–461 (2020). 10.5114/wiitm.2019.89658 PMC7457188 32904573

1052. Min L Utility of activated carbon nanoparticle (CNP) during total thyroidectomy for clinically nodal positive papillary thyroid carcinoma (PTC) World J. Surg. 2020 44 356 362 10.1007/s00268-019-05113-9 31399795 Min, L. et al. Utility of activated carbon nanoparticle (CNP) during total thyroidectomy for clinically nodal positive papillary thyroid carcinoma (PTC). World J. Surg. 44 , 356–362 (2020). 31399795 10.1007/s00268-019-05113-9

1053. Zhang D Application of carbon nanoparticles in endoscopic thyroidectomy via bilateral areola approach: total thyroidectomy plus central lymph node dissection J. Laparoendosc. Adv. S. 2019 29 1038 1041 10.1089/lap.2019.0102 30939054 Zhang, D. et al. Application of carbon nanoparticles in endoscopic thyroidectomy via bilateral areola approach: total thyroidectomy plus central lymph node dissection. J. Laparoendosc. Adv. S. 29 , 1038–1041 (2019). 10.1089/lap.2019.0102 30939054

1054. Zhang C The potential role of carbon nanoparticles-assisted biopsy for sentinel lymph nodes of incidental thyroid carcinoma Gland Surg 2019 8 370 377 10.21037/gs.2019.07.08 31538061 PMC6723016 Zhang, C. et al. The potential role of carbon nanoparticles-assisted biopsy for sentinel lymph nodes of incidental thyroid carcinoma. Gland Surg 8 , 370–377 (2019). 31538061 10.21037/gs.2019.07.08 PMC6723016

1055. Zhang X Shen YP Li JG Chen G Clinical feasibility of imaging with indocyanine green combined with carbon nanoparticles for sentinel lymph node identification in papillary thyroid microcarcinoma Medicine 2019 98 e16935 10.1097/MD.0000000000016935 31490376 PMC6738994 Zhang, X., Shen, Y. P., Li, J. G. & Chen, G. Clinical feasibility of imaging with indocyanine green combined with carbon nanoparticles for sentinel lymph node identification in papillary thyroid microcarcinoma. Medicine 98 , e16935 (2019). 31490376 10.1097/MD.0000000000016935 PMC6738994

1056. Qian YC Application of carbon nano-particles in total thyroidectomy combined with lymphadenectomy in area VI. Zhonghua er bi yan hou tou jing wai ke za zhi = Chin. J. Otorhinolaryngol Head .Neck Surgery 2019 54 28 32 10.3760/cma.j.issn.1673-0860.2019.01.007 30704166 Qian, Y. C. et al. Application of carbon nano-particles in total thyroidectomy combined with lymphadenectomy in area VI. Zhonghua er bi yan hou tou jing wai ke za zhi = Chin. J. Otorhinolaryngol . Head .Neck Surgery 54 , 28–32 (2019). 10.3760/cma.j.issn.1673-0860.2019.01.007 30704166

1057. Yan S Zhao W Wang B Zhang L Preoperative injection of carbon nanoparticles is beneficial to the patients with thyroid papillary carcinoma: From a prospective study of 102 cases Medicine 2018 97 e11364 10.1097/MD.0000000000011364 29979421 PMC6076069 Yan, S., Zhao, W., Wang, B. & Zhang, L. Preoperative injection of carbon nanoparticles is beneficial to the patients with thyroid papillary carcinoma: From a prospective study of 102 cases. Medicine 97 , e11364 (2018). 29979421 10.1097/MD.0000000000011364 PMC6076069

1058. Wang B The function of carbon nanoparticles to improve lymph node dissection and identification of parathyroid glands during thyroid reoperation for carcinoma Medicine 2018 97 e11778 10.1097/MD.0000000000011778 30095634 PMC6133593 Wang, B. et al. The function of carbon nanoparticles to improve lymph node dissection and identification of parathyroid glands during thyroid reoperation for carcinoma. Medicine 97 , e11778 (2018). 30095634 10.1097/MD.0000000000011778 PMC6133593

1059. Liu Y Carbon nanoparticle lymph node tracer improves the outcomes of surgical treatment in papillary thyroid cancer Cancer Biomark 2018 23 227 233 10.3233/CBM-181386 30198867 PMC13078537 Liu, Y. et al. Carbon nanoparticle lymph node tracer improves the outcomes of surgical treatment in papillary thyroid cancer. Cancer Biomark 23 , 227–233 (2018). 30198867 10.3233/CBM-181386 PMC13078537

1060. Cheng X Intraoperative carbon nanoparticles mapping in secondary total thyroidectomy for recurrent thyroid nodules: results of a 8-criterion case-match study (case control study) Int. J. Surg. 2018 60 210 215 10.1016/j.ijsu.2018.11.014 30472362 Cheng, X. et al. Intraoperative carbon nanoparticles mapping in secondary total thyroidectomy for recurrent thyroid nodules: results of a 8-criterion case-match study (case control study). Int. J. Surg. 60 , 210–215 (2018). 30472362 10.1016/j.ijsu.2018.11.014

1061. Xu XF Gu J The application of carbon nanoparticles in the lymph node biopsy of cN0 papillary thyroid carcinoma: a randomized controlled clinical trial Asian J. Surg. 2017 40 345 349 10.1016/j.asjsur.2015.11.004 26783035 Xu, X. F. & Gu, J. The application of carbon nanoparticles in the lymph node biopsy of cN0 papillary thyroid carcinoma: a randomized controlled clinical trial. Asian J. Surg. 40 , 345–349 (2017). 26783035 10.1016/j.asjsur.2015.11.004

1062. Wang L Application of carbon nanoparticles in lymph node dissection and parathyroid protection during thyroid cancer surgeries: a systematic review and meta-analysis OncoTargets Ther 2017 10 1247 1260 10.2147/OTT.S131012 PMC5338936 28280359 Wang, L. et al. Application of carbon nanoparticles in lymph node dissection and parathyroid protection during thyroid cancer surgeries: a systematic review and meta-analysis. OncoTargets Ther 10 , 1247–1260 (2017). 10.2147/OTT.S131012 PMC5338936 28280359

1063. Liu J Do carbon nanoparticles really improve thyroid cancer surgery? A retrospective analysis of real-world data World J. Surg. Oncol. 2020 18 84 10.1186/s12957-020-01852-5 32359365 PMC7196221 Liu, J. et al. Do carbon nanoparticles really improve thyroid cancer surgery? A retrospective analysis of real-world data. World J. Surg. Oncol. 18 , 84 (2020). 32359365 10.1186/s12957-020-01852-5 PMC7196221

1064. Su AP Carbon nanoparticles facilitate lymph nodes dissection and parathyroid glands identification in reoperation of papillary thyroid cancer Medicine 2017 96 e8380 10.1097/MD.0000000000008380 29095266 PMC5682785 Su, A. P. et al. Carbon nanoparticles facilitate lymph nodes dissection and parathyroid glands identification in reoperation of papillary thyroid cancer. Medicine 96 , e8380 (2017). 29095266 10.1097/MD.0000000000008380 PMC5682785

1065. Zhang D A randomized comparison of carbon nanoparticles in endoscopic lymph node dissection via the bilateral areola approach for papillary thyroid cancer Surg. Laparo. Endo. Per. 2020 30 291 299 10.1097/SLE.0000000000000793 32574006 Zhang, D. et al. A randomized comparison of carbon nanoparticles in endoscopic lymph node dissection via the bilateral areola approach for papillary thyroid cancer. Surg. Laparo. Endo. Per. 30 , 291–299 (2020). 10.1097/SLE.0000000000000793 32574006

1066. Liu X Identifying parathyroid glands with carbon nanoparticle suspension does not help protect parathyroid function in thyroid surgery: a prospective, randomized control clinical study Surg. Innov. 2016 23 381 389 10.1177/1553350615624787 26783268 Liu, X. et al. Identifying parathyroid glands with carbon nanoparticle suspension does not help protect parathyroid function in thyroid surgery: a prospective, randomized control clinical study. Surg. Innov. 23 , 381–389 (2016). 26783268 10.1177/1553350615624787

1067. Jiang Y Jiang Z Wang M Ma L Current understandings and clinical translation of nanomedicines for breast cancer therapy Adv. Drug Deliver. Rev. 2022 180 114034 10.1016/j.addr.2021.114034 34736986 Jiang, Y., Jiang, Z., Wang, M. & Ma, L. Current understandings and clinical translation of nanomedicines for breast cancer therapy. Adv. Drug Deliver. Rev. 180 , 114034 (2022). 10.1016/j.addr.2021.114034 34736986

1068. Yu W Hu C Gao H Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages Adv. Drug Deliver. Rev. 2021 178 113909 10.1016/j.addr.2021.113909 34352354 Yu, W., Hu, C. & Gao, H. Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages. Adv. Drug Deliver. Rev. 178 , 113909 (2021). 10.1016/j.addr.2021.113909 34352354

1069. Afzal M Nanomedicine in treatment of breast cancer—a challenge to conventional therapy Semin. Cancer Biol. 2021 69 279 292 10.1016/j.semcancer.2019.12.016 31870940 Afzal, M. et al. Nanomedicine in treatment of breast cancer—a challenge to conventional therapy. Semin. Cancer Biol. 69 , 279–292 (2021). 31870940 10.1016/j.semcancer.2019.12.016

1070. Chowdhury P Bioactive nanotherapeutic trends to combat triple negative breast cancer Bioact. Mater. 2021 6 3269 3287 33778204 10.1016/j.bioactmat.2021.02.037 PMC7970221 Chowdhury, P. et al. Bioactive nanotherapeutic trends to combat triple negative breast cancer. Bioact. Mater. 6 , 3269–3287 (2021). 33778204 10.1016/j.bioactmat.2021.02.037 PMC7970221

1071. Mirza Z Karim S Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges Semin. Cancer Biol. 2021 69 226 237 10.1016/j.semcancer.2019.10.020 31704145 Mirza, Z. & Karim, S. Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. Semin. Cancer Biol. 69 , 226–237 (2021). 31704145 10.1016/j.semcancer.2019.10.020

1072. Zhang P A PD-L1 antibody-conjugated PAMAM dendrimer nanosystem for simultaneously inhibiting glycolysis and promoting immune response in fighting breast cancer Adv. Mater. 2023 35 2305215 10.1002/adma.202305215 37522451 Zhang, P. et al. A PD-L1 antibody-conjugated PAMAM dendrimer nanosystem for simultaneously inhibiting glycolysis and promoting immune response in fighting breast cancer. Adv. Mater. 35 , 2305215 (2023). 10.1002/adma.202305215 37522451

1073. Xiong Y Nanoparticle-based photothermal therapy for breast cancer non-invasive treatment Adv. Mater. 2023 10 e2305140 10.1002/adma.202305140 37561994 Xiong, Y. et al. Nanoparticle-based photothermal therapy for breast cancer non-invasive treatment. Adv. Mater. 10 , e2305140 (2023). 10.1002/adma.202305140 37561994

1074. Alamdari SG Recent advances in nanoparticle-based photothermal therapy for breast cancer J. Control. Release 2022 349 269 303 10.1016/j.jconrel.2022.06.050 35787915 Alamdari, S. G. et al. Recent advances in nanoparticle-based photothermal therapy for breast cancer. J. Control. Release 349 , 269–303 (2022). 35787915 10.1016/j.jconrel.2022.06.050

1075. Ashrafizadeh, M. et al. (Nano)platforms in breast cancer therapy: drug/gene delivery, advanced nanocarriers and immunotherapy. Med. Res. Rev . 43 , 2115–2176 (2023). 10.1002/med.21971 37165896

1076. Wang Q Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours Nat. Nanotechnol. 2024 19 95 105 10.1038/s41565-023-01498-w 37709950 Wang, Q. et al. Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours. Nat. Nanotechnol. 19 , 95–105 (2024). 37709950 10.1038/s41565-023-01498-w

1077. Martin JD Cabral H Stylianopoulos T Jain RK Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges Nat. Rev. Clin. Oncol. 2020 17 251 266 10.1038/s41571-019-0308-z 32034288 PMC8272676 Martin, J. D., Cabral, H., Stylianopoulos, T. & Jain, R. K. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat. Rev. Clin. Oncol. 17 , 251–266 (2020). 32034288 10.1038/s41571-019-0308-z PMC8272676

1078. Ravi Kiran A Tumor microenvironment and nanotherapeutics: intruding the tumor fort Biomater. Sci.-UK 2021 9 7667 7704 10.1039/D1BM01127H 34673853 Ravi Kiran, A. et al. Tumor microenvironment and nanotherapeutics: intruding the tumor fort. Biomater. Sci.-UK 9 , 7667–7704 (2021). 10.1039/D1BM01127H 34673853

1079. Kim J Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy J. Control. Release 2021 332 109 126 10.1016/j.jconrel.2021.02.002 33571549 Kim, J. et al. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy. J. Control. Release 332 , 109–126 (2021). 33571549 10.1016/j.jconrel.2021.02.002

1080. Mendes BB Sousa DP Conniot J Conde J Nanomedicine-based strategies to target and modulate the tumor microenvironment Trends Cancer 2021 7 847 862 10.1016/j.trecan.2021.05.001 34090865 Mendes, B. B., Sousa, D. P., Conniot, J. & Conde, J. Nanomedicine-based strategies to target and modulate the tumor microenvironment. Trends Cancer 7 , 847–862 (2021). 34090865 10.1016/j.trecan.2021.05.001

1081. Oh HJ Microfluidic reconstitution of tumor microenvironment for nanomedical applications Adv. Healthc. Mater. 2021 10 e2002122 10.1002/adhm.202002122 33576178 Oh, H. J. et al. Microfluidic reconstitution of tumor microenvironment for nanomedical applications. Adv. Healthc. Mater. 10 , e2002122 (2021). 33576178 10.1002/adhm.202002122

1082. Xu Y Xiong J Sun X Gao H Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy Acta Pharm. Sin. B 2022 12 4327 4347 10.1016/j.apsb.2022.11.001 36561994 PMC9764075 Xu, Y., Xiong, J., Sun, X. & Gao, H. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Acta Pharm. Sin. B 12 , 4327–4347 (2022). 36561994 10.1016/j.apsb.2022.11.001 PMC9764075

1083. Sia CS Stimuli-responsive nanoassemblies for targeted delivery against tumor and its microenvironment. BBA-Rev Cancer 2022 1877 188779 10.1016/j.bbcan.2022.188779 35977690 Sia, C. S. et al. Stimuli-responsive nanoassemblies for targeted delivery against tumor and its microenvironment. BBA-Rev . Cancer 1877 , 188779 (2022). 10.1016/j.bbcan.2022.188779 35977690

1084. Musazzi UM Marini V Casiraghi A Minghetti P Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials? Drug Discov. Today 2017 22 870 882 10.1016/j.drudis.2017.01.016 28189800 Musazzi, U. M., Marini, V., Casiraghi, A. & Minghetti, P. Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials? Drug Discov. Today 22 , 870–882 (2017). 28189800 10.1016/j.drudis.2017.01.016

1085. Cortez-Jugo C Czuba-Wojnilowicz E Tan A Caruso F A focus on “Bio” in bio-nanoscience: the impact of biological factors on nanomaterial interactions Adv. Healthc. Mater. 2021 10 e2100574 10.1002/adhm.202100574 34170631 Cortez-Jugo, C., Czuba-Wojnilowicz, E., Tan, A. & Caruso, F. A focus on “Bio” in bio-nanoscience: the impact of biological factors on nanomaterial interactions. Adv. Healthc. Mater. 10 , e2100574 (2021). 34170631 10.1002/adhm.202100574

1086. Dutt Y Therapeutic applications of nanobiotechnology J. Nanobiotechnol. 2023 21 148 10.1186/s12951-023-01909-z PMC10163736 37149615 Dutt, Y. et al. Therapeutic applications of nanobiotechnology. J. Nanobiotechnol. 21 , 148 (2023). 10.1186/s12951-023-01909-z PMC10163736 37149615

1087. Yang RS Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment Environ. Health Persp. 2007 115 1339 1343 10.1289/ehp.10290 PMC1964885 17805425 Yang, R. S. et al. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ. Health Persp. 115 , 1339–1343 (2007). 10.1289/ehp.10290 PMC1964885 17805425

1088. Khan MK In vivo biodistribution of dendrimers and dendrimer nanocomposites - implications for cancer imaging and therapy Technol. Cancer Res. T. 2005 4 603 613 10.1177/153303460500400604 16292880 Khan, M. K. et al. In vivo biodistribution of dendrimers and dendrimer nanocomposites - implications for cancer imaging and therapy. Technol. Cancer Res. T. 4 , 603–613 (2005). 10.1177/153303460500400604 16292880

1089. Donaldson K Poland CA Nanotoxicity: challenging the myth of nano-specific toxicity Curr. Opin. Biotech 2013 24 724 734 10.1016/j.copbio.2013.05.003 23768801 Donaldson, K. & Poland, C. A. Nanotoxicity: challenging the myth of nano-specific toxicity. Curr. Opin. Biotech 24 , 724–734 (2013). 23768801 10.1016/j.copbio.2013.05.003

1090. Nel A Xia T Madler L Li N Toxic potential of materials at the nanolevel Science 2006 311 622 627 10.1126/science.1114397 16456071 Nel, A., Xia, T., Madler, L. & Li, N. Toxic potential of materials at the nanolevel. Science 311 , 622–627 (2006). 16456071 10.1126/science.1114397

1091. Domingues C Where is nano today and where is it headed? A review of nanomedicine and the dilemma of nanotoxicology ACS Nano 2022 16 9994 10041 10.1021/acsnano.2c00128 35729778 Domingues, C. et al. Where is nano today and where is it headed? A review of nanomedicine and the dilemma of nanotoxicology. ACS Nano 16 , 9994–10041 (2022). 35729778 10.1021/acsnano.2c00128

1092. Zhang P Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects Med 2023 4 147 167 10.1016/j.medj.2022.12.001 36549297 Zhang, P. et al. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects. Med 4 , 147–167 (2023). 36549297 10.1016/j.medj.2022.12.001

1093. Vilas-Boas V Vinken M Hepatotoxicity induced by nanomaterials: mechanisms and in vitro models Arch. Toxicol. 2021 95 27 52 10.1007/s00204-020-02940-x 33155068 Vilas-Boas, V. & Vinken, M. Hepatotoxicity induced by nanomaterials: mechanisms and in vitro models. Arch. Toxicol. 95 , 27–52 (2021). 33155068 10.1007/s00204-020-02940-x

1094. Jiang W Considerations for designing preclinical cancer immune nanomedicine studies Nat. Nanotechnol. 2021 16 6 15 10.1038/s41565-020-00817-9 33349682 PMC8103921 Jiang, W. et al. Considerations for designing preclinical cancer immune nanomedicine studies. Nat. Nanotechnol. 16 , 6–15 (2021). 33349682 10.1038/s41565-020-00817-9 PMC8103921

1095. Moosavian SA Bianconi V Pirro M Sahebkar A Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy Semin. Cancer Biol. 2021 69 337 348 10.1016/j.semcancer.2019.09.025 31585213 Moosavian, S. A., Bianconi, V., Pirro, M. & Sahebkar, A. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. Semin. Cancer Biol. 69 , 337–348 (2021). 31585213 10.1016/j.semcancer.2019.09.025

1096. Yang J Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers Adv. Drug Deliver. Rev. 2022 190 114525 10.1016/j.addr.2022.114525 36100142 Yang, J. et al. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers. Adv. Drug Deliver. Rev. 190 , 114525 (2022). 10.1016/j.addr.2022.114525 36100142

1097. Pei Z Lei H Cheng L Bioactive inorganic nanomaterials for cancer theranostics Chem. Soc. Rev. 2023 52 2031 2081 10.1039/D2CS00352J 36633202 Pei, Z., Lei, H. & Cheng, L. Bioactive inorganic nanomaterials for cancer theranostics. Chem. Soc. Rev. 52 , 2031–2081 (2023). 36633202 10.1039/D2CS00352J

1098. Younis MA Clinical translation of nanomedicines: challenges, opportunities, and keys Adv. Drug Deliver. Rev. 2022 181 114083 10.1016/j.addr.2021.114083 34929251 Younis, M. A. et al. Clinical translation of nanomedicines: challenges, opportunities, and keys. Adv. Drug Deliver. Rev. 181 , 114083 (2022). 10.1016/j.addr.2021.114083 34929251

1099. Fan D Nanomedicine in cancer therapy Signal Transduct. Tar. 2023 8 293 10.1038/s41392-023-01536-y PMC10404590 37544972 Fan, D. et al. Nanomedicine in cancer therapy. Signal Transduct. Tar. 8 , 293 (2023). 10.1038/s41392-023-01536-y PMC10404590 37544972